

[0826] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, and/or diagnosed with the compositions of the invention include, but are not limited to, type II collagen-induced arthritis, antiphospholipid syndrome, dermatitis, allergic encephalomyelitis, myocarditis, relapsing polychondritis, rheumatic heart disease, neuritis, uveitis ophthalmia, polyendocrinopathies, Reiter's Disease, Stiff-Man Syndrome, autoimmune pulmonary inflammation, autism, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disorders.

[0827] Additional disorders that are likely to have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, scleroderma with anti-collagen antibodies (often characterized, e.g., by nucleolar and other nuclear antibodies), mixed connective tissue disease (often characterized, e.g., by antibodies to extractable nuclear antigens (e.g., ribonucleoprotein)), polymyositis (often characterized, e.g., by nonhistone ANA), pernicious anemia (often characterized, e.g., by antiparietal cell, microsomes, and intrinsic factor antibodies), idiopathic Addison's disease (often characterized, e.g., by humoral and cell-mediated adrenal cytotoxicity, infertility (often characterized, e.g., by antispermatozoal antibodies), glomerulonephritis (often characterized, e.g., by glomerular basement membrane antibodies or immune complexes), bullous pemphigoid (often characterized, e.g., by IgG and complement in basement membrane), Sjogren's syndrome (often characterized, e.g., by multiple tissue antibodies, and/or a specific nonhistone ANA (SS-B)), diabetes mellitus (often characterized, e.g., by cell-mediated and humoral islet cell antibodies), and adrenergic drug resistance (including adrenergic drug resistance with asthma or cystic fibrosis) (often characterized, e.g., by beta-adrenergic receptor antibodies).

[0828] Additional disorders that may have an autoimmune component that may be treated, prevented, diagnosed and/or prognosed with the compositions of the invention include, but are not limited to, chronic active hepatitis (often characterized, e.g., by smooth muscle antibodies), primary biliary cirrhosis (often characterized, e.g., by mitochondria antibodies), other endocrine gland failure (often characterized, e.g., by specific tissue antibodies in some cases), vitiligo (often characterized, e.g., by melanocyte antibodies), vasculitis (often characterized, e.g., by Ig and complement in vessel walls and/or low serum complement), post-MI (often characterized, e.g., by myocardial

antibodies), cardiotomy syndrome (often characterized, e.g., by myocardial antibodies), urticaria (often characterized, e.g., by IgG and IgM antibodies to IgE), atopic dermatitis (often characterized, e.g., by IgG and IgM antibodies to IgE), asthma (often characterized, e.g., by IgG and IgM antibodies to IgE), and many other inflammatory, granulomatous, degenerative, and atrophic disorders.

[0829] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using for example, antagonists or agonists, polypeptides or polynucleotides, or antibodies of the present invention. In a specific preferred embodiment, rheumatoid arthritis is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0830] In another specific preferred embodiment, systemic lupus erythematosus is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention. In another specific preferred embodiment, idiopathic thrombocytopenia purpura is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0831] In another specific preferred embodiment IgA nephropathy is treated, prevented, and/or diagnosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention.

[0832] In a preferred embodiment, the autoimmune diseases and disorders and/or conditions associated with the diseases and disorders recited above are treated, prevented, diagnosed and/or prognosed using polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention

[0833] In preferred embodiments, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a immunosuppressive agent(s).

[0834] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, prognosing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the

pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells, including but not limited to, leukopenia, neutropenia, anemia, and thrombocytopenia. Alternatively, Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with an increase in certain (or many) types of hematopoietic cells, including but not limited to, histiocytosis.

[0835] Allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, diagnosed and/or prognosed using polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof. Moreover, these molecules can be used to treat, prevent, prognose, and/or diagnose anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

[0836] Additionally, polypeptides or polynucleotides of the invention, and/or agonists or antagonists thereof, may be used to treat, prevent, diagnose and/or prognose IgE-mediated allergic reactions. Such allergic reactions include, but are not limited to, asthma, rhinitis, and eczema. In specific embodiments, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate IgE concentrations *in vitro* or *in vivo*.

[0837] Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention have uses in the diagnosis, prognosis, prevention, and/or treatment of inflammatory conditions. For example, since polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists of the invention may inhibit the activation, proliferation and/or differentiation of cells involved in an inflammatory response, these molecules can be used to prevent and/or treat chronic and acute inflammatory conditions. Such inflammatory conditions include, but are not limited to, for example, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome), ischemia-reperfusion injury, endotoxin lethality, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, over production of cytokines (e.g., TNF or IL-1), respiratory disorders (e.g., asthma and allergy);

gastrointestinal disorders (e.g., inflammatory bowel disease); cancers (e.g., gastric, ovarian, lung, bladder, liver, and breast); CNS disorders (e.g., multiple sclerosis; ischemic brain injury and/or stroke, traumatic brain injury, neurodegenerative disorders (e.g., Parkinson's disease and Alzheimer's disease); AIDS-related dementia; and prion disease); cardiovascular disorders (e.g., atherosclerosis, myocarditis, cardiovascular disease, and cardiopulmonary bypass complications); as well as many additional diseases, conditions, and disorders that are characterized by inflammation (e.g., hepatitis, rheumatoid arthritis, gout, trauma, pancreatitis, sarcoidosis, dermatitis, renal ischemia-reperfusion injury, Grave's disease, systemic lupus erythematosus, diabetes mellitus, and allogenic transplant rejection).

[0838] Because inflammation is a fundamental defense mechanism, inflammatory disorders can effect virtually any tissue of the body. Accordingly, polynucleotides, polypeptides, and antibodies of the invention, as well as agonists or antagonists thereof, have uses in the treatment of tissue-specific inflammatory disorders, including, but not limited to, adrenalitis, alveolitis, angiocholecystitis, appendicitis, balanitis, blepharitis, bronchitis, bursitis, carditis, cellulitis, cervicitis, cholecystitis, chorditis, cochlitis, colitis, conjunctivitis, cystitis, dermatitis, diverticulitis, encephalitis, endocarditis, esophagitis, eustachitis, fibrosis, folliculitis, gastritis, gastroenteritis, gingivitis, glossitis, hepatosplenitis, keratitis, labyrinthitis, laryngitis, lymphangitis, mastitis, media otitis, meningitis, metritis, mucitis, myocarditis, myositis, myringitis, nephritis, neuritis, orchitis, osteochondritis, otitis, pericarditis, peritendonitis, peritonitis, pharyngitis, phlebitis, poliomyelitis, prostatitis, pulpitis, retinitis, rhinitis, salpingitis, scleritis, sclerochoroiditis, scrotitis, sinusitis, spondylitis, steatitis, stomatitis, synovitis, syringitis, tendonitis, tonsillitis, urethritis, and vaginitis.

[0839] In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat organ transplant rejections and graft-versus-host disease. Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. Polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or

chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD. In specific embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, that inhibit an immune response, particularly the activation, proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing experimental allergic and hyperacute xenograft rejection.

[0840] In other embodiments, polypeptides, antibodies, or polynucleotides of the invention, and/or agonists or antagonists thereof, are useful to diagnose, prognose, prevent, and/or treat immune complex diseases, including, but not limited to, serum sickness, post streptococcal glomerulonephritis, polyarteritis nodosa, and immune complex-induced vasculitis.

[0841] Polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the invention can be used to treat, detect, and/or prevent infectious agents. For example, by increasing the immune response, particularly increasing the proliferation activation and/or differentiation of B and/or T cells, infectious diseases may be treated, detected, and/or prevented. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may also directly inhibit the infectious agent (refer to section of application listing infectious agents, etc), without necessarily eliciting an immune response.

[0842] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a vaccine adjuvant that enhances immune responsiveness to an antigen. In a specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance tumor-specific immune responses.

[0843] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-viral immune responses. Anti-viral immune responses that may be enhanced using the compositions of the invention as an adjuvant, include virus and virus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of:

AIDS, meningitis, Dengue, EBV, and hepatitis (e.g., hepatitis B). In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a virus, disease, or symptom selected from the group consisting of: HIV/AIDS, respiratory syncytial virus, Dengue, rotavirus, Japanese B encephalitis, influenza A and B, parainfluenza, measles, cytomegalovirus, rabies, Junin, Chikungunya, Rift Valley Fever, herpes simplex, and yellow fever.

[0844] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-bacterial or anti-fungal immune responses. Anti-bacterial or anti-fungal immune responses that may be enhanced using the compositions of the invention as an adjuvant, include bacteria or fungus and bacteria or fungus associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: tetanus, Diphtheria, botulism, and meningitis type B.

[0845] In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to a bacteria or fungus, disease, or symptom selected from the group consisting of: *Vibrio cholerae*, *Mycobacterium leprae*, *Salmonella typhi*, *Salmonella paratyphi*, *Meisseria meningitidis*, *Streptococcus pneumoniae*, Group B streptococcus, *Shigella spp.*, Enterotoxigenic *Escherichia coli*, Enterohemorrhagic *E. coli*, and *Borrelia burgdorferi*.

[0846] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an adjuvant to enhance anti-parasitic immune responses. Anti-parasitic immune responses that may be enhanced using the compositions of the invention as an adjuvant, include parasite and parasite associated diseases or symptoms described herein or otherwise known in the art. In specific embodiments, the compositions of the invention are used as an adjuvant to enhance an immune response to a parasite. In another specific embodiment, the compositions of the invention are used as an adjuvant to enhance an immune response to Plasmodium (malaria) or Leishmania.

[0847] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat

infectious diseases including silicosis, sarcoidosis, and idiopathic pulmonary fibrosis; for example, by preventing the recruitment and activation of mononuclear phagocytes.

[0848] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an antigen for the generation of antibodies to inhibit or enhance immune mediated responses against polypeptides of the invention.

[0849] In one embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (e.g., mouse, rat, rabbit, hamster, guinea pig, pigs, micro-pig, chicken, camel, goat, horse, cow, sheep, dog, cat, non-human primate, and human, most preferably human) to boost the immune system to produce increased quantities of one or more antibodies (e.g., IgG, IgA, IgM, and IgE), to induce higher affinity antibody production and immunoglobulin class switching (e.g., IgG, IgA, IgM, and IgE), and/or to increase an immune response.

[0850] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell responsiveness to pathogens.

[0851] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an activator of T cells.

[0852] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent that elevates the immune status of an individual prior to their receipt of immunosuppressive therapies.

[0853] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to induce higher affinity antibodies.

[0854] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to increase serum immunoglobulin concentrations.

[0855] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to accelerate recovery of immunocompromised individuals.

[0856] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among aged populations and/or neonates.

[0857] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an immune system enhancer prior to, during, or after bone marrow transplant and/or other transplants (e.g., allogeneic or xenogeneic organ transplantation). With respect to transplantation, compositions of the invention may be administered prior to, concomitant with, and/or after transplantation. In a specific embodiment, compositions of the invention are administered after transplantation, prior to the beginning of recovery of T-cell populations. In another specific embodiment, compositions of the invention are first administered after transplantation after the beginning of recovery of T cell populations, but prior to full recovery of B cell populations.

[0858] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having an acquired loss of B cell function. Conditions resulting in an acquired loss of B cell function that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, HIV Infection, AIDS, bone marrow transplant, and B cell chronic lymphocytic leukemia (CLL).

[0859] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to boost immunoresponsiveness among individuals having a temporary immune deficiency. Conditions resulting in a temporary immune deficiency that may be ameliorated or treated by administering the polypeptides, antibodies, polynucleotides and/or agonists or antagonists thereof, include, but are not limited to, recovery from viral infections (e.g., influenza), conditions associated with malnutrition, recovery from infectious mononucleosis, or conditions associated with stress, recovery from measles, recovery from blood transfusion, and recovery from surgery.

[0860] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a regulator of antigen presentation by monocytes, dendritic cells, and/or B-cells. In one embodiment,

polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention enhance antigen presentation or antagonizes antigen presentation in vitro or in vivo. Moreover, in related embodiments, said enhancement or antagonism of antigen presentation may be useful as an anti-tumor treatment or to modulate the immune system.

[0861] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as an agent to direct an individual's immune system towards development of a humoral response (i.e. TH2) as opposed to a TH1 cellular response.

[0862] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means to induce tumor proliferation and thus make it more susceptible to anti-neoplastic agents. For example, multiple myeloma is a slowly dividing disease and is thus refractory to virtually all anti-neoplastic regimens. If these cells were forced to proliferate more rapidly their susceptibility profile would likely change.

[0863] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a stimulator of B cell production in pathologies such as AIDS, chronic lymphocyte disorder and/or Common Variable Immunodeficiency.

[0864] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for generation and/or regeneration of lymphoid tissues following surgery, trauma or genetic defect. In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in the pretreatment of bone marrow samples prior to transplant.

[0865] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a gene-based therapy for genetically inherited disorders resulting in immuno-incompetence/immunodeficiency such as observed among SCID patients.

[0866] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of activating monocytes/macrophages to defend against parasitic diseases that effect monocytes such as Leishmania.

[0867] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of regulating secreted cytokines that are elicited by polypeptides of the invention.

[0868] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used in one or more of the applications described herein, as they may apply to veterinary medicine.

[0869] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of blocking various aspects of immune responses to foreign agents or self. Examples of diseases or conditions in which blocking of certain aspects of immune responses may be desired include autoimmune disorders such as lupus, and arthritis, as well as immunoresponsiveness to skin allergies, inflammation, bowel disease, injury and diseases/disorders associated with pathogens.

[0870] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for preventing the B cell proliferation and Ig secretion associated with autoimmune diseases such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus and multiple sclerosis.

[0871] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a inhibitor of B and/or T cell migration in endothelial cells. This activity disrupts tissue architecture or cognate responses and is useful, for example in disrupting immune responses, and blocking sepsis.

[0872] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for chronic hypergammaglobulinemia evident in such diseases as monoclonal gammopathy of undetermined significance (MGUS), Waldenstrom's disease, related idiopathic monoclonal gammopathies, and plasmacytomas.

[0873] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed for instance to inhibit polypeptide chemotaxis and activation of macrophages and their precursors, and of neutrophils, basophils, B lymphocytes and some T-cell subsets, e.g., activated and CD8 cytotoxic T cells and natural killer cells, in certain autoimmune and chronic inflammatory

and infective diseases. Examples of autoimmune diseases are described herein and include multiple sclerosis, and insulin-dependent diabetes.

[0874] The polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed to treat idiopathic hyper-eosinophilic syndrome by, for example, preventing eosinophil production and migration.

[0875] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit complement mediated cell lysis.

[0876] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used to enhance or inhibit antibody dependent cellular cytotoxicity.

[0877] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may also be employed for treating atherosclerosis, for example, by preventing monocyte infiltration in the artery wall.

[0878] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed to treat adult respiratory distress syndrome (ARDS).

[0879] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be useful for stimulating wound and tissue repair, stimulating angiogenesis, and/or stimulating the repair of vascular or lymphatic diseases or disorders. Additionally, agonists and antagonists of the invention may be used to stimulate the regeneration of mucosal surfaces.

[0880] In a specific embodiment, polynucleotides or polypeptides, and/or agonists thereof are used to diagnose, prognose, treat, and/or prevent a disorder characterized by primary or acquired immunodeficiency, deficient serum immunoglobulin production, recurrent infections, and/or immune system dysfunction. Moreover, polynucleotides or polypeptides, and/or agonists thereof may be used to treat or prevent infections of the joints, bones, skin, and/or parotid glands, blood-borne infections (e.g., sepsis, meningitis, septic arthritis, and/or osteomyelitis), autoimmune diseases (e.g., those disclosed herein), inflammatory disorders, and malignancies, and/or any disease or disorder or condition associated with these infections, diseases, disorders and/or malignancies) including, but not limited to, CVID, other primary immune deficiencies, HIV disease, CLL, recurrent

bronchitis, sinusitis, otitis media, conjunctivitis, pneumonia, hepatitis, meningitis, herpes zoster (e.g., severe herpes zoster), and/or pneumocystis carni. Other diseases and disorders that may be prevented, diagnosed, prognosed, and/or treated with polynucleotides or polypeptides, and/or agonists of the present invention include, but are not limited to, HIV infection, HTLV-BLV infection, lymphopenia, phagocyte bactericidal dysfunction anemia, thrombocytopenia, and hemoglobinuria.

[0881] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention are used to treat, and/or diagnose an individual having common variable immunodeficiency disease ("CVID"; also known as "acquired agammaglobulinemia" and "acquired hypogammaglobulinemia") or a subset of this disease.

[0882] In a specific embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to diagnose, prognose, prevent, and/or treat cancers or neoplasms including immune cell or immune tissue-related cancers or neoplasms. Examples of cancers or neoplasms that may be prevented, diagnosed, or treated by polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, Hodgkin's disease, non-Hodgkin's lymphoma, acute lymphocytic anemia (ALL) Chronic lymphocyte leukemia, plasmacytomas, multiple myeloma, Burkitt's lymphoma, EBV-transformed diseases, and/or diseases and disorders described in the section entitled "Hyperproliferative Disorders" elsewhere herein.

[0883] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a therapy for decreasing cellular proliferation of Large B-cell Lymphomas.

[0884] In another specific embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are used as a means of decreasing the involvement of B cells and Ig associated with Chronic Myelogenous Leukemia.

[0885] In specific embodiments, the compositions of the invention are used as an agent to boost immunoresponsiveness among B cell immunodeficient individuals, such as, for example, an individual who has undergone a partial or complete splenectomy.

[0886] Antagonists of the invention include, for example, binding and/or inhibitory antibodies, antisense nucleic acids, ribozymes or soluble forms of the polypeptides of the

present invention (e.g., Fc fusion protein; see, e.g., Example 9). Agonists of the invention include, for example, binding or stimulatory antibodies, and soluble forms of the polypeptides (e.g., Fc fusion proteins; see, e.g., Example 9). polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention may be employed in a composition with a pharmaceutically acceptable carrier, e.g., as described herein.

[0887] In another embodiment, polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention are administered to an animal (including, but not limited to, those listed above, and also including transgenic animals) incapable of producing functional endogenous antibody molecules or having an otherwise compromised endogenous immune system, but which is capable of producing human immunoglobulin molecules by means of a reconstituted or partially reconstituted immune system from another animal (see, e.g., published PCT Application Nos. WO98/24893, WO/9634096, WO/9633735, and WO/9110741). Administration of polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention to such animals is useful for the generation of monoclonal antibodies against the polypeptides, antibodies, polynucleotides and/or agonists or antagonists of the present invention.

Blood-Related Disorders

[0888] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hemostatic (the stopping of bleeding) or thrombolytic (clot dissolving) activity. For example, by increasing hemostatic or thrombolytic activity, polynucleotides or polypeptides, and/or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies, hemophilia), blood platelet diseases, disorders, and/or conditions (e.g., thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

[0889] In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, diagnose, prognose, and/or treat thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used for the prevention of occlusion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

[0890] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to prevent, diagnose, prognose, and/or treat diseases and disorders of the blood and/or blood forming organs associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 3, column 2 (Library Code).

[0891] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to modulate hematopoietic activity (the formation of blood cells). For example, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to increase the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes (B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of anemias and leukopenias described below. Alternatively, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to decrease the quantity of all or subsets of blood cells, such as, for example, erythrocytes, lymphocytes

(B or T cells), myeloid cells (e.g., basophils, eosinophils, neutrophils, mast cells, macrophages) and platelets. The ability to decrease the quantity of blood cells or subsets of blood cells may be useful in the prevention, detection, diagnosis and/or treatment of leukocytes, such as, for example eosinophilia.

[0892] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be used to prevent, treat, or diagnose blood dyscrasias.

[0893] Anemias are conditions in which the number of red blood cells or amount of hemoglobin (the protein that carries oxygen) in them is below normal. Anemia may be caused by excessive bleeding, decreased red blood cell production, or increased red blood cell destruction (hemolysis). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias. Anemias that may be treated prevented or diagnosed by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include iron deficiency anemia, hypochromic anemia, microcytic anemia, chlorosis, hereditary sideroblastic anemia, idiopathic acquired sideroblastic anemia, red cell aplasia, megaloblastic anemia (e.g., pernicious anemia, (vitamin B12 deficiency) and folic acid deficiency anemia), aplastic anemia, hemolytic anemias (e.g., autoimmune hemolytic anemia, microangiopathic hemolytic anemia, and paroxysmal nocturnal hemoglobinuria). The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with diseases including but not limited to, anemias associated with systemic lupus erythematosus, cancers, lymphomas, chronic renal disease, and enlarged spleens. The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias arising from drug treatments such as anemias associated with methyldopa, dapsone, and/or sulfadruugs. Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing anemias associated with abnormal red blood cell architecture including but not limited to, hereditary spherocytosis, hereditary elliptocytosis, glucose-6-phosphate dehydrogenase deficiency, and sickle cell anemia.

[0894] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing hemoglobin

abnormalities, (e.g., those associated with sickle cell anemia, hemoglobin C disease, hemoglobin S-C disease, and hemoglobin E disease). Additionally, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating thalassemias, including, but not limited to major and minor forms of alpha-thalassemia and beta-thalassemia.

[0895] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating bleeding disorders including, but not limited to, thrombocytopenia (e.g., idiopathic thrombocytopenic purpura, and thrombotic thrombocytopenic purpura), Von Willebrand's disease, hereditary platelet disorders (e.g., storage pool disease such as Chediak-Higashi and Hermansky-Pudlak syndromes, thromboxane A2 dysfunction, thromboasthenia, and Bernard-Soulier syndrome), hemolytic-uremic syndrome, hemophelias such as hemophilia A or Factor VII deficiency and Christmas disease or Factor IX deficiency, Hereditary Hemorrhagic Telangiectasia, also known as Rendu-Osler-Weber syndrome, allergic purpura (Henoch Schonlein purpura) and disseminated intravascular coagulation.

[0896] The effect of the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention on the clotting time of blood may be monitored using any of the clotting tests known in the art including, but not limited to, whole blood partial thromboplastin time (PTT), the activated partial thromboplastin time (aPTT), the activated clotting time (ACT), the recalcified activated clotting time, or the Lee-White Clotting time.

[0897] Several diseases and a variety of drugs can cause platelet dysfunction. Thus, in a specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating acquired platelet dysfunction such as platelet dysfunction accompanying kidney failure, leukemia, multiple myeloma, cirrhosis of the liver, and systemic lupus erythematosus as well as platelet dysfunction associated with drug treatments, including treatment with aspirin, ticlopidine, nonsteroidal anti-inflammatory drugs (used for arthritis, pain, and sprains), and penicillin in high doses.

[0898] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing,

preventing, and/or treating diseases and disorders characterized by or associated with increased or decreased numbers of white blood cells. Leukopenia occurs when the number of white blood cells decreases below normal. Leukopenias include, but are not limited to, neutropenia and lymphocytopenia. An increase in the number of white blood cells compared to normal is known as leukocytosis. The body generates increased numbers of white blood cells during infection. Thus, leukocytosis may simply be a normal physiological parameter that reflects infection. Alternatively, leukocytosis may be an indicator of injury or other disease such as cancer. Leukocytoses, include but are not limited to, eosinophilia, and accumulations of macrophages. In specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukopenia. In other specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukocytosis.

[0899] Leukopenia may be a generalized decreased in all types of white blood cells, or may be a specific depletion of particular types of white blood cells. Thus, in specific embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating decreases in neutrophil numbers, known as neutropenia. Neutropenias that may be diagnosed, prognosed, prevented, and/or treated by the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention include, but are not limited to, infantile genetic agranulocytosis, familial neutropenia, cyclic neutropenia, neutropenias resulting from or associated with dietary deficiencies (e.g., vitamin B 12 deficiency or folic acid deficiency), neutropenias resulting from or associated with drug treatments (e.g., antibiotic regimens such as penicillin treatment, sulfonamide treatment, anticoagulant treatment, anticonvulsant drugs, anti-thyroid drugs, and cancer chemotherapy), and neutropenias resulting from increased neutrophil destruction that may occur in association with some bacterial or viral infections, allergic disorders, autoimmune diseases, conditions in which an individual has an enlarged spleen (e.g., Felty syndrome, malaria and sarcoidosis), and some drug treatment regimens.

[0900] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating

lymphocytopenias (decreased numbers of B and/or T lymphocytes), including, but not limited lymphocytopenias resulting from or associated with stress, drug treatments (e.g., drug treatment with corticosteroids, cancer chemotherapies, and/or radiation therapies), AIDS infection and/or other diseases such as, for example, cancer, rheumatoid arthritis, systemic lupus erythematosus, chronic infections, some viral infections and/or hereditary disorders (e.g., DiGeorge syndrome, Wiskott-Aldrich Syndrome, severe combined immunodeficiency, ataxia telangiectasia).

[0901] The polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with macrophage numbers and/or macrophage function including, but not limited to, Gaucher's disease, Niemann-Pick disease, Letterer-Siwe disease and Hand-Schuller-Christian disease.

[0902] In another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders associated with eosinophil numbers and/or eosinophil function including, but not limited to, idiopathic hypereosinophilic syndrome, eosinophilia-myalgia syndrome, and Hand-Schuller-Christian disease.

[0903] In yet another embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating leukemias and lymphomas including, but not limited to, acute lymphocytic (lymphoblastic) leukemia (ALL), acute myeloid (myelocytic, myelogenous, myeloblastic, or myelomonocytic) leukemia, chronic lymphocytic leukemia (e.g., B cell leukemias, T cell leukemias, Sezary syndrome, and Hairy cell leukemia), chronic myelocytic (myeloid, myelogenous, or granulocytic) leukemia, Hodgkin's lymphoma, non-hodgkin's lymphoma, Burkitt's lymphoma, and mycosis fungoides.

[0904] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in diagnosing, prognosing, preventing, and/or treating diseases and disorders of plasma cells including, but not limited to, plasma cell dyscrasias, monoclonal gammaopathies, monoclonal gammopathies of undetermined significance, multiple myeloma, macroglobulinemia, Waldenstrom's macroglobulinemia, cryoglobulinemia, and Raynaud's phenomenon.

[0905] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing myeloproliferative disorders, including but not limited to, polycythemia vera, relative polycythemia, secondary polycythemia, myelofibrosis, acute myelofibrosis, agnogenic myelod metaplasia, thrombocythemia, (including both primary and seconday thrombocythemia) and chronic myelocytic leukemia.

[0906] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as a treatment prior to surgery, to increase blood cell production.

[0907] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to enhance the migration, phagocytosis, superoxide production, antibody dependent cellular cytotoxicity of neutrophils, eosinophils and macrophages.

[0908] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to stem cells pheresis. In another specific embodiment, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase the number of stem cells in circulation prior to platelet pheresis.

[0909] In other embodiments, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful as an agent to increase cytokine production.

[0910] In other embodiements, the polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention may be useful in preventing, diagnosing, and/or treating primary hematopoietic disorders.

Hyperproliferative Disorders

[0911] In certain embodiments, polynucleotides or polypeptides, or agonists or antagonists of the present invention can be used to treat or detect hyperproliferative disorders, including neoplasms. Polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through

direct or indirect interactions. Alternatively, Polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other cells which can inhibit the hyperproliferative disorder.

[0912] For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative disorders can be treated. This immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating hyperproliferative disorders, such as a chemotherapeutic agent.

[0913] Examples of hyperproliferative disorders that can be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

[0914] Similarly, other hyperproliferative disorders can also be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative disorders include, but are not limited to: Acute Childhood Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, Adult (Primary) Hepatocellular Cancer, Adult (Primary) Liver Cancer, Adult Acute Lymphocytic Leukemia, Adult Acute Myeloid Leukemia, Adult Hodgkin's Disease, Adult Hodgkin's Lymphoma, Adult Lymphocytic Leukemia, Adult Non-Hodgkin's Lymphoma, Adult Primary Liver Cancer, Adult Soft Tissue Sarcoma, AIDS-Related Lymphoma, AIDS-Related Malignancies, Anal Cancer, Astrocytoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer, Brain Stem Glioma, Brain Tumors, Breast Cancer, Cancer of the Renal Pelvis and Ureter, Central Nervous System (Primary) Lymphoma, Central Nervous System Lymphoma, Cerebellar Astrocytoma, Cerebral Astrocytoma, Cervical Cancer, Childhood (Primary) Hepatocellular Cancer, Childhood (Primary) Liver Cancer, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia, Childhood Brain Stem Glioma, Childhood Cerebellar Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Extracranial Germ Cell Tumors, Childhood Hodgkin's Disease,

Childhood Hodgkin's Lymphoma, Childhood Hypothalamic and Visual Pathway Glioma, Childhood Lymphoblastic Leukemia, Childhood Medulloblastoma, Childhood Non-Hodgkin's Lymphoma, Childhood Pineal and Supratentorial Primitive Neuroectodermal Tumors, Childhood Primary Liver Cancer, Childhood Rhabdomyosarcoma, Childhood Soft Tissue Sarcoma, Childhood Visual Pathway and Hypothalamic Glioma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Colon Cancer, Cutaneous T-Cell Lymphoma, Endocrine Pancreas Islet Cell Carcinoma, Endometrial Cancer, Ependymoma, Epithelial Cancer, Esophageal Cancer, Ewing's Sarcoma and Related Tumors, Exocrine Pancreatic Cancer, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Extrahepatic Bile Duct Cancer, Eye Cancer, Female Breast Cancer, Gaucher's Disease, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Tumors, Germ Cell Tumors, Gestational Trophoblastic Tumor, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular Cancer, Hodgkin's Disease, Hodgkin's Lymphoma, Hypergammaglobulinemia, Hypopharyngeal Cancer, Intestinal Cancers, Intraocular Melanoma, Islet Cell Carcinoma, Islet Cell Pancreatic Cancer, Kaposi's Sarcoma, Kidney Cancer, Laryngeal Cancer, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer, Lymphoproliferative Disorders, Macroglobulinemia, Male Breast Cancer, Malignant Mesothelioma, Malignant Thymoma, Medulloblastoma, Melanoma, Mesothelioma, Metastatic Occult Primary Squamous Neck Cancer, Metastatic Primary Squamous Neck Cancer, Metastatic Squamous Neck Cancer, Multiple Myeloma, Multiple Myeloma/Plasma Cell Neoplasm, Myelodysplastic Syndrome, Myelogenous Leukemia, Myeloid Leukemia, Myeloproliferative Disorders, Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin's Lymphoma During Pregnancy, Nonmelanoma Skin Cancer, Non-Small Cell Lung Cancer, Occult Primary Metastatic Squamous Neck Cancer, Oropharyngeal Cancer, Osteo-/Malignant Fibrous Sarcoma, Osteosarcoma/Malignant Fibrous Histiocytoma, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, Ovarian Epithelial Cancer, Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor, Pancreatic Cancer, Paraproteinemias, Purpura, Parathyroid Cancer, Penile Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Primary Central Nervous System Lymphoma, Primary Liver Cancer, Prostate Cancer, Rectal Cancer, Renal Cell Cancer, Renal Pelvis and Ureter Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcoidosis

Sarcomas, Sezary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Neck Cancer, Stomach Cancer, Supratentorial Primitive Neuroectodermal and Pineal Tumors, T-Cell Lymphoma, Testicular Cancer, Thymoma, Thyroid Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Transitional Renal Pelvis and Ureter Cancer, Trophoblastic Tumors, Ureter and Renal Pelvis Cell Cancer, Urethral Cancer, Uterine Cancer, Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma, Vulvar Cancer, Waldenstrom's Macroglobulinemia, Wilms' Tumor, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[0915] In another preferred embodiment, polynucleotides or polypeptides, or agonists or antagonists of the present invention are used to diagnose, prognose, prevent, and/or treat premalignant conditions and to prevent progression to a neoplastic or malignant state, including but not limited to those disorders described above. Such uses are indicated in conditions known or suspected of preceding progression to neoplasia or cancer, in particular, where non-neoplastic cell growth consisting of hyperplasia, metaplasia, or most particularly, dysplasia has occurred (for review of such abnormal growth conditions, see Robbins and Angell, 1976, Basic Pathology, 2d Ed., W. B. Saunders Co., Philadelphia, pp. 68-79.)

[0916] Hyperplasia is a form of controlled cell proliferation, involving an increase in cell number in a tissue or organ, without significant alteration in structure or function. Hyperplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, angiofollicular mediastinal lymph node hyperplasia, angiolympoid hyperplasia with eosinophilia, atypical melanocytic hyperplasia, basal cell hyperplasia, benign giant lymph node hyperplasia, cementum hyperplasia, congenital adrenal hyperplasia, congenital sebaceous hyperplasia, cystic hyperplasia, cystic hyperplasia of the breast, denture hyperplasia, ductal hyperplasia, endometrial hyperplasia, fibromuscular hyperplasia, focal epithelial hyperplasia, gingival hyperplasia, inflammatory fibrous hyperplasia, inflammatory papillary hyperplasia, intravascular papillary endothelial hyperplasia, nodular hyperplasia of prostate, nodular regenerative hyperplasia, pseudoepitheliomatous hyperplasia, senile sebaceous hyperplasia, and verrucous hyperplasia.

[0917] Metaplasia is a form of controlled cell growth in which one type of adult or fully differentiated cell substitutes for another type of adult cell. Metaplastic disorders which can be diagnosed, prognosis, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, agnogenic myeloid metaplasia, apocrine metaplasia, atypical metaplasia, autoparenchymatous metaplasia, connective tissue metaplasia, epithelial metaplasia, intestinal metaplasia, metaplastic anemia, metaplastic ossification, metaplastic polyps, myeloid metaplasia, primary myeloid metaplasia, secondary myeloid metaplasia, squamous metaplasia, squamous metaplasia of amnion, and symptomatic myeloid metaplasia.

[0918] Dysplasia is frequently a forerunner of cancer, and is found mainly in the epithelia; it is the most disorderly form of non-neoplastic cell growth, involving a loss in individual cell uniformity and in the architectural orientation of cells. Dysplastic cells often have abnormally large, deeply stained nuclei, and exhibit pleomorphism. Dysplasia characteristically occurs where there exists chronic irritation or inflammation. Dysplastic disorders which can be diagnosed, prognosis, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, anhidrotic ectodermal dysplasia, anterofacial dysplasia, asphyxiating thoracic dysplasia, atriodigital dysplasia, bronchopulmonary dysplasia, cerebral dysplasia, cervical dysplasia, chondroectodermal dysplasia, cleidocranial dysplasia, congenital ectodermal dysplasia, craniodiaphysial dysplasia, craniocarpotarsal dysplasia, craniometaphysial dysplasia, dentin dysplasia, diaphysial dysplasia, ectodermal dysplasia, enamel dysplasia, encephalo-ophthalmic dysplasia, dysplasia epiphysialis hemimelia, dysplasia epiphysialis multiplex, dysplasia epiphysialis punctata, epithelial dysplasia, faciogitogenital dysplasia, familial fibrous dysplasia of jaws, familial white folded dysplasia, fibromuscular dysplasia, fibrous dysplasia of bone, florid osseous dysplasia, hereditary renal-retinal dysplasia, hidrotic ectodermal dysplasia, hypohidrotic ectodermal dysplasia, lymphopenic thymic dysplasia, mammary dysplasia, mandibulofacial dysplasia, metaphysial dysplasia, Mondini dysplasia, monostotic fibrous dysplasia, mucoepithelial dysplasia, multiple epiphysial dysplasia, oculoauriculovertebral dysplasia, oculodentodigital dysplasia, oculovertebral dysplasia, odontogenic dysplasia, ophthalmomandibulomelic dysplasia, periapical cemental dysplasia, polyostotic fibrous

dysplasia, pseudoachondroplastic spondyloepiphysial dysplasia, retinal dysplasia, septo-optic dysplasia, spondyloepiphysial dysplasia, and ventriculoradial dysplasia.

[0919] Additional pre-neoplastic disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention (including polynucleotides, polypeptides, agonists or antagonists) include, but are not limited to, benign dysproliferative disorders (e.g., benign tumors, fibrocystic conditions, tissue hypertrophy, intestinal polyps, colon polyps, and esophageal dysplasia), leukoplakia, keratoses, Bowen's disease, Farmer's Skin, solar cheilitis, and solar keratosis.

[0920] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose and/or prognose disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 3, column 2 (Library Code).

[0921] In another embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat cancers and neoplasms, including, but not limited to those described herein. In a further preferred embodiment, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention conjugated to a toxin or a radioactive isotope, as described herein, may be used to treat acute myelogenous leukemia.

[0922] Additionally, polynucleotides, polypeptides, and/or agonists or antagonists of the invention may affect apoptosis, and therefore, would be useful in treating a number of diseases associated with increased cell survival or the inhibition of apoptosis. For example, diseases associated with increased cell survival or the inhibition of apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders such as, multiple sclerosis,

Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[0923] In preferred embodiments, polynucleotides, polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

[0924] Additional diseases or conditions associated with increased cell survival that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endothelirosarcoma, lymphangiosarcoma, lymphangioendothelirosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, angioblastoma, acoustic neuroma, oligodendrogioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0925] Diseases associated with increased apoptosis that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, retinitis pigmentosa, cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

[0926] Hyperproliferative diseases and/or disorders that could be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention, include, but are not limited to, neoplasms located in the liver, abdomen, bone, breast, digestive system, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous system (central and peripheral), lymphatic system, pelvis, skin, soft tissue, spleen, thorax, and urogenital tract.

[0927] Similarly, other hyperproliferative disorders can also be diagnosed, prognosed, prevented, and/or treated by polynucleotides, polypeptides, and/or agonists or antagonists of the invention. Examples of such hyperproliferative disorders include, but are not limited to: hypergammaglobulinemia, lymphoproliferative disorders, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

[0928] Another preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or protein fusions or fragments thereof.

[0929] Thus, the present invention provides a method for treating cell proliferative disorders by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

[0930] Another embodiment of the present invention provides a method of treating cell-proliferative disorders in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the poynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference). In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule, chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

[0931] Polynucleotides of the present invention may be useful in repressing expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the normal function of the protein.

[0932] For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any other method described throughout the specification. The polynucleotide of the present invention may

be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

[0933] The polynucleotides of the present invention may be delivered directly to cell proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

[0934] By "cell proliferative disease" is meant any human or animal disease or disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

[0935] Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

[0936] The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a mammalian, preferably human, patient for treating one or more of the described disorders. Methods for producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

[0937] A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

[0938] In particular, the antibodies, fragments and derivatives of the present invention are useful for treating a subject having or developing cell proliferative and/or differentiation disorders as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

[0939] The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

[0940] It is preferred to use high affinity and/or potent *in vivo* inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or Kd less than 5×10^{-6} M, 10^{-6} M, 5×10^{-7} M, 10^{-7} M, 5×10^{-8} M, 10^{-8} M, 5×10^{-9} M, 10^{-9} M, 5×10^{-10} M, 10^{-10} M, 5×10^{-11} M, 10^{-11} M, 5×10^{-12} M, 10^{-12} M, 5×10^{-13} M, 10^{-13} M, 5×10^{-14} M, 10^{-14} M, 5×10^{-15} M, and 10^{-15} M.

[0941] Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al., Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

[0942] Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference). Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, anti-inflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React.;20(1):3-15 (1998), which are all hereby incorporated by reference).

[0943] Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such

therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

[0944] In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

[0945] Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

Renal Disorders

[0946] Polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose disorders of the renal system. Renal disorders which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, kidney failure, nephritis, blood vessel disorders of kidney, metabolic and congenital kidney disorders, urinary disorders of the kidney, autoimmune disorders, sclerosis and necrosis, electrolyte imbalance, and kidney cancers.

[0947] Kidney diseases which can be diagnosed, prognosed, prevented, and/or treated with compositions of the invention include, but are not limited to, acute kidney failure, chronic kidney failure, atherosclerotic renal failure, end-stage renal disease, inflammatory diseases of the kidney (e.g., acute glomerulonephritis, postinfectious glomerulonephritis, rapidly progressive glomerulonephritis, nephrotic syndrome, membranous glomerulonephritis, familial nephrotic syndrome, membranoproliferative glomerulonephritis I and II, mesangial proliferative glomerulonephritis, chronic

glomerulonephritis, acute tubulointerstitial nephritis, chronic tubulointerstitial nephritis, acute post-streptococcal glomerulonephritis (PSGN), pyelonephritis, lupus nephritis, chronic nephritis, interstitial nephritis, and post-streptococcal glomerulonephritis), blood vessel disorders of the kidneys (e.g., kidney infarction, atheroembolic kidney disease, cortical necrosis, malignant nephrosclerosis, renal vein thrombosis, renal underperfusion, renal retinopathy, renal ischemia-reperfusion, renal artery embolism, and renal artery stenosis), and kidney disorders resulting from urinary tract disease (e.g., pyelonephritis, hydronephrosis, urolithiasis (renal lithiasis, nephrolithiasis), reflux nephropathy, urinary tract infections, urinary retention, and acute or chronic unilateral obstructive uropathy.)

[0948] In addition, compositions of the invention can be used to diagnose, prognose, prevent, and/or treat metabolic and congenital disorders of the kidney (e.g., uremia, renal amyloidosis, renal osteodystrophy, renal tubular acidosis, renal glycosuria, nephrogenic diabetes insipidus, cystinuria, Fanconi's syndrome, renal fibrocystic osteosis (renal rickets), Hartnup disease, Bartter's syndrome, Liddle's syndrome, polycystic kidney disease, medullary cystic disease, medullary sponge kidney, Alport's syndrome, nail-patella syndrome, congenital nephrotic syndrome, CRUSH syndrome, horseshoe kidney, diabetic nephropathy, nephrogenic diabetes insipidus, analgesic nephropathy, kidney stones, and membranous nephropathy), and autoimmune disorders of the kidney (e.g., systemic lupus erythematosus (SLE), Goodpasture syndrome, IgA nephropathy, and IgM mesangial proliferative glomerulonephritis).

[0949] Compositions of the invention can also be used to diagnose, prognose, prevent, and/or treat sclerotic or necrotic disorders of the kidney (e.g., glomerulosclerosis, diabetic nephropathy, focal segmental glomerulosclerosis (FSGS), necrotizing glomerulonephritis, and renal papillary necrosis), cancers of the kidney (e.g., nephroma, hypernephroma, nephroblastoma, renal cell cancer, transitional cell cancer, renal adenocarcinoma, squamous cell cancer, and Wilm's tumor), and electrolyte imbalances (e.g., nephrocalcinosis, pyuria, edema, hydronephritis, proteinuria, hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypophosphatemia, and hyperphosphatemia).

[0950] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biostatic injectors, particle accelerators,

gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

Cardiovascular Disorders

[0951] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose cardiovascular disorders, including, but not limited to, peripheral artery disease, such as limb ischemia.

[0952] Cardiovascular disorders include, but are not limited to, cardiovascular abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include, but are not limited to, aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome, levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogy of Fallot, ventricular heart septal defects.

[0953] Cardiovascular disorders also include, but are not limited to, heart disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous), pneumopericardium, postpericardiectomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

[0954] Arrhythmias include, but are not limited to, sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

[0955] Heart valve diseases include, but are not limited to, aortic valve insufficiency, aortic valve stenosis, hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

[0956] Myocardial diseases include, but are not limited to, alcoholic cardiomyopathy, congestive cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

[0957] Myocardial ischemias include, but are not limited to, coronary disease, such as angina pectoris, coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

[0958] Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Lerche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular disorders, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, atacia

telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

[0959] Aneurysms include, but are not limited to, dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

[0960] Arterial occlusive diseases include, but are not limited to, arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

[0961] Cerebrovascular disorders include, but are not limited to, carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia (including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

[0962] Embolisms include, but are not limited to, air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and thromboembolisms. Thrombosis include, but are not limited to, coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

[0963] Ischemic disorders include, but are not limited to, cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion injuries, and peripheral limb ischemia. Vasculitis includes, but is not limited to, aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

[0964] Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, ballistic injectors, particle accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral

or suppositorial solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides may be administered as part of a Therapeutic, described in more detail below. Methods of delivering polynucleotides are described in more detail herein.

Respiratory Disorders

[0965] Polynucleotides or polypeptides, or agonists or antagonists of the present invention may be used to treat, prevent, diagnose, and/or prognose diseases and/or disorders of the respiratory system.

[0966] Diseases and disorders of the respiratory system include, but are not limited to, nasal vestibulitis, nonallergic rhinitis (e.g., acute rhinitis, chronic rhinitis, atrophic rhinitis, vasomotor rhinitis), nasal polyps, and sinusitis, juvenile angiofibromas, cancer of the nose and juvenile papillomas, vocal cord polyps, nodules (singer's nodules), contact ulcers, vocal cord paralysis, laryngoceles, pharyngitis (e.g., viral and bacterial), tonsillitis, tonsillar cellulitis, parapharyngeal abscess, laryngitis, laryngceles, and throat cancers (e.g., cancer of the nasopharynx, tonsil cancer, larynx cancer), lung cancer (e.g., squamous cell carcinoma, small cell (oat cell) carcinoma, large cell carcinoma, and adenocarcinoma), allergic disorders (eosinophilic pneumonia, hypersensitivity pneumonitis (e.g., extrinsic allergic alveolitis, allergic interstitial pneumonitis, organic dust pneumoconiosis, allergic bronchopulmonary aspergillosis, asthma, Wegener's granulomatosis (granulomatous vasculitis), Goodpasture's syndrome)), pneumonia (e.g., bacterial pneumonia (e.g., *Streptococcus pneumoniae* (pneumococcal pneumonia), *Staphylococcus aureus* (staphylococcal pneumonia), Gram-negative bacterial pneumonia (caused by, e.g., *Klebsiella* and *Pseudomas* spp.), *Mycoplasma pneumoniae* pneumonia, *Hemophilus influenzae* pneumonia, *Legionella pneumophila* (Legionnaires' disease), and *Chlamydia psittaci* (Psittacosis)), and viral pneumonia (e.g., influenza, chickenpox (varicella).

[0967] Additional diseases and disorders of the respiratory system include, but are not limited to bronchiolitis, polio (poliomyelitis), croup, respiratory syncytial viral infection, mumps, erythema infectiosum (fifth disease), roseola infantum, progressive rubella panencephalitis, german measles, and subacute sclerosing panencephalitis), fungal pneumonia (e.g., Histoplasmosis, Coccidioidomycosis, Blastomycosis, fungal infections in

people with severely suppressed immune systems (e.g., cryptococcosis, caused by *Cryptococcus neoformans*; aspergillosis, caused by *Aspergillus spp.*; candidiasis, caused by *Candida*; and mucormycosis)), *Pneumocystis carinii* (pneumocystis pneumonia), atypical pneumonias (e.g., *Mycoplasma* and *Chlamydia spp.*), opportunistic infection pneumonia, nosocomial pneumonia, chemical pneumonitis, and aspiration pneumonia, pleural disorders (e.g., pleurisy, pleural effusion, and pneumothorax (e.g., simple spontaneous pneumothorax, complicated spontaneous pneumothorax, tension pneumothorax)), obstructive airway diseases (e.g., asthma, chronic obstructive pulmonary disease (COPD), emphysema, chronic or acute bronchitis), occupational lung diseases (e.g., silicosis, black lung (coal workers' pneumoconiosis), asbestososis, berylliosis, occupational asthma, byssinosis, and benign pneumoconioses), Infiltrative Lung Disease (e.g., pulmonary fibrosis (e.g., fibrosing alveolitis, usual interstitial pneumonia), idiopathic pulmonary fibrosis, desquamative interstitial pneumonia, lymphoid interstitial pneumonia, histiocytosis X (e.g., Letterer-Siwe disease, Hand-Schüller-Christian disease, eosinophilic granuloma), idiopathic pulmonary hemosiderosis, sarcoidosis and pulmonary alveolar proteinosis), Acute respiratory distress syndrome (also called, e.g., adult respiratory distress syndrome), edema, pulmonary embolism, bronchitis (e.g., viral, bacterial), bronchiectasis, atelectasis, lung abscess (caused by, e.g., *Staphylococcus aureus* or *Legionella pneumophila*), and cystic fibrosis.

Anti-Angiogenesis Activity

[0968] The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of

eye disorders, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995); Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, Advances in Cancer Research, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

[0969] The present invention provides for treatment of diseases or disorders associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, *Medicine*, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating an angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat a cancer or tumor. Cancers which may be treated with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma; Kaposi's sarcoma; leiomyosarcoma; non- small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

[0970] Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists

may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.

[0971] Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating other disorders, besides cancers, which involve angiogenesis. These disorders include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrobulbar fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiomyoma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

[0972] For example, within one aspect of the present invention methods are provided for treating hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

[0973] Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists of the invention are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted above, the present invention also provides methods for treating neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrobulbar fibroplasia and macular degeneration.

[0974] Moreover, Ocular disorders associated with neovascularization which can be treated with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrobulbar fibroplasia, uveitis, retinopathy of prematurity macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalm.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalm.* 22:291-312 (1978).

[0975] Thus, within one aspect of the present invention methods are provided for treating neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of disorders can result in corneal neovascularization, including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

[0976] Within particularly preferred embodiments of the invention, may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a

high probability of inducing an angiogenic response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

[0977] Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance. The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

[0978] Within another aspect of the present invention, methods are provided for treating neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

[0979] Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist

and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photoagulation.

[0980] Within another aspect of the present invention, methods are provided for treating retrothalic fibroplasia, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreous injection and/or via intraocular implants.

[0981] Additionally, disorders which can be treated with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiobroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome, pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

[0982] Moreover, disorders and/or states, which can be treated, prevented, diagnosed, and/or prognosed with the polynucleotides, polypeptides, agonists and/or agonists of the invention include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrothalic fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations, hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiobroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence such as cat scratch disease (*Rochele minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

[0983] In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and fertilization have occurred, thus providing an effective method of birth control, possibly a "morning

after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

[0984] Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

[0985] Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti-angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized during abdominal cancer resection surgery (e.g., subsequent to colon resection) in order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

[0986] Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

[0987] Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of

tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

[0988] The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

[0989] Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[0990] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetone and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[0991] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdanyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdanyl complexes include, for example, molybdanyl acetylacetone. Other suitable

tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[0992] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

Diseases at the Cellular Level

[0993] Diseases associated with increased cell survival or the inhibition of apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as antagonists or agonists of the present invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's

disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection.

[0994] In preferred embodiments, polynucleotides, polypeptides, and/or antagonists of the invention are used to inhibit growth, progression, and/or metastasis of cancers, in particular those listed above.

[0995] Additional diseases or conditions associated with increased cell survival that could be treated or detected by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangi endotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendrogioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

[0996] Diseases associated with increased apoptosis that could be treated, prevented, diagnosed, and/or prognosed using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, include, but are not limited to, AIDS;

neurodegenerative disorders (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune disorders (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestasis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic shock, cachexia and anorexia.

Wound Healing and Epithelial Cell Proliferation

[0997] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing, and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and antimetabolites. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote dermal reestablishment subsequent to dermal loss

[0998] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to increase the adherence of skin grafts to a wound bed and to stimulate re-epithelialization from the wound bed. The following are types of grafts that polynucleotides or polypeptides, agonists or antagonists of the present invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts,

autodermic graft, autoepidermic grafts, avacular grafts, Blair-Brown grafts, bone graft, brephoplasty grafts, cutis graft, delayed graft, dermic graft, epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omenpal graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, can be used to promote skin strength and to improve the appearance of aged skin.

[0999] It is believed that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. Polynucleotides or polypeptides, agonists or antagonists of the present invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

[1000] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may have a cytoprotective effect on the small intestine mucosa. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

[1001] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. Polynucleotides or polypeptides, as well as agonists or

antagonists of the present invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with polynucleotides or polypeptides, agonists or antagonists of the present invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to treat diseases associate with the under expression.

[1002] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to prevent and heal damage to the lungs due to various pathological states. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of aveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated using polynucleotides or polypeptides, agonists or antagonists of the present invention. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

[1003] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic

substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins known in the art).

[1004] In addition, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

Neural Activity and Neurological Diseases

[1005] The polynucleotides, polypeptides and agonists or antagonists of the invention may be used for the diagnosis and/or treatment of diseases, disorders, damage or injury of the brain and/or nervous system. Nervous system disorders that can be treated with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not limited to, nervous system injuries, and diseases or disorders which result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated in a patient (including human and non-human mammalian patients) according to the methods of the invention, include but are not limited to, the following lesions of either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, or syphilis; (5) degenerative lesions, in

which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to, degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6) lesions associated with nutritional diseases or disorders, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including, but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

[1006] In one embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of hypoxia. In a further preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat or prevent neural cell injury associated with cerebral hypoxia. In one non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention, are used to treat or prevent neural cell injury associated with cerebral ischemia. In another non-exclusive aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with cerebral infarction.

[1007] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a stroke. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a stroke.

[1008] In another preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent neural cell injury associated with a heart attack. In a specific embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat or prevent cerebral neural cell injury associated with a heart attack.

[1009] The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture either in the presence or absence of hypoxia or hypoxic conditions; (2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, e.g., choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, in Zhang *et al.*, *Proc Natl Acad Sci USA* 97:3637-42 (2000) or in Arakawa *et al.*, *J. Neurosci.*, 10:3507-15 (1990); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk *et al.*, *Exp. Neurol.*, 70:65-82 (1980), or Brown *et al.*, *Ann. Rev. Neurosci.*, 4:17-42 (1981); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, e.g., weakness, motor neuron conduction velocity, or functional disability.

[1010] In specific embodiments, motor neuron disorders that may be treated according to the invention include, but are not limited to, disorders such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as disorders that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar

palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

[1011] Further, polypeptides or polynucleotides of the invention may play a role in neuronal survival; synapse formation; conductance; neural differentiation, etc. Thus, compositions of the invention (including polynucleotides, polypeptides, and agonists or antagonists) may be used to diagnose and/or treat or prevent diseases or disorders associated with these roles, including, but not limited to, learning and/or cognition disorders. The compositions of the invention may also be useful in the treatment or prevention of neurodegenerative disease states and/or behavioural disorders. Such neurodegenerative disease states and/or behavioral disorders include, but are not limited to, Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Tourette Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder, panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors, including disorders in feeding, sleep patterns, balance, and perception. In addition, compositions of the invention may also play a role in the treatment, prevention and/or detection of developmental disorders associated with the developing embryo, or sexually-linked disorders.

[1012] Additionally, polypeptides, polynucleotides and/or agonists or antagonists of the invention, may be useful in protecting neural cells from diseases, damage, disorders, or injury, associated with cerebrovascular disorders including, but not limited to, carotid artery diseases (e.g., carotid artery thrombosis, carotid stenosis, or Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis (e.g., carotid artery thrombosis, sinus thrombosis, or Wallenberg's Syndrome), cerebral hemorrhage (e.g., epidural or subdural hematoma, or subarachnoid hemorrhage), cerebral infarction, cerebral ischemia (e.g., transient cerebral ischemia, Subclavian Steal Syndrome, or vertebrobasilar insufficiency), vascular dementia (e.g., multi-infarct), leukomalacia, periventricular, and vascular headache (e.g., cluster headache or migraines).

[1013] In accordance with yet a further aspect of the present invention, there is provided a process for utilizing polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, for therapeutic purposes, for example, to stimulate neurological cell proliferation and/or differentiation. Therefore, polynucleotides,

polypeptides, agonists and/or antagonists of the invention may be used to treat and/or detect neurologic diseases. Moreover, polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used as a marker or detector of a particular nervous system disease or disorder.

[1014] Examples of neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include brain diseases, such as metabolic brain diseases which includes phenylketonuria such as maternal phenylketonuria, pyruvate carboxylase deficiency, pyruvate dehydrogenase complex deficiency, Wernicke's Encephalopathy, brain edema, brain neoplasms such as cerebellar neoplasms which include infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms, supratentorial neoplasms, canavan disease, cerebellar diseases such as cerebellar ataxia which include spinocerebellar degeneration such as ataxia telangiectasia, cerebellar dysynergia, Friederich's Ataxia, Machado-Joseph Disease, olivopontocerebellar atrophy, cerebellar neoplasms such as infratentorial neoplasms, diffuse cerebral sclerosis such as encephalitis periaxialis, globoid cell leukodystrophy, metachromatic leukodystrophy and subacute sclerosing panencephalitis.

[1015] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include cerebrovascular disorders (such as carotid artery diseases which include carotid artery thrombosis, carotid stenosis and Moyamoya Disease), cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformations, cerebral artery diseases, cerebral embolism and thrombosis such as carotid artery thrombosis, sinus thrombosis and Wallenberg's Syndrome, cerebral hemorrhage such as epidural hematoma, subdural hematoma and subarachnoid hemorrhage, cerebral infarction, cerebral ischemia such as transient cerebral ischemia, Subclavian Steal Syndrome and vertebrobasilar insufficiency, vascular dementia such as multi-infarct dementia, periventricular leukomalacia, vascular headache such as cluster headache and migraine.

[1016] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include dementia such as AIDS Dementia Complex, presenile dementia such as

Alzheimer's Disease and Creutzfeldt-Jakob Syndrome, senile dementia such as Alzheimer's Disease and progressive supranuclear palsy, vascular dementia such as multi-infarct dementia, encephalitis which include encephalitis periaxialis, viral encephalitis such as epidemic encephalitis, Japanese Encephalitis, St. Louis Encephalitis, tick-borne encephalitis and West Nile Fever, acute disseminated encephalomyelitis, meningoencephalitis such as uveomeningoencephalitic syndrome, Postencephalitic Parkinson Disease and subacute sclerosing panencephalitis, encephalomalacia such as periventricular leukomalacia, epilepsy such as generalized epilepsy which includes infantile spasms, absence epilepsy, myoclonic epilepsy which includes MERRF Syndrome, tonic-clonic epilepsy, partial epilepsy such as complex partial epilepsy, frontal lobe epilepsy and temporal lobe epilepsy, post-traumatic epilepsy, status epilepticus such as Epilepsia Partialis Continua, and Hallervorden-Spatz Syndrome.

[1017] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hydrocephalus such as Dandy-Walker Syndrome and normal pressure hydrocephalus, hypothalamic diseases such as hypothalamic neoplasms, cerebral malaria, narcolepsy which includes cataplexy, bulbar poliomyelitis, cerebri pseudotumor, Rett Syndrome, Reye's Syndrome, thalamic diseases, cerebral toxoplasmosis, intracranial tuberculoma and Zellweger Syndrome, central nervous system infections such as AIDS Dementia Complex, Brain Abscess, subdural empyema, encephalomyelitis such as Equine Encephalomyelitis, Venezuelan Equine Encephalomyelitis, Necrotizing Hemorrhagic Encephalomyelitis, Visna, and cerebral malaria.

[1018] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include meningitis such as arachnoiditis, aseptic meningitis such as viral meningitis which includes lymphocytic choriomeningitis, Bacterial meningitis which includes Haemophilus Meningitis, Listeria Meningitis, Meningococcal Meningitis such as Waterhouse-Friderichsen Syndrome, Pneumococcal Meningitis and meningeal tuberculosis, fungal meningitis such as Cryptococcal Meningitis, subdural effusion, meningoencephalitis such as uveomeningoencephalitic syndrome, myelitis such as transverse myelitis, neurosyphilis such as tabes dorsalis, poliomyelitis which includes bulbar poliomyelitis and postpoliomyelitis syndrome, prion diseases (such as Creutzfeldt-

Jakob Syndrome, Bovine Spongiform Encephalopathy, Gerstmann-Straussler Syndrome, Kuru, Scrapie), and cerebral toxoplasmosis.

[1019] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include central nervous system neoplasms such as brain neoplasms that include cerebellar neoplasms such as infratentorial neoplasms, cerebral ventricle neoplasms such as choroid plexus neoplasms, hypothalamic neoplasms and supratentorial neoplasms, meningeal neoplasms, spinal cord neoplasms which include epidural neoplasms, demyelinating diseases such as Canavan Diseases, diffuse cerebral sceloris which includes adrenoleukodystrophy, encephalitis periaxialis, globoid cell leukodystrophy, diffuse cerebral sclerosis such as metachromatic leukodystrophy, allergic encephalomyelitis, necrotizing hemorrhagic encephalomyelitis, progressive multifocal leukoencephalopathy, multiple sclerosis, central pontine myelinolysis, transverse myelitis, neuromyelitis optica, Scrapie, Swayback, Chronic Fatigue Syndrome, Visna, High Pressure Nervous Syndrome, Meningism, spinal cord diseases such as amyotonia congenita, amyotrophic lateral sclerosis, spinal muscular atrophy such as Werdnig-Hoffmann Disease, spinal cord compression, spinal cord neoplasms such as epidural neoplasms, syringomyelia, Tabes Dorsalis, Stiff-Man Syndrome, mental retardation such as Angelman Syndrome, Cri-du-Chat Syndrome, De Lange's Syndrome, Down Syndrome, Gangliosidoses such as gangliosidoses G(M1), Sandhoff Disease, Tay-Sachs Disease, Hartnup Disease, homocystinuria, Laurence-Moon-Biedl Syndrome, Lesch-Nyhan Syndrome, Maple Syrup Urine Disease, mucolipidosis such as fucosidosis, neuronal ceroid-lipofuscinosis, oculocerebrorenal syndrome, phenylketonuria such as maternal phenylketonuria, Prader-Willi Syndrome, Rett Syndrome, Rubinstein-Taybi Syndrome, Tuberous Sclerosis, WAGR Syndrome, nervous system abnormalities such as holoprosencephaly, neural tube defects such as anencephaly which includes hydranencephaly, Arnold-Chairi Deformity, encephalocele, meningocele, meningomyelocele, spinal dysraphism such as spina bifida cystica and spina bifida occulta.

[1020] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include hereditary motor and sensory neuropathies which include Charcot-Marie Disease, Hereditary optic atrophy, Refsum's Disease, hereditary spastic paraplegia, Werdnig-

Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies such as Congenital Analgesia and Familial Dysautonomia, Neurologic manifestations (such as agnosia that include Gerstmann's Syndrome, Amnesia such as retrograde amnesia, apraxia, neurogenic bladder, cataplexy, communicative disorders such as hearing disorders that includes deafness, partial hearing loss, loudness recruitment and tinnitus, language disorders such as aphasia which include agraphia, anomia, broca aphasia, and Wernicke Aphasia, Dyslexia such as Acquired Dyslexia, language development disorders, speech disorders such as aphasia which includes anomia, broca aphasia and Wernicke Aphasia, articulation disorders, communicative disorders such as speech disorders which include dysarthria, echolalia, mutism and stuttering, voice disorders such as aphonia and hoarseness, decerebrate state, delirium, fasciculation, hallucinations, meningism, movement disorders such as angelman syndrome, ataxia, athetosis, chorea, dystonia, hypokinesia, muscle hypotonia, myoclonus, tic, torticollis and tremor, muscle hypertonia such as muscle rigidity such as stiff-man syndrome, muscle spasticity, paralysis such as facial paralysis which includes Herpes Zoster Oticus, Gastroparesis, Hemiplegia, ophthalmoplegia such as diplopia, Duane's Syndrome, Horner's Syndrome, Chronic progressive external ophthalmoplegia such as Kearns Syndrome, Bulbar Paralysis, Tropical Spastic Paraparesis, Paraplegia such as Brown-Sequard Syndrome, quadriplegia, respiratory paralysis and vocal cord paralysis, paresis, phantom limb, taste disorders such as ageusia and dysgeusia, vision disorders such as amblyopia, blindness, color vision defects, diplopia, hemianopsia, scotoma and subnormal vision, sleep disorders such as hypersomnia which includes Kleine-Levin Syndrome, insomnia, and somnambulism, spasm such as trismus, unconsciousness such as coma, persistent vegetative state and syncope and vertigo, neuromuscular diseases such as amyotonia congenita, amyotrophic lateral sclerosis, Lambert-Eaton Myasthenic Syndrome, motor neuron disease, muscular atrophy such as spinal muscular atrophy, Charcot-Marie Disease and Werdnig-Hoffmann Disease, Postpoliomyelitis Syndrome, Muscular Dystrophy, Myasthenia Gravis, Myotonia Atrophica, Myotonia Confinita, Nemaline Myopathy, Familial Periodic Paralysis, Multiplex Paramyoclonus, Tropical Spastic Paraparesis and Stiff-Man Syndrome, peripheral nervous system diseases such as acrodynia, amyloid neuropathies, autonomic nervous system diseases such as Adie's Syndrome, Barre-Lieou Syndrome, Familial Dysautonomia, Horner's Syndrome, Reflex Sympathetic Dystrophy and Shy-Drager

Syndrome, Cranial Nerve Diseases such as Acoustic Nerve Diseases such as Acoustic Neuroma which includes Neurofibromatosis 2, Facial Nerve Diseases such as Facial Neuralgia, Melkersson-Rosenthal Syndrome, ocular motility disorders which includes amblyopia, nystagmus, oculomotor nerve paralysis, ophthalmoplegia such as Duane's Syndrome, Horner's Syndrome, Chronic Progressive External Ophthalmoplegia which includes Kearns Syndrome, Strabismus such as Esotropia and Exotropia, Oculomotor Nerve Paralysis, Optic Nerve Diseases such as Optic Atrophy which includes Hereditary Optic Atrophy, Optic Disk Drusen, Optic Neuritis such as Neuromyelitis Optica, Papilledema, Trigeminal Neuralgia, Vocal Cord Paralysis, Demyelinating Diseases such as Neuromyelitis Optica and Swayback, and Diabetic neuropathies such as diabetic foot.

[1021] Additional neurologic diseases which can be treated or detected with polynucleotides, polypeptides, agonists, and/or antagonists of the present invention include nerve compression syndromes such as carpal tunnel syndrome, tarsal tunnel syndrome, thoracic outlet syndrome such as cervical rib syndrome, ulnar nerve compression syndrome, neuralgia such as causalgia, cervico-brachial neuralgia, facial neuralgia and trigeminal neuralgia, neuritis such as experimental allergic neuritis, optic neuritis, polyneuritis, polyradiculoneuritis and radiculitis such as polyradiculitis, hereditary motor and sensory neuropathies such as Charcot-Marie Disease, Hereditary Optic Atrophy, Refsum's Disease, Hereditary Spastic Paraparesis and Werdnig-Hoffmann Disease, Hereditary Sensory and Autonomic Neuropathies which include Congenital Analgesia and Familial Dysautonomia, POEMS Syndrome, Sciatica, Gustatory Sweating and Tetany).

Endocrine Disorders

[1022] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognosis disorders and/or diseases related to hormone imbalance, and/or disorders or diseases of the endocrine system.

[1023] Hormones secreted by the glands of the endocrine system control physical growth, sexual function, metabolism, and other functions. Disorders may be classified in two ways: disturbances in the production of hormones, and the inability of tissues to

respond to hormones. The etiology of these hormone imbalance or endocrine system diseases, disorders or conditions may be genetic, somatic, such as cancer and some autoimmune diseases, acquired (e.g., by chemotherapy, injury or toxins), or infectious. Moreover, polynucleotides, polypeptides, antibodies, and/or agonists or antagonists of the present invention can be used as a marker or detector of a particular disease or disorder related to the endocrine system and/or hormone imbalance.

[1000] Endocrine system and/or hormone imbalance and/or diseases encompass disorders of uterine motility including, but not limited to: complications with pregnancy and labor (e.g., pre-term labor, post-term pregnancy, spontaneous abortion, and slow or stopped labor); and disorders and/or diseases of the menstrual cycle (e.g., dysmenorrhea and endometriosis).

[1001] Endocrine system and/or hormone imbalance disorders and/or diseases include disorders and/or diseases of the pancreas, such as, for example, diabetes mellitus, diabetes insipidus, congenital pancreatic agenesis, pheochromocytoma—islet cell tumor syndrome; disorders and/or diseases of the adrenal glands such as, for example, Addison's Disease, corticosteroid deficiency, virilizing disease, hirsutism, Cushing's Syndrome, hyperaldosteronism, pheochromocytoma; disorders and/or diseases of the pituitary gland, such as, for example, hyperpituitarism, hypopituitarism, pituitary dwarfism, pituitary adenoma, panhypopituitarism, acromegaly, gigantism; disorders and/or diseases of the thyroid, including but not limited to, hyperthyroidism, hypothyroidism, Plummer's disease, Graves' disease (toxic diffuse goiter), toxic nodular goiter, thyroiditis (Hashimoto's thyroiditis, subacute granulomatous thyroiditis, and silent lymphocytic thyroiditis), Pendred's syndrome, myxedema, cretinism, thyrotoxicosis, thyroid hormone coupling defect, thymic aplasia, Hurthle cell tumours of the thyroid, thyroid cancer, thyroid carcinoma, Medullary thyroid carcinoma; disorders and/or diseases of the parathyroid, such as, for example, hyperparathyroidism, hypoparathyroidism; disorders and/or diseases of the hypothalamus.

[1002] In specific embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists of those polypeptides (including antibodies) as well as fragments and variants of those polynucleotides, polypeptides, agonists and antagonists, may be used to diagnose, prognose, treat, prevent, or ameliorate

diseases and disorders associated with aberrant glucose metabolism or glucose uptake into cells.

[1003] In a specific embodiment, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists and/or antagonists thereof may be used to diagnose, prognose, treat, prevent, and/or ameliorate type I diabetes mellitus (insulin dependent diabetes mellitus, IDDM).

[1004] In another embodiment, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists and/or antagonists thereof may be used to diagnose, prognose, treat, prevent, and/or ameliorate type II diabetes mellitus (insulin resistant diabetes mellitus).

[1005] Additionally, in other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or antagonists thereof (especially neutralizing or antagonistic antibodies) may be used to diagnose, prognose, treat, prevent, or ameliorate conditions associated with (type I or type II) diabetes mellitus, including, but not limited to, diabetic ketoacidosis, diabetic coma, nonketotic hyperglycemic-hyperosmolar coma, seizures, mental confusion, drowsiness, cardiovascular disease (e.g., heart disease, atherosclerosis, microvascular disease, hypertension, stroke, and other diseases and disorders as described in the "Cardiovascular Disorders" section), dyslipidemia, kidney disease (e.g., renal failure, nephropathy other diseases and disorders as described in the "Renal Disorders" section), nerve damage, neuropathy, vision impairment (e.g., diabetic retinopathy and blindness), ulcers and impaired wound healing, infections (e.g., infectious diseases and disorders as described in the "Infectious Diseases" section, especially of the urinary tract and skin), carpal tunnel syndrome and Dupuytren's contracture.

[1006] In other embodiments, the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to regulate the animal's weight. In specific embodiments the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most preferably a human, in order to control the animal's weight by modulating a biochemical pathway involving insulin. In still other embodiments the polynucleotides and/or polypeptides corresponding to this gene and/or agonists or antagonists thereof are administered to an animal, preferably a mammal, and most

preferably a human, in order to control the animal's weight by modulating a biochemical pathway involving insulin-like growth factor.

[1007] In addition, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases of the testes or ovaries, including cancer. Other disorders and/or diseases of the testes or ovaries further include, for example, ovarian cancer, polycystic ovary syndrome, Klinefelter's syndrome, vanishing testes syndrome (bilateral anorchia), congenital absence of Leydig's cells, cryptorchidism, Noonan's syndrome, myotonic dystrophy, capillary haemangioma of the testis (benign), neoplasias of the testis and neo-testis.

[1008] Moreover, endocrine system and/or hormone imbalance disorders and/or diseases may also include disorders and/or diseases such as, for example, polyglandular deficiency syndromes, pheochromocytoma, neuroblastoma, multiple Endocrine neoplasia, and disorders and/or cancers of endocrine tissues.

[1009] In another embodiment, a polypeptide of the invention, or polynucleotides, antibodies, agonists, or antagonists corresponding to that polypeptide, may be used to diagnose, prognose, prevent, and/or treat endocrine diseases and/or disorders associated with the tissue(s) in which the polypeptide of the invention is expressed, including one, two, three, four, five, or more tissues disclosed in Table 3, column 2 (Library Code).

Reproductive System Disorders

[1010] The polynucleotides or polypeptides, or agonists or antagonists of the invention may be used for the diagnosis, treatment, or prevention of diseases and/or disorders of the reproductive system. Reproductive system disorders that can be treated by the compositions of the invention, include, but are not limited to, reproductive system injuries, infections, neoplastic disorders, congenital defects, and diseases or disorders which result in infertility, complications with pregnancy, labor, or parturition, and postpartum difficulties.

[1011] Reproductive system disorders and/or diseases include diseases and/or disorders of the testes, including testicular atrophy, testicular feminization, cryptorchism (unilateral and bilateral), anorchia, ectopic testis, epididymitis and orchitis (typically resulting from infections such as, for example, gonorrhea, mumps, tuberculosis, and syphilis), testicular

torsion, vasitis nodosa, germ cell tumors (e.g., seminomas, embryonal cell carcinomas, teratocarcinomas, choriocarcinomas, yolk sac tumors, and teratomas), stromal tumors (e.g., Leydig cell tumors), hydrocele, hematocoele, varicocele, spermatocele, inguinal hernia, and disorders of sperm production (e.g., immotile cilia syndrome, aspermia, asthenozoospermia, azoospermia, oligospermia, and teratozoospermia).

[1012] Reproductive system disorders also include disorders of the prostate gland, such as acute non-bacterial prostatitis, chronic non-bacterial prostatitis, acute bacterial prostatitis, chronic bacterial prostatitis, prostatodystonia, prostatosis, granulomatous prostatitis, malacoplakia, benign prostatic hypertrophy or hyperplasia, and prostate neoplastic disorders, including adenocarcinomas, transitional cell carcinomas, ductal carcinomas, and squamous cell carcinomas.

[1013] Additionally, the compositions of the invention may be useful in the diagnosis, treatment, and/or prevention of disorders or diseases of the penis and urethra, including inflammatory disorders, such as balanoposthitis, balanitis xerotica obliterans, phimosis, paraphimosis, syphilis, herpes simplex virus, gonorrhea, non-gonococcal urethritis, chlamydia, mycoplasma, trichomonas, HIV, AIDS, Reiter's syndrome, condyloma acuminatum, condyloma latum, and pearly penile papules; urethral abnormalities, such as hypospadias, epispadias, and phimosis; premalignant lesions, including Erythroplasia of Queyrat, Bowen's disease, Bowenoid paplosis, giant condyloma of Buscke-Lowenstein, and verrucous carcinoma; penile cancers, including squamous cell carcinomas, carcinoma in situ, verrucous carcinoma, and disseminated penile carcinoma; urethral neoplastic disorders, including penile urethral carcinoma, bulbomembranous urethral carcinoma, and prostatic urethral carcinoma; and erectile disorders, such as priapism, Peyronie's disease, erectile dysfunction, and impotence.

[1014] Moreover, diseases and/or disorders of the vas deferens include vasculitis and CBAVD (congenital bilateral absence of the vas deferens); additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the seminal vesicles, including hydatid disease, congenital chloride diarrhea, and polycystic kidney disease.

[1015] Other disorders and/or diseases of the male reproductive system include, for example, Klinefelter's syndrome, Young's syndrome, premature ejaculation, diabetes

mellitus, cystic fibrosis, Kartagener's syndrome, high fever, multiple sclerosis, and gynecomastia.

[1016] Further, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases and/or disorders of the vagina and vulva, including bacterial vaginosis, candida vaginitis, herpes simplex virus, chancroid, granuloma inguinale, lymphogranuloma venereum, scabies, human papillomavirus, vaginal trauma, vulvar trauma, adenosis, chlamydia vaginitis, gonorrhea, trichomonas vaginitis, condyloma acuminatum, syphilis, molluscum contagiosum, atrophic vaginitis, Paget's disease, lichen sclerosus, lichen planus, vulvodynia, toxic shock syndrome, vaginismus, vulvovaginitis, vulvar vestibulitis, and neoplastic disorders, such as squamous cell hyperplasia, clear cell carcinoma, basal cell carcinoma, melanomas, cancer of Bartholin's gland, and vulvar intraepithelial neoplasia.

[1017] Disorders and/or diseases of the uterus include dysmenorrhea, retroverted uterus, endometriosis, fibroids, adenomyosis, anovulatory bleeding, amenorrhea, Cushing's syndrome, hydatidiform moles, Asherman's syndrome, premature menopause, precocious puberty, uterine polyps, dysfunctional uterine bleeding (e.g., due to aberrant hormonal signals), and neoplastic disorders, such as adenocarcinomas, leiomyosarcomas, and sarcomas. Additionally, the polypeptides, polynucleotides, or agonists or antagonists of the invention may be useful as a marker or detector of, as well as in the diagnosis, treatment, and/or prevention of congenital uterine abnormalities, such as bicornuate uterus, septate uterus, simple unicornuate uterus, unicornuate uterus with a noncavitory rudimentary horn, unicornuate uterus with a non-communicating cavitary rudimentary horn, unicornuate uterus with a communicating cavitary horn, arcuate uterus, utricle didelfus, and T-shaped uterus.

[1018] Ovarian diseases and/or disorders include anovulation, polycystic ovary syndrome (Stein-Leventhal syndrome), ovarian cysts, ovarian hypofunction, ovarian insensitivity to gonadotropins, ovarian overproduction of androgens, right ovarian vein syndrome, amenorrhea, hirsutism, and ovarian cancer (including, but not limited to, primary and secondary cancerous growth, Sertoli-Leydig tumors, endometrioid carcinoma of the ovary, ovarian papillary serous adenocarcinoma, ovarian mucinous adenocarcinoma, and Ovarian Krukenberg tumors).

[1019] Cervical diseases and/or disorders include cervicitis, chronic cervicitis, mucopurulent cervicitis, cervical dysplasia, cervical polyps, Nabothian cysts, cervical erosion, cervical incompetence, and cervical neoplasms (including, for example, cervical carcinoma, squamous metaplasia, squamous cell carcinoma, adenosquamous cell neoplasia, and columnar cell neoplasia).

[1020] Additionally, diseases and/or disorders of the reproductive system include disorders and/or diseases of pregnancy, including miscarriage and stillbirth, such as early abortion, late abortion, spontaneous abortion, induced abortion, therapeutic abortion, threatened abortion, missed abortion, incomplete abortion, complete abortion, habitual abortion, missed abortion, and septic abortion; ectopic pregnancy, anemia, Rh incompatibility, vaginal bleeding during pregnancy, gestational diabetes, intrauterine growth retardation, polyhydramnios, HELLP syndrome, abruptio placentae, placenta previa, hyperemesis, preeclampsia, eclampsia, herpes gestationis, and urticaria of pregnancy. Additionally, the polynucleotides, polypeptides, and agonists or antagonists of the present invention may be used in the diagnosis, treatment, and/or prevention of diseases that can complicate pregnancy, including heart disease, heart failure, rheumatic heart disease, congenital heart disease, mitral valve prolapse, high blood pressure, anemia, kidney disease, infectious disease (e.g., rubella, cytomegalovirus, toxoplasmosis, infectious hepatitis, chlamydia, HIV, AIDS, and genital herpes), diabetes mellitus, Graves' disease, thyroiditis, hypothyroidism, Hashimoto's thyroiditis, chronic active hepatitis, cirrhosis of the liver, primary biliary cirrhosis, asthma, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenic purpura, appendicitis, ovarian cysts, gallbladder disorders, and obstruction of the intestine.

[1021] Complications associated with labor and parturition include premature rupture of the membranes, pre-term labor, post-term pregnancy, postmaturity, labor that progresses too slowly, fetal distress (e.g., abnormal heart rate (fetal or maternal), breathing problems, and abnormal fetal position), shoulder dystocia, prolapsed umbilical cord, amniotic fluid embolism, and aberrant uterine bleeding.

[1022] Further, diseases and/or disorders of the postdelivery period, including endometritis, myometritis, parametritis, peritonitis, pelvic thrombophlebitis, pulmonary embolism, endotoxemia, pyelonephritis, saphenous thrombophlebitis, mastitis, cystitis, postpartum hemorrhage, and inverted uterus.

[1023] Other disorders and/or diseases of the female reproductive system that may be diagnosed, treated, and/or prevented by the polynucleotides, polypeptides, and agonists or antagonists of the present invention include, for example, Turner's syndrome, pseudohermaphroditism, premenstrual syndrome, pelvic inflammatory disease, pelvic congestion (vascular engorgement), frigidity, anorgasmia, dyspareunia, ruptured fallopian tube, and Mittelschmerz.

Infectious Disease

[1024] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to treat or detect infectious agents. For example, by increasing the immune response, particularly increasing the proliferation and differentiation of B and/or T cells, infectious diseases may be treated. The immune response may be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may also directly inhibit the infectious agent, without necessarily eliciting an immune response.

[1025] Viruses are one example of an infectious agent that can cause disease or symptoms that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention. Examples of viruses, include, but are not limited to Examples of viruses, include, but are not limited to the following DNA and RNA viruses and viral families: Arbovirus, Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae, Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae (Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae), Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus), and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a variety of diseases or symptoms, including, but not limited to: arthritis, bronchiolitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta),

Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat AIDS.

[1026] Similarly, bacterial and fungal agents that can cause disease or symptoms and that can be treated or detected by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following Gram-Negative and Gram-positive bacteria, bacterial families, and fungi: Actinomyces (e.g., *Nocardia*), Acinetobacter, *Cryptococcus neoformans*, Aspergillus, Bacillaceae (e.g., *Bacillus anthrasis*), Bacteroides (e.g., *Bacteroides fragilis*), Blastomycosis, Bordetella, Borrelia (e.g., *Borrelia burgdorferi*), Brucella, Candidia, Campylobacter, Chlamydia, Clostridium (e.g., *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Clostridium tetani*), Coccidioides, Corynebacterium (e.g., *Corynebacterium diphtheriae*), Cryptococcus, Dermatocycoses, *E. coli* (e.g., Enterotoxigenic *E. coli* and Enterohemorrhagic *E. coli*), Enterobacter (e.g. *Enterobacter aerogenes*), Enterobacteriaceae (Klebsiella, Salmonella (e.g., *Salmonella typhi*, *Salmonella enteritidis*, *Salmonella typhi*), Serratia, Yersinia, Shigella), Erysipelothrix, Haemophilus (e.g., *Haemophilus influenza* type B), Helicobacter, Legionella (e.g., *Legionella pneumophila*), Leptospira, Listeria (e.g., *Listeria monocytogenes*), Mycoplasma, Mycobacterium (e.g., *Mycobacterium leprae* and *Mycobacterium tuberculosis*), Vibrio (e.g., *Vibrio cholerae*), Neisseriaceae (e.g., *Neisseria gonorrhoea*, *Neisseria meningitidis*), Pasteurellacea, Proteus, Pseudomonas (e.g., *Pseudomonas aeruginosa*), Rickettsiaceae, Spirochetes (e.g., Treponema spp., Leptospira spp., Borrelia spp.), Shigella spp., Staphylococcus (e.g., *Staphylococcus aureus*), Meningococcus, Pneumococcus and Streptococcus (e.g.,

Streptococcus pneumoniae and Groups A, B, and C Streptococci), and Ureaplasmas. These bacterial, parasitic, and fungal families can cause diseases or symptoms, including, but not limited to: antibiotic-resistant infections, bacteremia, endocarditis, septicemia, eye infections (e.g., conjunctivitis), uveitis, tuberculosis, gingivitis, bacterial diarrhea, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, dental caries, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease, dysentery, paratyphoid fever, food poisoning, Legionella disease, chronic and acute inflammation, erythema, yeast infections, typhoid, pneumonia, gonorrhea, meningitis (e.g., mengitis types A and B), chlamydia, syphilis, diphtheria, leprosy, brucellosis, peptic ulcers, anthrax, spontaneous abortions, birth defects, pneumonia, lung infections, ear infections, deafness, blindness, lethargy, malaise, vomiting, chronic diarrhea, Crohn's disease, colitis, vaginosis, sterility, pelvic inflammatory diseases, candidiasis, paratuberculosis, tuberculosis, lupus, botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocytoses), toxemia, urinary tract infections, wound infections, nosocomial infections. Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat or detect any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat: tetanus, diphtheria, botulism, and/or meningitis type B.

[1027] Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardias, Helminthiasis, Leishmaniasis, Schistosoma, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g., *Plasmodium virax*, *Plasmodium falciparum*, *Plasmodium malariae* and *Plasmodium ovale*). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these

symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

[1028] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a vaccine to raise an immune response against infectious disease.

Regeneration

[1029] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention can be used to differentiate, proliferate, and attract cells, leading to the regeneration of tissues. (See, Science 276:59-87 (1997)). The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects, trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

[1030] Tissues that could be regenerated using the present invention include organs (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

[1031] Moreover, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated include of tendinitis, carpal tunnel syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

[1032] Similarly, nerve and brain tissue could also be regenerated by using polynucleotides or polypeptides, as well as agonists or antagonists of the present invention, to proliferate and differentiate nerve cells. Diseases that could be treated using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic disorders (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated using the polynucleotides or polypeptides, as well as agonists or antagonists of the present invention.

Gastrointestinal Disorders

[1033] Polynucleotides or polypeptides, or agonists or antagonists of the present invention, may be used to treat, prevent, diagnose, and/or prognose gastrointestinal disorders, including inflammatory diseases and/or conditions, infections, cancers (e.g., intestinal neoplasms (carcinoid tumor of the small intestine, non-Hodgkin's lymphoma of the small intestine, small bowel lymphoma)), and ulcers, such as peptic ulcers.

[1034] Gastrointestinal disorders include dysphagia, odynophagia, inflammation of the esophagus, peptic esophagitis, gastric reflux, submucosal fibrosis and stricturing, Mallory-Weiss lesions, leiomyomas, lipomas, epidermal cancers, adeoncarcinomas, gastric retention disorders, gastroenteritis, gastric atrophy, gastric/stomach cancers, polyps of the stomach, autoimmune disorders such as pernicious anemia, pyloric stenosis, gastritis (bacterial, viral, eosinophilic, stress-induced, chronic erosive, atrophic, plasma cell, and Ménétrier's), and peritoneal diseases (e.g., chyloperitoneum, hemoperitoneum, mesenteric cyst, mesenteric lymphadenitis, mesenteric vascular occlusion, panniculitis, neoplasms, peritonitis, pneumoperitoneum, bubphrenic abscess.).

[1035] Gastrointestinal disorders also include disorders associated with the small intestine, such as malabsorption syndromes, distension, irritable bowel syndrome, sugar intolerance, celiac disease, duodenal ulcers, duodenitis, tropical sprue, Whipple's disease, intestinal lymphangiectasia, Crohn's disease, appendicitis, obstructions of the ileum,

Meckel's diverticulum, multiple diverticula, failure of complete rotation of the small and large intestine, lymphoma, and bacterial and parasitic diseases (such as Traveler's diarrhea, typhoid and paratyphoid, cholera, infection by Roundworms (*Ascariasis lumbricooides*), Hookworms (*Ancylostoma duodenale*), Threadworms (*Enterobius vermicularis*), Tapeworms (*Taenia saginata*, *Echinococcus granulosus*, *Diphyllobothrium spp.*, and *T. solium*).

[1036] Liver diseases and/or disorders include intrahepatic cholestasis (alagille syndrome, biliary liver cirrhosis), fatty liver (alcoholic fatty liver, reye syndrome), hepatic vein thrombosis, hepatolenticular degeneration, hepatomegaly, hepatopulmonary syndrome, hepatorenal syndrome, portal hypertension (esophageal and gastric varices), liver abscess (amebic liver abscess), liver cirrhosis (alcoholic, biliary and experimental), alcoholic liver diseases (fatty liver, hepatitis, cirrhosis), parasitic (hepatitis echinococcosis, fascioliasis, amebic liver abscess), jaundice (hemolytic, hepatocellular, and cholestatic), cholestasis, portal hypertension, liver enlargement, ascites, hepatitis (alcoholic hepatitis, animal hepatitis, chronic hepatitis (autoimmune, hepatitis B, hepatitis C, hepatitis D, drug induced), toxic hepatitis, viral human hepatitis (hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E), Wilson's disease, granulomatous hepatitis, secondary biliary cirrhosis, hepatic encephalopathy, portal hypertension, varices, hepatic encephalopathy, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular adenoma, hemangiomas, bile stones, liver failure (hepatic encephalopathy, acute liver failure), and liver neoplasms (angiomyolipoma, calcified liver metastases, cystic liver metastases, epithelial tumors, fibrolamellar hepatocarcinoma, focal nodular hyperplasia, hepatic adenoma, hepatobiliary cystadenoma, hepatoblastoma, hepatocellular carcinoma, hepatoma, liver cancer, liver hemangioendothelioma, mesenchymal hamartoma, mesenchymal tumors of liver, nodular regenerative hyperplasia, benign liver tumors (Hepatic cysts [Simple cysts, Polycystic liver disease, Hepatobiliary cystadenoma, Choledochal cyst], Mesenchymal tumors [Mesenchymal hamartoma, Infantile hemangioendothelioma, Hemangioma, Peliosis hepatis, Lipomas, Inflammatory pseudotumor, Miscellaneous], Epithelial tumors [Bile duct epithelium (Bile duct hamartoma, Bile duct adenoma), Hepatocyte (Adenoma, Focal nodular hyperplasia, Nodular regenerative hyperplasia)], malignant liver tumors [hepatocellular, hepatoblastoma, hepatocellular carcinoma, cholangiocellular, cholangiocarcinoma,

cystadenocarcinoma, tumors of blood vessels, angiosarcoma, Karposi's sarcoma, hemangiendothelioma, other tumors, embryonal sarcoma, fibrosarcoma, leiomyosarcoma, rhabdomyosarcoma, carcinosarcoma, teratoma, carcinoid, squamous carcinoma, primary lymphoma]), peliosis hepatitis, erythrohepatic porphyria, hepatic porphyria (acute intermittent porphyria, porphyria cutanea tarda), Zellweger syndrome).

[1037] Pancreatic diseases and/or disorders include acute pancreatitis, chronic pancreatitis (acute necrotizing pancreatitis, alcoholic pancreatitis), neoplasms (adenocarcinoma of the pancreas, cystadenocarcinoma, insulinoma, gastrinoma, and glucagonoma, cystic neoplasms, islet-cell tumors, panceoblastoma), and other pancreatic diseases (e.g., cystic fibrosis, cyst (pancreatic pseudocyst, pancreatic fistula, insufficiency)).

[1038] Gallbladder diseases include gallstones (cholelithiasis and choledocholithiasis), postcholecystectomy syndrome, diverticulosis of the gallbladder, acute cholecystitis, chronic cholecystitis, bile duct tumors, and mucocele.

[1039] Diseases and/or disorders of the large intestine include antibiotic-associated colitis, diverticulitis, ulcerative colitis, acquired megacolon, abscesses, fungal and bacterial infections, anorectal disorders (e.g., fissures, hemorrhoids), colonic diseases (colitis, colonic neoplasms [colon cancer, adenomatous colon polyps (e.g., villous adenoma), colon carcinoma, colorectal cancer], colonic diverticulitis, colonic diverticulosis, megacolon [Hirschsprung disease, toxic megacolon]; sigmoid diseases [proctocolitis, sigmoid neoplasms]), constipation, Crohn's disease, diarrhea (infantile diarrhea, dysentery), duodenal diseases (duodenal neoplasms, duodenal obstruction, duodenal ulcer, duodenitis), enteritis (enterocolitis), HIV enteropathy, ileal diseases (ileal neoplasms, ileitis), immunoproliferative small intestinal disease, inflammatory bowel disease (ulcerative colitis, Crohn's disease), intestinal atresia, parasitic diseases (anisakiasis, balantidiasis, blastocystis infections, cryptosporidiosis, dientamoebiasis, amebic dysentery, giardiasis), intestinal fistula (rectal fistula), intestinal neoplasms (cecal neoplasms, colonic neoplasms, duodenal neoplasms, ileal neoplasms, intestinal polyps, jejunal neoplasms, rectal neoplasms), intestinal obstruction (afferent loop syndrome, duodenal obstruction, impacted feces, intestinal pseudo-obstruction [cecal volvulus], intussusception), intestinal perforation, intestinal polyps (colonic polyps, gardner syndrome, peutz-jeghers syndrome), jejunal diseases (jejunal neoplasms), malabsorption

syndromes (blind loop syndrome, celiac disease, lactose intolerance, short bowel syndrome, tropical sprue, whipple's disease), mesenteric vascular occlusion, pneumatosis cystoides intestinalis, protein-losing enteropathies (intestinal lymphangiectasis), rectal diseases (anus diseases, fecal incontinence, hemorrhoids, proctitis, rectal fistula, rectal prolapse, rectocele), peptic ulcer (duodenal ulcer, peptic esophagitis, hemorrhage, perforation, stomach ulcer, Zollinger-Ellison syndrome), postgastrectomy syndromes (dumping syndrome), stomach diseases (e.g., achlorhydria, duodenogastric reflux (bile reflux), gastric antral vascular ectasia, gastric fistula, gastric outlet obstruction, gastritis (atrophic or hypertrophic), gastroparesis, stomach dilatation, stomach diverticulum, stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, hyperplastic gastric polyp), stomach rupture, stomach ulcer, stomach volvulus), tuberculosis, visceroptosis, vomiting (e.g., hematemesis, hyperemesis gravidarum, postoperative nausea and vomiting) and hemorrhagic colitis.

[1040] Further diseases and/or disorders of the gastrointestinal system include biliary tract diseases, such as, gastroschisis, fistula (e.g., biliary fistula, esophageal fistula, gastric fistula, intestinal fistula, pancreatic fistula), neoplasms (e.g., biliary tract neoplasms, esophageal neoplasms, such as adenocarcinoma of the esophagus, esophageal squamous cell carcinoma, gastrointestinal neoplasms, pancreatic neoplasms, such as adenocarcinoma of the pancreas, mucinous cystic neoplasm of the pancreas, pancreatic cystic neoplasms, pancreaticoblastoma, and peritoneal neoplasms), esophageal disease (e.g., bullous diseases, candidiasis, glycogenic acanthosis, ulceration, barrett esophagus varices, atresia, cyst, diverticulum (e.g., Zenker's diverticulum), fistula (e.g., tracheoesophageal fistula)), motility disorders (e.g., CREST syndrome, deglutition disorders, achalasia, spasm, gastroesophageal reflux), neoplasms, perforation (e.g., Boerhaave syndrome, Mallory-Weiss syndrome), stenosis, esophagitis, diaphragmatic hernia (e.g., hiatal hernia); gastrointestinal diseases, such as, gastroenteritis (e.g., cholera morbus, norwalk virus infection), hemorrhage (e.g., hematemesis, melena, peptic ulcer hemorrhage), stomach neoplasms (gastric cancer, gastric polyps, gastric adenocarcinoma, stomach cancer)), hernia (e.g., congenital diaphragmatic hernia, femoral hernia, inguinal hernia, obturator hernia, umbilical hernia, ventral hernia), and intestinal diseases (e.g., cecal diseases (appendicitis, cecal neoplasms)).

Chemotaxis

[1041] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

[1042] Polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat inflammation, infection, hyperproliferative disorders, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can be used to treat wounds.

[1043] It is also contemplated that polynucleotides or polypeptides, as well as agonists or antagonists of the present invention may inhibit chemotactic activity. These molecules could also be used to treat disorders. Thus, polynucleotides or polypeptides, as well as agonists or antagonists of the present invention could be used as an inhibitor of chemotaxis.

Binding Activity

[1044] A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

[1045] Preferably, the molecule is closely related to the natural ligand of the polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991)). Similarly, the molecule can be closely related to the natural receptor to which the

polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can be rationally designed using known techniques.

[1046] Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide. Preferred cells include cells from mammals, yeast, Drosophila, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

[1047] The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

[1048] Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

[1049] Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

[1050] Additionally, the receptor to which the polypeptide of the present invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labeled. The polypeptides can be labeled by a

variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

[1051] Following fixation and incubation, the slides are subjected to auto-radiographic analysis. Positive pools are identified and sub-pools are prepared and re-transfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

[1052] As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

[1053] Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of the polypeptide of the present invention thereby effectively generating agonists and antagonists of the polypeptide of the present invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998); each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptide of the present invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous

molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF), insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-derived neurotrophic factor (GDNF).

[1054] Other preferred fragments are biologically active fragments of the polypeptide of the present invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity.

[1055] Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and ^3H thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of ^3H thymidine in each case. The amount of fibroblast cell proliferation is measured by liquid scintillation chromatography which measures the incorporation of ^3H thymidine. Both agonist and antagonist compounds may be identified by this procedure.

[1056] In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential

agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

[1057] All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues.

[1058] Therefore, the invention includes a method of identifying compounds which bind to a polypeptide of the invention comprising the steps of: (a) incubating a candidate binding compound with a polypeptide of the present invention; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with a polypeptide of the present invention, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Targeted Delivery

[1059] In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

[1060] As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

[1061] In another embodiment, the invention provides a method for the specific destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

[1062] By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubicin, and phenoxyacetamide derivatives of doxorubicin.

Drug Screening

[1063] Further contemplated is the use of the polypeptides of the present invention, or the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the activity of these polypeptides following binding.

[1064] This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in solution, or located

intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present invention.

[1065] Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

[1066] Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein. Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

[1067] This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

Antisense And Ribozyme (Antagonists)

[1068] In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to cDNA sequences contained in cDNA plasmid:Z identified for example, in Table 1. In one embodiment, antisense sequence is generated internally, by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, J., *Neurochem.* 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for example, in Okano, J., *Neurochem.* 56:560 (1991); Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research* 6:3073 (1979); Cooney et al., *Science* 241:456 (1988); and Dervan et al., *Science* 251:1300 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

[1069] For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These experiments were performed *in vitro* by incubating cells with the oligoribonucleotide. A similar procedure for *in vivo* use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoR1 site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl₂, 10MM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoR1/Hind III site of the retroviral vector PMV7 (WO 91/15580).

[1070] For example, the 5' coding portion of a polynucleotide that encodes the polypeptide of the present invention may be used to design an antisense RNA oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA

oligonucleotide hybridizes to the mRNA *in vivo* and blocks translation of the mRNA molecule into receptor polypeptide.

[1071] In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding the polypeptide of the present invention or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Benoist and Chambon, Nature 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., Cell 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., Proc. Natl. Acad. Sci. U.S.A. 78:1441-1445 (1981), the regulatory sequences of the metallothionein gene (Brinster, et al., Nature 296:39-42 (1982)), etc.

[1072] The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of the present invention. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the hybridizing nucleic acid, the more base mismatches with a RNA it may contain and still form a stable duplex (or triplex as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

[1073] Oligonucleotides that are complementary to the 5' end of the message, e.g., the 5' untranslated sequence up to and including the AUG initiation codon, should work most

efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., 1994, *Nature* 372:333-335. Thus, oligonucleotides complementary to either the 5'- or 3'- non-translated, non-coding regions of polynucleotide sequences described herein could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the 5'-, 3'- or coding region of mRNA of the present invention, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

[1074] The polynucleotides of the invention can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, e.g., Letsinger et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86:6553-6556; Lemaitre et al., 1987, Proc. Natl. Acad. Sci. 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., 1988, *BioTechniques* 6:958-976) or intercalating agents. (See, e.g., Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

[1075] The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine,

5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiacytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

[1076] The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose, 2-fluoroarabinose, xylulose, and hexose.

[1077] In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

[1078] In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al., 1987, FEBS Lett. 215:327-330).

[1079] Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

[1080] While antisense nucleotides complementary to the coding region sequence could be used, those complementary to the transcribed untranslated region are most preferred.

[1081] Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published October 4, 1990; Sarver et al, *Science* 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, *Nature* 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within the nucleotide sequence of SEQ ID NO:X. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

[1082] As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g., for improved stability, targeting, etc.) and should be delivered to cells which express *in vivo*. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

[1083] Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

[1084] The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular cataract

surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

[1085] The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

[1086] The antagonist/agonist may also be employed to treat the diseases described herein.

[1087] Thus, the invention provides a method of treating disorders or diseases, including but not limited to the disorders or diseases listed throughout this application, associated with overexpression of a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

Binding Peptides and Other Molecules

[1088] The invention also encompasses screening methods for identifying polypeptides and nonpolypeptides that bind polypeptides of the invention, and the binding molecules identified thereby. These binding molecules are useful, for example, as agonists and antagonists of the polypeptides of the invention. Such agonists and antagonists can be used, in accordance with the invention, in the therapeutic embodiments described in detail, below.

[1089] This method comprises the steps of:

1. contacting polypeptides of the invention with a plurality of molecules; and
2. identifying a molecule that binds the polypeptides of the invention.

[1090] The step of contacting the polypeptides of the invention with the plurality of molecules may be effected in a number of ways. For example, one may contemplate immobilizing the polypeptides on a solid support and bringing a solution of the plurality of molecules in contact with the immobilized polypeptides. Such a procedure would be akin to an affinity chromatographic process, with the affinity matrix being comprised of the immobilized polypeptides of the invention. The molecules having a selective affinity for the polypeptides can then be purified by affinity selection. The nature of the solid support, process for attachment of the polypeptides to the solid support, solvent, and conditions of

the affinity isolation or selection are largely conventional and well known to those of ordinary skill in the art.

[1091] Alternatively, one may also separate a plurality of polypeptides into substantially separate fractions comprising a subset of or individual polypeptides. For instance, one can separate the plurality of polypeptides by gel electrophoresis, column chromatography, or like method known to those of ordinary skill for the separation of polypeptides. The individual polypeptides can also be produced by a transformed host cell in such a way as to be expressed on or about its outer surface (e.g., a recombinant phage). Individual isolates can then be "probed" by the polypeptides of the invention, optionally in the presence of an inducer should one be required for expression, to determine if any selective affinity interaction takes place between the polypeptides and the individual clone. Prior to contacting the polypeptides with each fraction comprising individual polypeptides, the polypeptides could first be transferred to a solid support for additional convenience. Such a solid support may simply be a piece of filter membrane, such as one made of nitrocellulose or nylon. In this manner, positive clones could be identified from a collection of transformed host cells of an expression library, which harbor a DNA construct encoding a polypeptide having a selective affinity for polypeptides of the invention. Furthermore, the amino acid sequence of the polypeptide having a selective affinity for the polypeptides of the invention can be determined directly by conventional means or the coding sequence of the DNA encoding the polypeptide can frequently be determined more conveniently. The primary sequence can then be deduced from the corresponding DNA sequence. If the amino acid sequence is to be determined from the polypeptide itself, one may use microsequencing techniques. The sequencing technique may include mass spectroscopy.

[1092] In certain situations, it may be desirable to wash away any unbound polypeptides from a mixture of the polypeptides of the invention and the plurality of polypeptides prior to attempting to determine or to detect the presence of a selective affinity interaction. Such a wash step may be particularly desirable when the polypeptides of the invention or the plurality of polypeptides are bound to a solid support.

[1093] The plurality of molecules provided according to this method may be provided by way of diversity libraries, such as random or combinatorial peptide or nonpeptide libraries which can be screened for molecules that specifically bind polypeptides of the

invention. Many libraries are known in the art that can be used, e.g., chemically synthesized libraries, recombinant (e.g., phage display libraries), and in vitro translation-based libraries. Examples of chemically synthesized libraries are described in Fodor et al., 1991, *Science* 251:767-773; Houghten et al., 1991, *Nature* 354:84-86; Lam et al., 1991, *Nature* 354:82-84; Medynski, 1994, *Bio/Technology* 12:709-710; Gallop et al., 1994, *J. Medicinal Chemistry* 37(9):1233-1251; Ohlmeyer et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:10922-10926; Erb et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:11422-11426; Houghten et al., 1992, *Biotechniques* 13:412; Jayawickreme et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:1614-1618; Salmon et al., 1993, *Proc. Natl. Acad. Sci. USA* 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, *Proc. Natl. Acad. Sci. USA* 89:5381-5383.

[1094] Examples of phage display libraries are described in Scott and Smith, 1990, *Science* 249:386-390; Devlin et al., 1990, *Science*, 249:404-406; Christian, R. B., et al., 1992, *J. Mol. Biol.* 227:711-718; Lenstra, 1992, *J. Immunol. Meth.* 152:149-157; Kay et al., 1993, *Gene* 128:59-65; and PCT Publication No. WO 94/18318 dated Aug. 18, 1994.

[1095] In vitro translation-based libraries include but are not limited to those described in PCT Publication No. WO 91/05058 dated Apr. 18, 1991; and Mattheakis et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:9022-9026.

[1096] By way of examples of nonpeptide libraries, a benzodiazepine library (see e.g., Bunin et al., 1994, *Proc. Natl. Acad. Sci. USA* 91:4708-4712) can be adapted for use. Peptoid libraries (Simon et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:9367-9371) can also be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh et al. (1994, *Proc. Natl. Acad. Sci. USA* 91:11138-11142).

[1097] The variety of non-peptide libraries that are useful in the present invention is great. For example, Ecker and Crooke, 1995, *Bio/Technology* 13:351-360 list benzodiazepines, hydantoins, piperazinediones, biphenyls, sugar analogs, beta-mercaptopketones, arylacetic acids, acylpiperidines, benzopyrans, cubanes, xanthines, aminimides, and oxazolones as among the chemical species that form the basis of various libraries.

[1098] Non-peptide libraries can be classified broadly into two types: decorated monomers and oligomers. Decorated monomer libraries employ a relatively simple

scaffold structure upon which a variety functional groups is added. Often the scaffold will be a molecule with a known useful pharmacological activity. For example, the scaffold might be the benzodiazepine structure.

[1099] Non-peptide oligomer libraries utilize a large number of monomers that are assembled together in ways that create new shapes that depend on the order of the monomers. Among the monomer units that have been used are carbamates, pyrrolinones, and morpholinos. Peptoids, peptide-like oligomers in which the side chain is attached to the alpha amino group rather than the alpha carbon, form the basis of another version of non-peptide oligomer libraries. The first non-peptide oligomer libraries utilized a single type of monomer and thus contained a repeating backbone. Recent libraries have utilized more than one monomer, giving the libraries added flexibility.

[1100] Screening the libraries can be accomplished by any of a variety of commonly known methods. See, e.g., the following references, which disclose screening of peptide libraries: Parmley and Smith, 1989, *Adv. Exp. Med. Biol.* 251:215-218; Scott and Smith, 1990, *Science* 249:386-390; Fowlkes et al., 1992; *BioTechniques* 13:422-427; Oldenburg et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:5393-5397; Yu et al., 1994, *Cell* 76:933-945; Staudt et al., 1988, *Science* 241:577-580; Bock et al., 1992, *Nature* 355:564-566; Tuerk et al., 1992, *Proc. Natl. Acad. Sci. USA* 89:6988-6992; Ellington et al., 1992, *Nature* 355:850-852; U.S. Pat. No. 5,096,815, U.S. Pat. No. 5,223,409, and U.S. Pat. No. 5,198,346, all to Ladner et al.; Rebar and Pabo, 1993, *Science* 263:671-673; and CT Publication No. WO 94/18318.

[1101] In a specific embodiment, screening to identify a molecule that binds polypeptides of the invention can be carried out by contacting the library members with polypeptides of the invention immobilized on a solid phase and harvesting those library members that bind to the polypeptides of the invention. Examples of such screening methods, termed "panning" techniques are described by way of example in Parmley and Smith, 1988, *Gene* 73:305-318; Fowlkes et al., 1992, *BioTechniques* 13:422-427; PCT Publication No. WO 94/18318; and in references cited herein.

[1102] In another embodiment, the two-hybrid system for selecting interacting proteins in yeast (Fields and Song, 1989, *Nature* 340:245-246; Chien et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:9578-9582) can be used to identify molecules that specifically bind to polypeptides of the invention.

[1103] Where the binding molecule is a polypeptide, the polypeptide can be conveniently selected from any peptide library, including random peptide libraries, combinatorial peptide libraries, or biased peptide libraries. The term "biased" is used herein to mean that the method of generating the library is manipulated so as to restrict one or more parameters that govern the diversity of the resulting collection of molecules, in this case peptides.

[1104] Thus, a truly random peptide library would generate a collection of peptides in which the probability of finding a particular amino acid at a given position of the peptide is the same for all 20 amino acids. A bias can be introduced into the library, however, by specifying, for example, that a lysine occur every fifth amino acid or that positions 4, 8, and 9 of a decapeptide library be fixed to include only arginine. Clearly, many types of biases can be contemplated, and the present invention is not restricted to any particular bias. Furthermore, the present invention contemplates specific types of peptide libraries, such as phage displayed peptide libraries and those that utilize a DNA construct comprising a lambda phage vector with a DNA insert.

[1105] As mentioned above, in the case of a binding molecule that is a polypeptide, the polypeptide may have about 6 to less than about 60 amino acid residues, preferably about 6 to about 10 amino acid residues, and most preferably, about 6 to about 22 amino acids. In another embodiment, a binding polypeptide has in the range of 15-100 amino acids, or 20-50 amino acids.

[1106] The selected binding polypeptide can be obtained by chemical synthesis or recombinant expression.

Other Activities

[1107] A polypeptide, polynucleotide, agonist, or antagonist of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. The polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.

[1108] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for treating wounds due to injuries, burns, post-operative tissue

repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

[1109] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed stimulate neuronal growth and to treat and prevent neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may have the ability to stimulate chondrocyte growth, therefore, they may be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

[1110] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

[1111] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for preventing hair loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, a polypeptide, polynucleotide, agonist, or antagonist of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

[1112] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed to maintain organs before transplantation or for supporting cell culture of primary tissues. A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

[1113] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

[1114] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, a polypeptide, polynucleotide, agonist, or antagonist of

the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

[1115] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to treat weight disorders, including but not limited to, obesity, cachexia, wasting disease, anorexia, and bulimia.

[1116] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive disorders), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

[1117] A polypeptide, polynucleotide, agonist, or antagonist of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

[1118] The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

Other Preferred Embodiments

[1119] Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or cDNA plasmid:V.

[1120] Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions identified for SEQ ID NO:X in Table I.

[1121] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or cDNA plasmid:V.

[1122] Further preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 500 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or cDNA plasmid:V.

[1123] A further preferred embodiment is a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ ID NO:X in the range of positions identified for SEQ ID NO:X in Table 1.

[1124] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X or the complementary strand thereto, and/or cDNA plasmid:V.

[1125] Also preferred is an isolated nucleic acid molecule which hybridizes under stringent hybridization conditions to a nucleic acid molecule comprising a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and/or cDNA plasmid:V, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

[1126] Also preferred is a composition of matter comprising a DNA molecule which comprises cDNA plasmid:V.

[1127] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of cDNA plasmid:V.

[1128] Also preferred is an isolated nucleic acid molecule, wherein said sequence of at least 50 contiguous nucleotides is included in the nucleotide sequence of an open reading frame sequence encoded by cDNA plasmid:V.

[1129] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by cDNA plasmid:V.

[1130] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 500 contiguous nucleotides in the nucleotide sequence encoded by cDNA plasmid:V.

[1131] A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence encoded by cDNA plasmid:V.

[1132] A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and a nucleotide sequence encoded by cDNA plasmid:V; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

[1133] Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[1134] A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and a nucleotide sequence encoded by cDNA plasmid:V.

[1135] The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[1136] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto or cDNA plasmid:V which encodes a protein, wherein the method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and a nucleotide sequence of cDNA plasmid:V.

[1137] The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

[1138] Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X or the complementary strand thereto and a nucleotide sequence encoded by cDNA plasmid:V. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

[1139] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or a polypeptide encoded by cDNA plasmid:V.

[1140] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or a polypeptide encoded by cDNA plasmid:V.

[1141] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or a polypeptide encoded by cDNA plasmid:V.

[1142] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or a polypeptide encoded by cDNA plasmid:V.

[1143] Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a polypeptide encoded by cDNA plasmid:V.

[1144] Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a portion of said polypeptide encoded by cDNA plasmid:V; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and/or the polypeptide sequence of SEQ ID NO:Y.

[1145] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of a polypeptide encoded by cDNA plasmid:V.

[1146] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of a polypeptide encoded by cDNA plasmid:V.

[1147] Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of a polypeptide encoded by cDNA plasmid:V.

[1148] Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1149] Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group and determining

whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

[1150] Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: a polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1151] Also preferred is the above method wherein said step of comparing sequences is performed by comparing the amino acid sequence determined from a polypeptide molecule in said sample with said sequence selected from said group.

[1152] Also preferred is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting polypeptide molecules in said sample, if any, comprising an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1153] Also preferred is the above method for identifying the species, tissue or cell type of a biological sample, which method comprises a step of detecting polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the above group.

[1154] Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a nucleic acid sequence identified in Table 1 encoding a polypeptide, which method comprises a step of detecting in a biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous

amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1155] In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

[1156] Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1157] Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

[1158] Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V.

[1159] Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

[1160] Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a human protein comprising an amino acid sequence selected from the group consisting of: polypeptide sequence of SEQ ID NO:Y; a polypeptide encoded by SEQ ID NO:X or the complementary strand thereto and a polypeptide encoded by cDNA plasmid:V. The isolated polypeptide produced by this method is also preferred.

[1161] Also preferred is a method of treatment of an individual in need of an increased level of a protein activity, which method comprises administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to increase the level of said protein activity in said individual.

[1162] Also preferred is a method of treatment of an individual in need of a decreased level of a protein activity, which method comprised administering to such an individual a Therapeutic comprising an amount of an isolated polypeptide, polynucleotide, immunogenic fragment or analogue thereof, binding agent, antibody, or antigen binding fragment of the claimed invention effective to decrease the level of said protein activity in said individual.

[1163] In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2.

[1164] Preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of c - d, where both c and d correspond to the positions of nucleotide residues shown in SEQ ID NO:X, and where d is greater than or equal to c + 14.

[1165] In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Plasmid: V	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
1	HCE1P80	2	973903	BG033745, AA476827, AV704156, AL137944, AI971680, AW297211, BF706130, AI520706, BF833782, BE907421, BE242671, AW936474, AW936371, AW190143, AW519008, AI432598, AI393538, AW295856, AA393801, BF687731, AI765546, BF898133, AA146856, BF217337, BE146273, AL532972, AI204615, BF437991, AA146855, AL021453.1, AK026002.1, AL355838.3, AL009047.1, AL354696.11, AL356806.4, AC010460.6, AC010977.4, AC013242.7, AP000426.3, AL512268.10, ACU09245.10, AP001001.4, AC022415.5, AC018517.6, AC005521.1, AC008163.2, AL138878.10, AC007881.4, AL136531.16, AL138976.5, AL050350.14, AL160254.10, AC004584.1, AL356379.10, AL158815.14, AL109751.19, AC005384.2, AC008736.6, AC022542.4, AL136160.18, AL591807.1, AL031681.16.
1	HCE1P80	22	1315876	
1	HCEJP80	23	1055553	
2	HUFGH53	3	1143339	AI672862, AI972278, AI090242, AI365229, AA524422, AI916766, AW242863, AW014261, AA044337, AI863149, AI658700, AI491865, AI341186, BF001214, AI658683, AW972265, AI680049, AI638089, AA044219, AA775576, AA034372, AI023942, AI276995, W25392, AA603067, AA034373, AI197784, W35182, AA339233, H55506, AW084219, AW168373, AA807088, AW151785, AI866798, AI673256, BF817402, AI473598, AI347701, AI799199, AI569309, AI866002, BF885085, BF815196, BG251264, AI474107, AI635367, AI682075, AI282731, AW089179, AW151714, AI633419, BE964767, AI696819, AW189424, AV682807, AW983822, AI491783, AI250848, AI933785, AI365256, AW085786, AI874151, AI932949, AW149869, AW023590, AI873644, AI697324, AI274013, AI539771, BG260144, AV682802, AI308032, AI251830, AI344785, BG058039, AI648502, AW954031, AW088899, AW168485, AI280670, AI590999, AI699011, AW088903, BG027280, BE613727, AI922901, AI922561, AI799195, AW004886, AI620864, AI859464, AI818578, BF921092, AW130863, AI687009, AW152550, AI538342, BF968910, BE963918, AI432736, AI249962, AI446373, AI636619, AIW191892, AW129230, AW167238, BF914091, AI860045, AI433970, AW079159, AI619716, AW082060, AI890806, AW087938, AI687065,

			AI539153, AI612759, BE963035, AW151729, BF816785, BF816455, AI867042, BF526861, AI566630, AI280661, BE061389, AI866608, BF814541, AI537617, BE963286, AI919345, AI922577, BF915537, AW834355, AI888621, AI476109, BF915208, BE072233, AI366549, AI636719, AI570966, AI610645, AI434242, BF904180, AI620093, AI811168, AI611743, AW083804, AA830821, AI696626, AI589993, BE964497, BE538466, AW265004, BE393551, AI598061, AI587606, AI677797, AI431909, BE965169, AI811684, AW188518, AI613449, AI254727, AI783861, AW192288, AW002174, N74355, AI520702, AI433021, AI859402, AW149227, AI800138, AI890182, AI628833, BF344652, BF795712, AW168031, AW264029, AW169275, AW167448, AW264727, AW083189, AW193203, AI680498, AI805688, AI953880, AI554427, BE907440, AW172723, BG249582, AI475394, AW169001, AI915576, AI868831, AW847410, AW163823, BF811780, BE928768, AI471548, AI559599, AV755332, AI689571, AI355849, AI860783, AI174394, AW189415, AI680457, AI805769, BF814449, BF920893, AI567351, BF339322, AI863321, AI569328, AI521386, AI371228, AI567243, AI952064, AI554218, AW081255, AI888944, AW198075, AW088134, AW079739, AI812015, AI498579, AI702406, AI470284, AI590686, AI468872, AI382670, AI921734, AI366638, AI802240, AW167918, AI560052, AI110306, AI584140, AI862144, AW085667, BG150947, AI628217, AI520810, AI866786, AI648567, AI400725, BE543089, Y07848.1, AL031186.8, Z95116.1, AL050138.1, BC008983.1, AL137461.1, Y14314.1, AL133645.1, BC006201.1, AL137463.1, AK024538.1, AK026408.1, AK026597.1, AL389939.1, AL133075.1, AL389978.1, AL137705.1, AB060929.1, AK026533.1, AK025349.1, AF218031.1, BC005151.1, AF358829.1, AL137556.1, BC003105.1, BC005678.1, AF091084.1, AK026591.1, AL359618.1, AL162062.1, AK025312.1, U39656.1, X69819.1, AL137300.1, AL080137.1, AB056768.1, AK026504.1, BC005858.1, AK000647.1, AF217987.1, AB048974.1, AF090903.1, AL389982.1, AL136749.1, AL080086.1, AF321617.1, BC003650.1, AK000450.1, AF026816.2, AK026947.1, BC001349.1, AJ242859.1, AF000145.1, BC008365.1, AF081197.1, AF081195.1, AL080060.1, AL137273.1, AI512761.1, AB052200.1, AF125949.1, AB049758.1, AK025383.1, BC006412.1, AL050393.1, BC006133.1, BC009033.1, BC003683.1, BC007355.1, AL133014.1, U80742.1, AL137294.1, AK026532.1,
--	--	--	---

				BC009341.1, AK000652.1, AL162083.1, AF159141.1, BC002839.1, AB048919.1, BC002343.1, BC006494.1, AB063084.1, AB049848.1, AB019565.1, AL122098.1, AL133104.1, AL133565.1, AL512754.1, BC004370.1, AB056427.1, AB060905.1, AB060211.1, BC007641.1, AL157479.1, BC000316.1, BC003682.1, AK025708.1, AL080074.1, AB055361.1, AL390167.1, AL117649.1, AF162270.1, BC006508.1, BC006164.1, AB063008.1, BC008485.1, AB063079.1, AL080158.1, BC000556.1, BC003687.1, AL442072.1, AF242525.1, S61953.1, AC002467.1, BC008780.1, AL136928.1, AB060912.1, AL122049.1, AK026086.1, AB048964.1, AK026528.1, AF217966.1, AL122050.1, AF218014.1, AL162003.1, AL137271.1, AF177336.1, AL359583.1, AL136844.1, AL133665.1, AL133098.1, AK027182.1, ALS12746.1, AK024601.1, AB047801.1, AL133557.1, AB060852.1, AL110221.1, BC006807.1, AK026608.1, AL157431.1, AL133568.1, AL136845.1, AL133113.1, BC008893.1, AL136784.1, AB047887.1, AF225424.1, AB055366.1, AK025491.1, AL136843.1, AL110280.1, AL080127.1, AL050149.1, AF217991.1, AL122093.1, AF003737.1, BC009026.1, AK026057.1, BC005890.1, AL049382.1, BC008417.1, AB063088.1, AK027193.1, AF113222.1, AL137538.1, AB055368.1, AK025524.1, BC009253.1, BC007198.1, AL136799.1, AK026865.1, AF078844.1, AL512718.1, AF219137.1, AK000445.1, AK026642.1, AL049465.1, AK026164.1, AF104032.1, AL133081.1, BC004951.1, AL122111.1, AB060863.1, AK025209.1, AL137648.1, AL162006.1, AK026592.1, AL117585.1, AK025573.1, AL136789.1, BC002342.1, AL353940.1, AF207829.1, AK027116.1, AL117432.1, AL512719.1, AL136790.1, AL050277.1, AL080124.1, AF271350.1, BC008387.1, AL359941.1, AL136622.1, AL133077.1, AK026526.1, AB047615.1, AK025906.1, AK026045.1, AB050534.1, AL353957.1, AK026885.1, L30117.1, AF183393.1, AK027164.1, AB060903.1, AL117440.1, AK026551.1, AL117435.1, AL110222.1, AK000718.1, AK026534.1, AF111112.1, AL162002.1, AK026855.1, AL137429.1, AK027113.1, AL137526.1, L19437.2, BC008070.1, AB055315.1.
2	HUFGH53	24	894857	A1672862, A1972278, A1090242, A1365229, AA524422, A1916766, AW242863, AW014261, AA044337, A1863149, A1658700, A1491865, A1344186, BF001214, A1658683, AW972265,

				AI680049, AI638089, AA044219, AA775576, AA034372, AI023942, AI276995, W25392, AA603067, AA034373, AI197784, W35182, H55506, AA339233, AL031186.8, Y07848.1, Z95116.1.
2	HUFGH53	25	1407421	
2	HUFGH53	26	1407330	
2	HUFGH53	27	1407326	
2	HUFGH53	28	1324108	
2	HUFGH53	29	1143314	
2	HUFGH53	30	1124368	
3	HWMM059	4	1426876	AI634846, BF589994, AI660577, AW873053, BE906672, AI241049, AW008561, BF750885, BE963035, AI280661, BF816455, AW088899, AI446003, AI566630, BF694790, BG120816, AI702073, AI537617, BE061389, AI919345, AI633419, AI10645, BF038804, AI554218, AI866002, BF817402, AI867042, AI539028, BE963918, AI859464, AW083804, AI921386, BF968504, AI674912, AI469811, AI627880, AI636719, AI608676, BF904180, BF726504, AI250663, AI433976, BF815196, AI619716, AI561299, AI612759, AW151729, AI699011, BF811780, BF909758, BE621256, AI364788, AI611743, BF914091, BE613727, AW168485, BF814335, BE968711, BF913616, AW103371, AI697324, AI933785, AI805688, BF915537, BG026746, AI365256, AW079159, AI251830, BE964767, BG058039, AI689175, BE928768, AI635464, BE875407, AW087938, AI366549, AI539153, BF816785, BF726237, AW131954, AW090494, AW834355, BF344652, BE393551, BE964089, BG031664, AI494201, AI610756, AA830821, AI963040, AI679916, AI079794, AW102785, BF814409, BE887861, AI921176, AW084219, AW103886, AI499652, AW082594, AI633306, BE967016, BE897632, BF814541, AI345746, N80094, AW858254, AI251205, BF915208, AV682496, AI868831, AI888953, AI886124, AI655932, AW151785, AV683272, AI431909, BF885085, AV690007, AI828731, BF795712, AI432736, AI687065, AW089179, AI696819, AI783861, BE785868, AI680498, AW192375, AI520809, AI922577, AI799234, AI498579, BE875786, AI696626, AW198075, BE904051, BE072233, AI589993, BE544111, BG179099, AI566507, AI264741, AI952360, BF726603, AI866741, AI680457, AI468872, AI866608, BE963286, AI698401, BE884910, AW079572, AI572418, AW172723, AI400725, AI568870, AI241819, BE964497, BE538466, BF854113, AW029263, AI952920, AW020095, AW103893, AI805638, AI805769, AI963062, AW195957, AI624668, BF342070, BE966388, AW071417, AI628292, AW021588, AW085667, AI801605, AI888429, BG181012, AI885974,

			AI493559, AI041772, AI613017, AI432040, BE964981, AW089258, AI628217, AI866887, AI812015, AW235035, BF910810, AW192226, AW168031, AI474076, AI886022, AI891157, AI249962, AI872914, AW104146, BG171779, BF037484, AW088903, AW151714, AW129230, BE246734, AI471361, AI678443, AI587288, AI696378, AW088134, BE965060, AI598113, AW051107, BF752252, BE964198, AI648502, BF924882, AI590645, AI539771, AA425380, AW082040, AW103195, AW084131, AI677797, BF921092, BF92469, AW117907, AI569616, BE965481, BF910849, BF812933, BF204844, AL110306, AI745713, BF725863, AL119791, AI888621, AL041150, AI888944, BE964512, AW858243, BG030364, BE966947, AI922365, AI274769, AI540850, N74355, AI133489, AI929108, AI648663, BC001349.1, BC003683.1, AK025414.1, AB056427.1, AK025209.1, AK025906.1, AL133104.1, AK000652.1, AL512718.1, AB063100.1, AL389978.1, AK000753.1, AK025383.1, AK026865.1, AK024538.1, AK025958.1, AB063008.1, BC008417.1, AF225424.1, BC003548.1, AB060826.1, AL080124.1, AL137556.1, AB063046.1, AB019565.1, AL122098.1, BC007198.1, BC008893.1, AL080060.1, AK026642.1, BC005678.1, AF104032.1, AL050024.1, AL512719.1, AB050534.1, AK025491.1, AL136928.1, AL512761.1, AK024601.1, AK027116.1, AB049758.1, AL389939.1, AF271350.1, AL050138.1, AL136843.1, U80742.1, AB060214.1, AL137526.1, BC006164.1, U39656.1, X69819.1, AB060929.1, AB056768.1, AL390167.1, AK027868.1, AL512754.1, BC003687.1, AB060863.1, AB063079.1, AK026608.1, AB060839.1, AL117432.1, AF11112.1, BC009033.1, AK026592.1, AF177336.1, BC008485.1, AB047801.1, AF207829.1, AK025772.1, BC008899.1, AL080137.1, BC006807.1, AL133077.1, AK026532.1, AK000618.1, AK027113.1, AK026959.1, AB052191.1, AL133093.1, AB047887.1, Z82022.1, AK026947.1, AK027193.1, AF162270.1, AB063084.1, BC009341.1, AL137476.1, AK026533.1, AK027114.1, AB051158.1, AF146568.1, AB050510.1, AK026045.1, BC008280.1, BC003682.1, AL080127.1, AL133075.1, Y14314.1, AL117440.1, AL136845.1, AK026551.1, AK000718.1, AL122110.1, AL122049.1, AK026480.1, AL133080.1, AL049382.1, AL133640.1, AB048919.1, AL117583.1, AL133098.1, AK026784.1, AL117585.1, AL162062.1, AL136864.1, AL133113.1, AL133072.1, AL122123.1, X72889.1
--	--	--	--

				AF348209.1, AL353625.5, AK026597.1, AB055374.1, AK027200.1, AB049848.1, AB060912.1, AK026086.1, AK000647.1, BC004951.1, AL359583.1, AL359618.1, AL162006.1, AL137538.1, AK026630.1, AK026452.1, AF125949.1, AF260566.1, AL353940.1, AL050277.1, BC004370.1, AF090901.1, AL137527.1, BC008387.1, AL133565.1, AL122121.1, AL136799.1, AK026408.1, AF078844.1, AK026464.1, X82434.1, AK026504.1, BC005890.1, AB063070.1, AF217966.1, AK000137.1, AF217987.1, BC004958.1, AK027164.1, AK025312.1, AK025524.1, AL442072.1, BC006412.1, BC008365.1, AL110280.1, AL136749.1, AL162002.1, BC008382.1, AL049466.1, BC008070.1, BC002839.1, AL512684.1, AK000445.1, AL080159.1, AK000432.1, AK026583.1, AB047615.1, L30117.1, AB056420.1, AB055366.1, AK025092.1, BC009212.1, S78214.1, AK025632.1, AL136768.1, AL050116.1, AL133016.1, AK025254.1, BC007021.1, AK000323.1, AK000391.1, AL136586.1, AK026534.1, AL137463.1, S61953.1, BC008780.1, AL162083.1, AB048964.1, AK025391.1, AB048953.1, AL122050.1, AF218014.1, AL136844.1, AL137459.1, AF113222.1, AL512746.1, AL117460.1, AB062938.1, AL133557.1, AB055303.1, AL359601.1, AB060887.1, AL117457.1, AL096744.1, AL359615.1, AL157431.1, AL133568.1, AL133014.1, AL359620.1, U91329.1, AF106862.1, AL110196.1, AK026542.1, AF219137.1, AF090896.1, AL359941.1, AL133067.1, Y16645.1, AL136786.1, AL080074.1, AK027204.1, AK025573.1, AK000486.1, AL110221.1, AK025484.1, AK026855.1, AJ012755.1, AK024524.1, AF003737.1, AF090934.1, AL137283.1, BC005151.1, AK026528.1, AK026629.1, AL359596.1, AB060916.1, AF183393.1, AK027160.1, AK025798.1, AB060852.1.
3	HWMM059	31	1356977	
4	HSSJ51	5	900561	BF526701, BF873331, BF929164, BF221973, AV688712, BF743216, AJ682301, BF929165, AA368885, BE295879, AI078870, BE270667, AI611295, BF963547, AA323287, BF763407, BF002002, BF002176.
5	HCEWD38	6	1284936	AA746177, AI510718, R37382, AI247745, R52665, AA323018, H49570, N55573, BG236027, AW966998, AA323159, AL039810, R13472, AL039789, BF322816, AW955388, BF879416, AA304816, AW964665, AA323409, R52713.
5	HCEWD38	32	616396	AA323018, AA323159, AW966998, R13472, AW955388, AA304816, AW964665, AA323409,

				R52713, AI132800. 4.
5	HCEWD38	33	411082	R37382, AA746177, AI150718, R52665, AI247745, AA323018, N55573, BG236027, H49570, AW966998, AA323159, R13472, AW955388, AL039810, AA304816, BF879416, AW964665, AA323409, AL039789, BF332816, R52713.
6	HUCMC56	7	1310874	R20045, AW965432, AA332557, R36770, R60458, AA340432, AW163243, AX018985, AX018987, M58583, S76975, AL117383.
6	HUCMC56	34	967258	R60458, AW163243.
7	HWLZU06	8	1310875	BF05285, BF882978, AW070344, AI805087, BF906443, AI083823, W92687, AI085548, AI083824, W92830, BE138819, AW192716, AW150070, BF588518, AA775561, BF764330, AW172659, M91217, AI393090, AW137263, F33371, W05570, R70460, AA339837, AI564511, AA359338, AW380993, AW960500, AW192211, AI924106, AA377546, AI346326, AI825277, BF724241, AI432310, AI144286, AA301724, AI619600, AI783751, AI470161, AI457948, AW190639, AI338249, AW025095, AL110261, AF086482.
7	HWLZU06	35	933581	BF055285, BF882978, AI346326, AI432310, AI144286, AI805087, AW070344, AI338249, BF906443, AI457948, AI083823, AI470161, AI085548, W92687, AI083824, W92830, BE138819, AW192716, AW150070, BF588518, AA775561, BF764330, AW172659, AI393090, M91217, F33371, W05570, AW137263, R70460, AA339837, AI928593, AI564511, AA359338, AW380993, AW960500, AI924106, AA377546, AW192211, AI825277, AA301724, AI619600, AI783751, BF724241, AI704632, AW190639, N76120, AW025095.
8	HDPBA69	9	905708	BF434049, BF525949, AI300176, BF342466, AI193100, AW953836, N32601, AA894528, BF526118, AI749282, AA917673, AI200645, AA577400, AW001112, AI342526, AI561024, AA922077, BF339231, BC060138, AI274361, AW629891, AI811138, AI682589, AI598054, BF821354, AA703086, BF821349, AW000838, AI687717, BF879161, AI346224, AI283829, AW966426, BF878968, AI718510, N38801, AA609464, AA443822, AI285277, AI141075, C17007, AA827271, AI274203, AI278912, AW953891, AA485613, AI291153, AI184968, AI815092, BF879241, AA922163, AA954441, W92736, AI523358, AI582743, AI272748, T95291, AI304507, AW858976, BF823040, R47871, H90673, R71353, AV689909, W92820, AW515183, AA640081, R47872, AI749077, AA508675, AA025765, AI352318, H66699, R66274, T27046, H78056, AI873364, H66689, AW029317, AI336608, H64116, AI872250, H42114, T95371, AA383872, R24350, AI749260, BF087543, T72087, AA025953, BF820542,

				BF737942, AA371827, N90491, BG012708, A1459266, D31533, H64951, BE769806, A368991, N69227, H01130, BF821339, H89819, R72785, BE769826, H01871, R62666, BF349116, N45434, R72786, AW374237, AW953834, H78057, T16823, AA295668, BE140683, AW277068, AW135690, AI088641, BF881707, AW374232, AW61009, H73228, R24669, H26462, T72232, T23681, H27838, H64952, BE769808, H70128, N47826, R43349, H83150, BF991147, AI476021, AI202813, AL514919, AL513597, AW605902, AL514627, AL513907, AL514791, AL513643, AL514691, AL513553, A1560012, AW105588, AL513693, AL514087, AL513911, AL514015, AI500553, AL513631, AL514473, BE966388, AI697137, AW195957, AI873731, AI567351, AI687728, AL514793, AI699857, AI630928, AW268253, BE785905, A1285735, AI436456, BG105445, AI613017, AV757455, AI499393, AI934036, BG260037, AL515041, AI679724, AI920968, AI862142, BF037097, BE964741, AI349645, AI625079, AI619502, AI281762, AI349772, AL047042, AI857296, AL514359, AL121270, AL513977, BF883916, A706777, AL036396, BE047863, BF882343, BG058208, AI671679, AI271786, AW148320, AI514929, BF055737, AW827249, AL513763, AI874109, AV711509, AL515375, AL119049, AL514867, AI597750, AI597918, AL514261, BE048071, AW827203, AI538716, AV655645, AV682476, AV729890, AI281745, AI045500, AI064830, BG036846, AI475134, AI673256, AL036802, AI580984, BG179993, AI863014, AV755207, BF724691, AI046849, AI868831, BE964812, BE965111, BF795712, BG257535, AL513999, BP971016, BG178488, BF726322, BG180996, AL513803, AV755581, AW071349, AV681857, AL515413, AI445025, AL121365, BF343172.
8	HDPBA69	36	906482	BF343049, BF525949, AI300176, BF342466, AW953836, AI749282, AA894528, N32601, BF526118, AI193100, AA577400, AI200645, AA917673, AW001112, AA703086, AI687717, AI342526, AI561024, BF339231, AI141075, AA922077, AW629891, AI274361, AI184968, AA922163, AI815092, BF821349, W92736, BF821354, AI682589, AW000838, BF879161, BF878968, AI346224, AI718510, AI283829, N38801, AW966426, AA443822, AA609464, C17007, AI285277, BG060138, AA827271, AW953891, AI274203, AA4485613, AI811138, AI278912, BF879241, AI291153, AI598054, AA954441, AW515183, AI272748, AI304507, T95291, AA508675, AW858976, AI582743, BF823040, R47871, R71353, AV689909, W92820, AA640081, R47872, AI749077, AI523358, AA025765, AI459266, H64116, T27046,

				A1352318, H66689, R66274, H78056, A1873364, H90673, H42114, A1336608, T95371, AA383872, R24350, A1749260, AW029317, BF087543, T72087, AA025953, AW135690, BF820542, H64951, BF37942, AA371827, H01130, H66699, N90491, BG012708, D31533, H01871, A1872250, BE769806, AA368991, N69227, H89819, BP821339, R72785, BE769826, R62666, BF349116, N45434, R72786, AW374237, AW953834, T16823, AA295668, BE140683, AW277068, A1088641, H78057, H73228, BF881707, AW374232, AW610099, H26462, R24669, A1202813, T23681, T72232, H27838, H64952, BE769808, H70128, N47826, R43349, H83150, A1281745, BF991147, A1476021, AL513597, AL513907, AL514791, AL514627, A1500553, AL514919, AL514691, AW605902, AL514473, AL513911, AL513553, AL514087, BE785905, AV757455, AL513693, AL514359, AL515041, AL515375, BE966388, AL513803, AL047042, AV706777, AI349772, A1285735, AL513631, BG058208, BF054789, A1873731, AV682476, AL514793, BE048071, AW827203, A1567351, A1064830, AL119049, AL513643, BF724691, A1687728, AV729890, BF795712, BF726322, AL121270, AV681857, AV755581, BE964994, A1679724, AW071349, AL046849, A1868831, AV758806, AI349645, A1863014, BG179993, A1815383, A1560012, AV757639, A1906328, AV655645, AL513817, BF970162, BG108147, AL515373, BE047863, A1673256, AL515047, AV682249, AI499393, AV758110, AV682772, BG257535, AL514935, BG036846, AV682441, AV681716, BG168696, BF883916, AV682330, BE964812, BG260037, AW162071, AW827211, AV681668, BF970161, A1934036, AI697137, AV733397, AI436456, AV682351, AV710479, AW195957, AV756477, AV681951, BE048135, AV682466, BF793644, A1671679, AV757327, AV681630, AL514543, AV682252, BF343172, AV711924, AL514803, AW268253, AV711509, AL515413, AV733326, AL514015, BE965891, A1521012, R17629, AA835433.
8	HDPBA69	37	906481	A1346224, A1291153, AA922163, A1352318, A1342526, W92736, AA577400, AW000838, AA508675, A1598054, A1815092, A1749077, A1523358, AA703086, N38801, A1718510, AW001112, AA025765, A1561024, H66689, AW515183, H66699, R47872, A1873364, A184968, AA894528, N32601, A1274361, A1274203, A1459266, A1200645, A1687717, A1682589, A1285277, AA917673, BG060138, A1193100, AA922077, A1283829, A1749260, A1272748, AA827271, A141075, AA443822, A1300176, A1749282, AA609464, A1278912, A1088641, T95291, A1582743, H90673, AA954441, H78057, A1304507, A1811138,

				AI336608, AW277068, AI202813, AW135690, H64952, H73228, T23681, N69227, R43349, T16823, AW966426, R72785, R72786, AA383872, AI281745, BF087543, R71353, BF820542, BF823040, AW610099, AW605902, BF879161, BF821354, D31533, BF879241, BF878968, AI281707, BE011964, AW858976, R24350, AA835433, AW105588.
8	HDPBA69	38	906480	BF343049, BF525949, BF339231, AW629891, R47871, T27046, H42114, H64116, BF342466, H64951, N90491, H01871, H01130, H98819, N45434, H26462, H27838, BF526118, T2232, H83150, BF991147, AA640081, N47826, BE769806, AV689909, BF737942, R17629.
9	HLWAE11	10	783071	AI344312, AI276017, AI476822, A1139478, AI160906, AI240398, AW001088, AA425919, AA011278, AA428788, AI354692, AI089176, AA622689, BF431807, AI968918, N68826, AI467807, BF436247, AW673768, AW135943, R24434, R16812, R31419, R31434, R24435, H83155, AI865939, R31418, AW673133, W67349, R31433, AA027080, R28030, BE542160, T81223, AI631986, AA677315, BF760063, AI872675, BF331923, BE926682, BE926741, AF329842.1, Z82188.2.
10	HSZAF47	11	1283068	AW298370, AI433823, AI239867, D62170, D61860.
10	HSZAF47	39	456551	AW298370, AI433823, AI239867, D62170, D61860, AF329839.1, AC007016.5.
11	HWTAY65	12	908762	AI916779, AW304481, AA732948, AI288625, AW965223, AA443244, AA194106, W79527, BF511014, AI038644, AA443206, W93527, AA346195, W79559, BE296248, AW975618, AW960414, AV724520, DS1799, C14389, C14331, AW960553, AW966531, AW964468, AV718692, AW956397, AV720791, AV718489, AW973541, AW965175, AW949645, AW978634, AW966013, AW973307, AV720533, AW973474, D81030, AW949642, AW966059, AV720211, C14429, AW959202, AW966053, D80212, AW964756, AW960465, AW959136, D80166, AV718707, AV719822, AV719557, AW959799, AV720731, D59859, AW964477, AW966022, AW966029, AV718938, D80188, AV718633, AW975613, D51423, D59619, AW965177, AW949630, AW978661, D80210, AW966075, AW973488, D80240, D80253, AW966065, AV719324, AW949629, AW975605, AW973334, AV718931, AV720878, AW966032, AW966534, AV699447, D58283, AW958993, AV722801, AV723927, AW949656, AW966041, AW949631, AW949643, AW949618, AW949657, D59275, AW973482,
11	HWTAY65	40	905611	AI916779, AW304481, AA732948, AI288625, AW965223, AA443244, AA194106, W79527, BF511014, AI038644, AA443206, W93527, AA346194, W79559, BE296248, AW975618, AW960414, AV724520, DS1799, C14389, C14331, AW960553, AW966531, AW964468, AV718692, AW956397, AV720791, AV718489, AW973541, AW965175, AW949645, AW978634, AW966013, AW973307, AV720533, AW973474, D81030, AW949642, AW966059, AV720211, C14429, AW959202, AW966053, D80212, AW964756, AW960465, AW959136, D80166, AV718707, AV719822, AV719557, AW959799, AV720731, D59859, AW964477, AW966022, AW966029, AV718938, D80188, AV718633, AW975613, D51423, D59619, AW965177, AW949630, AW978661, D80210, AW966075, AW973488, D80240, D80253, AW966065, AV719324, AW949629, AW975605, AW973334, AV718931, AV720878, AW966032, AW966534, AV699447, D58283, AW958993, AV722801, AV723927, AW949656, AW966041, AW949631, AW949643, AW949618, AW949657, D59275, AW973482,

				AV721386, D80022, AV700889, D80195, AA30578, D80219, AW975621, AW978648, D80043, AW959597, D59467, AW960473, AW959570, AW949654, AW965163, D80391, D80164, AW966030, AW966054, AV720203, AV720150, AW966050, AV719188, D59787, AW958992, D80227, AW966062, AV718440, AV719783, AV720028, D59502, AV699550, AW959628, AW962082, BE269743, AV719468, AV718800, AW965185, AW965197, AW965196, AW973485, AW965184, AW960454, D57483, AV718844, AV720464, AV718770, AW959062, AW956434, AW964488, AW949641, D59610, AV699927, AA305409, D80366, D80024, D59889, D80196, AW973330, C15076, AW973447, AW949632, AW959582, D59927, AW949653, AW949655, D80269, D80038, D50979, AW959469, D51022, D80193, AW177440, D50995, AW964532, AW962245, AW964737, AW965158, AW949646, AW949633, AW949658, D80241, AW960532, D80378, AW966043, AV720812, D80045, AV720220, D51060, AW753053, AW966023, AV723097, AV699866, AW179328, D80248, AW960564, AW973490, D81026, AW752082, AW960504, AW965176, AW966389, AW975623, AV744690, AV699652, AW966330, AW178893, AV699746, AV718530, AV720616, D80522, AV701004, C14014, AV700229, AW973445, AW973465, T03269, C75259, AW960570, AV699479, AW962395, AV701335, AV718681, AV701043, AV701332, AV701017, AV701248, AV719000, AV701431, AV699682, AA514188, AA514186, AV719628, AV720654, D80268, D80251, AV742001, AV742667, AW753067, AV701125, AV701166, AV742430, AV701149, AW378532, AV742048, D80133, AV699669, AW966331, AW360811, AW377671, AV738340, AW177501, AW973473, AW177511, AW966332, AV720151.
12	HHGDP51	13	1310873	AI652297, BF967925, AW769372, BE857943, AA446941, BF115527, AI209086, AA443365, BF051939, D59611, AW204677, AI446405, AI918554, BE538466, BE965527, AW079768, BF816041, BF816031, AW082600, AW893295, BF885675, BF915537, AI537837, AA464646, AI582912, BF971113, AA835966, AI865116, AI620093, AI573026, AW058233, AV735118, AI889147, AI371228, AI349957, AA848053, AI345005, AI627880, AW084132, AW020592, BE613727, BG057418, AI345014, AW022494, N22406, AW020288, AI560679, BF913615, AW059713, AI636719, BE966928, BF817746, BF925348, BF915316, AI349814, BE875407, AW858254, AI583578, AW083804, AA830821, BG105895, AW075084, AI310925, BE904051, AI312399, AI349937, AI623736, AI334884, AI307543, AW411043, AI345251, BE245461,

			AW071412, AI307708, AI312325, AW071395, AV738918, BE964937, AI242736, AI340659, AW071377, AI311159, AI340644, BE138684, BF885000, AV736474, AI334930, AI309443, AI471909, AI307520, AI345026, AI307454, AI752007, AI340664, AI310592, AI307542, AI569632, AW151138, AI345817, BE621040, AI345739, AI345674, AI312143, BE965355, AI349637, AI334920, AW071276, AI310927, AI307578, AI336488, F32537, AI364788, AW082623, BE155168, AI636619, BG179295, AI349955, AW075093, AL046463, AI312432, AW084097, AI918408, BE172412, AI312357, BE907440, AI475151, AI680226, AI312237, W33163, AI250627, AW500379, AI950664, BE897632, AI873638, AI37643, AI866608, BE964700, AW073898, AW268261, BE271279, AA468418, AA514684, BF038804, AI805688, AI349213, AI611743, BE965169, AW263804, AI249877, BE965503, AI804505, AW900453, AI951222, AI888621, BF868927, AI696626, AI357599, AW149876, AI589993, AI365256, AW079334, BF909758, BE964497, BE910005, AI553669, AW085786, AI345677, AI636788, BF814449, AW265004, AW999906, BE393551, AI886055, AV738628, AI472536, AI677797, AI452857, AW196105, W81248, AW191844, BG113493, AI366959, AW074301, AI249946, AI244380, AI784233, AA493923, AI344935, AV648263, BG113236, BG178735, AW130430, AI28574, AW059828, AI738867, AI589428, AI805769, AI434242, AI345397, AW025533, BF572734, BE172499, BF924897, BE313517, BE964078, AW193467, BF872670, AI280670, AI802372, AI921420, AI446124, AI688848, AI499986, AI540606, AW089572, AI345737, AV738730, BG058217, AI345114, N99092, BE138712, AI915295, AI254226, BF814072, AI307210, AI590423, AI866786, AI336513, AI500659, AI336662, BG001293, AI336634, AI345261, AI868204, AI702301, AI307569, BF680133, AW079432, AI348895, AI345736, AW068845, AI313320, AI050666, AW081383, AI336495, N74355, AF120268, I41145, AI18777, AK024545, AF085809, AF107847, AL049460, AR068466, L13297, AJ301634, AF219137, S77771, AI137521, I89947, I48978, A08913, AF155148, AL389935, I89931, A08912, A08910, A08911, AR087170, A08909, AR038854, A08907, AI133104, A08908, AI122111, AF119856, AF125949, AF090896, X62773, S76508, I89934, AB019565, X62580, U42031, AF113676, E02253, E01812, AF254119, U91329, AF207829, AL035458, AF271350, AF094850, AK024601, AB025103, AF176651, AL080158, AB048995, E08631, AI137300, AK000652, AI133093, X87582, AK026590, AB051158, AF305835,
--	--	--	--

				AF217991, AB049848, X99257, AK026651, AB049629, AF114818, AL133098, AJ242859, AL117585, AL080127, U00686, AF040751, AL137705, A12297, A93016, I00734, AK026395, AL162083, AF119894, AK024594, AK000445, L40363, AB047897, AL133081, AK000212, AK025669, AK025573, AF188698, AB049758, E00617, EO0717, EO0778, AX027129, AF261883, A18788, AJ006417, U75370, U57352, AK025889, E02914, AL137283, AL133645, X70685, U57715, AK026541, II7767, AB046642, AB044390, AK000291, AL110225, AL38951, S53987, AL117394, AF119358, AF057300, AF057299, AF242525, I89944, AK026592, AK027105, AF117959, I09360, AK026571, AR038969, E15582, AK026924, AF11847, AL137547, X59414, AL110222, AK024538, AK026608, D55641, Z22828, AK026591, AF078844, AL080060, Y16258, Y16257, E02756, Y16256, AF065135, AF130054, Z72491, AF203473, AL353957, AF119909, AK025208, AL137648, U66274, AR079011, AR079012, A90832, AL137555, AL137659, AL117629, U77594, AK025383, AF030165, AF012536, AF003737, AK026533, AF116676, AB047248, AL389978, AF159141, AK027104, AF067420, U90884, AL359600, AF116644, AF031147, I26207, AL157479, AF017790, AK025541, AL117578, AK026452, X54971, AX011676, AL080137, AF000145, U72620, AB047904, AC004227, AK026600, A08916, AK026629, S75997, AF113694, AR068751, AF110329, AL133067, AL049464, S63521, AF022813, AL137557, AL133558, AX046603, AK026353, AF051325, AB047966, AX005848, AX005804, AX014095, AK025084, I46765, AL137459, AB026675, AK025491, AK025349, AF311287, AB038698, U68233, I92592, E07108, AR059883, AF130068, AF036268, AF260566, AK000391, AF016271, AF178432, AL389939, AF040723, AB029065, AF114168, AC010128, AC005902, AL137276, AL110171, AF314091, Y10655, AF116691, X76228, AL133054, AF090943, AF218031, AK025391, AK027129, AF218004, AB047615, AK025906, AF069506, AK026164, AL359596, M30514, AL050280, I52013.
12	HHGDP51	41	857703	AI652297, BF967925, AW769372, BE857943, BF115527, AA446941, AI209086, AA443365, D59611, BF059139, AW204677.
13	HBCBS41, HDMBJ47	14	I310706	BF525534, BF525878, AI188462, AV706177, AA835791, AI573089, AV706657, AA828067, BF338495, AI141312, AI961924, AA563724, AI829025, AV733099, AA464950, AA845819, AA618072, AI343736, AA576567, AI370917, AA622849, AI591077, AA039329, AW084144, AI719443, AA978073, BE819803, AI968544, AA910242, AI344535, AI554230, BF994888,

				AI299970, AA948689, AA828804, BE219403, AI298788, AA775331, AV702739, AA937438, N49449, T70926, AI299637, AA516376, H27042, AI565682, AA933874, AV706862, AA953314, AW951361, AA838059, AA865068, AA636921, AA338264, R68898, AV707811, AV703148, AI097249, AI879461, AA394279, AA582298, BE138913, AA879122, AW238763, H26166, AA039414, AW383740, BF951235, AW951363, AI125081, AA577157, AA582289, BF591527, AA603650, AA465026, AA837695, N54606, T95006, AI299684, AA828749, AW137828, BF945969, AI720693, AA834499, H26167, T91949, N33604, AW087254, AA295894, AA293797, R68796, BG236868, AA988656, AI817977, T49380, AA628820, AA379748, AW628890, AI589170, AI582116, T49379, AW316492, BF842441, AW815770, AA984912, AI581583, AI000183, TS4931, TS3963, AI079151, R36633, T71284, TS5380, AA369370, BG059309, AA369514, AI869893, T94953, BE465572, T86178, AI950559, T70988, T86179, AI749183, AA369395, AI344355, BG153207, AI582011, AI826458, AW797707, AA486985, T72982, AA913653, AA362998, R28940, T72203, AI749099, BF951201, N76686, AW798220, AA369611, T71421, AA603651, AI676040, T28386, AL080021, BF379002, AA369396, BG012359, R39712, AI734970, AL047857, AA913190, AA318607, AW816674, AI719214, D45294, R10854, BF870900, X03084, K03430, M36278, BG272985, BG677431.
13	HBCBS41, HDMBJ47	42	I225229	BF525534, BF525878, AI188462, AV706177, AI573089, AA835791, AV706657, AA828067, BF338495, AI141312, AI961924, AA563724, AI829025, AV733099, AA576567, AA464950, AA845819, AA618072, AI343736, AI370917, AA622849, AW084144, AA039329, AI591077, AI719443, AA978073, BE819803, AI968544, AA910242, AI344535, AI554230, BF994888, AI299970, AI298788, AA948689, AA828804, BE219403, AV702739, AA775331, AA937438, N49449, AI299637, AA516376, T70926, H27042, AI565682, AA933874, AV706862, AA953314, AW951361, AA838059, AA865068, AI097249, AA636921, AA338264, R68898, AV707811, AV703148, AI879461, AA394279, AA582298, BE138913, AA879122, AW238763, H26166, AA039414, AW383740, BF951235, AW951363, AI125081, AA577157, AA582289, BF591527, AI299684, AA603650, AA465026, AA837695, AW137828, N54606, T95006, AA828747, BF945969, AI720693, AA834499, H26167, T91949, N33604, BG236868, AW087254, AA295894, AA293797, R68796, AA988656, AI817977, T49380, AA628820, AA379748, AW628890, AI589170, AW516492, AI079151,

				AI582116, T49379, BF842441, AW815770, AA984912, AI581583, A1000183, T84931, T53963, R36633, T71284, T53830, AA369370, AI950559, BG059309, AA369514, AA869893, T94953, BE465572, T86178, T70988, T86179, AI749183, AA369395, AI344355, AI826458, BG153207, AI582011, AW797707, AA486985, T72982, AA913653, AA362998, R28940, T72203, AI749099, BF951201, N76686, AW798220, AA369611, AI676040, T71421, AA603651, T28386, AI080021, BF379002, AA369396, BG012359, R39712, AI734970, AL047857, AA913190, AA318607, AW816674, AI719214, D45294, R10854, BF870900.
13	HBCBS41, HDMBJ47	43	933547	AI188462, AA835791, AV706657, BF338495, AI141312, AA563724, AA828067, AI573089, AI829025, AI961924, AA576567, AV733099, AA464950, AA622849, AW084144, AI370917, AA845819, AA618072, AI343736, AA039329, AI591077, AA910242, AI719443, AA978073, AI968544, AI344535, AI298788, AI554230, AV702739, AI299970, AA948689, BF994888, T70926, AI299637, AA516376, BF525534, BE219403, AA775331, AA937438, N49449, H27042, AI565682, AI097249, AA838059, AA933874, AA865068, AV706862, AA953314, AA663921, BF945969, BE819803, AV706177, R68898, AA879122, BF525878, AA582298, AV707811, AI879461, AV703148, AA603650, AA394279, AA039414, BE138913, AW383740, H26166, AW238763, AA582289, BF951235, AA577157, BF591527, AI299684, AW951361, AI125081, NS4606, T95006, N33604, AI1720693, AW137828, AA834499, H26167, BG236868, AA465026, T91949, AA28804, AA295894, AW087254, R68796, AA293797, AW951363, AI817977, T49380, AA988656, AA628820, AW628890, AW516492, BF842441, AI079151, AW815770, AI582116, AI589170, AA984912, R36633, AI000183, AI581583, AA837695, T71284, T53830, AI950559, AA369370, BG059309, T94953, AA869893, BE465572, AI826458, T86179, T86178, AI749183, T53963, AA369395, AI344355, BG153207, AA486985, R28940, AA913653, AW797707, AI582011, AI749099, AW798220, AA369514, BF951201, AA603651, AA379748, AI676040, T71421, T28386, N76686, R39712, AI734970, AA362998, AL047857, AA913190, AA369611, BF379002, AA318607, T70988, AW816674, AA369396, T72203, AI719214, BF870900.
13	HBCBS41, HDMBJ47	44	967511	BF525534, BF525878, AV706657, AI188462, AV706177, AW084144, AA618072, AI573089, AA835791, BF338495, AA828067, AI141312, AI961924, AA563724, AI829025, AV733099, AA576567, AA464950, AA845819, AI343736, AI370917, AA838059, AA622849, AA039329,

				AI591077, BE138913, AI719443, AA978073, BE19803, AI968544, AA910242, AI344535, AI554230, BF994888, AI299970, AA948689, AA828804, BE219403, AI298788, AI565682, AA775331, N54606, AV702739, AA937438, N49449, N33604, AI299637, AA516376, T70926, AI079151, H27042, AI817977, R68796, AV706862, T95006, AA93874, AW951361, AA953314, AA865068, AA988656, AA663921, AA338264, AI097249, R68898, AA984912, AV707811, AV703148, AI879461, AA582298, AA394279, AA879122, AW238763, H26166, AA039414, AW383740, BF951235, R36633, AW951363, AA582289, AI125081, BF591527, T86179, AA603650, AA465026, AA577157, AA837695, AI299684, AA569124, BF945969, AA828747, AW137828, AI582011, AI720693, AA834499, H26167, AA913653, T91949, AA486985, AW087254, AA295894, AA293797, BG236868, T71421, T49380, AA628820, AA379748, AI589170, AW628890, AW516492, AI582116, T49379, BF842441, AW815770, AI000183, T84931, AI581583, TS3963, T71284, T53830, AA913190, AI734970, AA369370, AI869893, BE465572, AA369514, T94953, AI950559, T86178, BG059309, T70988, AI749183, AA369395, AI344355, BG153207, AI826458, AW797707, T72982, AA362998, R28940, AI749099, T72203, BF951201, N76686, AW798220, AA369611, AI473594, AA603651, AI676040, AL080021, T28386, BF379002, AA369396, BG012359, R39712, AL047857, BF437726, AA318607, AW816674, BF870900, AI719214, D45294, BF870899, R10854.
14	HDPRZ06	15	1384228	BE622709, BE622543, AW195694, AA449506, BE349118, AW836407, BE218589, BE018663, AI671569, AI990535, AI338971, AI656295, BF352595, BF352547, BF353066, AA449077, BF902513, BF756315, AA991669, AA971051, AA009692, AA837005, AA009411, AA639511, AA365182, AA365181, AW236877, AI766763, BF214429, AW983562, AV704180, BF195732, AV703542, BF352031, AA045125, AV706910, BF368967, T03588, BE142783, AV704660, AV706223, AV727314, AV701643, AV660516, AV727978, AV726502, AV703591, AV731070, AV703266, AV660258, AV705550, AV727238, AV728436, AV706851, AV652001, AV705518, AV725577, AV727954, AV729424, AV727139, AV702322, AV725618, AV705992, AV726337, AV653353, AV704626, AW959346, AV727822, AV728743, AV702149, AV652528, AV728404, AV651897, AV725441, AV725031, AV707024, AV708786, AV725582, AV709580, AV708872, AV726194, AV704144, AV726392, AV727618, AV727583, AW955629, AV725991, AV729255, AV703168, AV726590, AV725255, AV703632,

				AV725596, AV701516, AV708858, AV651955, AV705481, AV728309, AV704590, AV729473, AV742050, AV707151, AW952013, AV687342, AV701874, AV706147, AV726830, AV729366, AV708520, AV704376, AV707882, AV728464, AV661286, AV703366, AV726480, AV704605, AW956292, AV706677, AV705453, AV704916, AV703086, AV706076, AV706718, AV707311, AV728546, AV702498, AV726542, AV706290, AV725321, AV706871, AV706734, AV702958, AV727018, AV709356, AV703417, AV727347, AV707770, AV701876, AV703761, AV703367, AV707556, AV701873, AV656240, AV702463, AV702781, AV652156, AV661744, AV709222, AV707009, AV726156, AV705234, AV707271, AV660096, AV708347, AV707329, AV706025, AV654287, AV725617, AV725393, AV703214, AV701879, AV706683, AV709939, AV704712, AV705655, AV727576, AV702417, AV701754, AV701184, AV703505, AV702164, AV709596, AV701704, AV728874, AV709776, AV729408, AV725927, AV703213, AV702280, AV729532, AV703388, AV707322, AV704879, AV647692, AV707268, AV726755, AV707088, AV703232, AV704442, AV727469, AV702783, AV706874, AV703927, AV702600, AV707401, AV702409, AV706035, AV705239, AV707420, AV706991, AV706104, AV709326, AV703137, AV704217, AV701783, AV706012, AV651075, AV709880, AV706330, AV704865, AV702102, AV651704, AV702673, AV705267, AV702637, AV646347, AV707640, AV729219, AV654035, AV703783, AV688061, AV706410, AV726628, AV701669, AV709886, AV701499, AV697350, AV702800, AV708320, AV702671, AV707589, AV707264, AV709256, AV703320, AV729220, AV729129, AV703844, AV702851, AV702625, AV727932, AV706882, AV648619, AV702817, AV727047, AV702354, AV655067, AV704954, AV702725, AV704245, AV647654, AF270513.1, AL117592.1, AJ244005.1, AJ244004.1, D78345.1, AJ244003.1, U94592.1, AJ244007.1, D50010.1, D13316.1, AB025273.1, AF144029.1, AJ276256.1, AJ276254.1, Z30183.1, AF058696.1, AB028859.1, Y14219.1, AB002449.1, X67155.2, AF271371.1, AF144028.1, AJ244006.1, D34614.1, D88547.1, AB005666.1, AB038216.1, X82834.1, AJ276255.1, AA887644.
14	HDPRZ06	45	1303540	BE622709, BE622543, AW195694, BE349118, AA449506, BE218589, AI671569, AI990535, AI656295, AA449077, BF902513, BE018663, AA971051, AA991669, AA009411, AA009692, AA837005, AA639511, AA365182, AA365181, AW236877, AI766763, BF214429, BE142783, AW971745, AA887644, AL134524, AW968355, AW877209, AW972092, AL119324, AW968356,

				AI432644, AW861944, AI623302, AW972093, AW968729, AW971740, AW858525, AI432653, AW858522, AW081103, AW972091, AI432654, AI431351, AI431323, AI432650, AL119457, AW972090, AW969229, AL119399, BE672759, AI431307, AI431316, AI432677, AL042544, AI431230, AI431328, AI431238, AL045327, AW804686, AW128900, AI431353, AI431312, AI432666, AI432655, AI431310, AW858455, AI431354, AL043152, AI431347, AI492519, BF448552, AW604723, AL043168, AI431321, AI431315, AI432675, AW858526, BE672748, AI432661, Z99396, AI431337, AI431246, AL042508, BE672745, AI791349, BE672719, BE672732, AI431243, AX041928, AL117592, AX041927, AR080280, AX030435, Y17793, AX030436, AR066494, AX046357, AJ251895, AF019249, AB026436, AR071207, AL133076, AF064854, AL133053, AL133049, AL133074, AR060234, AL122101, AR054110, AX040974, AX041002, A81671, AJ279014, AL133068, AX040958, AL096720, AR069079, AL049423, AL133655, U30290, AC012104, E13998.
14	HDPRZ06	46	I223606	
15	HKB1F69	16	I286614	AI417523, BG120479, AI749321, AW057748, AW043700, AW057920, AW305168, AA608713, AW474850, AA404349, BF594226, BF541540, AW022120, AA579971, AA629969, AI127940, AU151624, AW005378, AA705289, AW377397, AI610162, AA625142, AI689091, AA87126, AA835810, AA181946, AI084438, AW450806, BE378048, BF149104, AI133172, AI269303, AI378772, AA470804, R56253, AA707300, AA725191, R99908, W42777, AI540847, AA766559, AA496910, T78435, AA256605, AA683171, AI536732, AW021074, BF589574, BF062307, AI359641, AA694404, AA903168, AA258076, AI537144, AI264091, AW191603, R42797, BF727469, N95366, AA354837, AA083067, AA134604, AW301165, Z41690, R48102, H48756, N66512, R40560, AI270253, C01933, AW473992, AA497072, R44523, R47988, T97892, AA362636, R49171, T23045, F04485, R55714, AW889340, BE155973, AA775162, AW902313, BE243585, T75572, AI967943, AL119457, AI042544, AI119399, AL119511, AW877209, AL119324, T97891, AA258647, AI042382, AI043152, AI079794, BG032704, AW970048, AI043168, AI037081, T61538, AI042866, BG113493, AW971745, BG164558, AI037104, AI54245, AI538028, BG168640, AI134524, BF525578, AI133559, BE536058, BG260144, BG029053, BE968711, BF970449, AW827289, AW827276, AV756359, BE047852, BF338723, BE785868, AI784219, BE876033, AI364788, BF038131, BG256592, BE880182, BF806065, BG034459, BF822127, BE874133,

			<p>AW673679, BG028528, BF885082, AV682462, BF726894, BE542893, BE782605, BF970362, BE893142, BG106619, AW088903, AI926669, AL079741, AV682052, BE877372, AA715307, AV755840, BG034373, BG033357, BE548542, BG163297, BE896632, BE881131, BG256705, BG110797, BG250841, AW020693, BF726237, BE874997, BF752999, BF814447, AI540759, BE011880, AW772685, BF032768, BF339322, BF032910, BE047952, AL045500, BE622183, BF107493, AI468872, BG027766, AW148716, AL045349, AV756030, BG254352, BG032208, BE910373, AW129230, BF916181, BF816037, AA938092, BE887488, BE904178, AI539771, AI916419, BE877769, BG032994, AI830259, AW162194, BF726207, BG168646, AW172273, AA641818, BF811793, AV729119, AI866082, BG109711, BG249582, AI269862, AI680498, AI494201, BE047737, BF753056, AW191003, BF911528, BE620444, BF968910, AI619723, AI224027, BF885080, BE895765, AI564448, BG110704, AV682467, BG251840, BG026482, BF814420, BE875243, AI699011, BE048071, AI436429, BF794756, BE963286, BF338002, AW151714, AV648430, AI610557, AI648684, BG034609, BG029667, AW834325, BF339594, AL042628, AL036214, AI433157, AI538885, AI554821, AW858243, BG252929, AW151136, BE897632, AC010198, AK026222, AK024247, U77594, AX030435, AJ251859, Y11587, AK024524, AK025431, I00734, E00617, E00717, E00778, AL162062, L10353, AL122049, U96683, A08916, A08910, A08909, AR080280, AL162002, AL390167, AK026647, I48978, S68736, AL389935, AF008439, AF130087, S61953, AF314091, AF067728, AX042059, AL389939, AJ238278, AL122098, AF177401, AF119337, AF162270, I89947, AK026959, A08913, L30117, I89931, AK024538, AB026436, AK025798, AL080127, X93495, AR087170, AB047904, AK025015, AL133072, AF183393, AL080159, AF155221, AF116644, AB048964, AF119909, AL117440, AL080137, AL137476, AX040958, AF119896, AR000496, U39656, X52128, AF090901, X81464, AK026408, I3392, AR059958, AK025524, AK027188, AB049758, AL137548, AL122110, AF113019, AL049283, AK026480, AL133080, AL049466, AK000432, AL162003, AK026885, I17767, AK026927, AL133077, AK026551, AL050393, AL389982, AL122121, AF116639, AK026464, AK025857, E05822, AL049382, Z82022, AF153205, AK027160, AL359601, Y14314, AR038854, AL133031, AL137463, AK027182, AF113689, AK025391, AF017152, AK000310, AF116649, A08912, AL359620, AL050138, AF113013, AJ012755, AF116631, AF271350, AF119883,</p>
--	--	--	---

				E03348, AL137526, L19437, AF097996, AF028823, AF218031, A65341, AB041801, AK026045, AB050534, AF130100, AF177336, AK025209, AX040974, AF130092, AL110221, E15569, S78214, AR020905, X76228, A07588, AF119878, EO2349, AF110640, AF218034, AP090900, AL133014, AK026532, AF111112, AF003737, AK026533, AF017437, AK026086, AK027121, AF106827, AL110296, AL049452, AK026624, E07108, AF158248, AL359618, AP061573, EO7361, AL080124, AL080060, AK000652, AL137556, I48979, AL389978, AF130055, AK026597, AL049430, AK026642, AF132676, AF225424, AB047941, AR070212, AF061836, AF111851, AB048974, AX020124, AK025312, AF125948, AF113676, AK000718, AK026534, AK027116, AK026865, AF078844, AL050277, AL357195, AL050024, AX019230, AF217966, AB047887, AK000137, AX014095, Z72491, AK027164, Y09972, AL137550, AK026452, AF205861, AK000690, AK000486, AF104032, AF175983, AF207829, AF026816, AL080086, AL359941, AL8777, AF130066, AK024588, AK027096, AL162008, AF119875, AK026583, AL133640, AB048919, AF119871, AF210052, AB052191, AK025084, AF217987, AF017790, AK025092, AL162006, AB048975, AK025632, A93350, AF116646, AK000647, AL117457, AL133016, AK025254, A45787, AK000323, AX010492, AF146568, AL122093, AK025208, AL133565, AL133606, AK027136, AJ006417, AL137479, X98834, AK026462, BE552256.
16	HOHBO69	17	I282370	BG114252, BF344333, AW029321, BE619018, BF591735, AI084509, BE877796, AW068693, BF002157, AW068694, AA872420, N23787, AW613589, AI752218, AW630180, AI752219, AI752163, AI750192, AI753307, AI752164, N24399, AA789067, BF197886, W19235, AI242724, AA233788, AW392772, AW068274, AA627580, AA853772, AA853676, H99150, H89055, AA853685, BF448509, BF741968, BF132395, AA577443, AW392783, H99383, D79968, D62487, AA853675, AA290849, AA283763, W25429, AA853686, X57527, J05042, X66977, AF044969, AF054891, S63458, X66976, AF055330, AC007275, AF170702, AL022143.
16	HOHBO69	47	I280342	None
17	HCEES60	18	I305240	BG251391, AL138070, AA639738, AL138071, R38469, AA317570, W30872, AA043621, AA853712, AI806793, AA702490, AA780815, AI751694, AL138787, M60832, M60833.
18	HDALV07	19	I316192	AR034253, D45371, AB012165, AJ131461, AR034252, U49915, AJ131460, AB012164.
19	HEQAH47	20	877634	AL519977, BE383449, AL043766, BF061686, BF221776, BF310701, BF060773, BF434074, BF062728, AI659849, BE313561, BF314046,

			BF316323, AI659290, AI824840, BF061701, BF312471, AI751263, AI685765, AI591068, AI587181, AI920932, AI400351, AI148305, AI955664, AI652541, AI675888, AI653379, AI424943, AI128448, BE313794, BF437698, AI275016, BE590996, AI561014, AI660936, AI491938, AI968617, BE047763, AI127265, AA643524, BF313828, AI866540, AI751264, AI828892, AI824814, AA970985, BE855979, AI589275, AI768084, AA477627, AW371357, AI926713, AI969893, AI335684, AA057195, AA478085, AW193325, AW002099, AI672890, AI991492, AI225080, AW191017, AI804237, AI918988, AI215462, AI660046, AW263221, AW166456, AW361968, AI923034, BF939318, AI672957, AW008276, AI421034, BF941981, AA101823, AI474549, BF514389, AA968480, AW591386, AI972480, AI758252, AI277535, AI611291, AI446797, AA627406, AW082500, AI673160, AA127893, AW085658, AA101824, AI491939, AI445814, AW513225, AI656563, W21432, AW590943, AA128143, AW196052, AW452957, AI419247, AI356191, BF593921, AI339204, AA973738, BF196865, AA973140, BF941530, AA423796, AA962026, AI572714, BF593478, AA057129, AA834119, AI333104, AI401697, AI539260, AI628325, AI345415, AW163834, AI590043, AI698391, AI440238, AL047763, AW130362, AI523973, AW150622, AW008166, BF531023, AA565269, AL042567, AI361701, AI619820, AI434731, AI653402, AI880111, AI500061, AI345688, AI862067, AI800648, BE393784, AI037602, AI872423, AI524179, AI289791, AI927233, AI565172, AI037582, AI866469, AI370623, AI079963, AI678446, BG250475, AW189716, BF090758, AW196720, AW129659, AW081383, AI784214, BE964705, AV659072, AI244343, AI445611, AI680467, AI250646, BG260772, BE877401, BE907624, BG034598, AI699823, BF724420, BE904851, BF750886, AI869125, AI869377, AI582932, BE957870, AI638644, AA659688, AI036241, AI972112, AI345612, BE867194, BF035213, BE905161, BE873695, BE877904, AI345416, BE967004, AI627714, AW188525, AI251221, AI036673, BG169738, BF525838, AI290677, BG256090, AI470717, AI499570, BE963809, AW051088, AW983832, AW117882, AI471282, AI621341, AI440239, AW130104, AI866127, W45039, AI536574, AI583558, AI583578, BG118199, AI889189, AW075382, AI348847, AW083572, AW161202, AI366959, AI633125, AI800341, AI310575, AI869765, AI860027, AI538564, AI335476, AI866040, AI915291, AW152182, AI538817, AW130534, AI274655, AW025279, AI284060, BE965159, AI866770, BF811804, AI581362, AI270295,
--	--	--	---

			BE891834, BF669151, AV681858, AW073824, AI589428, AL050138.1, AF088916.1, BC007530.1, AF162780.1, Y09340.1, AL137480.1, BC00090.1, AK026542.1, AL080146.1, BC007522.1, BC001675.1, BC002491.1, AL162002.1, AB060889.1, BC006091.1, AJ012582.1, AL137558.1, AL389935.1, BC001199.1, AK026462.1, AL161802.15, AL117587.1, BC001166.1, AF183393.1, BC007571.1, BC003104.1, BC002631.1, AB055303.1, AB060887.1, BC007767.1, AL136765.1, BC006345.1, AK000618.1, BC008708.1, BC006119.1, Y14040.1, BC008364.1, BC001785.1, BC004925.1, AF249267.3, AL080154.1, AK027161.1, AL080110.1, AL117438.1, BC003410.1, BC003569.1, BC008382.1, AK024974.1, AK027160.1, AL136864.1, BC003101.1, AK000655.1, AL049382.1, AB047627.1, AL137292.1, BC008591.1, AL137530.1, AK027102.1, AK025435.1, AF044323.1, BC001964.1, U73682.1, AB060876.1, BC002911.1, BC003587.1, BC002370.1, AL442083.1, AF132730.1, BC000570.1, AL136752.1, AL136893.1, AL137495.1, AK026633.1, AL359583.1, BC002535.1, AL117416.1, BC006410.1, AL512718.1, AL137574.1, BC003590.1, AL133088.1, X66417.1, AL137461.1, U70981.1, AK024533.1, BC003573.1, AB050410.1, BC003591.1, AK025099.1, ZS2022.1, AF271781.1, BC002471.1, AB050431.1, BC005854.1, AK025113.1, AL137256.1, AF369701.1, AL080148.1, AL133049.1, X53587.1, AF026816.2, AL359941.1, BC004945.1, BC004292.1, AK000418.1, AL136850.1, AL080159.1, AB060897.1, AF339775.1, BC004908.1, BC009333.1, AL137533.1, AF195092.1, BC007381.1, BC008649.1, AK027095.1, S76508.1, BC005002.1, X83544.1, BC004119.1, Y14314.1, BC000235.1, AL389982.1, BC006181.1, AL136784.1, BC001082.1, BC000751.1, AK024588.1, AK025860.1, AK025084.1, AB063074.1, S77771.1, U37359.1, BC002473.1, AL136774.1, BC005070.1, BC000860.1, AL133559.1, S61953.1, AK000476.1, BC000199.1, AB060864.1, AF245044.1, AL137478.1, BC008686.1, BC006103.1, BC005816.1, BC007460.1, AK025798.1, BC002466.1, AF124728.1, AF104032.1, AL137550.1, AF106862.1, X82434.1, L19437.2, AL137557.1, AL162003.1, BC004899.1, AK026164.1, AL137271.1, AB060837.1, AF141289.1, AB060916.1, BC004395.1, AK025350.1, AL137554.1, BC002356.1, AL353956.1, BC001844.1, AL080126.1
--	--	--	--

				AL050092.1, BC008078.1, BC008417.1, AF271350.1, AL512751.1, BC007453.1, BC009026.1, AF131773.1, AL136615.1, BC000253.1, AK026647.1, AK026744.1, AL136844.1, AB056420.1, BC008717.1, BC008723.1, AL133062.1, BC006161.1, AF081571.1, AL050155.1, AF230496.1, AC026464.6, AF242525.1, BC002516.1, AF239683.1, BC004349.1, AL512684.1, AL133081.1, AF131821.1, AB047953.1, BC001763.1, AB048974.1, AJ299431.1, AL050149.1, BC005843.1, AF184965.1, AL136586.1, AL137488.1, AK024747.1, AL136768.1, AL122121.1, AL110280.1, AC006288.1, AK026506.1, BC004960.1, AL136884.1.
19	HEQAH47	48	I254417	
20	HATNA88	21	1282006	BG032839, AI217963, AW665995, BG178505, AI032401, AI016792, AW973741, AA889643, BE041602, AW983637, AW983608, AW983601, AW983610, AW983628, AW983645, AW983688, AW983603, AW983607, AW983625, AW983640, AW983612, AW983642, AW983617, AW983624, AW983634, AW983687, AW983602, AW983630, AW983635, AW983636, AW983689, AW983616, AW983639, AW983609, AW983644, AW983618, AW983604, AW983611, AW983615, AW983619, AW983686, AW983622, AW983633, AW983605, AW983626, AW983631, AW983643, AW983627, AW983620, AW983638, AW983632, AW983613, AW983685, AW983621, AW983592, AA559283, AW983641, AW983623, AW983589, AW983593, BF349085, AW983594, AW983614, AA583866, AA883836, AA557662, AA593227, BF512098, AI275909, AA578056, AL445985, AX047347, AF178931.
20	HATNA88	49	I285117	

TABLE 3

cDNA Plasmid: V	Library Code(s)
HCE1P80	H0052 H0179 H0253 H0266 H0375 H0543 H0551 H0575 H0618 H0790 L1290 S0027
HUFGH53	H0009 H0012 H0024 H0059 H0087 H0208 H0483 H0506 H0529 H0540 H0617 H0622 H0624 H0625 H0660 H0672 H0687 L1290 S0038 S0354 S0374 S0418 S0444 S6026
HWMMO59	H0024 H0392 H0617 L1290 S0358 S0444
HSSJJ51	H0030 H0052 H0087 H0100 H0251 H0253 H0286 H0318 H0445 H0486 H0550 H0594 H0599 H0618 H0619 H0693 H0713 H0757 H0762 L1290 S0037 S0196 S0280 S0378 S0436 S0476
HCEWD38	H0052 H0194 H0261 H0581 L1290
HUCMC56	H0013 H0144 H0178 H0244 H0563 H0570 H0624 L1290 S0051 S0442
HWLZU06	H0549 S0222 S0406 S0436
HDPBA69	H0009 H0014 H0031 H0039 H0062 H0063 H0090 H0108 H0122 H0123 H0163 H0189 H0213 H0252 H0264 H0309 H0333 H0343 H0345 H0352 H0375 H0376 H0427 H0444 H0445 H0486 H0506 H0509 H0510 H0521 H0522 H0553 H0555 H0570 H0575 H0581 H0583 H0595 H0597 H0619 H0620 H0622 H0638 H0644 H0652 H0658 H0661 H0662 H0663 H0666 H0668 H0672 H0682 H0710 H0713 H0726 H0753 H0754 H0757 H0762 H0773 H0774 H0777 L1290 S0106 S0190 S0212 S0280 S0282 S0330 S0354 S0358 S0360 S0362 S0374 S0376 S0378 S0384 S0406 S0408 S0434 S0436 S0438 S0440 S0442
HLWAE11	H0050 H0056 H0266 H0521 H0553 L1290
HSZAF47	H0013 H0321 L1290
HWTAY65	H0012 H0013 H0019 H0123 H0351 H0352 H0550 H0553 H0570 L1290 S0007
HHGDP51	H0424 H0455 H0617 L1290
HBCBS41	H0004 H0009 H0014 H0031 H0042 H0068 H0086 H0087 H0090 H0124 H0144 H0190 H0255 H0263 H0309 H0327 H0329 H0351 H0370 H0375 H0376 H0393 H0415 H0421 H0427 H0441 H0445 H0486 H0489 H0521 H0522 H0538 H0549 H0550 H0553 H0555 H0575 H0581 H0583 H0587 H0591 H0592 H0606 H0617 H0638 H0641 H0644 H0646 H0649 H0653 H0658 H0659 H0662 H0672 H0673 H0689 H0690 H0710 H0716 H0722 H0726 H0753 H0754 H0755 H0762 H0768 H0777 H0778 H0789 L1290 S0010 S0031 S0036 S0044 S0260 S0280 S0328 S0354 S0356 S0358 S0360 S0374 S0376 S0406 S0408 S0434 S0436 S0440 S0442 S0444 T0068
HDPRZ06	H0124 H0188 H0250 H0271 H0328 H0486 H0521 H0522 H0539 H0540 H0580 H0638 H0641 H0645 L1290 S0044 S0116 S0344 S0426 S0434 T0006
HKB1F69	H0013 H0384 H0412 H0616 H0659 H0688 L1290 S0007 S0026

	S0222 S0402 S0444
HOHBO69	H0024 H0050 H0100 H0266 H0486 H0519 H0538 H0544 H0545 H0550 H0551 H0575 H0593 H0615 H0619 H0622 H0623 H0653 H0665 H0667 H0770 H0771 L1290 S0015 S0022 S0028 S0032 S0040 S0126 S0134 S0180 S0196 S0208 S0212 S0250 S0276 S0298 S0360 S0390 S0418 S0420 S0434 S3014
HCEES60	H0052 H0123 H0135 H0144 H0251 H0594 H0615 H0622 H0628 H0645 L1290 S0040 S0126 S0142 S0344 S0420 S0430 T0082
HDALV07	H0081 H0427 H0706 H0713 H0716 H0717 H0725 L1290 S0212 S0260 S0280 S6022
HEQAH47	H0544
HATNA88	H0599 H0616 H0708 H0713 L1290 S0216

TABLE 4

SEQ ID NO: X	Cytologic Band or Chromosome:	OMIM Reference(s):
2	22q13.2	188826 602049
4	17q25.2	603967 606800
5	14q11.2	162080 182600 186880 190195 600243 602279 603593 605463 606439 606675
7	11q23.3	176000 236680 261640 600644 602574 603113 604763 605201 607086
9	22q13.1	103050 124030 138981 182380 188826 190040 218040 602049 603590
12	11q11	606860
13	1p36.3-p34.1	115665 116600 120550 120570 120575 121800 130500 138140 142461 153390 153454 155600 164780 167410 171760 172411 172430 178300 185470 211420 256700 600423 600975 601990 602023 603324 603490 603688 603776 604630 604933 605225 605425 605747 605909 605995 606210 606324 606693 606811 606928 606953 606996 607093 607215
17	7p15-p12	107776 138079 139191 142958 142959 153880 165240 180104 203740 261670 600994 601472 601583 603023 603284 606224 606246
18	3q27	109565 120520 142640 210200 228960 600044 602322 603273 603285 603945 603959 605229 605441 605552 607037

TABLE 5

Library Code	Library Description	Disease
H0004	Human Adult Spleen	
H0009	Human Fetal Brain	
H0012	Human Fetal Kidney	
H0013	Human 8 Week Whole Embryo	
H0014	Human Gall Bladder	
H0019	Human Fetal Heart	
H0024	Human Fetal Lung III	
H0030	Human Placenta	
H0031	Human Placenta	
H0039	Human Pancreas Tumor	disease
H0042	Human Adult Pulmonary	
H0050	Human Fetal Heart	
H0052	Human Cerebellum	
H0056	Human Umbilical Vein, Endo. remake	
H0059	Human Uterine Cancer	disease
H0062	Human Thymus	
H0063	Human Thymus	
H0068	Human Skin Tumor	disease
H0081	Human Fetal Epithelium (Skin)	
H0086	Human epithelioid sarcoma	disease
H0087	Human Thymus	
H0090	Human T-Cell Lymphoma	disease
H0100	Human Whole Six Week Old Embryo	
H0108	Human Adult Lymph Node, subtracted	
H0122	Human Adult Skeletal Muscle	
H0123	Human Fetal Dura Mater	
H0124	Human Rhabdomyosarcoma	disease
H0135	Human Synovial Sarcoma	
H0144	Nine Week Old Early Stage Human	
H0163	Human Synovium	
H0178	Human Fetal Brain	
H0179	Human Neutrophil	
H0188	Human Normal Breast	
H0189	Human Resting Macrophage	
H0190	Human Activated Macrophage (LPS)	
H0194	Human Cerebellum, subtracted	
H0208	Early Stage Human Lung, subtracted	
H0213	Human Pituitary, subtracted	
H0244	Human 8 Week Whole Embryo, subtracted	
H0250	Human Activated Monocytes	
H0251	Human Chondrosarcoma	disease
H0252	Human Osteosarcoma	disease

H0253	Human adult testis, large inserts	
H0255	breast lymph node cDNA library	
H0261	H. cerebellum, Enzyme subtracted	
H0263	human colon cancer	disease
H0264	human tonsils	
H0266	Human Microvascular Endothelial Cells, fract. A	
H0271	Human Neutrophil, Activated	
H0286	Human OB MG63 treated (10 nM E2) fraction I	
H0309	Human Chronic Synovitis	disease
H0318	HUMAN B CELL LYMPHOMA	disease
H0321	HUMAN SCHWANOMA	disease
H0327	human corpus colosum	
H0328	human ovarian cancer	disease
H0329	Dermatofibrosarcoma Protuberance	disease
H0333	Hemangiopericytoma	disease
H0343	stomach cancer (human)	disease
H0345	SKIN	
H0351	Glioblastoma	disease
H0352	wilm's tumor	disease
H0370	H. Lymph node breast Cancer	disease
H0375	Human Lung	
H0376	Human Spleen	
H0384	Brain, Kozak	
H0392	H. Meningioma, M1	
H0393	Fetal Liver, subtraction II	
H0412	Human umbilical vein endothelial cells, IL-4 induced	
H0415	H. Ovarian Tumor, II, OV5232	disease
H0421	Human Bone Marrow, re-excision	
H0424	Human Pituitary, subt IX	
H0427	Human Adipose	
H0441	H. Kidney Cortex, subtracted	
H0444	Spleen metastatic melanoma	disease
H0445	Spleen, Chronic lymphocytic leukemia	disease
H0455	H. Striatum Depression, subt	
H0483	Breast Cancer cell line, MDA 36	
H0486	Hodgkin's Lymphoma II	disease
H0489	Crohn's Disease	disease
H0506	Ulcerative Colitis	
H0509	Liver, Hepatoma	disease
H0510	Human Liver, normal	
H0519	NTERA2, control	
H0521	Primary Dendritic Cells, lib 1	
H0522	Primary Dendritic cells, frac 2	
H0529	Myeloid Progenitor Cell Line	
H0538	Merkel Cells	

H0539	Pancreas Islet Cell Tumor	disease
H0540	Skin, burned	
H0543	T cell helper II	
H0544	Human endometrial stromal cells	
H0545	Human endometrial stromal cells-treated with progesterone	
H0549	H. Epididymus, caput & corpus	
H0550	H. Epididymus, cauda	
H0551	Human Thymus Stromal Cells	
H0553	Human Placenta	
H0555	Rejected Kidney, lab 4	disease
H0563	Human Fetal Brain, normalized 50021F	
H0570	Human Fetal Brain, normalized C500H	
H0575	Human Adult Pulmonary,re-excision	
H0580	Dendritic cells, pooled	
H0581	Human Bone Marrow, treated	
H0583	B Cell lymphoma	disease
H0587	Healing groin wound, 7.5 hours post incision	disease
H0591	Human T-cell lymphoma,re-excision	disease
H0592	Healing groin wound - zero hr post-incision (control)	disease
H0593	Olfactory epithelium,nasalcavity	
H0594	Human Lung Cancer,re-excision	disease
H0595	Stomach cancer (human),re-excision	disease
H0597	Human Colon, re-excision	
H0599	Human Adult Heart,re-excision	
H0606	Human Primary Breast Cancer,re-excision	disease
H0615	Human Ovarian Cancer Reexcision	disease
H0616	Human Testes, Reexcision	
H0617	Human Primary Breast Cancer Reexcision	disease
H0618	Human Adult Testes, Large Inserts, Reexcision	
H0619	Fetal Heart, reexcision	
H0620	Human Fetal Kidney, Reexcision	
H0622	Human Pancreas Tumor, Reexcision	disease
H0623	Human Umbilical Vein, Reexcision	
H0624	12 Week Early Stage Human II, Reexcision	
H0625	Ku 812F Basophils Line	
H0628	Human Pre-Differentiated Adipocytes	
H0638	CD40 activated monocyte dendritic cells	
H0641	LPS activated derived dendritic cells	
H0644	Human Placenta (re-excision)	
H0645	Fetal Heart, re-excision	
H0646	Lung, Cancer (4005313 A3): Invasive Poorly Differentiated Lung Adenocarcinoma,	
H0649	Lung, Normal: (4005313 B1)	
H0652	Lung, Normal: (4005313 B1)	

H0653	Stromal Cells	
H0658	Ovary, Cancer (9809C332): Poorly differentiated adenocarcinoma	disease
H0659	Ovary, Cancer (15395A1F): Grade II Papillary Carcinoma	disease
H0660	Ovary, Cancer: (15799A1F) Poorly differentiated carcinoma	disease
H0661	Breast, Cancer: (4004943 A5)	disease
H0662	Breast, Normal: (400522B2)	
H0663	Breast, Cancer: (4005522 A2)	disease
H0665	Stromal cells 3.88	
H0666	Ovary, Cancer: (4004332 A2)	disease
H0667	Stromal cells(HBM3.18)	
H0668	stromal cell clone 2.5	
H0672	Ovary, Cancer: (4004576 A8)	
H0673	Human Prostate Cancer, Stage B2, re-excision	
H0682	Ovarian cancer, Serous Papillary Adenocarcinoma	
H0687	Human normal ovary(#9610G215)	
H0688	Human Ovarian Cancer(#9807G017)	
H0689	Ovarian Cancer	
H0690	Ovarian Cancer, # 9702G001	
H0693	Normal Prostate #ODQ3958EN	
H0706	Human Adult Skeletal Muscle	
H0708	Human Skeletal Muscle	
H0710	Acute Myeloid Leukemia /SGAH (Patient #6)	
H0713	Adipose tissue (diabetic type I, obese) #41706	
H0716	Adipose tissue (diabetic type II)#41689	
H0717	Adipose tissue (diabetic type II) #41661	
H0722	Diabetic Liver 99-09-A281a	
H0725	Normal Adipose Tissue #41838-08	
H0726	Normal skeletal muscle #96-08-A171	
H0753	pancreatic cancer sample # 4004959 A1	
H0754	Pancreatic cancer #14677A1L	
H0755	Pancreatic cancer sample#4004959 A1	
H0757	normal pancreas #400556A8	
H0762	Normal Pancreas 42206	
H0768	Lung cancer	
H0770	Esophageal Cancer #2109A5A ductal carcinoma	
H0771	esophageal cancer #0011C075Ra	
H0773	Malignant Esophagus #9706C049	
H0774	Prostate infiltrated by adenocarcinoma #4007645B1	
H0777	esophageal cancer #9902C094	
H0778	Esophageal Cancer #9804C013Rb	
H0789	renal cell carcinoma of kidney	
H0790	HMC-1 untreated	

L1290	Soares_testis_NHT	
S0007	Early Stage Human Brain	
S0010	Human Amygdala	
S0015	Kidney medulla	
S0022	Human Osteoclastoma Stromal Cells - unamplified	
S0026	Stromal cell TP274	
S0027	Smooth muscle, serum treated	
S0028	Smooth muscle,control	
S0031	Spinal cord	
S0032	Smooth muscle-ILb induced	
S0036	Human Substantia Nigra	
S0037	Smooth muscle, ILb induced	
S0038	Human Whole Brain #2 - Oligo dT > 1.5Kb	
S0040	Adipocytes	
S0044	Prostate BPH	disease
S0051	Human Hypothalamus,Schizophrenia	disease
S0106	STRIATUM DEPRESSION	disease
S0116	Bone marrow	
S0126	Osteoblasts	
S0134	Apoptotic T-cell	
S0142	Macrophage-oxLDL	
S0180	Bone Marrow Stroma, TNF&LPS ind	disease
S0190	Prostate BPH,Lib 2, subtracted	
S0196	Synovial IL-1/TNF stimulated	
S0208	Messangial cell, frac 1	
S0212	Bone Marrow Stromal Cell, untreated	
S0216	Neutrophils IL-1 and LPS induced	
S0222	H. Frontal cortex,epileptic,re-excision	disease
S0250	Human Osteoblasts II	disease
S0260	Spinal Cord, re-excision	
S0276	Synovial hypoxia-RSF subtracted	
S0280	Human Adipose Tissue, re-excision	
S0282	Brain Frontal Cortex, re-excision	
S0298	Bone marrow stroma,treated	
S0328	Palate carcinoma	disease
S0330	Palate normal	
S0344	Macrophage-oxLDL, re-excision	
S0354	Colon Normal II	
S0356	Colon Carcinoma	disease
S0358	Colon Normal III	
S0360	Colon Tumor II	disease
S0362	Human Gastrocnemius	
S0374	Normal colon	
S0376	Colon Tumor	disease
S0378	Pancreas normal PCA4 No	

S0384	Tongue carcinoma	disease
S0390	Smooth muscle, control, re-excision	
S0402	Adrenal Gland,normal	
S0406	Rectum tumour	
S0408	Colon, normal	
S0418	CHME Cell Line,treated 5 hrs	
S0420	CHME Cll Line,untreated	
S0426	Monocyte activated, re-excision	
S0430	Aryepiglottis Normal	
S0434	Stomach Normal	disease
S0436	Stomach Tumour	disease
S0438	Liver Normal Met5No	
S0440	Liver Tumour Met 5 Tu	
S0442	Colon Normal	
S0444	Colon Tumor	disease
S0476	Epithelial-TNF α and INF induced	
S3014	Smooth muscle, serum induced,re-exc	
S6022	H. Adipose Tissue	
S6026	Frontal Lobe, Dementia	
T0006	Human Pineal Gland	
T0068	Normal Ovary, Premenopausal	
T0082	Human Adult Retina	

TABLE 6

OMIM Reference	Description
103050	Adenylosuccinase deficiency Autism, succinylpurinemic
107776	Colton blood group, 110450 [Aquaporin-1 deficiency]
109565	Lymphoma, B-cell
115665	Cataract, congenital, Volkmann type
116600	Cataract, posterior polar
120520	Membranous glomerulonephritis, antenatal [Neutral endopeptidase deficiency]
120550	C1q deficiency, type A
120570	C1q deficiency, type B
120575	C1q deficiency, type C
121300	Coproporphyrria Harderoporphyrinuria
121800	Corneal dystrophy, crystalline, Schnyder
124030	Debrisquine sensitivity Parkinsonism, susceptibility to

126453	Dystonia, primary cervical Blepharospasm, primary benign, 606798
130500	Elliptocytosis-1
138079	Diabetes mellitus, neonatal-onset, 606176 Hyperinsulinism, familial, 602485 MODY, type II, 125851
138140	Glucose transport defect, blood-brain barrier, 606777
138981	Pulmonary alveolar proteinosis, 265120
139191	Growth hormone deficient dwarfism
142461	Dyssegmental dysplasia, Silberman-Handmaker type, 224410 Schwartz-Jampel syndrome, type 1, 255800
142640	Thrombophilia due to HRG deficiency Thrombophilia due to elevated HRG
142958	Radioulnar synostosis with amegakaryocytic thrombocytopenia, 605432
142959	Guttmacher syndrome, 176305 Hand-foot-uterus syndrome, 140000
146200	Hypoparathyroidism, familial
153390	SCID due to LCK deficiency
153454	Ehlers-Danlos syndrome, type VI, 225400
153880	Macular dystrophy, dominant cystoid
155600	Malignant melanoma, cutaneous
162080	Retinitis pigmentosa, autosomal dominant
164780	1p36 deletion syndrome
165240	Greig cephalopolysyndactyly syndrome, 175700 Pallister-Hall syndrome, 146510 Polydactyly, postaxial, types A1 and B, 174200 Polydactyly, preaxial, type IV, 174700
167410	Rhabdomyosarcoma, alveolar, 268220
171760	Hypophosphatasia, adult, 146300 Hypophosphatasia, childhood, 241510 Hypophosphatasia, infantile, 241500
172411	Colorectal cancer, resistance to
172430	Enolase deficiency
176000	Porphyria, acute intermittent Porphyria, acute intermittent, nonerythroid variant
178300	Ptosis, hereditary congenital, 1
180104	Retinitis pigmentosa-9
182380	Glucose/galactose malabsorption, 606824
182600	Spastic paraplegia-3A
185470	Pheochromocytoma, extraadrenal, and cervical paraganglioma, 115310
186880	Leukemia/lymphoma, T-cell
188826	Sorsby fundus dystrophy, 136900
190040	Dermatofibrosarcoma protuberans Giant-cell fibroblastoma

	Meningioma, SIS-related
190195	Ichthyosiform erythroderma, congenital, 242100 Ichthyosis, lamellar, autosomal recessive, 242300
190300	Tremor, familial essential, 1
203740	Alpha-ketoglutarate dehydrogenase deficiency
210200	3-Methylcrotonylglycinuria I
211420	Breast cancer, ductal
218040	Costello syndrome
228960	[Kininogen deficiency]
236680	Hydrocephalus syndrome
256700	Neuroblastoma
258900	Oroticaciduria
261630	Phenylketonuria due to dihydropteridine reductase deficiency
261640	Phenylketonuria due to PTS deficiency
261670	Myopathy due to phosphoglycerate mutase deficiency
600044	Thrombocytopenia, essential, 187950
600243	Temperature-sensitive apoptosis
600423	Hirschsprung disease, cardiac defects, and autonomic dysfunction
600467	Malignant hyperthermia susceptibility 4
600532	Parkinson disease, susceptibility to, 168600
600593	Craniosynostosis, Adelaide type
600644	Cleft lip/palate ectodermal dysplasia syndrome, 225000 Ectodermal dysplasia, Margarita Island type, 225060 Zlotogora-Ogur syndrome, 225000
600882	Charcot-Marie-Tooth disease, type 2B
600975	Glaucoma 3, primary infantile, B
600994	Deafness, autosomal dominant 5
601472	Charcot-Marie-Tooth neuropathy, type 2D
601583	Wilms tumor susceptibility-5
601990	Neuroblastoma
602023	Bartter syndrome, 241200 Bartter syndrome, antenatal, 601678
602049	Neutrophil immunodeficiency syndrome
602279	Oculopharyngeal muscular dystrophy, 164300 Oculopharyngeal muscular dystrophy, autosomal recessive, 257950
602322	Dyskeratosis congenita, 127550
602574	Deafness, autosomal dominant 12, 601842 Deafness, autosomal dominant 8, 601543 Deafness, autosomal recessive 21, 603629
602630	Holoprosencephaly-4, 142946
602773	Renal cell carcinoma 4
603023	Leukemia, acute lymphoblastic
603113	Lung cancer, 211980
603273	ADULT syndrome, 103285 Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3,

	604292 Hay-Wells syndrome, 106260 Limb-mammary syndrome, 603543 Split-hand/foot malformation, type 4, 605289
603284	Cerebral cavernous malformations-2
603285	Cerebral cavernous malformations-3
603324	Deafness, autosomal dominant 2, 600101 Deafness, autosomal dominant, with peripheral neuropathy Deafness, autosomal recessive Erythrokeratoderma variabilis, 133200
603490	XY female
603590	Meningioma
603593	Lysinuric protein intolerance, 222700
603688	Prostate cancer-brain cancer susceptibility
603776	Hypercholesterolemia, familial, 3
603945	Leukoencephalopathy with vanishing white matter, 603896
603959	Hypomagnesemia, primary, 248250
603967	Cramps, familial, potassium-aggravated Hyperkalemic periodic paralysis, 170500 Hypokalemic periodic paralysis, 170400 Myotonia congenita, atypical, acetazolamide-responsive, 170500 Paramyotonia congenita, 168300
604365	Retinal degeneration, autosomal recessive, prominin-related
604484	Neuropathy, hereditary motor and sensory, Okinawa type
604630	Obesity, mild, early-onset, 601665
604763	Leukemia, acute myeloid
604802	Huntington disease-like 3
604831	Ellis-van Creveld syndrome, 225500 Weyers acrodental dysostosis, 193530
604933	Adenomatous polyposis of the colon, susceptibility to, 175100
605201	Hypoalphalipoproteinemia, primary
605225	Inflammatory bowel disease-7, 266600
605229	Spastic paraparesis 14, autosomal recessive
605389	Hypotrichosis simplex
605425	Erythrokeratoderma variabilis with erythema gyratum repens, 133200
605441	Adiponectin deficiency
605463	Radiation sensitivity/chromosome instability syndrome, autosomal dominant
605480	Systemic lupus erythematosus, susceptibility to, 3, 152700
605543	Parkinson disease 4, autosomal dominant, Lewy body
605552	Abdominal obesity-metabolic syndrome
605747	Hypercholesterolemia, familial, autosomal recessive, 603813
605841	Narcolepsy, 161400
605909	Parkinson disease, 168600
605995	Charcot-Marie-Tooth neuropathy, type 2A, 118210

606210	Muscular dystrophy, rigid spine, 1, 602771
606224	Anemia, hemolytic, due to UMPH1 deficiency, 266120
606246	Endometrial stromal tumors
606324	Parkinson disease, 168600
606439	Spastic paraplegia-3A, 182600
606675	Inflammatory bowel disease-4, 266600
606693	Kufor-Rakeb syndrome
606800	Glycogen storage disease II, 232300
606811	Hyperprolinemia, type II, 239510
606860	Angioedema, hereditary, 106100
606928	[Bone mineral density variability 3], 601884
606953	Galactose epimerase deficiency, 230350
606996	Senior-Loken syndrome 4
607037	Peroxisomal bifunctional enzyme deficiency, 261515
607086	Aortic aneurysm, familial thoracic I
607093	Homocystinuria due to MTHFR deficiency, 236250
607107	Nasopharyngeal carcinoma 1, 161550
607215	Nephronophtisis 4, 606966

[1166] Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

EXAMPLES

Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

[1167] Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector. Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited Plasmid</u>
Lambda Zap	pBluescript (pBS)
Uni-Zap XR	pBluescript (pBS)
Zap Express	pBK
lafmid BA	plafmid BA
pSport1	pSport1
pCMVSport 2.0	pCMVSport 2.0
pCMVSport 3.0	pCMVSport 3.0
pCR®2.1	pCR®2.1

[1168] Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short et al., *Nucleic Acids Res.*, 16:7583-7600 (1988); Alting-Mees et al., *Nucleic Acids Res.*, 17:9494 (1989)) and pBK (Alting-Mees et al., *Strategies*, 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS-. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single

stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

[1169] Vectors pSport1, pCMVSport 2.0 and pCMVSport 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., *Focus* 15:59 (1993)). Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR®2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, *Nuc. Acids Res.*, 16:9677-9686 (1988) and Mead et al., *BioTechnology*, 9 (1991)). Preferably, a polynucleotide of the present invention does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

[1170] The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA Plasmid:V identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

[1171] Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ ID NO:X.

[1172] Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with ^{32}P - γ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring, NY (1982)). The plasmid

mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for bacterial colony screening (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

[1173] Alternatively, two primers of 17-20 nucleotides derived from both ends of the SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the desired cDNA using the deposited cDNA plasmid as a template. The polymerase chain reaction is carried out under routine conditions, for instance, in 25 μ l of reaction mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is 1.5-5 mM MgCl₂, 0.01% (w/v) gelatin, 20 μ M each of dATP, dCTP, dGTP, dTTP, 25 pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR (denaturation at 94°C for 1 min; annealing at 55°C for 1 min; elongation at 72°C for 1 min) are performed with a Perkin-Elmer Cetus automated thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and the DNA band with expected molecular weight is excised and purified. The PCR product is verified to be the selected sequence by subcloning and sequencing the DNA product.

[1174] Several methods are available for the identification of the 5' or 3' non-coding portions of a gene which may not be present in the deposited clone. These methods include but are not limited to, filter probing, clone enrichment using specific probes, and protocols similar or identical to 5' and 3' "RACE" protocols which are well known in the art. For instance, a method similar to 5' RACE is available for generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et al., *Nucleic Acids Res.*, 21(7):1683-1684 (1993)).

[1175] Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a population of RNA presumably containing full-length gene RNA transcripts. A primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known

sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

[1176] This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

[1177] This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide

[1178] A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X, according to the method described in Example 1. (See also, Sambrook.)

Example 3: Tissue Distribution of Polypeptide

[1179] Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with P³² using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™ column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

[1180] Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70°C overnight, and the films developed according to standard procedures.

Example 4: Chromosomal Mapping of the Polynucleotides

[1181] An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95°C; 1 minute, 56°C; 1 minute, 70°C. This cycle is repeated 32 times followed by one 5 minute cycle at 70°C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

Example 5: Bacterial Expression of a Polypeptide

[1182] A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI and initiation/stop codons, if necessary, to clone the amplified product into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp^R), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning sites.

[1183] The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial

RBS. The ligation mixture is then used to transform the *E. coli* strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which expresses the lacI repressor and also confers kanamycin resistance (Kan^r). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

[1184] Clones containing the desired constructs are grown overnight (O/N) in liquid culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The cells are grown to an optical density 600 (O.D.⁶⁰⁰) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

[1185] Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4°C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrotri-acetic acid ("Ni-NTA") affinity resin column (available from QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

[1186] Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

[1187] The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM immidazole. Immidazole is removed by a final dialyzing step against PBS or 50 mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4°C or frozen at -80°C.

[1188] In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains: 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

[1189] DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

[1190] The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

Example 6: Purification of a Polypeptide from an Inclusion Body

[1191] The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10°C.

[1192] Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10°C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

[1193] The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by

centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

[1194] The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4°C overnight to allow further GuHCl extraction.

[1195] Following high speed centrifugation (30,000 xg) to remove insoluble particles, the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4°C without mixing for 12 hours prior to further purification steps.

[1196] To clarify the refolded polypeptide solution, a previously prepared tangential filtration unit equipped with 0.16 µm membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

[1197] Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant A₂₈₀ monitoring of the effluent. Fractions containing the polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

[1198] The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 µg of purified protein is loaded.

The purified protein can also be tested for endotoxin/LPS contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System

[1199] In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40") is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak *Drosophila* promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

[1200] Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., *Virology* 170:31-39 (1989).

[1201] Specifically, the cDNA sequence contained in the deposited clone is amplified using the PCR protocol described in Example 1 using primers with appropriate restriction sites and initiation/stop codons. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does not need a second signal peptide. Alternatively, the vector can be modified (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin NO: 1555 (1987).

[1202] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[1203] The plasmid is digested with the corresponding restriction enzymes and optionally, can be dephosphorylated using calf intestinal phosphatase, using routine procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

[1204] The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

[1205] Five μ g of a plasmid containing the polynucleotide is co-transfected with 1.0 μ g of a commercially available linearized baculovirus DNA ("BaculoGoldTM baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One μ g of BaculoGoldTM virus DNA and 5 μ g of the plasmid are mixed in a sterile well of a microtiter plate containing 50 μ l of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 μ l Lipofectin plus 90 μ l Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to SF9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is then incubated for 5 hours at 27° C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27° C for four days.

[1206] After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then resuspended in a microcentrifuge tube containing 200 μ l of Grace's medium and the suspension containing

the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4° C.

[1207] To verify the expression of the polypeptide, Sf9 cells are grown in Grace's medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5 µCi of ³⁵S-methionine and 5 µCi ³⁵S-cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

[1208] Microsequencing of the amino acid sequence of the amino terminus of purified protein may be used to determine the amino terminal sequence of the produced protein.

Example 8: Expression of a Polypeptide in Mammalian Cells

[1209] The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which mediates the initiation of transcription of mRNA, a protein coding sequence, and signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLV, HIV1 and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

[1210] Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden), pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSport 2.0, and pCMVSport 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

[1211] Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable

marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

[1212] The transfected gene can also be amplified to express large amounts of the encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt et al., *J. Biol. Chem.*, 253:1357-1370 (1978); Hamlin et al., *Biochem. et Biophys. Acta*, 1097:107-143 (1990); Page et al., *Biotechnology*, 9:64-68 (1991)). Another useful selection marker is the enzyme glutamine synthase (GS) (Murphy et al., *Biochem J.*, 227:277-279 (1991); Bebbington et al., *BioTechnology*, 10:169-175 (1992)). Using these markers, the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

[1213] Derivatives of the plasmid pSV2-dhfr (ATCC Accession No.: 37146), the expression vectors pC4 (ATCC Accession No.: 209646) and pC6 (ATCC Accession No.: 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., *Molecular and Cellular Biology*, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., *Cell*, 41:521-530 (1985)). Multiple cloning sites, e.g., with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

[1214] Specifically, the plasmid pC6, for example, is digested with appropriate restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

[1215] A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1 using primers with appropriate restrictions sites and initiation/stop codons, if necessary. The vector can be modified to include a heterologous signal sequence if necessary for secretion. (See, e.g., WO 96/34891.)

[1216] The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("Geneclean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

[1217] The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

[1218] Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five μ g of the expression plasmid pC6 is cotransfected with 0.5 μ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1 μ M, 2 μ M, 5 μ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200 μ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

Example 9: Protein Fusions

[1219] The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., *Nature*, 331:84-86 (1988)) The polypeptides can also be fused to heterologous polypeptide sequences to facilitate secretion and intracellular trafficking (e.g., KDEL). Moreover, fusion to IgG-1, IgG-3, and albumin increases the halflife time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or

homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

[1220] Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector, and initiation/stop codons, if necessary.

[1221] For example, if pC4 (Accession No.: 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

[1222] If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCGGAGCCCAAATCTTGTACACAAACTCACACATGCCACCGTGGCCAGCACCTGAAT
TCGAGGGTGACCGTCAGTCTTCTCTCCCCCAAAACCCAAGGACACCCCATGATCTCCCG
GACTCCTGAGGTCACTGGCTGGTGGACGTAAGCCACGAAGACCCCTGAGGTCAAGTTCAA
CTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGGAGCAGTACA
ACAGCACGTACCGTGTTGTCAGCGTCCTCACCGTCTGCACCAAGGACTGGCTGAATGGCAAGG
AGTACAAGTCAAGGTCTTCAACAAAGCCCTCCAAACCCCCATCGAGAAAACCATTCTCAAAG
CCAAAGGGCAGCCCCGAGAACCAACAGGTGTACACCCCTGCCCTATCCGGGATGAGCTGACCA
AGAACCCAGGTGACGCTGACCTGCCCTGGTCAAAGGCTCTATCCAAGCGACATGCCGTGGAGT
GGGAGAGCAATGGGCAGCGGAGAACAACTACAAGACCAAGCAGCCTCCGTGCTGGACTCCGAC
GGCTCCTTCTCTACAGCAAGCTACCGTGGACAAGAGCAGGTGGAGCAGGGGAACCTC

TTCTCATGCTCCGTATGCATGAGGCTCTGCACAACCACTACACGCAGAAAGAGCCTCTCCCTGT
CTCCGGGTAAATGAGTGCACGGCCGCACTCTAGAGGAT (SEQ ID NO:1)

Example 10: Formulating a Polypeptide

[1223] The invention also provides methods of treatment and/or prevention of diseases or disorders (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By Therapeutic is meant polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

[1224] The polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

[1225] As a general proposition, the total pharmaceutically effective amount of polypeptide administered parenterally per dose will be in the range of about 1 $\mu\text{g}/\text{kg}/\text{day}$ to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the polypeptide is typically administered at a dose rate of about 1 $\mu\text{g}/\text{kg}/\text{hour}$ to about 50 $\mu\text{g}/\text{kg}/\text{hour}$, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

[1226] Pharmaceutical compositions containing the polypeptide of the invention are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any

type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

[1227] The polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules. Sustained-release matrices include polylactides (U.S. Pat. NO: 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers*, 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.*, 12:98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988).

[1228] In a preferred embodiment, compositions of the invention are formulated in a biodegradable, polymeric drug delivery system, for example as described in U.S. Patent Nos. 4,938,763; 5,278,201; 5,278,202; 5,324,519; 5,340,849; and 5,487,897 and in International Publication Numbers WO01/35929, WO00/24374, and WO00/06117 which are hereby incorporated by reference in their entirety. In specific preferred embodiments the compositions of the invention are formulated using the ATRIGEL® Biodegradable System of Atrix Laboratories, Inc. (Fort Collins, Colorado).

[1229] Examples of biodegradable polymers which can be used in the formulation of compositions of the invention include, but are not limited to, polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrate, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), poly(methyl vinyl ether), poly(maleic anhydride), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, and copolymers, terpolymers, or combinations or mixtures of the above materials. The preferred polymers are those that have a lower degree of crystallization and are more hydrophobic. These polymers and copolymers are more soluble in the biocompatible solvents than the highly crystalline polymers such as polyglycolide and chitin which also have a high degree of hydrogen-bonding. Preferred materials with the desired solubility parameters are the polylactides, polycaprolactones, and copolymers of these with glycolide in which there are more

amorphous regions to enhance solubility. In specific preferred embodiments, the biodegradable polymers which can be used in the formulation of compositions of the invention are poly(lactide-co-glycolides). Polymer properties such as molecular weight, hydrophobicity, and lactide/glycolide ratio may be modified to obtain the desired drug release profile (See, e.g., Ravivarapu et al., Journal of Pharmaceutical Sciences 89:732-741 (2000), which is hereby incorporated by reference in its entirety).

[1230] It is also preferred that the solvent for the biodegradable polymer be non-toxic, water miscible, and otherwise biocompatible. Examples of such solvents include, but are not limited to, N-methyl-2-pyrrolidone, 2-pyrrolidone, C2 to C6 alkanols, C1 to C15 alcohols, diols, triols, and tetraols such as ethanol, glycerine propylene glycol, butanol; C3 to C15 alkyl ketones such as acetone, diethyl ketone and methyl ethyl ketone; C3 to C15 esters such as methyl acetate, ethyl acetate, ethyl lactate; alkyl ketones such as methyl ethyl ketone, C1 to C15 amides such as dimethylformamide, dimethylacetamide and caprolactam; C3 to C20 ethers such as tetrahydrofuran, or solketal; tweens, triacetin, propylene carbonate, decylmethylsulfoxide, dimethyl sulfoxide, oleic acid, 1-dodecylazacycloheptan-2-one. Other preferred solvents are benzyl alcohol, benzyl benzoate, dipropylene glycol, tributyrin, ethyl oleate, glycerin, glycofural, isopropyl myristate, isopropyl palmitate, oleic acid, polyethylene glycol, propylene carbonate, and triethyl citrate. The most preferred solvents are N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, triacetin, and propylene carbonate because of the solvating ability and their compatibility.

[1231] Additionally, formulations comprising compositions of the invention and a biodegradable polymer may also include release-rate modification agents and/or pore-forming agents. Examples of release-rate modification agents include, but are not limited to, fatty acids, triglycerides, other like hydrophobic compounds, organic solvents, plasticizing compounds and hydrophilic compounds. Suitable release rate modification agents include, for example, esters of mono-, di-, and tricarboxylic acids, such as 2-ethoxyethyl acetate, methyl acetate, ethyl acetate, diethyl phthalate, dimethyl phthalate, dibutyl phthalate, dimethyl adipate, dimethyl succinate, dimethyl oxalate, dimethyl citrate, triethyl citrate, acetyl tributyl citrate, acetyl triethyl citrate, glycerol triacetate, di(n-butyl) sebacate, and the like; polyhydroxy alcohols, such as propylene glycol, polyethylene glycol, glycerin, sorbitol, and the like; fatty acids; triesters of glycerol, such as

triglycerides, epoxidized soybean oil, and other epoxidized vegetable oils; sterols, such as cholesterol; alcohols, such as C_{sub}6 -C_{sub}12 alkanols, 2-ethoxyethanol, and the like. The release rate modification agent may be used singly or in combination with other such agents. Suitable combinations of release rate modification agents include, but are not limited to, glycerin/propylene glycol, sorbitol/glycerine, ethylene oxide/propylene oxide, butylene glycol/adipic acid, and the like. Preferred release rate modification agents include, but are not limited to, dimethyl citrate, triethyl citrate, ethyl heptanoate, glycerin, and hexanediol. Suitable pore-forming agents that may be used in the polymer composition include, but are not limited to, sugars such as sucrose and dextrose, salts such as sodium chloride and sodium carbonate, polymers such as hydroxylpropylcellulose, carboxymethylcellulose, polyethylene glycol, and polyvinylpyrrolidone. Solid crystals that will provide a defined pore size, such as salt or sugar, are preferred.

[1232] In specific preferred embodiments the compositions of the invention are formulated using the BEMA™ BioErodible Mucoadhesive System, MCA™ MucoCutaneous Absorption System, SMP™ Solvent MicroParticle System, or BCP™ BioCompatible Polymer System of Atrix Laboratories, Inc. (Fort Collins, Colorado).

[1233] Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. USA*, 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci. USA*, 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

[1234] For parenteral administration, in one embodiment, the polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides.

[1235] Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

[1236] The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

[1237] The polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

[1238] Any polypeptide to be used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

[1239] Polypeptides ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous polypeptide solution, and the resulting mixture is

lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

[1240] The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

[1241] The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG (e.g., THERACYS®), MPL and nonviable preparations of *Corynebacterium parvum*. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomylitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

[1242] The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. In preferred embodiments, therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to antidiabetic agents (e.g., a biguanide antidiabetic agent, a glitazone antidiabetic agent, and a sulfonylurea antidiabetic agent). In additional embodiments, therapeutic agents that may be administered in combination with the Therapeutics of the invention, include chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, and/or therapeutic treatments described below. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

[1243] In one embodiment, the Therapeutics of the invention are administered in combination with an anticoagulant. Anticoagulants that may be administered with the compositions of the invention include, but are not limited to, heparin, low molecular weight heparin, warfarin sodium (e.g., COUMADIN®), dicumarol, 4-hydroxycoumarin, anisindione (e.g., MIRADONTM), acenocoumarol (e.g., nicoumalone, SINTHROMETM), indan-1,3-dione, phenprocoumon (e.g., MARCUMARTM), ethyl biscoumacetate (e.g., TROMEXANTM), and aspirin. In a specific embodiment, compositions of the invention are administered in combination with heparin and/or warfarin. In another specific embodiment, compositions of the invention are administered in combination with warfarin. In another specific embodiment, compositions of the invention are administered in combination with warfarin and aspirin. In another specific embodiment, compositions of the invention are administered in combination with heparin. In another specific embodiment, compositions of the invention are administered in combination with heparin and aspirin.

[1244] In another embodiment, the Therapeutics of the invention are administered in combination with thrombolytic drugs. Thrombolytic drugs that may be administered with the compositions of the invention include, but are not limited to, plasminogen, lys-

plasminogen, alpha2-antiplasmin, streptokinase (e.g., KABIKINASE™), antiresplace (e.g., EMINASE™), tissue plasminogen activator (t-PA, altevase, ACTIVASE™), urokinase (e.g., ABBOKINASE™), sauruplase, (Prourokinase, single chain urokinase), and aminocaproic acid (e.g., AMICAR™). In a specific embodiment, compositions of the invention are administered in combination with tissue plasminogen activator and aspirin.

[1245] In another embodiment, the Therapeutics of the invention are administered in combination with antiplatelet drugs. Antiplatelet drugs that may be administered with the compositions of the invention include, but are not limited to, aspirin, dipyridamole (e.g., PERSANTINE™), and ticlopidine (e.g., TICLID™).

[1246] In specific embodiments, the use of anti-coagulants, thrombolytic and/or antiplatelet drugs in combination with Therapeutics of the invention is contemplated for the prevention, diagnosis, and/or treatment of thrombosis, arterial thrombosis, venous thrombosis, thromboembolism, pulmonary embolism, atherosclerosis, myocardial infarction, transient ischemic attack, unstable angina. In specific embodiments, the use of anticoagulants, thrombolytic drugs and/or antiplatelet drugs in combination with Therapeutics of the invention is contemplated for the prevention of occlusion of saphenous grafts, for reducing the risk of periprocedural thrombosis as might accompany angioplasty procedures, for reducing the risk of stroke in patients with atrial fibrillation including nonrheumatic atrial fibrillation, for reducing the risk of embolism associated with mechanical heart valves and or mitral valves disease. Other uses for the therapeutics of the invention, alone or in combination with antiplatelet, anticoagulant, and/or thrombolytic drugs, include, but are not limited to, the prevention of occlusions in extracorporeal devices (e.g., intravascular canulas, vascular access shunts in hemodialysis patients, hemodialysis machines, and cardiopulmonary bypass machines).

[1247] In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and/or protease inhibitors (PIs). NRTIs that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). NNRTIs that may be administered in combination with the

Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), DESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIXIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

[1248] Additional NRTIs include LODENOSINE™ (F-ddA; an acid-stable adenosine NRTI; Triangle/Abbott); COVIRACIL™ (emtricitabine/FTC; structurally related to lamivudine (3TC) but with 3- to 10-fold greater activity *in vitro*; Triangle/Abbott); dOTC (BCH-10652, also structurally related to lamivudine but retains activity against a substantial proportion of lamivudine-resistant isolates; Biochem Pharma); Adefovir (refused approval for anti-HIV therapy by FDA; Gilead Sciences); PREVEON® (Adefovir Dipivoxil, the active prodrug of adefovir; its active form is PMEA-pp); TENOFOVIR™ (bis-POC PMPA, a PMPA prodrug; Gilead); DAPD/DXG (active metabolite of DAPD; Triangle/Abbott); D-D4FC (related to 3TC, with activity against AZT/3TC-resistant virus); GW420867X (Glaxo Wellcome); ZIAGEN™ (abacavir/159U89; Glaxo Wellcome Inc.); CS-87 (3'azido-2',3'-dideoxyuridine; WO 99/66936); and S-acyl-2-thioethyl (SATE)-bearing prodrug forms of β-L-FD4C and β-L-FddC (WO 98/17281).

[1249] Additional NNRTIs include COACTINON™ (Emivirine/MKC-442, potent NNRTI of the HEPT class; Triangle/Abbott); CAPRAVIRINE™ (AG-1549/S-1153, a next generation NNRTI with activity against viruses containing the K103N mutation; Agouron); PNU-142721 (has 20- to 50-fold greater activity than its predecessor delavirdine and is active against K103N mutants; Pharmacia & Upjohn); DPC-961 and DPC-963 (second-generation derivatives of efavirenz, designed to be active against viruses with the K103N mutation; DuPont); GW-420867X (has 25-fold greater activity than HBY097 and is active against K103N mutants; Glaxo Wellcome); CALANOLIDE A (naturally occurring agent from the latex tree; active against viruses containing either or both the Y181C and K103N mutations); and Propolis (WO 99/49830).

[1250] Additional protease inhibitors include LOPINAVIR™ (ABT378/r; Abbott Laboratories); BMS-232632 (an azapeptide; Bristol-Myers Squibb); TIPRANAVIR™ (PNU-140690, a non-peptidic dihydropyrone; Pharmacia & Upjohn); PD-178390 (a nonpeptidic dihydropyrone; Parke-Davis); BMS 232632 (an azapeptide; Bristol-Myers Squibb); L-756,423 (an indinavir analog; Merck); DMP-450 (a cyclic urea compound; Avid & DuPont); AG-1776 (a peptidomimetic with *in vitro* activity against protease inhibitor-resistant viruses; Agouron); VX-175/GW-433908 (phosphate prodrug of amprenavir; Vertex & Glaxo Wellcome); CGP61755 (Ciba); and AGENERASE™ (amprenavir; Glaxo Wellcome Inc.).

[1251] Additional antiretroviral agents include fusion inhibitors/gp41 binders. Fusion inhibitors/gp41 binders include T-20 (a peptide from residues 643-678 of the HIV gp41 transmembrane protein ectodomain which binds to gp41 in its resting state and prevents transformation to the fusogenic state; Trimeris) and T-1249 (a second-generation fusion inhibitor; Trimeris).

[1252] Additional antiretroviral agents include fusion inhibitors/chemokine receptor antagonists. Fusion inhibitors/chemokine receptor antagonists include CXCR4 antagonists such as AMD 3100 (a bicyclam), SDF-1 and its analogs, and ALX40-4C (a cationic peptide), T22 (an 18 amino acid peptide; Trimeris) and the T22 analogs T134 and T140; CCR5 antagonists such as RANTES (9-68), AOP-RANTES, NNY-RANTES, and TAK-779; and CCR5/CXCR4 antagonists such as NSC 651016 (a distamycin analog). Also included are CCR2B, CCR3, and CCR6 antagonists. Chemokine receptor agonists such as RANTES, SDF-1, MIP-1 α , MIP-1 β , etc., may also inhibit fusion.

[1253] Additional antiretroviral agents include integrase inhibitors. Integrase inhibitors include dicaffeoylquinic (DFQA) acids; L-chicoric acid (a dicaffeoyltartaric (DCTA) acid); quinalizarin (QLC) and related anthraquinones; ZINTEVIR™ (AR 177, an oligonucleotide that probably acts at cell surface rather than being a true integrase inhibitor; Arondex); and naphthols such as those disclosed in WO 98/50347.

[1254] Additional antiretroviral agents include hydroxyurea-like compounds such as BCX-34 (a purine nucleoside phosphorylase inhibitor; Biocryst); ribonucleotide reductase inhibitors such as DIDOX™ (Molecules for Health); inosine monophosphate

dehydrogenase (IMPDH) inhibitors such as VX-497 (Vertex); and mycopholic acids such as CellCept (mycophenolate mofetil; Roche).

[1255] Additional antiretroviral agents include inhibitors of viral integrase, inhibitors of viral genome nuclear translocation such as arylene bis(methylketone) compounds; inhibitors of HIV entry such as AOP-RANTES, NNY-RANTES, RANTES-IgG fusion protein, soluble complexes of RANTES and glycosaminoglycans (GAG), and AMD-3100; nucleocapsid zinc finger inhibitors such as dithiane compounds; targets of HIV Tat and Rev; and pharmacoenhancers such as ABT-378.

[1256] Other antiretroviral therapies and adjunct therapies include cytokines and lymphokines such as MIP-1 α , MIP-1 β , SDF-1 α , IL-2, PROLEUKIN™ (aldesleukin/L2-7001; Chiron), IL-4, IL-10, IL-12, and IL-13; interferons such as IFN- α 2a; antagonists of TNFs, NF κ B, GM-CSF, M-CSF, and IL-10; agents that modulate immune activation such as cyclosporin and prednisone; vaccines such as Remune™ (HIV Immunogen), APL 400-003 (Apollon), recombinant gp120 and fragments, bivalent (B/E) recombinant envelope glycoprotein, rgp120CM235, MN rgp120, SF-2 rgp120, gp120/soluble CD4 complex, Delta JR-FL protein, branched synthetic peptide derived from discontinuous gp120 C3/C4 domain, fusion-competent immunogens, and Gag, Pol, Nef, and Tat vaccines; gene-based therapies such as genetic suppressor elements (GSEs; WO 98/54366), and intrakines (genetically modified CC chemokines targeted to the ER to block surface expression of newly synthesized CCR5 (Yang *et al.*, PNAS 94:11567-72 (1997); Chen *et al.*, *Nat. Med.* 3:1110-16 (1997)); antibodies such as the anti-CXCR4 antibody 12G5, the anti-CCR5 antibodies 2D7, 5C7, PA8, PA9, PA10, PA11, PA12, and PA14, the anti-CD4 antibodies Q4120 and RPA-T4, the anti-CCR3 antibody 7B11, the anti-gp120 antibodies 17b, 48d, 447-52D, 257-D, 268-D and 50.1, anti-Tat antibodies, anti-TNF- α antibodies, and monoclonal antibody 33A; aryl hydrocarbon (AH) receptor agonists and antagonists such as TCDD, 3,3',4,4',5-pentachlorobiphenyl, 3,3',4,4'-tetrachlorobiphenyl, and α -naphthoflavone (WO 98/30213); and antioxidants such as γ -L-glutamyl-L-cysteine ethyl ester (γ -GCE; WO 99/56764).

[1257] In a further embodiment, the Therapeutics of the invention are administered in combination with an antiviral agent. Antiviral agents that may be administered with the

Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

[1258] In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™, KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with

PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent an opportunistic *Toxoplasma gondii* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

[1259] In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rapamycin, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-sulfamethoxazole, and vancomycin.

[1260] In other embodiments, the Therapeutics of the invention are administered in combination with immunostimulants. Immunostimulants that may be administered in combination with the Therapeutics of the invention include, but are not limited to, levamisole (e.g., ERGAMISOL™), isoprinosine (e.g. INOSIPLEX™), interferons (e.g. interferon alpha), and interleukins (e.g., IL-2).

[1261] In other embodiments, Therapeutics of the invention are administered in combination with immunosuppressive agents. Immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisolone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other immunosuppressive agents that act by suppressing the function of responding T cells. Other immunosuppressive agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to, prednisolone, methotrexate, thalidomide, methoxsalen, rapamycin, leflunomide, mizoribine (BREDININ™), brequinar, deoxyspergualin, and azaspirane (SKF 105685), ORTHOCLONE OKT® 3 (muromonab-CD3), SANDIMMUNE™, NEORAL™, SANGLYTA™ (cyclosporine), PROGRAF® (FK506, tacrolimus), CELLCEPT® (mycophenolate mofetil, of which the active metabolite is mycophenolic acid), IMURANT™ (azathioprine), glucocorticosteroids, adrenocortical steroids such as DELTASONE™ (prednisone) and HYDELTRASOL™ (prednisolone), FOLEX™ and MEXATE™ (methotrexate), OXSORALEN-ULTRA™

(methoxsalen) and RAPAMUNE™ (sirolimus). In a specific embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

[1262] In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations. Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but are not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULINTM, GAMMAGARD S/D™, ATGAM™ (antithymocyte globulin), and GAMIMUNE™. In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation therapy (e.g., bone marrow transplant).

[1263] In certain embodiments, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, corticosteroids (e.g. betamethasone, budesonide, cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone), nonsteroidal anti-inflammatory drugs (e.g., diclofenac, diflunisal, etodolac, fenoprofen, flufenamic acid, flurbiprofen, ibuprofen, indomethacin, ketoprofen, meclofenamate, mefenamic acid, meloxicam, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tenoxicam, tiaprofenic acid, and tolmetin.), as well as antihistamines, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone, guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

[1264] In an additional embodiment, the compositions of the invention are administered alone or in combination with an anti-angiogenic agent. Anti-angiogenic agents that may be administered with the compositions of the invention include, but are not limited to, Angiostatin (Entremed, Rockville, MD), Tropomin-1 (Boston Life Sciences, Boston, MA), anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel (Taxol), Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of

Metalloproteinase-2, VEGI, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

[1265] Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

[1266] Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetone and vanadyl sulfate including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

[1267] Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetone. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

[1268] A wide variety of other anti-angiogenic factors may also be utilized within the context of the present invention. Representative examples include, but are not limited to, platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells), (Murata et al., Cancer Res. 51:22-26, (1991)); Sulphated Polysaccharide Peptidoglycan Complex (SP-PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-3,4-dehydroproline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-

propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., *J. Bio. Chem.* 267:17321-17326, (1992)); Chymostatin (Tomkinson et al., *Biochem J.* 286:475-480, (1992)); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin (Ingber et al., *Nature* 348:555-557, (1990)); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, *J. Clin. Invest.* 79:1440-1446, (1987)); anticolagenase-serum; alpha2-antiplasmin (Holmes et al., *J. Biol. Chem.* 262(4):1659-1664, (1987)); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4- chloroanthronilic acid disodium or "CCA"; (Takeuchi et al., *Agents Actions* 36:312-316, (1992)); and metalloproteinase inhibitors such as BB94.

[1269] Additional anti-angiogenic factors that may also be utilized within the context of the present invention include Thalidomide, (Celgene, Warren, NJ); Angiostatic steroid; AGM-1470 (H. Brem and J. Folkman *J Pediatr. Surg.* 28:445-51 (1993)); an integrin alpha v beta 3 antagonist (C. Stogard et al., *J Clin. Invest.* 103:47-54 (1999)); carboxynaminolmidazole; Carboxyamidotriazole (CAI) (National Cancer Institute, Bethesda, MD); Conbretastatin A-4 (CA4P) (OXiGENE, Boston, MA); Squalamine (Magainin Pharmaceuticals, Plymouth Meeting, PA); TNP-470, (Tap Pharmaceuticals, Deerfield, IL); ZD-0101 AstraZeneca (London, UK); APRA (CT2584); Benefin, Byrostatin-1 (SC339555); CGP-41251 (PKC 412); CM101; Dexrazoxane (ICRF187); DMXAA; Endostatin; Flavopiridol; Genestein; GTE; ImmTher; Iressa (ZD1839); Octreotide (Somatostatin); Panretin; Penacillamine; Photopoint; PI-88; Prinomastat (AG-3340) Purlytin; Suradista (FCE26644); Tamoxifen (Nolvadex); Tazarotene; Tetrathiomolybdate; Xeloda (Capecitabine); and 5-Fluorouracil.

[1270] Anti-angiogenic agents that may be administered in combination with the compounds of the invention may work through a variety of mechanisms including, but not limited to, inhibiting proteolysis of the extracellular matrix, blocking the function of endothelial cell-extracellular matrix adhesion molecules, by antagonizing the function of angiogenesis inducers such as growth factors, and inhibiting integrin receptors expressed on proliferating endothelial cells. Examples of anti-angiogenic inhibitors that interfere with extracellular matrix proteolysis and which may be administered in combination with the compositions of the invention include, but are not limited to, AG-3340 (Agouron, La Jolla, CA), BAY-12-9566 (Bayer, West Haven, CT), BMS-275291 (Bristol Myers Squibb,

Princeton, NJ), CGS-27032A (Novartis, East Hanover, NJ), Marimastat (British Biotech, Oxford, UK), and Metastat (Aeterna, St-Foy, Quebec). Examples of anti-angiogenic inhibitors that act by blocking the function of endothelial cell-extracellular matrix adhesion molecules and which may be administered in combination with the compositions of the invention include, but are not limited to, EMD-121974 (Merck KGaA Darmstadt, Germany) and Vitaxin (Ixsys, La Jolla, CA/MedImmune, Gaithersburg, MD). Examples of anti-angiogenic agents that act by directly antagonizing or inhibiting angiogenesis inducers and which may be administered in combination with the compositions of the invention include, but are not limited to, Angiozyme (Ribozyme, Boulder, CO), Anti-VEGF antibody (Genentech, S. San Francisco, CA), PTK-787/ZK-225846 (Novartis, Basel, Switzerland), SU-101 (Sugen, S. San Francisco, CA), SU-5416 (Sugen/ Pharmacia Upjohn, Bridgewater, NJ), and SU-6668 (Sugen). Other anti-angiogenic agents act to indirectly inhibit angiogenesis. Examples of indirect inhibitors of angiogenesis which may be administered in combination with the compositions of the invention include, but are not limited to, IM-862 (Cytran, Kirkland, WA), Interferon-alpha, IL-12 (Roche, Nutley, NJ), and Pentosan polysulfate (Georgetown University, Washington, DC).

[1271] In particular embodiments, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of an autoimmune disease, such as for example, an autoimmune disease described herein.

[1272] In a particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of arthritis. In a more particular embodiment, the use of compositions of the invention in combination with anti-angiogenic agents is contemplated for the treatment, prevention, and/or amelioration of rheumatoid arthritis.

[1273] In another embodiment, the polynucleotides encoding a polypeptide of the present invention are administered in combination with an angiogenic protein, or polynucleotides encoding an angiogenic protein. Examples of angiogenic proteins that may be administered with the compositions of the invention include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2, VEGF-3, epidermal growth factor alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin-like growth

factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

[1274] In additional embodiments, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to alkylating agents such as nitrogen mustards (for example, Mechlorethamine, Cyclophosphamide, Cyclophosphamide Ifosfamide, Melphalan (L-sarcolysin), and Chlorambucil), ethylenimines and methylmelamines (for example, Hexamethylmelamine and Thiotepa), alkyl sulfonates (for example, Busulfan), nitrosoureas (for example, Carmustine (BCNU), Lomustine (CCNU), Semustine (methyl-CCNU), and Streptozocin (streptozotocin)), triazenes (for example, Dacarbazine (DTIC; dimethyltriazenoimidazolecarboxamide)), folic acid analogs (for example, Methotrexate (amethopterin)), pyrimidine analogs (for example, Fluorouracil (5-fluorouracil; 5-FU), Flouxuridine (fluorodeoxyuridine; FudR), and Cytarabine (cytosine arabinoside)), purine analogs and related inhibitors (for example, Mercaptopurine (6-mercaptopurine; 6-MP), Thioguanine (6-thioguanine; TG), and Pentostatin (2'-deoxycoformycin)), vinca alkaloids (for example, Vinblastine (VLB, vinblastine sulfate)) and Vincristine (vincristine sulfate)), epipodophyllotoxins (for example, Etoposide and Teniposide), antibiotics (for example, Dactinomycin (actinomycin D), Daunorubicin (daunomycin; rubidomycin), Doxorubicin, Bleomycin, Plicamycin (mithramycin), and Mitomycin (mitomycin C), enzymes (for example, L-Asparaginase), biological response modifiers (for example, Interferon-alpha and interferon-alpha-2b), platinum coordination compounds (for example, Cisplatin (cis-DDP) and Carboplatin), anthracenedione (Mitoxantrone), substituted ureas (for example, Hydroxyurea), methylhydrazine derivatives (for example, Procarbazine (N-methylhydrazine; MIH)), adrenocorticosteroids (for example, Prednisone), progestins (for example, Hydroxyprogesterone caproate, Medroxyprogesterone, Medroxyprogesterone acetate, and Megestrol acetate), estrogens (for example, Diethylstilbestrol (DES), Diethylstilbestrol diphosphate, Estradiol, and Ethynodiol estradiol), antiestrogens (for example, Tamoxifen), androgens (Testosterone propionate, and Fluoxymesterone), antiandrogens (for example, Flutamide), gonadotropin-releasing hormone analogs (for example, Leuprolide), other hormones and hormone analogs (for example,

methyltestosterone, estramustine, estramustine phosphate sodium, chlorotrianisene, and testolactone), and others (for example, dacarbazine, glutamic acid, and mitotane).

[1275] In one embodiment, the compositions of the invention are administered in combination with one or more of the following drugs: infliximab (also known as RemicadeTM Centocor, Inc.), Trocaine (Roche, RO-32-3555), Leflunomide (also known as AravaTM from Hoechst Marion Roussel), KineretTM (an IL-1 Receptor antagonist also known as Anakinra from Amgen, Inc.)

[1276] In a specific embodiment, compositions of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or combination of one or more of the components of CHOP. In one embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies, human monoclonal anti-CD20 antibodies. In another embodiment, the compositions of the invention are administered in combination with anti-CD20 antibodies and CHOP, or anti-CD20 antibodies and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with Rituximab. In a further embodiment, compositions of the invention are administered with Rituximab and CHOP, or Rituximab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. In a specific embodiment, compositions of the invention are administered in combination with tositumomab. In a further embodiment, compositions of the invention are administered with tositumomab and CHOP, or tositumomab and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. The anti-CD20 antibodies may optionally be associated with radioisotopes, toxins or cytotoxic prodrugs.

[1277] In another specific embodiment, the compositions of the invention are administered in combination ZevalinTM. In a further embodiment, compositions of the invention are administered with ZevalinTM and CHOP, or ZevalinTM and any combination of one or more of the components of CHOP, particularly cyclophosphamide and/or prednisone. ZevalinTM may be associated with one or more radionuclides. Particularly preferred isotopes are ⁹⁰Y and ¹¹¹In.

[1278] In an additional embodiment, the Therapeutics of the invention are administered in combination with cytokines. Cytokines that may be administered with the Therapeutics

of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.

[1279] In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-IBBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No. WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), OPG, and neutrokinin-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-IBB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904), DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms CD154, CD70, and CD153.

[1280] In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth Factor (GDGF), as disclosed in European Patent Number EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., *Growth Factors*, 4:259-268 (1993); Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International

Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent Number DE19639601. The above mentioned references are herein incorporated by reference in their entireties.

[1281] In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

[1282] In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention include, but are not limited to, granulocyte macrophage colony stimulating factor (GM-CSF) (sargramostim, LEUKINE™, PROKINET™), granulocyte colony stimulating factor (G-CSF) (filgrastim, NEUPOGEN™), macrophage colony stimulating factor (M-CSF, CSF-1) erythropoietin (epoetin alfa, EPOGEN™, PROCRIT™), stem cell factor (SCF, c-kit ligand, steel factor), megakaryocyte colony stimulating factor, PIXY321 (a GMCSF/IL-3 fusion protein), interleukins, especially any one or more of IL-1 through IL-12, interferon-gamma, or thrombopoietin.

[1283] In certain embodiments, Therapeutics of the present invention are administered in combination with adrenergic blockers, such as, for example, acebutolol, atenolol, betaxolol, bisoprolol, carteolol, labetalol, metoprolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, and timolol.

[1284] In another embodiment, the Therapeutics of the invention are administered in combination with an antiarrhythmic drug (e.g., adenosine, amiodarone, bretylium, digitalis, digoxin, digitoxin, dilaizem, disopyramide, esmolol, flecainide, lidocaine, mexiletine, moricizine, phenytoin, procainamide, N-acetyl procainamide, propafenone, propranolol, quinidine, sotalol, tocainide, and verapamil).

[1285] In another embodiment, the Therapeutics of the invention are administered in combination with diuretic agents, such as carbonic anhydrase-inhibiting agents (e.g., acetazolamide, dichlorphenamide, and methazolamide), osmotic diuretics (e.g., glycerin, isosorbide, mannitol, and urea), diuretics that inhibit $\text{Na}^+ \text{-K}^+ \text{-}2\text{Cl}^-$ symport (e.g., furosemide, bumetanide, azosemide, piretanide, tripamide, ethacrynic acid, muzolimine, and torsemide), thiazide and thiazide-like diuretics (e.g., bendroflumethiazide, benzthiazide, chlorothiazide, hydrochlorothiazide, hydroflumethiazide, methyclothiazide, polythiazide, trichormethiazide, chlorthalidone, indapamide, metolazone, and quinethazone), potassium sparing diuretics (e.g., amiloride and triamterene), and mineralcorticoid receptor antagonists (e.g., spironolactone, canrenone, and potassium canrenoate).

[1286] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for endocrine and/or hormone imbalance disorders. Treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, ^{127}I , radioactive isotopes of iodine such as ^{131}I and ^{123}I ; recombinant growth hormone, such as HUMATROPETM (recombinant somatropin); growth hormone analogs such as PROTROPINTM (somatrem); dopamine agonists such as PARLODELTM (bromocriptine); somatostatin analogs such as SANDOSTATINTM (octreotide); gonadotropin preparations such as PREGNYLTM, A.P.L.TM and PROFASITM (chorionic gonadotropin (CG)), PERGONALTM (menotropins), and METRODINTM (urofollitropin (uFSH)); synthetic human gonadotropin releasing hormone preparations such as FACTRELTM and LUTREPULSETM (gonadorelin hydrochloride); synthetic gonadotropin agonists such as LUPRONTM (leuprolide acetate), SUPPRELINTM (histrelin acetate), SYNARELTM (nafarelin acetate), and ZOLADEXTM (goserelin acetate); synthetic preparations of thyrotropin-releasing hormone such as RELEFACT TRHTM and THYPINONETM (protirelin); recombinant human TSH such as THYROGENTM; synthetic preparations of the sodium salts of the natural isomers of thyroid hormones such as L-T₄TM, SYNTHROIDTM and LEVOTHROIDTM (levothyroxine sodium), L-T₃TM, CYTOMELTM and TRIOSTATTM (liothyroine sodium), and THYROLARTM (liotrix); antithyroid compounds such as 6-n-propylthiouracil (propylthiouracil), 1-methyl-2-mercaptoimidazole and TAPAZOLETM (methimazole), NEO-MERCAZOLETM.

(carbamazole); beta-adrenergic receptor antagonists such as propranolol and esmolol; Ca^{2+} channel blockers; dexamethasone and iodinated radiological contrast agents such as TELEPAQUE™ (iopanoic acid) and ORAGRAFIN™ (sodium ipodate).

[1287] Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, estrogens or conjugated estrogens such as ESTRACE™ (estradiol), ESTINYL™ (ethinyl estradiol), PREMARIN™, ESTRATAB™, ORTHO-EST™, OGEN™ and estropipate (estrone), ESTROVIS™ (quinestrol), ESTRADERM™ (estradiol), DELESTROGEN™ and VALERGENT™ (estradiol valerate), DEPO-ESTRADIOL CYPIONATE™ and ESTROJECT LA™ (estradiol cypionate); antiestrogens such as NOLVADEX™ (tamoxifen), SEROPHENETM and CLOMID™ (clomiphene); progestins such as DURALUTINTM (hydroxyprogesterone caproate), MPA™ and DEPO-PROVERATM (medroxyprogesterone acetate), PROVERA™ and CYCRIN™ (MPA), MEGACE™ (megestrol acetate), NORLUTINTM (norethindrone), and NORLUTATE™ and AYGESTINTM (norethindrone acetate); progesterone implants such as NORPLANT SYSTEM™ (subdermal implants of norgestrel); antiprogestins such as RU 486™ (mifepristone); hormonal contraceptives such as ENovid™ (norethynodrel plus mestranol), PROGESTASERT™ (intrauterine device that releases progesterone), LOESTRINTM, BREVICON™, MODICON™, GENORA™, NELONA™, NORINYLM, OVACON-35™ and OVACON-50™ (ethinyl estradiol/norethindrone), LEVLEN™, NORDETTE™, TRI-LEVLEN™ and TRIPHASIC-21™ (ethinyl estradiol/levonorgestrel) LO/OVRAL™ and OVRAL™ (ethinyl estradiol/norgestrel), DEMULENT™ (ethinyl estradiol/ethynodiol diacetate), NORINYLM, ORTHO-NOVUM™, NORETHIN™, GENORA™, and NELOVATM (norethindrone/mestranol), DESOGEN™ and ORTHO-CEPT™ (ethinyl estradiol/desogestrel), ORTHO-CYCLEN™ and ORTHO-TRICYCLEN™ (ethinyl estradiol/norgestimate), MICRONOR™ and NOR-QD™ (norethindrone), and OVRETTE™ (norgestrel).

[1288] Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to, testosterone esters such as methenolone acetate and testosterone undecanoate; parenteral and oral androgens such as TESTOJECT-50™ (testosterone), TESTEX™ (testosterone propionate), DELATESTRYL™ (testosterone

enanthane), DEPO-TESTOSTERONE™ (testosterone cypionate), DANOCRINE™ (danazol), HALOTESTINT™ (fluoxymesterone), ORETOM METHYL™, TESTRED™ and VIRILON™ (methyltestosterone), and OXANDRIN™ (oxandrolone); testosterone transdermal systems such as TESTODERM™; androgen receptor antagonist and 5-alpha-reductase inhibitors such as ANDROCUR™ (ciproterone acetate), EULEXIN™ (flutamide), and PROSCAR™ (finasteride); adrenocorticotropic hormone preparations such as CORTROSYN™ (cosyntropin); adrenocortical steroids and their synthetic analogs such as ACLOVATE™ (aclometasone dipropionate), CYCLOCORT™ (amcinonide), BECLOVENT™ and VANCERIL™ (beclomethasone dipropionate), CELESTONE™ (betamethasone), BENISONE™ and UTICORT™ (betamethasone benzoate), DIPROSONE™ (betamethasone dipropionate), CELESTONE PHOSPHATE™ (betamethasone sodium phosphate), CELESTONE SOLUSPAN™ (betamethasone sodium phosphate and acetate), BETA-VAL™ and VALISONE™ (betamethasone valerate), TEMOVATE™ (clobetasol propionate), CLODERM™ (clocortolone pivalate), CORTEFTM and HYDROCORTONE™ (cortisol (hydrocortisone)), HYDROCORTONE ACETATE™ (cortisol (hydrocortisone) acetate), LOCOID™ (cortisol (hydrocortisone) butyrate), HYDROCORTONE PHOSPHATE™ (cortisol (hydrocortisone) sodium phosphate), A-HYDROCORT™ and SOLU CORTEFTM (cortisol (hydrocortisone) sodium succinate), WESTCORT™ (cortisol (hydrocortisone) valerate), CORTISONE ACETATE™ (cortisone acetate), DESOWEN™ and TRIDESILON™ (desonide), TOPICORT™ (desoximetasone), DECADRON™ (dexamethasone), DECADRON LA™ (dexamethasone acetate), DECADRON PHOSPHATE™ and HEXADROL PHOSPHATE™ (dexamethasone sodium phosphate), FLORONE™ and MAXIFLOR™ (diflorasone diacetate), FLORINEF ACETATE™ (fludrocortisone acetate), AEROBID™ and NASALIDE™ (flunisolide), FLUONID™ and SYNALAR™ (fluocinolone acetonide), LIDEX™ (fluocinonide), FLUOR-OP™ and FML™ (fluorometholone), CORDRAN™ (flurandrenolide), HALOG™ (halcinonide), HMS LIZUIFILM™ (medrysone), MEDROL™ (methylprednisolone), DEPO-MEDROL™ and MEDROL ACETATE™ (methylprednisone acetate), A-METHAPRED™ and SOLUMEDROL™ (methylprednisolone sodium succinate), ELOCON™ (mometasone furoate),

HALDRONE™ (paramethasone acetate), DELTA-CORTEF™ (prednisolone), ECONOPRED™ (prednisolone acetate), HYDELTRASOL™ (prednisolone sodium phosphate), HYDELTRA-T.B.A™ (prednisolone tebutate), DELTASONE™ (prednisone), ARISTOCORT™ and KENACORT™ (triamcinolone), KENALOG™ (triamcinolone acetonide), ARISTOCORT™ and KENACORT DIACETATE™ (triamcinolone diacetate), and ARISTOSPAN™ (triamcinolone hexacetonide); inhibitors of biosynthesis and action of adrenocortical steroids such as CYTADREN™ (aminoglutethimide), NIZORAL™ (ketoconazole), MODRASTANE™ (trilostane), and METOPIRONE™ (metyrapone);

[1289] Additional treatments for endocrine and/or hormone imbalance disorders include, but are not limited to bovine, porcine or human insulin or mixtures thereof; insulin analogs; recombinant human insulin such as HUMULIN™ and NOVOLIN™; oral hypoglycemic agents such as ORAMIDE™ and ORINASE™ (tolbutamide), DIABINESE™ (chlorpropamide), TOLAMIDE™ and TOLINASE™ (tolazamide), DYMELOR™ (acetohexamide), glibenclamide, MICRONASE™, DIBETA™ and GLYNASE™ (glyburide), GLUCOTROL™ (glipizide), and DIAMICRON™ (gliclazide), GLUCOPHAGE™ (metformin), PRECOSE™ (acarbose), AMARYL™ (glimepiride), and cigitazone; thiazolidinediones (TZDs) such as rosiglitazone, AVANDIA™ (rosiglitazone maleate) ACTOSTM (pioglitazone), and troglitazone; alpha-glucosidase inhibitors; bovine or porcine glucagon; somatostatins such as SANDOSTATIN™ (octreotide); and diazoxides such as PROGLYCEM™ (diazoxide). In still other embodiments, Therapeutics of the invention are administered in combination with one or more of the following: a biguanide antidiabetic agent, a glitazone antidiabetic agent, and a sulfonylurea antidiabetic agent.

[1290] In one embodiment, the Therapeutics of the invention are administered in combination with treatments for uterine motility disorders. Treatments for uterine motility disorders include, but are not limited to, estrogen drugs such as conjugated estrogens (e.g., PREMARIN® and ESTRATAB®), estradiols (e.g., CLIMARA® and ALORA®), estropipate, and chlorotrianiisene; progestin drugs (e.g., AMEN® (medroxyprogesterone), MICRONOR® (norethidrone acetate), PROMETRIUM® progesterone, and megestrol acetate); and estrogen/progesterone combination therapies such as, for example,

conjugated estrogens/medroxyprogesterone (e.g., PREMPROTM and PREMPHASE[®]) and norethindrone acetate/ethinyl estradiol (e.g., FEMHRTTM).

[1291] In an additional embodiment, the Therapeutics of the invention are administered in combination with drugs effective in treating iron deficiency and hypochromic anemias, including but not limited to, ferrous sulfate (iron sulfate, FEOSOLTM), ferrous fumarate (e.g., FEOSTATTTM), ferrous gluconate (e.g., FERGONTTM), polysaccharide-iron complex (e.g., NIFEREXTM), iron dextran injection (e.g., INFEDTM), cupric sulfate, pyridoxine, riboflavin, Vitamin B₁₂, cyanocobalamin injection (e.g., REDISOLTM, RUBRAMIN PCTM), hydroxocobalamin, folic acid (e.g., POLVITETTM), leucovorin (folinic acid, 5-CHOH4PteGlu, citrovorum factor) or WELLCOVORIN (Calcium salt of leucovorin), transferrin or ferritin.

[1292] In certain embodiments, the Therapeutics of the invention are administered in combination with agents used to treat psychiatric disorders. Psychiatric drugs that may be administered with the Therapeutics of the invention include, but are not limited to, antipsychotic agents (e.g., chlorpromazine, chlorprothixene, clozapine, fluphenazine, haloperidol, loxapine, mesoridazine, molindone, olanzapine, perphenazine, pimozide, quetiapine, risperidone, thioridazine, thiothixene, trifluoperazine, and triflupromazine), antimanic agents (e.g., carbamazepine, divalproex sodium, lithium carbonate, and lithium citrate), antidepressants (e.g., amitriptyline, amoxapine, bupropion, citalopram, clomipramine, desipramine, doxepin, fluvoxamine, fluoxetine, imipramine, isocarboxazid, maprotiline, mirtazapine, nefazodone, nortriptyline, paroxetine, phenelzine, protriptyline, sertraline, tranylcypromine, trazodone, trimipramine, and venlafaxine), antianxiety agents (e.g., alprazolam, buspirone, chlordiazepoxide, clorazepate, diazepam, halazepam, lorazepam, oxazepam, and prazepam), and stimulants (e.g., d-amphetamine, methylphenidate, and pemoline).

[1293] In other embodiments, the Therapeutics of the invention are administered in combination with agents used to treat neurological disorders. Neurological agents that may be administered with the Therapeutics of the invention include, but are not limited to, antiepileptic agents (e.g., carbamazepine, clonazepam, ethosuximide, phenobarbital, phenytoin, primidone, valproic acid, divalproex sodium, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, zonisamide, diazepam, lorazepam, and clonazepam), antiparkinsonian agents (e.g., levodopa/carbidopa,

selegiline, amantidine, bromocriptine, pergolide, ropinirole, pramipexole, benztrapine; biperiden; ethopropazine; procyclidine; trihexyphenidyl, tolcapone), and ALS therapeutics (e.g. riluzole).

[1294] In another embodiment, Therapeutics of the invention are administered in combination with vasodilating agents and/or calcium channel blocking agents. Vasodilating agents that may be administered with the Therapeutics of the invention include, but are not limited to, Angiotensin Converting Enzyme (ACE) inhibitors (e.g., papaverine, isoxsuprine, benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, spirapril, trandolapril, and nylidrin), and nitrates (e.g., isosorbide dinitrate, isosorbide mononitrate, and nitroglycerin). Examples of calcium channel blocking agents that may be administered in combination with the Therapeutics of the invention include, but are not limited to amlodipine, bepridil, diltiazem, felodipine, flunarizine, isradipine, nicardipine, nifedipine, nimodipine, and verapamil.

[1295] In certain embodiments, the Therapeutics of the invention are administered in combination with treatments for gastrointestinal disorders. Treatments for gastrointestinal disorders that may be administered with the Therapeutic of the invention include, but are not limited to, H₂ histamine receptor antagonists (e.g., TAGAMETTM (cimetidine), ZANTACTM (ranitidine), PEPCIDTM (famotidine), and AXIDTM (nizatidine)); inhibitors of H⁺, K⁺ ATPase (e.g., PREVACIDTM (lansoprazole) and PRILOSECTM (omeprazole)); Bismuth compounds (e.g., PEPTO-BISMOLTM (bismuth subsalicylate) and DE-NOLTM (bismuth subcitrate)); various antacids; sucralfate; prostaglandin analogs (e.g. CYTOTECTTM (misoprostol)); muscarinic cholinergic antagonists; laxatives (e.g., surfactant laxatives, stimulant laxatives, saline and osmotic laxatives); antidiarrheal agents (e.g., LOMOTILTM (diphenoxylate), MOTOFENTM (diphenoxin), and IMODIUMTM (loperamide hydrochloride)), synthetic analogs of somatostatin such as SANDOSTATINTM (octreotide), antiemetic agents (e.g., ZOFTRANTM (ondansetron), KYTRILTM (granisetron hydrochloride), tropisetron, dolasetron, metoclopramide, chlorpromazine, perphenazine, prochlorperazine, promethazine, thiethylperazine, triflupromazine, domperidone, haloperidol, droperidol, trimethobenzamide, dexamethasone, methylprednisolone, dronabinol, and nabilone); D2 antagonists (e.g., metoclopramide, trimethobenzamide and chlorpromazine); bile salts; chenodeoxycholic

acid; ursodeoxycholic acid; and pancreatic enzyme preparations such as pancreatin and pancrelipase.

[1296] In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

Example 11: Method of Treating Decreased Levels of the Polypeptide

[1297] It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a polypeptide in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted and/or soluble form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

[1298] For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided in Example 10.

Example 12: Method of Treating Increased Levels of the Polypeptide

[1299] Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

[1300] For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The antisense polynucleotides of the present invention can be formulated using techniques and formulations described herein (e.g., see Example 10) or otherwise known in the art.

Example 13: Method of Treatment Using Gene Therapy - Ex Vivo

[1301] One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS, penicillin and streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

[1302] At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks.

[1303] pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

[1304] The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

[1305] The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then

added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

[1306] Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

[1307] The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

Example 14: Gene Therapy Using Endogenous ACRP30-Like Genes

[1308] Another method of gene therapy according to the present invention involves operably associating the endogenous ACRP30-Like gene sequence with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

[1309] Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of the endogenous ACRP30-Like gene, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the ACRP30-Like gene so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting

sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

[1310] The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

[1311] In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

[1312] Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous ACRP30-Like gene sequence. This results in the expression of ACRP30-Like polypeptides in the cell. Expression may be detected by immunological staining, or any other method known in the art.

[1313] Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na₂HPO₄, 6 mM dextrose). The cells are re-centrifuged, the supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately 3X10⁶ cells/ml. Electroporation should be performed immediately following resuspension.

[1314] Plasmid DNA is prepared according to standard techniques. For example, to construct a plasmid for targeting to the ACRP30-Like locus, plasmid pUC18 (MBI

Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3'end. Two ACRP30-Like non-coding gene sequences are amplified via PCR: one ACRP30-Like non-coding sequence (ACRP30-Like fragment 1) is amplified with a HindIII site at the 5' end and an Xba site at the 3'end; the other ACRP30-Like non-coding sequence (ACRP30-Like fragment 2) is amplified with a BamHI site at the 5'end and a HindIII site at the 3'end. The CMV promoter and ACRP30-Like fragments are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; ACRP30-Like fragment 1 - XbaI; ACRP30-Like fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-digested pUC18 plasmid.

[1315] Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120 μ g/ml. 0.5 ml of the cell suspension (containing approximately 1.5×10^6 cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960 μ F and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

[1316] Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

[1317] The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

Example 15: Method of Treatment Using Gene Therapy - In Vivo

[1318] Another aspect of the present invention is using *in vivo* gene therapy methods

to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) ACRP30-Like sequences into an animal to increase or decrease the expression of the ACRP30-Like polypeptide. The ACRP30-Like polynucleotide may be operatively linked to a promoter or any other genetic elements necessary for the expression of the ACRP30-Like polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO: 5693622, 5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997), Chao J et al., *Pharmacol. Res.*, 35(6):517-522 (1997), Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997), Schwartz et al., *Gene Ther.*, 3(5):405-411 (1996), Tsurumi Y. et al., *Circulation*, 94(12):3281-3290 (1996) (incorporated herein by reference).

[1319] The ACRP30-Like polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The ACRP30-Like polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

[1320] The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the ACRP30-Like polynucleotides may also be delivered in liposome formulations (such as those taught in Felgner et al., *Ann. NY Acad. Sci.*, 772:126-139 (1995) and Abdallah et al., *Biol. Cell*, 85(1):1-7 (1995)) which can be prepared by methods well known to those skilled in the art.

[1321] The ACRP30-Like polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

[1322] The polynucleotide constructs can be delivered to the interstitial space of tissues

within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

[1323] For the naked ACRP30-Like polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked ACRP30-Like polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

[1324] The dose response effects of injected ACRP30-Like polynucleotide in muscle *in vivo* is determined as follows. Suitable ACRP30-Like template DNA for production of mRNA coding for ACRP30-Like polypeptide is prepared in accordance with a standard recombinant DNA methodology. The template DNA, which may be either circular or

linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

[1325] Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The ACRP30-Like template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

[1326] After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for ACRP30-Like protein expression. A time course for ACRP30-Like protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of ACRP30-Like DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice. The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using ACRP30-Like naked DNA.

Example 16: Production of an Antibody

a) Hybridoma Technology

[1327] The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing ACRP30-Like polypeptide(s) are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of ACRP30-Like polypeptide(s) is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

[1328] Monoclonal antibodies specific for ACRP30-Like polypeptide(s) are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J.

Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with ACRP30-Like polypeptide(s) or, more preferably, with a secreted ACRP30-Like polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

[1329] The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the ACRP30-Like polypeptide(s).

[1330] Alternatively, additional antibodies capable of binding to ACRP30-Like polypeptide(s) can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the ACRP30-Like protein-specific antibody can be blocked by ACRP30-Like polypeptide(s). Such antibodies comprise anti-idiotypic antibodies to the ACRP30-Like protein-specific antibody and are used to immunize an animal to induce formation of further ACRP30-Like protein-specific antibodies.

[1331] For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al.,

U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).

b) Isolation Of Antibody Fragments Directed Against ACRP30-Like Polypeptide(s) From A Library Of scFvs

[1332] Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against ACRP30-Like polypeptide(s) to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library.

[1333] A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 109 E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to innoculate 50 ml of 2xTY-AMP-GLU, 2 x 108 TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

[1334] M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37°C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium

by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 μm filter (Minisart NML; Sartorius) to give a final concentration of approximately 1013 transducing units/ml (ampicillin-resistant clones).

Panning of the Library.

[1335] Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 $\mu\text{g}/\text{ml}$ or 10 $\mu\text{g}/\text{ml}$ of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 1013 TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 $\mu\text{g}/\text{ml}$ ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders.

[1336] Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

Example 17: [³H]-2-Deoxyglucose Uptake Assay

[1337] Adipose, skeletal muscle, and liver are insulin-sensitive tissues. Insulin can stimulate glucose uptake/transport into these tissues. In the case of adipose and skeletal muscle, insulin initiates the signal transduction that eventually leads to the translocation of GLUT4, the glucose transporter 4 molecule, from a specialized intracellular compartment to the cell surface. Once on the cell surface, GLUT4 allows for glucose uptake/transport.

[1338] A number of adipose and muscle related cell-lines can be used to test for glucose uptake/transport activity in the presence of an ACRP-30 Like polypeptide of the invention. In particular, the 3T3-L1 murine fibroblast cells and the L6 murine skeletal muscle cells can be differentiated into 3T3-L1 adipocytes and into myotubes, respectively, to serve as appropriate *in vitro* models for the ³H-2-deoxyglucose uptake assay (Haspel et al., 1999, J Membr Biol, 169 (1): 45-53; Tsakiridis et al., 1995, Endocrinology, 136(10): 4315-22). Briefly, 2×10^5 cells/100 μ L of adipocytes or differentiated L6 cells are transferred to 96-well Tissue-Culture, "TC", treated, i.e. coated with 50 μ g/mL of poly-L-lysine, plates for 4 hours at 37 °C. The cells are washed once with HEPES buffered saline. Insulin, or an ACRP-30 Like polypeptide, is added at various dilutions (e.g., 5 nM, 10 nM, 100 nM, and 500 nM for insulin) in HEPES buffered saline for 30 min at 37 °C. A final concentration of 10 μ M cytochalasin B is added to measure the non-specific uptake. The cells are washed three times with HEPES buffered saline. Labeled, i.e. 10 μ M of [³H]-2-deoxyglucose, and unlabeled, i.e. 2-deoxyglucose, are added for 10 minutes at room temperature. The cells are washed three times with cold Phosphate Buffered Saline, "PBS". The cells are lysed upon the addition of 150 μ L/well of 0.05 N NaOH and subsequent incubation with shaking for 20 minutes at room temperature. Samples are then transferred to a scintillation vial to which is added 5 mL of scintillation fluid. The vials are counted in a Beta-Scintillation counter. Maximal responses of about 5-fold and 3-fold that of controls for adipocytes and myotubes, respectively, are to be expected.

[1339] It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

[1340] The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties.

[1341] Certain ACRP-30-Like polynucleotides and polypeptides of the present invention, including antibodies, were disclosed in U.S. provisional application number 60/328,419, filed October 12, 2001, the specification and sequence listing of which are herein incorporated by reference in their entireties.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 180, Table I.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard

Manassas, Virginia 20110-2209

United States of America

Date of deposit October 13, 1999	Accession Number PTA-844
---	---------------------------------

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*)

This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

	For receiving Office use only			For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application 11 OCT 2002	<input type="checkbox"/> This sheet was received by the International Bureau on:				
Authorized officer 	Authorized officer				

ATCC Deposit No. PTA-844**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-844

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 180, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit: September 2, 1999	Accession Number: PTA-623
---------------------------------------	------------------------------

- C. ADDITIONAL INDICATIONS (*leave blank if not applicable*) This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*of the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

	For receiving Office use only			For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application 11 OCT 2002	<input type="checkbox"/> This sheet was received by the International Bureau on:				
Authorized officer 	Authorized officer				

ATCC Deposit No. PTA-623**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-623

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 181, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
August 13, 1999	PTA-536

- C. ADDITIONAL INDICATIONS** (*leave blank if not applicable*) This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

	For receiving Office use only			For International Bureau use only			
<input checked="" type="checkbox"/> This sheet was received with the international application 11 OCT 2002		<input type="checkbox"/> This sheet was received by the International Bureau on:					
Authorized officer 		Authorized officer					

Revised Form PCT/RO/134 (January 2001)

Petrol 34cp.sollst

ATCC Deposit No. PTA-536**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-536**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 181, Table I.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit September 10, 2001	Accession Number PTA-3696
---	----------------------------------

- C. ADDITIONAL INDICATIONS (*leave blank if not applicable*) This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)


Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

For receiving Office use only			For International Bureau use only		
<input checked="" type="checkbox"/> This sheet was received with the international application 11 OCT 2002		<input type="checkbox"/> This sheet was received by the International Bureau on:			
Authorized officer 		Authorized officer			

ATCC Deposit No. PTA-3696**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-3696

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 181, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
October 5, 2000	PTA-2574
C. ADDITIONAL INDICATIONS (<i>leave blank if not applicable</i>)	This information is continued on an additional sheet <input type="checkbox"/>

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the International Bureau later (*specify the general nature of the indications e.g. "Accession Number of Deposit"*)

For receiving Office use only				For International Bureau use only				
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:						
11 OCT 2002								
Authorized officer 		Authorized officer						

ATCC Deposit No. PTA-2574**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-2574

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 181, Table I.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
October 5, 2000	PTA-2575

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*)

This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

	For receiving Office use only			For International Bureau use only		
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:				
11 OCT 2002						
Authorized officer 		Authorized officer				

ATCC Deposit No. PTA-2575**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-2575

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 182, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
July 27, 1998	203071

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*) This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

	For receiving Office use only			For International Bureau use only		
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:				
11 OCT 2002						
Authorized officer 		Authorized officer				

ATCC Deposit No. 203071**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: 203071

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 182, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit	Accession Number
June 19, 1997	209124

- C. ADDITIONAL INDICATIONS (*leave blank if not applicable*) This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC). Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the International Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

<input checked="" type="checkbox"/>	For receiving Office use only			For International Bureau use only			
<input checked="" type="checkbox"/> This sheet was received with the international application		<input type="checkbox"/> This sheet was received by the International Bureau on:					
11 OCT 2002							
Authorized officer		Authorized officer			Pctrol34ep.solist		

Revised Form PCT/RO/134 (January 2001)

ATCC Deposit No. 209124**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: 209124

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 182, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit September 27, 1999	Accession Number PTA-791
---	---------------------------------

- C. ADDITIONAL INDICATIONS (*leave blank if not applicable*) This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the International Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

	For receiving Office use only			For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application 11 OCT 2002				<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer 	Authorized officer				

Revised Form PCT/RM444 (January 2001)

Patrol34ep.solist

ATCC Deposit No. PTA-791**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-791

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

**INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
OR OTHER BIOLOGICAL MATERIAL**

(PCT Rule 13bis)

- A.** The indications made below relate to the deposited microorganism or other biological material referred to in the description on Page 182, Table 1.

B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet

Name of depositary institution: American Type Culture Collection

Address of depositary institution (*including postal code and country*)

10801 University Boulevard
Manassas, Virginia 20110-2209
United States of America

Date of deposit June 11, 2001	Accession Number PTA-3449
--------------------------------------	----------------------------------

C. ADDITIONAL INDICATIONS (*leave blank if not applicable*)

This information is continued on an additional sheet

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (*if the indications are not for all designated States*)

Europe

In respect of those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which the application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28(4) EPC).

Continued on additional sheets

E. SEPARATE FURNISHING OF INDICATIONS (*leave blank if not applicable*)

The indications listed below will be submitted to the international Bureau later (*specify the general nature of the indications e.g., "Accession Number of Deposit"*)

For receiving Office use only		For International Bureau use only	
<input checked="" type="checkbox"/> This sheet was received with the international application 11 OCT 2002		<input type="checkbox"/> This sheet was received by the International Bureau on:	
Authorized officer 		Authorized officer	

ATCC Deposit No. PTA-3449**CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

NORWAY

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

AUSTRALIA

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

FINLAND

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

ATCC Deposit No.: PTA-3449

UNITED KINGDOM

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

DENMARK

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

SWEDEN

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

NETHERLANDS

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

CLAIMS

We claim:

1. An isolated nucleic acid molecule comprising a polynucleotide selected from the group consisting of:

(a) the polynucleotide shown as SEQ ID NO:X or the polynucleotide encoded by a cDNA included in ATCC Deposit No:Z;

(b) a polynucleotide encoding a biologically active polypeptide fragment of SEQ ID NO:Y or a biologically active polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z;

(c) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z;

(d) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(c), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises a nucleotide sequence encoding a soluble polypeptide.

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z.

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide comprises the entire nucleotide sequence of SEQ ID NO:X or a cDNA included in ATCC Deposit No:Z.

5. The isolated nucleic acid molecule of claim 2, wherein the polynucleotide is DNA.

6. The isolated nucleic acid molecule of claim 3, wherein the polynucleotide is RNA.

7. A vector comprising the isolated nucleic acid molecule of claim 1.

8. A host cell comprising the vector of claim 7.

9. A recombinant host cell comprising the nucleic acid molecule of claim 1 operably limited to a heterologous regulating element which controls gene expression.

10. A method of producing a polypeptide comprising expressing the encoded polypeptide from the host cell of claim 9 and recovering said polypeptide.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) the polypeptide shown as SEQ ID NO:Y or the polypeptide encoded by the cDNA;

(b) a polypeptide fragment of SEQ ID NO:Y or the polypeptide encoded by the cDNA;

(c) a polypeptide epitope of SEQ ID NO:Y or the polypeptide encoded by the cDNA; and

(d) a variant of SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, comprising a polypeptide having SEQ ID NO:Y.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and

(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

(a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. A method of screening for molecules which modify activities of the polypeptide of claim 11 comprising:

- (a) contacting said polypeptide with a compound suspected of having agonist or antagonist activity; and
- (b) assaying for activity of said polypeptide.

22. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount the polypeptide of claim 11.

<110> Human Genome Sciences, Inc. et al.

<120> ACRP-30-like Polynucleotides, Polypeptides, and Antibodies

<130> PT316PCT

<150> 60/328,419

<151> 2001-10-12

<160> 107

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

ggatccgga	gccccaaatct	tctgacaaaa	ctcacacatg	cccaccgtgc	ccgaccaactg	60
aattcgagg	tgccacggta	gtcttcctct	tccccccaaa	acccaaggac	acctctatg	120
tctccggac	tctggaggtc	acatgcgtgg	tggtgacgt	aaggccacaa	gaccctgagg	180
tcaagtcaa	ctggtagctg	gacggcgtgg	aggtgcataa	tggcaagaca	aaggcccg	240
aggacgaga	caacacgtac	tacgggtgg	tcagcgtctt	caccgtcttg	caccaggact	300
ggctgtatgg	caaggagtag	aagtgcacgg	tctccacaaa	agccctccca	accccccattg	360
agaaaaacat	cttccaaagcc	aaaggccacgc	ccccagaaacc	acagggttac	acctctgccc	420
catccggga	tgactgtgacc	aaaacccagg	tcagctgtac	ctggctgttc	aaaggcttt	480
atccacggca	cattccgggt	gagtgggaga	gcaatggggca	gcccggaaac	aactacaaga	540
ccacgcctc	cgtgtgtgac	tccgacggtt	cttttcttct	ctacagcaag	ctcacggtg	600
acaagagcg	gtggcagcag	ggggaaacgtt	tcttcatgttc	cggtatgtat	gagggtcttg	660
acaaccata	cacgcagaag	agccctctccc	tgcttcgggg	taaatgatgt	cgacggccgc	720
gactcttagag	gat					733

<210> 2

<211> 3522

<212> DNA

<213> Homo sapiens

<400> 2

ggcacgagg	tggacattcg	agccttagtgc	ctcgacagg	actcgccac	ctggcccttc	60
tgcacccact	ggccagctca	agaggttgg	atatggactt	tcttcatttc	ctggccttcc	120
tctttgtct	gtctttgtgt	gggtgggggg	ccacaggac	tcgtgggg	tccctggacc	180
caagctgtga	gatcttcaaa	aaatggtttgc	aggtgttgc	ggccgggg	ctgttggcac	240
tgaagaacct	ggcacacgtc	aacgcacatcc	accggcataa	caatgttctt	gttgtcatgc	300
tcggaaaggct	ctttaagggt	tcggaggatc	ccccggaaat	gtcttccgt	gtctgttgc	360
tcggataggat	ggccctggccc	caggacgaga	actgttgc	tgcgttttcc	cacgtgttg	420
agaacacggc	cttcttcggc	gtatgttgc	tgcgttcc	gaggatgtg	cacttattt	480
ttgaccacaa	cttcaactgg	aacctctca	tcggctgggg	tatcgtttc	tgcacccaga	540
caggcgttct	caaccgggg	ccccactctc	ccatcttcag	ctgtatggcc	caggagctgg	600
ggatcgtgt	gaaaggactcc	aaatccctca	accctttatca	aatcgaccgc	acagagtca	660
ttcccaaggac	tgaccatgg	cagaaggccc	tgagatggaaa	agagaacaggc	cgaaaggaaag	720
aggagaagcg	gaaaggatc	ccccaaagg	ccaggatctt	catgtccca	tctgtgttat	780
agcccttggag	caggctcagg	ttcagggggg	cacaaggagg	catgtccggg	ggaaaggaaag	840
gtgtqagtgt	gttgtgtgt	gagagcacca	gtctggccct	tcccaaaagg	gaggccacat	900
ttggccggcc	cccttggagct	gggtgtgtgc	ccccatgtaa	ggggactgtac	ctcagatggc	960
tggtttttct	ctcaggggcc	tcctgtgtgc	ggggccctca	gaggatttt	tgctggaaaat	1020
atggccctgt	gcagactgt	ggggggggca	ggaggatgtc	tgctgtggcc	ctgtgtgttg	1080
ctggaaacct	ctggggccat	ggccctggcc	cttggggggg	aaggccgaga	actatggttt	1140
gacccacggg	tcagggttgc	accctgtgt	ttggcccttt	gtgtcataca	gtgtccgttc	1200
acaggcttcc	ggcccttcgtc	agagacacaa	taaaaggccat	ggaccctttt	ggaccgcacca	1260
aggctgttg	ggacactgt	ggggggccat	ggcccttcgt	ggatgtatag	acagcttgg	1320
ggatgcctct	ggcccaccc	ggggggcccc	ggcccttcgt	agggcagaga	agaaggggcc	1380
ttggcttggg	cctctctgtc	ctacgccttc	actggccctt	aaaaatgttt	ggtgttggga	1440
aaggacttgg	aagtgccttg	ggacactggg	aacatgttgc	tcaagaagac	cttggagcaa	

catgtccct	gtcctcagat	gtctggggac	agtcatggag	caagcacagg	gaagtcagct	1560
gtgtctctt	ggcagccgctg	gaagacatgc	aaacctgtggg	tggggggctg	cagggggaca	1620
ggccgcagcc	ctcgaggagg	ctggctctcg	caatggctgc	cctaactgtc	atgggtcaga	1680
cagtttcccg	tctccggggg	ccacaggccc	ggaatggctc	atggggcatg	tggcccttggg	1740
tagggcagct	gccccctact	catggccccc	caacgagacg	gaggggaaagg	ctttagtgag	1800
aattcttagt	ctgccttctt	gacccttcca	agtccggatc	tgcctttaa	aggagcagag	1860
aaaaaccatcc	agatccccctc	gacacccaggc	cccccttaccac	tgacagacca	caagtggat	1920
ctgagtgta	gccccctcaga	lttgcgtact	ggcccttggc	cacccctccc	tgtctgcag	1980
cttcatgtgc	aaaatgttaatt	tgatgttatac	tgatattccct	gcccagccct	aaacctgtttc	2040
tctgaggctg	gccccctact	ggggctcgag	cagcaaaaggg	aaagccaagcc	ttagagaagc	2100
ctcatggaa	ggcccaagaaac	atcctgtcacc	catcaggatc	tccgaagttac	ggggacaaga	2160
agcagctgga	agagactgtt	tggtgggggc	ttggaggagt	gtctggaaac	tttccccatc	2220
agaaaaggccc	tcacatggca	tgggaggccag	ggcgtgttgc	tggttttttttgc	tcacacagaa	2280
tagtttccatc	ttcccccttc	cttcttcagg	ttttgttgac	tttttttttttttgc	tttttttttttttgc	2340
gtctgtgaac	taaagggtgt	gtccatggca	ttaacagtgg	agggtgttca	gttttttttttttgc	2400
gtctgtgaaca	aagaatgggg	aaaaatgtc	aaacgcggaa	aggaaatgttt	gttttttttttttgc	2460
agaatggaaag	tatataccac	agtatgggg	aggggctgtc	cataggactt	caagggggcc	2520
gttacaaatgt	tttttttttttttgc	aaataatccat	ttttaggtttt	ttttaggtttt	ttttaggtttt	2580
ccctatgtat	atggaaaggaa	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	2640
ggggggggggat	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	2700
accctatattt	cttcatca	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	2760
ttccctgtgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	2820
aaggaggcc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	2880
cagagaaggt	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	2940
gttggcggca	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3000
ttcaatgttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3060
gtcatttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3120
gccccccccc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3180
cagtttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3240
atggccatgttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3300
cttccttgcac	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3360
gcccccaatgttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3420
cctcttggc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3480
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	3522

<210> 3

<211> 2007

<212> DNA

<213> Homo sapiens

<400> 3

ccaaaggcttc	ggcgccggac	ggcgccgtgt	ggcggatgggg	ggggccgggg	gtttggggcc	60
tgttttgcct	cggggtctgt	ctccgggggg	ggccggctgc	gtggggatcc	ggggcagctc	120
cggtttccgg	acggcggaaac	ttgtgtctct	atgtgttgc	cgcgcaccc	tcatgcac	180
tgccagaatgg	cacccatgtt	cacggcgatgt	ttccggatct	ccccctggcc	atggatgttc	240
cgggggaggc	ctacacaaact	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	300
ccggggctgt	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	360
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	420
ggccggccac	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	480
tgaagggtgt	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	540
caccacgtac	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	600
cgggggatgt	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	660
ccaaaggaga	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	720
ttccggccac	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	780
ccggggatctt	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	840
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	900
acttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	960
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1020
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1080
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1140
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1200
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1260
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1320
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1380
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1440
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1500
tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	tttttttttttttgc	1560

tgcgtctgc	gatccaggc	ccaaaggac	tgaggagtc	aggagctgg	gctcgacca	1620
tgacagatg	acaggcagg	ggccatctt	ctcccccctc	ccccaccaa	cttcggggag	1680
ccctccgtc	ccctccctc	cttgttgc	agtgtctgg	tcccccaccc	gagggtcagg	1740
tgcccaatcc	tctgactgga	taacgggggg	ttcttgcct	cagtcttcc	ctctgagccc	1800
ccaggccctc	ccgcacatca	ggttggggat	ggggacatgg	agagggagg	gcgcctact	1860
cctgcaatg	cttgcacag	atgcacagg	gttagatgt	gtctggcaat	aaaggccct	1920
actgttcc	ccgcacaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1980
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2007

<210> 4
<211> 901
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (872)..(872)
<223> n equals a,t,g, or c

<400> 4	ccacgcgtcc	gccggccggg	ctgtctcagg	gtctgagcc	cgggacagggt	gtgggtgtag	60
ctccatccagg	gtccccactgg	gccccctacc	tgctctctcc	tccccccage	ggatcttctt	120	
cggtcccccc	ggacccctcg	gtcagaagt	gaccgcggag	actctgttc	acgagttca	180	
ggagctgtcg	aaagaggcca	cggaacgcgg	gttctcagg	cttctggacc	cyctgctgcc	240	
ccaggggccgc	ctggccgcgg	ttgtggcga	ggccttccac	tgcggctgc	agggtccccg	300	
ccgggtggac	aacggggacgc	ttgtggagct	gcatgtttc	cagggtctcg	ctggccaaag	360	
tgccatctctg	cggtggacgg	gtgtggacgt	ggctctgggt	cgttccagg	ccccctgttc	420	
cggtatcttc	cgtgttctcg	caatgttcg	ctgggacacc	agttgtcgg	agggtcaagg	480	
ccgggtggcc	ggccggggacg	ttgtgtgtgt	tccatctgt	attgtgtccc	ttgtggcagg	540	
ccacacgtgc	ctggggggcc	tccaggccgt	ggagggacca	acgggggtct	tacgttaca	600	
gggtcgaggd	ctgtcgacgg	tcgacatgtt	tcgtgtttg	ttggacaatgg	660		
ctccggggcc	gtccctacc	tccaggccgg	ctccaggcttc	tcgggtgtc	tcctgggac	720	
gtgaggggcgc	ccaggggggc	ttggcggagg	tcggccgg	atccggggga	ccctctact	780	
gtatggccgtg	gtccacacaa	taaagaccc	tccaccyca	aaaaaaaaaa	aaaaaaaaaa	840	
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	900	
g						901	

<210> 5
<211> 1558
<212> DNA
<213> Homo sapiens

<400> 5	cgagaaacgc	cggttccgt	tctgtcgca	gagaccccg	agaccgcgc	ggggagacgg	60
agggtctgt	gttgggggg	actctgtgt	gtctgtacgg	ccccccaccc	tctcttctg	120	
caactcgctc	ctccggaa	ctttttcccc	tgctctttt	cttttccatgg	gtctgtcgat	180	
ccggccggac	ctggccggga	ggggcttgg	ccggccgggg	atgtcttgg	ggccggccgg	240	
gaggggccgc	cgggggccgg	ggggcccccgg	cgaggatgg	gtctccctgt	gacaggact	300	
ttgtgtgg	tactgttgc	tctttttttt	tgctcttgc	ctgggtctgg	gtogggtcgc	360	
ccatgtccag	ggggaaacgc	aggagtgg	ggggactgtgg	gagctggcgt	ccccctccgg	420	
ccatcgccgg	aggggcgaa	aaaaatcgat	aaaaatcgat	cccgatcagg	acccgggggt	480	
ccgtcttc	cggtgttgc	gtctgtgt	ccccgggtac	tccatgttacc	cgccgacccg	540	
cggtccccc	atccatca	ctatcttgg	ggggggaaa	gggtggccgg	gagatgtgg	600	
cctccaaagg	aatatggca	aaacaggctc	acggggggcc	agggggccaca	ctgggaccaa	660	
aggccagaag	ggcttccatgg	ggggccctgg	ggacgggtgc	aaagggccact	acgcggccct	720	
ttcggtggc	cgaaagaacg	ccatgcacag	caaacactac	tacccagacgg	tgtatcttgc	780	
caecggatgc	gtqaacactt	acgaccactt	caacatgtt	acccggcaqt	tctactgtca	840	
ctgtccggc	ctctactt	tcagcttca	ctgtcaccac	tggaaacaga	aggagacacta	900	
ctgtcacatc	atgaaagaac	aggaggagg	gggtgtttt	ttccggcagg	ttggccggcc	960	
cacatcatc	caaaaggccaa	gtctgtgt	ggactgtcg	ggggggacc	agggtgtgg	1020	
cacccatcc	aaaggccgg	gtggaaacgt	cattttcc	gaggaggctgg	acacatcat	1080	
cacccatcc	gtgttccatgg	tcggacacgc	caccatcc	tagtggcc	gcacacttct	1140	
ttctctcgc	caccccttcc	cctctcgctc	tgtgtaccc	agggtgtcgg	accaggctga	1200	
ccccccggcc	tccctcccgaa	ccactggact	gggtttggca	ttcaatgtgaa	1260		
ccgccttggcc	acacagaaag	ccaaaggat	cggtgtcccc	agatccggca	1320		
agagctgacg	gcatgatgaa	tcaccaggc	ggggcaccgg	cgagaaccc	ctgggacactt	1380	

ccgcggccct	ctctgcacac	atcctaagt	gaccggcac	ggcgagacgc	gggtggcg	1440
agggtctca	agggtgcggc	accggcgctc	cagtcccttg	aaataattag	gcaaatttca	1500
aagggtctca	aaggagcaaa	gtaaacctgt	gaggacaag	aaaaaaaaaa	aaaaaaaaaa	1558

<210> 6
<211> 1313
<212> DNA
<213> Homo sapiens

<400> 6	ggcacgagcc	tagagagggc	agactatcag	ggtcggcggc	gtgagaatcc	agggagagga	60
gccaacacag	aaggaggca	gaagaccgg	gcacttgtg	gttcagagc	ccctcagcca		120
tgtggggac	caaggcacac	tggcacag	gtccccata	cagtcccg	ctgccttgc		180
ttctgtctc	tctggccct	ggggccgggt	ggggccagga	ggggtcagag	ccgtccgc		240
tgaggggga	gtgcgtgt	gtctgtgagc	ctggccggat	tgctgcagg	gggcgggg		300
gagccgcct	ggggaggca	ccccctggc	gatgtggc	ttcgtgcgtc	cgaaggccacc		360
accatgagcc	acggggaaa	acccggata	gcacccatgt	ggccatctac	ttcgcacagg		420
tctctggac	cgaggccgt	ggcccttgg	ggcccttgg	ctccctgtc	gcccctgtcc		480
gggggtgtca	cagttcccg	ttccatgtgg	tgaaaggta	caacccggaa	actgtccagg		540
tgagctgtat	gtggaaacag	tgccgtgtca	tctcagccct	tgccaatgt	ctcgacgtga		600
cccgggggc	agcccaacag	tctgtgtac	tgcccttgg	ccctggggac	cgtgtctc		660
tgcgtcgcg	caactgggt	ttactgggt	gttggaaata	ctcaagtttc	tctgggttcc		720
tcatctcc	tctctggaga	ccccaaacctt	tcagaacata	gaatccagcc	ccctgacaact		780
tttcttcgc	cttcttcgc	ccaaaaacag	cagaggcagg	agagagactc	cccttggtc		840
ctatcccaac	tcttcgtat	ggccctgtg	ccaaacaccc	aagttaaga	gaagagcaga		900
gtctggagaca	ggtatacaga	gctggaaatgt	gaccatggaa	aacatcgata	accatgcata		960
ctctggctgt	accatccctt	gaaactgtc	cacccttgg	gttggaaactt	tagtccctcc		1020
acactctgtac	tgcgtcc	ttccctcccg	cttcctcact	gagttatctt	cactgttactt		1080
gttcaggatcat	atccctacta	tctcttttc	tctgtatctg	tgctgtctta	ttctctctt		1140
taggttctct	atccatctgg	ttccatgtat	tcttccttc	agacccttc	ctgcagtagt		1200
gtctaaaccc	ccctctctt	ttcttatccc	gtctgaccat	tgcccgagcc	tggtatgtat		1260
ttataataaaa	acaactatag	aatgtgaaa	aaaaaaaaaa	aaaaaaaaaa	aaa		1313

<210> 7
<211> 1312
<212> DNA
<213> Homo sapiens

<220>	<221> misc_feature						
<222> (27)..(27)							
<223> n equals a,t,g, or c							

<220>	<221> misc_feature						
<222> (1204)..(1204)							
<223> n equals a,t,g, or c							

<220>	<221> misc_feature						
<222> (1225)..(1225)							
<223> n equals a,t,g, or c							

<400> 7	gtcgccctg	ctgttgcgtc	tactgcncg	ctgtgtcccc	gtgcggggc	agaacgacac	60
ggagcccatc	gtgtcgagg	gcaagtgcct	gggtgggtgc	gactccagcc	cgtcggcgga		120
cggccctc	acccctcccc	taggcacatc	ctgtgcgtcc	ggcagcgc	agggtccctt		180
ctccgcac	cggagcacca	accacggcc	gtccagatgt	agcaacccga	ccatqaccat		240
ctatgtcgac	caggtagat	taaatattgg	caacacttgc	gatcttgctt	ccatgtatatt		300
tgttagacccg	agaaaaaggga	ttttagatgt	ctacttcac	gtgttcaag	tgatataacag		360
acaaacccatc	cagggtcgtat	taatgtcaga	ttgttccacca	gtgtatctgg	cttttgcagg		420
agacccaggat	gtcaccagag	aaatgtctgt	caatggctgt	ctgtgtctca	tgaaaaggga		480
agacaaatgt	catttcataac	gttgagagg	caacacttgc	gggggtctga	aaatactccac		540
atttcggc	tttttgggtt	ttccctatca	aacacagac	ccctttagat	gtgggggaat		600
ggcaaaatgg	accaggact	ccgccttta	aaatctactgg	aattggacac			660
cttttttca	accccgta	gacttgtca	tgagaatgtat	gattttctt	gaaacctcca		720
gtactttkt	ttttgtttt	tggatatactg	acaatccctc	ggaaacctgg	cctctaatta		780

gttttagatg	acaaggctt	aaggagaaat	gaaaattatcg	atttgagcaa	tttgtactg	840
tgtattgtaa	gtcaaatatcg	gattttattatcg	ttggggatcat	ggacccctt	ttgtttgtatg	900
tttgtatgtc	gtccccaaacgg	aaggagact	cctgactcca	ggatggctg	cagggtgcag	960
tcaggcctg	aagttagggc	ccaaagaatg	accacactgt	ggacagtct	tgacatgtgt	1020
tctgtgtgt	tctgtatagc	cttaaaaaaa	agaatgtgg	cacttttatt	ctgttatttt	1080
ccccccacca	ttgtggctgg	aggacttggg	aggggggatgg	ggacatttggg	gaacctgttc	1140
aagaatgtgt	ttatccagag	aaggcaattt	ttgcacgatt	ggggactgcaa	ttttgttttt	1200
gtantgttt	tggttttttc	cttgnnaaad	ctttactttt	cctttccaca	ctcagcttt	1260
cctccctea	ccccccatttt	aatttttct	ttgggggggt	tgaaggagag	aa	1312

<210> 8

<211> 1022

<212> DNA

<213> Homo sapiens

<400> 8

gcagccagg	cttgcggg	cgcgatggcc	ggcacggccc	cgacggcg	ccggggctc	50
cgggagagaa	aggcgaggcc	ggggggccgg	gactcgccgg	actctggggg	gaccggggcc	120
cgcggagaa	ggggggaccc	ggggggccca	ccggggctcc	cgggggatgc	tcgggtcctc	180
cgcgcctgc	cttcgcgc	aaggcctccg	agacgggggt	gcttcgcgg	tctgacgcac	240
ccttgcctt	ccacggctgt	cttggtaaacg	agcagggaca	ttacgacgcc	gtacccggca	300
agtgcaccc	ccaggctcg	gggggtact	acttcgcgt	catggccacc	gtctaccggg	350
ccagcctca	ttttgtatcg	tttggaaatg	gcgaatccat	tgccctttt	ttccatgttt	420
tcgggggtgt	gccaagecca	gcctcgctct	cgggggggcc	catggtgagg	ctggagcttg	480
aggaccaatg	gttgggtcg	ttgggttgg	gttgcatact	tgccatctat	gcacgatca	540
agacagacag	caccttcc	ggattttccg	tttacttccg	ctggcacage	tcggcagttt	600
tttgcgttagt	ccacccatcg	agtgcgtcc	ttctgttact	ctttagaaagg	gggttgtggg	660
ctgacaacca	ggtcattcc	gggggtccgg	ccccctggaa	tatgtgtaa	gacttagggg	720
gtggggtaga	gacttctccg	ttctgtctgt	ggcaaggaaat	ggggacacgt	gtctgtctcg	780
atcaggctcg	gcacatggg	ggatggccgg	gattttcgc	aaagaccaga	ggatgtgtgt	840
gtgtgcggaa	gttgaatgg	cccaatgtgt	ctgggtccagg	agccccacgt	gggggtgtct	900
cttcgggtc	ctctgtttt	ttggatccctc	ccccccctct	ctctgttctg	ggccggggcc	960
tttttgcaga	gtactctaa	tttacccatcg	aaaaaaa	aaaaaaa	aaaaaaa	1020
aa						1022

<210> 9

<211> 1254

<212> DNA

<213> Homo sapiens

<400> 9

acgcgtccga	gcagatctga	ggacatctct	gtgccaggcc	agaaaccggc	cacctgcagt	60
tcccttcgg	ggatggacgt	ggggcccg	ttccctccca	accttgggt	gaagctgtcg	120
ctgctctgt	ttgtgtcgcc	cttcagggg	caagccaa	cagggtgtca	cgggatccca	180
gggatggccg	ggctccgggg	ggcaggccagg	aaaggatgtt	acggacggact	ggggggggcc	240
aaaggggagc	cggaaatccc	ggccatccc	gggatggcc	gacccaaagg	gcagaaggga	300
gaacccgggt	tacccggccca	ttctggggaa	atggccca	ttgggacccc	ttggatgtcc	360
gggggtccgg	ggcccatggg	catcccttgg	gaggccagg	aggaggggag	atacaagcag	420
aaattttccatg	cgtgttccac	gttcaatccg	cagacccccc	agccccctgt	acccaaacgc	480
ttgtatcgat	ttcaacgggt	tttcaccaaa	ccgcaggag	tatattgacac	gagcaactgg	540
aagtccatct	gcaaaatccc	cgcccttac	tacttgcgt	accacgcgtc	gtatatacgcc	600
aaacctgtcg	ttgtgtgtca	cgccacggcc	aaaggatgtt	ttccatcttgc	ttggccacacg	660
ttccaaaaacca	atcaggctaa	ttccggccgt	gtgtgtgtca	ttttgtcgagg	ggggcaggagg	720
ttgtgtccgg	ttgtcaatgt	ttactacatgt	atggggggca	ttccagggtt	tgacaggttc	780
ttccgggtct	ttctgtctt	ccccccatcg	ggccggcaga	tgccgtcgag	ccccacgggc	840
ttcccaaccte	tttcagggtt	ttgtatggat	ccacccatgt	ttccagggtt	catcccttgc	900
tagaccatcc	tccccccacca	ttggacttct	ctcccaagg	ggccacccctgt	acccacccccc	960
actgcacccc	ctccccatgg	ttctctcttct	ttctctgtac	tttttttagga	gtcaactgtt	1020
gtgtgtgtcc	ttggacactt	aaaccatgtcc	ttctgtgtact	ggcattttttt	tttttttttt	1080
ttttcaatgt	ttggaaagggg	ttggggatgtt	tataaaaaaa	ttatgtaaaatc	aaaaaaa	1140
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1200
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1254

<210> 10

<211> 1618

<212> DNA

<213> Homo sapiens

<210> 11
<211> 1336
<212> DNA
<213> Homo sapiens

<210> 12
<211> 1114
<212> DNA
<213> *Homo sapiens*

<400> 12
ggcacgagga gtttcttgc tccggacgcc cctggacgtg gcgggcagcc gcgagggtaa 60

ccaccatgt	ccccctgggt	ctcttggcct	gtgccttccc	ctgtgtgtct	gaccactgc	120
ttggcgccgt	tgcgtcgagg	gactttccgg	aaaggccccc	tcaactgttc	tgacggctgc	180
ctggccccca	ggggcccccc	ggccccccc	gagcccccaag	gccttcaggg	atgtatggac	240
gaatgggtt	tccctggaaa	gacggcccaag	atggacacqca	cggcqacccg	ggggacacqcg	300
gagaggaaag	tccaccgtgc	cggcagatgt	accggggaaa	gcacagggcca	aaggccaaag	360
ccggggccat	tggggcggt	gccccccctg	gcccccaagg	gtcaaacgt	acccccggg	420
acgtggca	accaaggcaag	aaaggggccca	aggcgaagaa	gggggagcc	ggcccttccag	480
gcccttcgt	ctgtggcagt	ggccatacc	agtacgttt	ctcggtggc	gtgaccaaga	540
gcttaccac	ggacggcgctg	ccccatca	gttacaaga	ttgtatgaac	gagggtggcc	600
actatacat	ttccacgggc	aatgtcgct	gcggcggtc	tggtatctac	tacttcacct	660
acgacatcac	gtctggatcc	aaacccggca	accacqatgt	gccttcaggg	tcacccatcc	720
gcacccggac	ctttgtatcc	aaacccggca	accacqatgt	gccttcaggg	tcacccatcc	780
tggctctcaa	ggacgggttc	aaagggttgg	tcagatgtt	tcacttcaggg	cagaacgggc	840
tcttcattgt	cccttactgg	acagacagcc	tctttatccgg	tttcatttaatc	ttatggccggcc	900
aggatgaccc	caacgggtt	tagacatcc	acggcggtc	tcacccatcc	ttatggccggcc	960
ctggatctgg	gttttacag	caagacacca	tcactgttgg	tcacccatcc	ttatggccggcc	1020
gagcggttct	agccctcagg	ttaccccttc	tcgtttttt	tttccttcatt	ttatggccggcc	1080
acccttttta	ttcatcaaaa	aaaaaaaaaa	aaaa			1114

<210> 13

<211> 659

<212> DNA

<213> Homo sapiens

<400> 13

ggcacagcac	gcccggcgtt	gtggggctcg	acgcgtggcc	cgggccgggg	caccaaccac	60
tccgttccaa	caccggatcc	gtcaacatgg	ggcgccgact	cgacggcgcc	ggccggcggt	120
tccgtcgcc	tctggggcc	gcctacttct	tcttccttcc	gctggggca	ctggccgtgt	180
agacgcgtgc	gttggatccgt	tgtggatccaa	ggcggcggat	ggggggatgg	attttacqacg	240
acggcgctgc	ggccggccgc	gagatggaca	ggcggcggat	gtatgttggc	ctggccggcg	300
ggcgccgcgt	ctggccgtcc	ggccggccgc	acggccggta	ggccggccatc	agcaacccacg	360
gcaatgtat	caccccttcc	ggcttccgtt	tgatccgg	tttcggccccc	ggccggccccc	420
cgggccctgg	ggccctggag	tcactgttgg	ccccggccca	gagaagagcc	cgggggggcc	480
aggggccgtc	atgcacggcc	ggggccgggg	tcggggatgc	tcggccggac	gcacccgcct	540
ccggggccgc	ctggggatcc	cccaataaaaa	ggaaaggccg	cacggcggac	ggccggccgg	600
ccagggaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	659

<210> 14

<211> 1195

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1147)..(1147)

<223> n equals a,t,g, or c

<400> 14

ccccacggctc	cgggggggac	tgagggggac	ggaaaggggc	cacgcgtgt	gkccatggga	60
ggggacccgt	ggggggaaag	cattttccgg	tctggggaa	ggaaatccg	cttcggaccg	120
aggcgatgt	gtctcggt	cttgggttcc	ctgtgtctca	gcggcgtgt	ctcacaggac	180
accgcgttc	caggggccgt	ctggatgtt	atgtatgt	agatcccatg	gggcggatcc	240
ccgtactgt	tgttgtcc	gttcttgggt	cttaatcgata	tctcccgagg	ccagcttcgg	300
tgcacccgg	ccccaggccat	cctctggatc	ccgggtatcc	tttggacac	tggcccccgt	360
ggccaaatcg	ggcccccgg	gataaaaagg	gagaaggcc	ttccagggt	ggctggagac	420
catgttgatgt	tcggagagaa	ggagacccat	gggatccctg	ggaaatccagg	aaaatgtggc	480
cccaaggccgt	ccatggggcc	taaaaggggc	ccaggggccc	tttggacccc	ggcccccggaa	540
gttgaatcg	gagactacaa	ggccacccat	aaaatcgct	tctctggcc	aaagaaaccatc	600
aacgtcccccc	ttccggggga	ccagacccat	cggttcgacc	acgtgtatcc	caatcgaa	660
aacaatattat	agcccccccg	ttggcaatcc	acccgtcaag	ttccgggtct	ctactacttc	720
acccatccac	ccacgttcg	aggggatcc	ttgggttcc	ttatcgctgg	ccggggatccgt	780
gcacacgg	tggtccactt	tcgtgtatc	gcctacaa	tttcggatgt	caccacccgt	840
ggcactgttc	tcaatgttgg	tcggggggat	acgttcc	ttggggccat	cgacaagaa	900
tcaactatgg	gtatgggg	ttccaaacac	atctttcc	ttggggccat	ttttccatgt	960
atggaggcc	gacctgtgg	ttccatccca	ttccatcccg	ttccatcccg	ttttccatgt	1020
cactatcc	ccaaacccac	cccttgc	gccaatgcac	acgtatggc	tttgttgaatg	1080
ctgtgagtg	aatgtataaa	taaaatcttc	aaaggccaaa	aaaaaaaag	cacttaatgt	1140

tggaaaggccgg	agatgcagtc	aacgtcggtt	tgactggggg	caagctggct	cacacagact	3000
tttagtgaat	gtactccca	tttagtgggg	tttttttttt	tccttttttt	tcctccctct	3060
aaagggtcg	ggggatgtc	aggggaaa	yaatgtatgt	taaaaactct	aaaggctttaa	3120
tatattcggt	ttgtatgtaa	tggaaggccgg	tgccatgtatgt	ttttccatag	ggcccaacat	3180
aaaggccctc	ccttcgtt	gagccccacc	tgccctacttg	catccggcc	ggctgcagrg	3240
agtggaggcc	acgctgtaca	tggccactgt	cttttcgtcc	acttctaact	gacaacttgt	3300
agaacttggaa	aggcttcac	ctgtatgtat	actttgggg	cccttgactgt	ggctgtactgt	3360
ttggccacagag	ttgtccgtcg	atgtgggtt	ggggaggggg	aggccgggg	gagccgggtca	3420
cggtgggtttgg	tttttatctgc	aggccgcatt	tgccggccat	tgctgttttt	tacactcgat	3480
cgcaaaatgtt	aaaaacatgtaa	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3540
tttagtttttttt	ctgttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3600
cgggcccttcg	cccaactgtca	atttatgggg	cttttttttt	tttttttttt	tttttttttt	3660
ctctttttatat	ggcatgtaca	atttatgttc	aaagacagggg	atgttcaata	aatgtggaaa	3720
ggccatccca	gttttttttt	aaaaaaaat	tttttttttt	tttttttttt	tttttttttt	3780
atagtgtatc	gttataatcaat	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3840
ttcggtttatc	ccaaatcttaa	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3900
acnnaaaaaacg	cccccacccgt	cccccccccc	tttttttttt	tttttttttt	tttttttttt	3951

<210> 16
<211> 1280
<212> DNA
<213> Homo sapiens

```
<220>
<221> misc_feature
<222> (81)..(82)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc_feature
<222> (1271)..(1271)
<223> n equals a,t,g, or c
```

```
<220>
<221> misc_feature
<222> (1279)..(1279)
<223> n equals a,t,q, or c
```

<210> 17
<211> 3764
<212> DNA
<213> Homo sapiens

<400> 17

ctgatactat	ttaaggtagc	cctgcaggta	ccgttcggga	attcgccggc	gcgtcgaccg	60
atcccttcgg	tgggagccag	cgagccttc	tcctgtatct	tacgtgccta	aggatccatgt	120
ttcacccatgg	gaatgagaaa	gttggggaaag	agtcatcaga	gcgtcttgct	actcaaatagt	180
ttgtccatgg	accaggcaga	tcagcatcata	ctggatctt	cttggaaagaa	atgttagaaac	240
tcaggccctcc	ccccaaatc	tgccctttta	taagaaaaaa	aagaaggctt	gtgaadggcg	300
agcagctctt	gtgttagaga	cagaaaccag	ccccaggatgt	gtcacaggaa	gtcacaggca	360
aggacattgg	tctttgtattt	gattcagcag	tcttgtcaag	tataaatgtt	atggctgtc	420
tgccctggcc	tctgcacgtc	ctggggatgt	tgcttacal	tttccctgagt	tccatcaggc	480
tcatttcaggc	tgggtccat	latggggata	agccgcgtcc	acctcaataat	ccttcctcaga	540
tgccaccaca	aattttccaaa	taccaggcccc	ttgggtcaga	agtagactctat	atgcctttgg	600
ccaaagatgg	ccttgcattg	ggcaaggaga	tgcccccattt	gagttatgtt	aaagagttatc	660
cacacccattc	ccaaatataat	tgaaaggatgg	aaaggccggcc	aaagaatgggg	aaggaaagccg	720
ttccaaagaa	aggccaaaggaa	ataccattag	cgatgtttac	aggggaaacaa	ggtccctgtg	780
gagagcctgg	cccaaggaga	ccacccggc	ccccctgttt	ggccaggatcat	gggatatactg	840
gaatttaaaaag	aaaaccaggg	ccaggatggat	atccaggatgt	tggaaaggcc	ggtatgcctg	900
gaatggccagg	ggaaaggccag	ggccatgggg	atgcctgggg	caaaaggaga	aattggacag	960
aaaggggaaaat	ttggggatcccc	ggggatcccc	ggaccacaaag	gaccccttgg	gcctcatggg	1020
cttcttgcgc	ttggggagcc	atggggccgg	ttgggttacca	ggcaacccagg	accaaaagggl	1080
gtatcggaggc	ccaaaggactt	accaggaccc	caaggccgttt	gggggttctaa	aggagacaaag	1140
ggcttcgggg	tgcggatgtc	ccggaggatgt	aaaggggcctc	caggatgtca	cgccctcccc	1200
ggccctgttt	gactgtttgg	ccggaggatgt	ttggggatgg	ttggggccccc	ttggggcccccag	1260
ggccccctgg	ggaaaggccag	ggctccaggaa	ggaaacttggc	cacaaggccg	tattttggta	1320
ccgggggttc	aaggacctcc	ttggatacc	ggaaatgttgg	agccaggccc	ggatggggatc	1380
ccaggccagg	caggattttc	atgggtggaa	ggggagccaaag	gtatgcctgg	gttaccaggaa	1440
ccccccaggcc	ttccaggatgt	ttggaaacca	ggcttccca	gaccaaaaagg	tgaccggggc	1500
atggggatgt	ttccctgggg	ttttggggat	aaaggggaga	aaaggaccaat	agggtccccc	1560
ggaaatgggg	tgccttcagg	aggccaggat	ctgcctggta	ttttccaggat	tatggggcccc	1620
ccagggtgtc	ttgggtttcc	ttggggaaaa	ggagaatgggt	ggatgtttagg	ggcacagggg	1680
ccaaagggtc	ccaaagggtt	ccaggccgg	ccaggcttcc	caggaaaggcc	aggtttctt	1740
gtgttaaagg	ggcccttcgtt	catgggggtt	ttggcaggtc	ccataggggcc	caaggggggaa	1800
gtctggccaa	aatgttacc	aggactccctt	ggttgtttcc	ggcttcttcgg	acttaaggaa	1860
gagccaggaa	tcccaagggtt	tcagggtttt	caggggcccc	caagttatcc	agggtttggg	1920
ggccctgttg	ggcccttttg	accatgggg	atttccaggcc	ccaaagggggg	ggccggccctc	1980
ccaggcccccc	ctgggtttcc	ttgtatgggg	aaaccggccgg	ttggcaggatgt	tatggggcccc	2040
ccaggggaaat	ctgggtccctt	ttgtgtttcc	ggccggctcg	ggctttccagg	acccccaggc	2100
cctccaggac	cttcaggacc	ccaccgtgt	atgcctccca	caccacccac	ccaggagagag	2160
tatctccggc	atatggggat	gggaatgttgc	ggccgttgc	ccccccatgtt	ctacgggggt	2220
aaaaaaaggcc	aaatgttgggg	ccggccatgtt	ggatgttgc	cattttccgtt	cgacttaacc	2280
gcaccccttcc	caccgggtgg	ggccggccatgt	aaatgttaca	aaatgttgc	taacggcaga	2340
caagaatcaca	accggccagac	aggatccatcc	acccgttgg	ttccctgggtt	ctactacttt	2400
gcataccacg	ttcaactgttca	ggggggcaac	gtgtttgttgc	tttattttca	gaacaacccag	2460
cccgatgtgt	acacgttgc	ccggatgtttt	aaagggtttcc	ttggccagggt	atctggggat	2520
goatgttgc	tgttcaggcc	ccggaggccgg	gttgccttc	aggatgttcc	agaaacaggct	2580
ccggaggatgt	atgcggggcc	gtatgtttcc	ttctttttttt	cgatgttattt	atgtatcccc	2640
atgtttttttt	atggggatgt	ttttttttttt	ttttttttttt	ttttttttttt	atggatgtttttt	2700
atgtaaaaaaat	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	2760
tatgttaaag	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	2820
atcccacacaa	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	2880
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	2940
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3000
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3060
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3120
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3180
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3240
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3300
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3360
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3420
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3480
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3540
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3600
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3660
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3720
ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	3764

<210> 18

<211> 2485

<212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <222> (2388)..(2388)
 <223> n equals a,t,g, or c

<220>
 <221> misc_feature
 <222> (2415)..(2415)
 <223> n equals a,t,g, or c

<220>
 <221> misc_feature
 <222> (2425)..(2425)
 <223> n equals a,t,g, or c

<220>
 <221> misc_feature
 <222> (2481)..(2481)
 <223> n equals a,t,g, or c

<400> 18

agggttccct ggctccccgt	gaatacgggc	cctccgggccc	ctcccgggcc	cccgggaccc	60
cctgtggccc	ctggggcctt	cgatgagact	ggcatcgccag	gtttgcacct	120
ggtgtggagg	gttcgtcgct	ggcaacgggg	ggcaacggcc	agtttggct	180
tctgccccatg	ccacacccggc	tcttcactcg	gtgtcacct	cgcccttccc	240
atgggtcgta	aatttgacccg	gacttcctac	aatggccaca	ggggcttacaa	300
ggcatcttca	cctggccctgt	ggggccgcgt	tactacttgc	tttaccatgt	360
ggcaccaacg	tgtgggtggc	cctgtacaaag	acaacgtgc	cgccacaccta	420
gtagataacaag	agggttacccgt	ggacccaggca	tctgggtggg	ccgtgtctcc	480
aacggccagg	tctgggtggca	gtatggctcg	gaccaggccc	acggcctcta	540
catatccatc	ccttcgttcc	aggatttcttg	cttcggccca	ataaaccggc	600
ctgtggccct	ggccctccct	ctttttatgg	tagagcacc	ttttcaatta	660
cttggaaaaaa	cttggaaaag	ctggaaacagag	ggggccgttg	cccttggccgg	720
tttttttttc	ccctgtatgc	atggctttat	ttttttttgg	aggggctgttgc	780
ttccccccaa	tgtgtgtgc	gtgtccgggc	tgaccacccat	aggggcccttgc	840
caggccccct	tgtgtcttgg	ttttttttgg	ggcccttgc	gtatgttttt	900
ccccaccccg	ccacgtgggg	agacagccct	ttccactgtgc	tccctgtatgg	960
aggaaagggg	cacccgggtt	cttcacagccc	tttggctgggg	tttcccttcacgc	1020
acccctccatc	tatgtacatgt	gttggggatcc	tttttttttt	tccctcaagg	1080
atggggggcc	atccgggtgg	cgatgtttgg	tttttttttt	ggaaaggggaga	1140
atgtctgtgc	acatcacatgt	tttttttttt	tttttttttt	tttttttttt	1200
accccttcctt	cactgttccca	tttttttttt	tttttttttt	tttttttttt	1260
acacacatgg	ggcggggggc	atgttttttt	tttttttttt	tttttttttt	1320
gccaaggcttc	gttttttttt	tttttttttt	tttttttttt	tttttttttt	1380
gaaatgtcaa	ccttcgttggaa	tttttttttt	tttttttttt	tttttttttt	1440
atcgaccatc	agcaaaatcg	tttttttttt	tttttttttt	tttttttttt	1500
ggctgttttt	cttataatggaa	tttttttttt	tttttttttt	tttttttttt	1560
aaaggcagacg	accccttcgtt	tttttttttt	tttttttttt	tttttttttt	1620
acggctccca	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1680
gggggtttatc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1740
cgacggactag	gggggggggt	tttttttttt	tttttttttt	tttttttttt	1800
gaatgtgttg	gttttttttt	tttttttttt	tttttttttt	tttttttttt	1860
caggccggat	ggcccttcata	tttttttttt	tttttttttt	tttttttttt	1920
gatggatgtt	ggggatgttt	tttttttttt	tttttttttt	tttttttttt	1980
ctgcaggccc	tcggcgttcgg	tttttttttt	tttttttttt	tttttttttt	2040
ctgggggtcat	tcgggtctgt	tttttttttt	tttttttttt	tttttttttt	2100
tccatgttga	aaatggggaa	tttttttttt	tttttttttt	tttttttttt	2160
agggtttctt	ccaaaccccttc	tttttttttt	tttttttttt	tttttttttt	2220
cttcactttt	ccaaaaggagg	tttttttttt	tttttttttt	tttttttttt	2280
tttttttttt	accatgtatca	tttttttttt	tttttttttt	tttttttttt	2340
ggactcttca	accaytttac	tttttttttt	tttttttttt	tttttttttt	2400
gggttcaaa	ggccatatttc	tttttttttt	tttttttttt	tttttttttt	2460
caggaaattt	aatttcagggt	tttttttttt	tttttttttt	tttttttttt	2485

<210> 19
<211> 1550
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1547)..(1547)
<223> n equals a,t,g, or c

<400> 19

ctcgatctg	tggttctgtat	tccataccag	aggggcttag	gatgttgtt	ctgggagctg	60
ttcactgtt	attagctctg	ccggctatg	accaggaaac	cacactcaa	ggccccggag	120
tctgttttc	cgtccccaa	ggggcctgc	cagggttgat	ggccggcatc	ccagggcatc	180
cgggccataa	tggggccca	ggccgtatg	gcagagatgg	cacccctgtt	gagaagggtg	240
agaaaaggaa	tccagggtt	atgggtctta	aggggagacat	cgggtaaaacc	ggatgtacccg	300
ggggctggaa	tccagggtt	tttccggaa	tccaaggcg	gaaaaggaaaa	cctggagaag	360
gtgtttatgt	ataccycc	gttccatgt	ttgggatgg	gacttacgtt	actatccca	420
acatgtccat	tgcgtttacc	aaagatctt	acaatcgcg	aacccactat	gatgtcttca	480
ctggtaaat	tgcgtttacc	atccgtggc	ttgtactat	ttgtcttacc	atcacatgtt	540
atatgaaagg	tgcgtttacc	aaaggccaa	ttttttttttt	ttttttttttt	ttttttttttt	600
atcagttttt	ggaaaataat	ttggggcagg	ctcccggttc	ttgtgtttttt	ttttttttttt	660
ttggcgacca	atgttgc	cagggtgt	ggggaaaggaa	gctgtttttt	ttttttttttt	720
ataatgacaa	tgcgtttacc	ttcagggct	ttttttttttt	ttttttttttt	ttttttttttt	780
caactaacta	gaggccctt	caggccaa	ttttttttttt	ttttttttttt	ttttttttttt	840
cggttagaa	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	900
catccat	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	960
tccctgggg	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1020
tatattttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1080
gtttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1140
gtcacacaa	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1200
ctagactgt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1260
tcccaccc	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1320
caaggtttcc	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1380
caatgtttcc	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1440
caacggggaa	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1500
ctggccagga	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	1550

<210> 20
<211> 1518
<212> DNA
<213> Homo sapiens

<400> 20

ccacgcgtcc	ggactca	aatggatctt	agaccactgt	ggagggccag	ggcgctgtatc	60
ttggctgacc	ggggcaacc	aaggaccgtt	tcattttgt	gat	aaacagg	120
aggccacaa	ggatgttca	agagatgtt	aggcgttcc	agggtttagat	ggggacaaag	180
cacaggcccg	ccatgttcc	aggctttag	ggccatgggg	ccgttcttgc	gggtgttgc	240
aacgggttgg	caactgttgc	ggggggatgc	aggggcttgc	cgaggggctt	tccagacacg	300
ttgggtgggg	ttgggtgggg	ttgggtgggg	ttgggtgggg	ttgggtgggg	ttgggtgggg	360
tgctgtggaa	tgctgtcggy	tgatggcg	tgatggcg	tgatggcg	tgatggcg	420
gtctccgtgg	gtctccgtgg	gtatggcg	gtatggcg	gtatggcg	gtatggcg	480
ctgcagggaga	gggtggggcc	ggatggcg	ggatggcg	ggatggcg	ggatggcg	540
gacccatccgg	atccatccgg	aaaggacgg	aaaggacgg	aaaggacgg	aaaggacgg	600
aaagtgttgg	ggggatgttgg	ggggatgttgg	ggggatgttgg	ggggatgttgg	ggggatgttgg	660
ctgtctgtttt	tttgccttgg	tttgccttgg	tttgccttgg	tttgccttgg	tttgccttgg	720
atgtatgtttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	780
acttgttgg	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	ttttttttttt	840
gttccaa	ggggatgttgg	ggggatgttgg	ggggatgttgg	ggggatgttgg	ggggatgttgg	900
ataaaggccgtt	ggccggagaa	caggccatcc	ccggccatcc	ccggccatcc	ccggccatcc	960
tgccgttgc	ggccggggac	ggccggggac	ggccggggac	ggccggggac	ggccggggac	1020
cgaggaggcc	gttccatcc	tttgccttgg	tttgccttgg	tttgccttgg	tttgccttgg	1080
acgggttgc	ttgggttccgg	ttgggttccgg	ttgggttccgg	ttgggttccgg	ttgggttccgg	1140
cggttccgg	ttgggttccgg	ttgggttccgg	ttgggttccgg	ttgggttccgg	ttgggttccgg	1200
gcccggccgg	gttccatcc	tttgccttgg	tttgccttgg	tttgccttgg	tttgccttgg	1260
ggagggttcc	ggccggccat	gtatggatcc	ggccggccat	gtatggatcc	ggccggccat	1320
aggggccggcc	tttgccttgg	tttgccttgg	tttgccttgg	tttgccttgg	tttgccttgg	1380

gtcgattccc	tgggctccag	gtccccccgc	gggggcgcgc	cccgccgcca	tactaaacga	1440
tcggagaata	aaggacatgt	gttttctaa	aaaaaaactaa	aaaaaaaaaa	aaaaaaaaaa	1500
aaaaaaaaaa	aaaaaaaaaa					1518

<210> 21
<211> 1545
<212> DNA
<213> Homo sapiens

<400> 21	ccacgcgtcc	gggtggctca	tgtataggag	acagttaaaa	agatgggggt	ggcattttct	60
	tcggagag	ttgtggggag	atgaccgtta	gtgtatggaa	ggccccctac	tctgcactgg	120
	cgagaccgc	aaaggctggag	tgaaaccgc	tgtggatggg	ccgcgcgc	ccggggaggt	180
	ggggcgctg	cgtggggaa	acaccaggag	gttggagcccc	ttttccctgt	aaggcaggagg	240
	ccaggatcc	gatggatgg	ccgggtttcc	ggggacccca	ggccccggca	gggtccctggc	300
	gggadaga	acccacggat	tcagatgtcg	tcatgttgc	catggaggatc	ttgtgggttc	350
	tgcttgcatt	tgaatctgc	acaggaaaca	taaaactaca	ggacacccgtc	aggcaaggcc	420
	acccctggat	ccctggggac	ccgggttccaa	atgggttgcg	tggaaaggatg	ggacgagacg	480
	gagcgaagg	tgacaaaaggc	gttcggaggag	aaccaggacg	tcttgcgc	ccggggaaagg	540
	atggcggcag	ttgggggggg	ggggatggat	gaggcaggatc	aaaaatgtgg	gcaaaaggca	600
	tcaaaatgtt	tcggggctca	aggatgtcc	caggaaaaca	ttggcccaag	gggttgcag	660
	ggccggatgg	agagaaaaac	ctccgggggg	ttccgggggg	ttccgggggg	ttccgggggg	720
	agggtggatgt	gggtccctact	gttcttgggg	ggccaaagggg	caacatgggg	ccttggggcc	780
	caactgtttt	acccggggcc	atggggccctt	ttggaaaaggc	tgttcccaag	ggagaaggctg	840
	gaccacggg	gccccgggtt	ggccggggat	ttccggggaa	aaagggttgtt	aaaggagatcc	900
	gaggagagaa	ggggaaaatac	ggtgagactt	tagtcttgc	aaaaatgtgt	ttcaatgtgg	960
	ggcttcacgtt	gttggggatgg	ttttccctgt	catgttgc	cattaaattt	gataagatcc	1020
	tgtataaaca	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1080
	gggtttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1140
	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	1200
	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	1260
	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	1320
	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	1380
	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	1440
	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	tcggggatgg	1500
	actatttttt	caggatgtttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1545

<210> 22
<211> 3543
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (3)..(3)
<223> n equals a,t,g, or c

<400> 22	ttntctgggg	aattcggcac	gagggtggac	cttcggggct	agctgttgc	acaggactcg	60
	ggccacctggc	cttcctgtcac	cgactggcca	gttcggggat	tttggatata	gacccttttc	120
	aattcctggc	cttccttttt	gttcgttgc	ttgtctggat	ggggggccaca	ggcaccttgc	180
	ggacccctttt	ggccaaacgc	ctggggatgt	aaaggaaatc	ttttgggggt	aaaggccgggg	240
	agcagctgtt	ggggacttgc	aaaggccggc	agctgttgc	catggggatc	cgttacaaagg	300
	tccttgcgtt	catgttgcgg	ggggccggat	ttttggggat	ggacttccgg	acagtgttca	360
	ccggctgtca	ttgtgtccca	gttggggccc	tttttttttt	tttttttttt	tttttttttt	420
	tctcccaatgt	gttggggatcc	ggggccggat	tttttttttt	tttttttttt	tttttttttt	480
	tttgcgtacta	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	540
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	600
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	660
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	720
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	780
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	840
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	900
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	960
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1020
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1080
	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1140

gcagaactag	gttctgagcc	acgggtcagg	gtgccaccct	gctgtggcc	ccactgtgtc	1200
acagacgtc	ctggcacagg	tccggcccccc	ttcgagaga	caacaataaa	gcccagcagac	1250
cctttgacc	gccaagggt	gggtggggaa	cttgaggagg	accaggggcc	ctcaggatgc	1320
tagaaacagc	ttggaggatg	ccttcgccecc	accaggaggg	gccccaggcc	ctggcagggc	1380
agagaaggaa	ggggcttgc	ttggccctcc	ttgttcttagc	ccatctactgc	ctttgcacaaa	1440
tgatgttgt	ttggaaaagg	cttggaaatg	cccttgggacc	ttggaaacat	ttagctcaag	1500
aagaccatgg	agecaacatga	tccctgtctc	catgtgtctg	gggacagtc	ttgagcaagc	1560
acagggaagt	cgcgttgc	tctctggcag	cgtctggaa	cagtcaacct	gtgggtgggg	1620
ggctgcagg	ggacaggccc	cagccctgc	ggaggccgtg	ctccgcata	gtgcgcctaa	1680
gtctgcattgc	tcagacagct	tcccgctcc	ggagggccaca	gggcaggagg	gtctcagagg	1740
gcatgtggcc	ctgggttaggg	cagtcgcctc	tctactatgc	ccctcccaag	caggaggagg	1800
agggtcttgc	gtgagaattc	tagtctgc	tctttgtact	tgccaagtc	ggatctgcct	1860
cttaaaggagg	cagagaaatc	tcatacagat	ccccctgcaca	cccaaggcccc	taccactgac	1920
agagcacacag	tgatgtttca	rtkgtagcccc	tccaratttg	ctgactggcc	ttggcccccac	1980
cctycctgt	ctgcagcttc	atggcaaaa	tgaaatttgat	ggtatctgt	tccctgc	2040
agcccttgc	tgtttcttc	agggtggccc	ttttactcggg	tcgcagcagc	aaagggaagg	2100
caagcccttag	aaaggccctca	tgaaagggggg	cagaacatcc	tcgcaccatc	agttaactcg	2160
aaftaaatggg	acaagaaatgg	gttggaaagag	agttgtgtgt	gggggtctgg	argatgtgtc	2220
ragaaatttc	ccatccatgg	ggggcccttc	ttggcagtc	aggcaggsc	gtgtgtgtgg	2280
actgtactcaa	cagacatagt	ttcatctcc	ccctggccct	tcacgggtt	gtgacccccc	2340
ccacatggac	acccggatgt	tgaaacttta	ggggctggcc	atggcattan	cagtgttggg	2400
tgtccagggtt	cttgcgtgtc	tgaaataaa	atggggcaaa	atggcacaag	caaggaaagg	2460
atgaagggtt	ttacttgagaa	tttttttttt	tttttttttt	tttttttttt	tttttttttt	2520
gggactcaag	ggggccctgtt	cagaattttt	ggggataaaa	atccactaga	ggatccatt	2580
gtttactgttgc	gttacaccct	atgtttatgg	aaaggatgtt	gttttttttt	aaattttttt	2640
acagatata	ccctatgggg	ggggatatttc	tttttttttt	tttttttttt	tttttttttt	2700
tgttccctgc	cttccggacc	tatttttttt	tttttttttt	tttttttttt	tttttttttt	2760
tcagctgtt	aaaccttgc	tggtccggca	tggtggagtc	gggtgtcagge	ccagcccccga	2820
agcttcctcc	tgccggaaagg	accaggccag	tcgcgttcc	tttcatgtca	gagatgtgtt	2880
gtgttgcgt	actttagcaga	tttttttttt	tttttttttt	tttttttttt	tttttttttt	2940
ctaagaacca	ggccgttgc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3000
gatcacatca	ggacagctcg	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3060
aacttttcac	ggcttcgtca	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3120
tgacagacat	ggggggggcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3180
ctggggcttc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3240
ggggcccccatt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3300
cttgcgtatgt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3360
ctgtatata	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3420
ctttttggc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3480
tggtaatcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	3540
						3543

<210> 23
<211> 3522
<212> DNA
<213> Homo sapiens

<400> 23						
ggcacgggt	tggaccttcg	agccctatgtc	cttcgcacagg	actcgccac	ctgccttc	60
tgcacggact	ggccagctca	agagttttgg	atatggaccc	tttcaatcc	ctggccttc	120
tctttgtct	gtttttgtct	gggtatgggg	ccacaggcc	cttgcaggacc	tccctggacc	180
caaggcttgc	gatcccttgc	aaatgtttgg	aggtgtggcc	ggggggccag	ctgttgcc	240
tgaaagggtt	ggccacatgc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	300
tcaaaagggt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	360
tcccatatgg	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	420
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	480
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	540
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	600
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	660
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	720
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	780
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	840
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	900
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	960
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1020
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1080
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1140

gagccacggg	tcagggtgcc	accctgtcgc	tggccccact	gtgtcacage	gtgccttggc	1200
acagggtccca	gccccttcg	agagacacaa	taaaaggccag	ggacccttt	ggaccgacca	1260
aggctgggg	gggactgtg	aggggccag	ggcccccct	ggatgttagat	acagttgg	1320
ggatgcctct	gcccccaac	gaggggcccc	ggcccccggc	gggcgcggat	aggaaaggdc	1380
tttgtctgg	cctctgtgc	ctacgcgc	actgccttgc	acaaatgtat	gttgttggg	1440
aaggacctgg	aagtgcctg	ggacccctgg	aacatttgc	lcaaqaacac	cttggagcaa	1500
catgcaccc	gtcttcagat	gttggggac	agtcttgcg	caagcacagg	gaagtca	1560
tgtctctct	ggcagecg	gaagacatgc	acctgtggg	tgggggctg	cagggggaca	1620
ggccgcaggg	ctgcaggagg	cggtgtccg	caatggctg	cataaagcttg	atgggtc	1680
cagttttccg	tctccgggg	ccacaggcc	ggaaagctgc	agagggtat	tgcccttgg	1740
tagggcagct	gccccctact	catggccctt	ccaaaggag	gaggggaaagg	ctttagtgc	1800
aattctagct	ctgccttott	gacccggcc	agtccggatc	tgcccttata	agagcagag	1860
aaaaccatcc	agatcccc	gacccccc	ccccctaccac	tgcacagqca	caaglgagat	1920
ctgagtgtt	gccccctaga	tttgtgact	ggcccttggc	cacccttccc	tgtctgcag	1980
cttcatttgc	aaaaatgaat	tgtatggata	ttatccct	gcccagccct	aacctgtttc	2040
tctggaggct	gcctccctac	ggggctcgag	caycaaaagg	agccaaggcc	ttagagaagc	2100
cttcatggag	ggcccaaaac	atcttcgc	catcgttac	tccggaaat	ggggacaaga	2160
agcagctgca	agagatgtgg	ttgtggggg	ttggggatgt	gtctgggaaat	tttccctatc	2220
agaaggcccc	tcaactggca	tgccggggc	ggcgtgtgg	ttggactgt	tcaacagaca	2280
tagtttccatc	tccaccatcc	cttccatcgg	ttgtgtgacc	caaggccat	ggacaccgg	2340
gtctgtgaa	taaaaaggctg	tgccatggca	ttaaacgttg	agggtgttca	gttcttgc	2400
gtcttggaa	aaagaatggg	aaaaatggc	aaagcaagg	aggaaatgg	ggttttatcg	2460
agaatggaaag	tatactccac	agatcgagg	aggggcttgc	cataggact	caaggggccc	2520
gttacagaat	ttttgggat	aaataccac	tagaggatc	cattgttac	ttgaggatca	2580
cctctatgtaa	atggaaatgg	tgaatggat	ttacaaaatt	attacacgca	tataccctat	2640
ggggaggata	ttccctgtt	tagctgaa	gtyaatgg	ttatgttcc	ctgcctccag	2700
acccatattt	cttcgtcatca	cgggaaaggc	tcagatttac	tggctcagct	gtttaactcg	2760
tccctgtggcc	aggcgttgg	gtctgggtgc	aggaccaggc	cgcaagctt	tccctgcgg	2820
aaggaccagg	ccatgcgtg	tctttttcat	gtctagagat	gttgggttgc	gtgtacttag	2880
cgagaaagg	gtttttttt	cccccttaact	ggagaaaaaa	tttcttaaga	accaggctcg	2940
gttggcagca	gacccatgtt	tcttgggg	gcagggggc	taaagcatac	ctcaggacag	3000
tcatgtgtgg	gtccatgtt	ggctgggg	tctttttat	gaataaaatc	tacgggtct	3060
gtcatttagca	ggatttgtat	attttgc	agagctggc	aactgcagag	caatgggaa	3120
gcccggcc	tgtgggtggca	agaccctggc	aacttgggc	caagctgggc	ttgtcttgc	3180
catgttgtt	tatccaaacc	aggctttt	acttcgcatt	cttcgcattt	tttgcggccc	3240
atggccatgt	gtttaaaaagg	tggaaatctgg	atttaaatgt	atcttcgtat	gtatgtgccc	3300
cttcgttcac	gggtttttgt	tcatccat	tattttacta	ctgcctgtt	tatatgcaga	3360
gccccatgt	ggggccctgtt	ttgttgcatt	ctccctatc	ggcccttctg	gcacctctt	3420
cttcctggcc	tttttttct	aataccgtca	tccctcttcc	aacctggta	atctgttct	3480
ttctgccttc	aaatgggcac	cttcaaaaaa	aaaaaaaaaa	aa		3522

<210> 24
<211> 1969
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (996)..(996)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (1040)..(1040)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (1058)..(1058)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (1068)..(1068)
<223> n equals a,t,g, or c

<400> 24

ccacgcgtcc	gcccggag	ggcgcctgtt	gcagcatgg	cgccccgg	gcttggcg	60
tgcgtcg	cgggttc	ctccgggg	ggccgcgtc	gtggacatc	ggggcagctc	120
cggttcgg	acgcggaa	tggtgtct	atgtgtgt	ccgcaccatc	tcatggccatc	180
tgcagaatg	cacctactt	cagcgatgt	tgacaaatc	ccccctggcc	atagactgtc	240
cgggggcag	ctacaact	gttgtgagat	ccacataca	gtgtatgtac	aaatatgtta	300
cccccgtga	gtggagggtc	tgccctggc	actcaggat	gagctgcgag	gaagtgtcg	360
cttcctgtt	cttcgtgg	cccatgtgtt	cgccgcgtac	catgcggcg	atggcgcttc	420
ggcccacgc	cttcctcggt	tgctcaact	gcacaaatg	gtcagagctg	acagagggc	480
tgaagggtg	ggggggcaag	atggccatgc	tgactgtcat	agacgcggcc	gtaccccaa	540
caccatgc	cctcgaggac	cttgcggcc	tctgggggtc	ccttcgtc	cagggcagcc	600
ccaaaggaga	tgccggcaat	cggggccca	tggggatgag	aggccccacc	gttccacagg	720
gccccccagg	gaccctggc	cgggttggag	ctgtgtggcc	cctctggatgg	agggggactc	780
ctggggcacc	agggtttct	ggccccctgt	ggccccccagg	cctctgtggg	ccaccccatg	840
cccgatctc	ccacgcgtt	ggcccaatgc	tgcccaaac	cttcaactgag	accaacaacc	900
actggggccca	ggggggccat	ggccctccagg	ggcccatgtgt	ccccctggcc	960	
cttcggcc	cacagggtt	cttggggactc	cttggtnatcat	aggggccccc	ggcccccactg	1020
gaccggaaagg	aatcttgg	cacccaggag	aaagggnng	aaagaanang	ctgcgtgggg	1080
agccctggcc	ccaaaggctt	gttggggcc	ggggggaaacc	tggccctlaag	ggagaccctg	1140
tgatggaaag	ccactggatc	agacgtgtgg	tgctggggcc	gcccctggcc	cacaggcacc	1200
ccccaggcttc	ttccggggca	gaggggccgac	atgcaccaa	cttccggat	ctgtggccccc	1260
aggagccgg	acgagaggg	ctgggggtgg	tgccggccccc	tgaggcagac	caggccaggc	1320
ttcccttcct	acettggact	tgccgcgtgc	ctccaggggac	cccccgttca	tattttat	1380
tgtcttcagg	gttccctctg	ccatcttaggc	cttaggggta	agcaggcttc	atgcctggca	1440
ccatgcacat	gttggggat	gacgcggcc	tgagggaga	ggcttggggc	tcagttttcc	1500
ttctgtgtt	gggggggggg	agggtttctt	ggaggggatag	aggtacaagg	cttctgttca	1560
ttctgtgtt	gacgcacttgc	gcccccaaggc	actgggggg	tcaggagctg	gggtctggca	1620
catgcagaga	tgacaggggc	ggggggccatc	ttctccccc	ttccggccatc	aaccttgggg	1680
agcccttcct	ttccggggat	ttctttgtgt	ccagtgtctg	gttcccccacc	ccgggggtcag	1740
gttgcggccat	ccttcgtact	gttccgggg	ggcttcttgc	ctcagtgttt	ccctctgtgc	1800
ccccaggccc	tcccgatct	cagggtggg	atggggatcat	ggagggaaat	ggccggcccta	1860
cttcctgtt	tgcttgttgc	agatggccagg	aggatgtat	gttctggccca	ataaaaggccc	1920
cttactgtt	ccccggaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1969
<210> 25						
<211> 2189						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (2)..(2)						
<223> n equals a,t,g, or c						
<220>						
<221> misc_feature						
<222> (4)..(4)						
<223> n equals a,t,g, or c						
<220>						
<221> misc_feature						
<222> (7)..(7)						
<223> n equals a,t,g, or c						
<400> 25						
gnandcgngt	acgactcact	ataggaaag	cttggtacgc	tgcaggatcc	gttccggaaat	60
tcccggtgt	acccacgcgt	ccgcgcggg	aggggccctg	gtgcagcatg	ggggggccgc	120
gggcttgggc	gtgtctctgc	ctcgggtcc	tgctcccccgg	aggcgccgct	ggctggagca	180
tcggggcagc	tccgttctcc	ggacgcggag	actgtgtctc	ctatgtgtgt	accggccacca	240
tctcatgc	tgtcgacaaat	ggcacccatc	ttcagcgatgt	gttcgcacaa	tgcctctggc	300
ccatgcgtgt	ttccggggatc	agctacacaaa	ttccggggat	gttcgcacaa	aaagggtatgt	360
aaacatgtat	gaccggccgt	gttggggatgt	gttcggccatgg	ggacttcggat	gtgagctgcg	420
aggaaatgtt	agctttttct	gttcggccatgg	ggccatgttgc	gttcggccatgt	accatggccgc	480
ggatgtgtgt	ttccggggatc	gttcggccatgg	gttcggccatgg	gttcggccatgg	gttcggccatgg	540
tgacagagcg	gttggggatgt	ttccggggatgt	gttcggccatgg	gttcggccatgg	gttcggccatgg	600
cgtacccctc	aaacccatgtt	ttccggggatgt	gttcggccatgg	gttcggccatgg	gttcggccatgg	660
cccgaggcag	ttccggggatgt	gttcggccatgg	gttcggccatgg	gttcggccatgg	gttcggccatgg	720

ggccccacccg ccccaaggga gatggccgca gtcggggccc aatggggatg agaggccac	780
cagggtccaca gggcccccca gggagccctg gccggggctgg actgtggggc accccctggc	840
agagggggacc tccctggccca ccagggttgc ctggccccc tgggccccca gcccctgtg	900
ggccacccca tggccggatc tccccagcatg gagacccatt gtgtccaaac accttactg	960
agaccaaaacaa ccaactggccc gagggccatcg ctgggcctcc aggccctcca gggccatgg	1020
gtccccctgg gctccctggc cccacaggta tccctggggat tccctgtcac ataggacccc	1080
caggccccac tgacccaaa ggaatcttg gccacccagg agagaaaggcc gagagagggc	1140
tgcgtggga gcctggccca caaggctctg ctggcagcg gggggaaacct gggcctaagg	1200
gagaggctgg tgagaaggac cactgggggg aggggttgc caagctacgt gaggctttga	1260
agatatttgc tgaggggtt ttaatcttgg aaacaatgtat tggtcttat gaacagagac	1320
tgggttctgg ggccggccctt gccggcacag cagccccccatg ctcccttggg gccaaggagg	1380
gcggacatgc aaccaactac cgatctgg ccccccaggag cggggacagag agaggctgag	1440
gtgtgtggc gccccctggg gagacccaggc caggcttccc ctcttactcg gactccggcc	1500
gtcgccctca gggacccccc otccatattt attaatgtcc tcagggtccc ttctggccatc	1560
tagggcttag ggtaagcg gtctcagtc tggcaccatg cacaatgtctg aggctgaaqca	1620
agggttggaga ggagggctt ggccctcagt ttccctctgt gaagtggggg gaggeaggcc	1680
ttcaaggagg gatagggata caaggcttcg ttccatctgc tgctctgagca tcacggccca	1740
aaggactgta ggaggacttgcg agctggggctt gggcacatgc agagatgaca ggccagggggg	1800
catgttcttcc cccctccca gacaaacccat cggggagcccc ttctgtcccc ctcccttctt	1860
gttgggttgcgt gtcgggttcc cccaccccgag gtcaaggctgc ccaatcttcg gactggatca	1920
ccgggggttc tttgccttcgat ttcttccttgc tgagccccca ggccctcccg catctcagg	1980
tggggatggg gacatggaga ggaaggggcc gcctacttcc gcaaattgttt gtgacagatg	2040
ccaggaggta gatgtgtctt ggccaaataa ggcccttacc tgatcccccg caaaaaaaaaa	2100
aaaaaaaaaa aaaaaaaaaa aaaaggccgg cgcgtctaga ggatccaagc ttacgtacgc	2160
gtgcayggcr gtcatagctc ttctatagtc	2189

<210> 26

<211> 1236

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (1)..(1)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (6)..(6)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (14)..(14)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (27)..(27)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (39)..(39)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (1230)..(1230)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (1232)..(1233)

<223> n equals a,t,g, or c

gcccccccaagg	gagccccctggc	cggggctggag	ctgtgggcac	ccctggagag	agggggacttc	780
ctggggccacc	aggggcccttc	ggccccccttg	ggccccccagg	ccctgttggg	ccaccccccattg	840
cccgatcttc	ccgatctttga	ggaccatctgc	tgcccaacac	cttcaactgag	accacaaccc	900
actggggccca	ggggcccaact	ggggccctccgg	ggcccttgggg	ggccatgggt	cccccttgggc	960
ctctggcc	cacagggttc	cttggggatgc	ctgggtcacat	aggggcccca	ggcccccactg	1020
gacccaaagg	aatcttggc	cacccaggag	agaagggcgaa	gagggggactg	cgttggggagc	1080
ctggggccca	aggcttggc	ggggcagccgg	ggggaccttg	ccttaaggga	gacccttggt	1140
agaagagcca	ctggAACCCAG	agctcgggtc	tggggcgggc	cttgcggca	caggcacccc	1200
cagctcttctt	cgggggcaaga	ggggccggacc	tgcacccaaac	tacccggatcg	tggccccccag	1260
gagccccggac	gagagggct	gagggtgtgg	ggggccccctg	aggcgacaaa	ggccaggctt	1320
ccccctccatc	ctggggatcg	ccagctgtcc	ccaggggaccg	ccctgtccata	tttataatg	1380
tctcagggt	cccttctgcc	atctaggctc	tagggtaaq	cagggtctcag	tctggggacc	1440
atgcacatgt	ctggggatcg	gaaaggggcc	agaggagagg	cttggggcttc	agtttccctc	1500
tgtgaatgg	ggggggggcc	gcttcgggg	aggggatagag	gtacaaagggt	tgcgttcate	1560
tgcgtctgg	gcatccaggc	ccaaaggccac	tgaggggatc	aggagctggg	gctcggcaca	1620
tgcagagatc	acaggccgg	ggggcagtctt	cttcccccc	ccccacccaa	cttccggggag	1680
cctctctgt	ccccccttc	tttgttgc	atgtgtgggt	tcccccaccc	gagggtcaggc	1740
tgccaaattc	tctggatgg	ccacccgggg	cttcttgcct	caatgtttcc	ctctgagcccc	1800
ccaggcccttc	ccgcacatca	gttgggggg	ggggacatgg	agaaaaagggg	ggcccttact	1860
ctcgaaaatg	cttggatcac	atggccaggag	gtatgtgt	gtctggccaaat	aaaggccctt	1920
acctgatccc	ccgcaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1967

<210> 29						
<211> 1967						
<212> DNA						
<213> Homo sapiens						
<400> 29						
ccacggcgtc	ggcgcggag	ggccgcctgg	ggcagcatgg	gggcccgggg	gttggggcc	60
tgcctgtctc	cgggctctg	ctccggggag	ggcggcgtc	gttggagatc	ggggcgactc	120
cgttctccgg	acgcaggaa	ttgttgcctc	atgttggta	ccgcacccatc	tcatggcatg	180
tgcagaatgg	tcacatctt	cacgcgttc	tgcaacatgc	ccccctggcc	atgagctgtc	240
cgggggccag	ctacacaaat	gtgggtgagac	ccacataca	gttgtatgtac	aaqatagtga	300
ccggccgtga	gttggggatgc	tgcccttggc	actcggatgt	gatgtcgccg	gaagtgtcag	360
cttctctgtc	cttcttgg	ccccatgtgt	ggggcgtac	catgggggg	atggcccttc	420
ggccacacatc	cttcttcagg	ttgttgcata	ggcagcaatgt	gtcagatgtc	acagagggcc	480
tgaagggtgc	ggggggccaa	atggatcatc	tgactgtcat	agacagccca	gtacccatcaa	540
cacccgtatc	ccctggggac	cttggggccgc	ttgggggttc	ccctctgtcc	caggggcggcc	600
ccggatgtgg	aggccctccg	ggaaacatcg	gtgtttttgg	gttcccccgg	ccccccggcc	660
ccaaaggggaa	tgccggcaat	cgggggccaa	ttggggatgg	ggcccaacca	gttccacagg	720
gccccccctgg	ggcccttggc	ggggctggag	ttgtggccac	ccctggagag	aggggaccc	780
ctggggccac	aggcccttc	ggccccctgg	ggccccccag	ccctgttggg	ccacccatcg	840
cccgatcttc	ccacggatcc	gacccatgtt	ttgtccacatc	cttcaactgt	accaacaaac	900
actggggcc	ggggccatgg	ggccctccgg	ggccatgggt	ccccctggcc	ccccccatcg	960
ctccgtggcc	cacagggttc	cttggggatc	ttgtgtccat	aggacccccc	ggcccccaactg	1020
gacccaaagg	aatcttcgtc	cacccaggag	agaagggcgaa	gagggggactg	cgttggggagc	1080
ctggggccca	aggcttcgtc	ggggccatgg	ggggacatgg	ccctaagggtt	gacccttgggt	1140
agaagaggca	ctggaaaccat	agctgggggt	ttggggccgg	cttgcggccca	caggcaaccc	1200
cagctcttc	cgggggcaaga	ggggccggaa	tgcacccaaat	tacccgtatc	tggccccccat	1260
gagccggggac	gagggggatc	ttggggatgt	ggggccccctg	aggccatgg	ggccaggctt	1320
cctctccatc	ctggacttcg	caatgtgtc	ccaggggatcg	ccccatccata	tttataatg	1380
tctcagggt	cccttcgtcc	atctagggtc	tagggtaaq	cagggtctcag	tctggggacc	1440
atgcacatgt	ctggggatcg	gaaagggtgt	agaggagagg	cttggggcc	atgttccctc	1500
tgtgaatgg	ggggggccgg	gtctcaatgg	aggatgtatgg	gtacaaagggt	tgcgttcate	1560
tgcgtctgg	gtatccggc	ccaaaggcat	tgagggtatcg	aggagctggg	gtctggcaca	1620
tcgcagatcc	acaggccgg	ggggcgttcc	cttccccctc	ccccacccaa	cttccggggag	1680
cctctctgt	cccccttc	tttgttgc	atgtgtgggt	tcccccaccc	gagggtcaggc	1740
tgccaaatcc	tctgtactgg	tcacccgggg	cttcttgcct	caatgtttcc	ctctgagcccc	1800
ccaggcccttc	ccgcacatca	gttggggatg	ggggacatgg	agaaaaagggg	ggcccttact	1860
ctcgaaaatg	cttggatcac	atggccaggag	gtatgtgt	gtctggccaaat	aaaggccctt	1920
acctgatccc	ccgcaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1967

<210> 30						
<211> 2006						
<212> DNA						
<213> Homo sapiens						

<210> 31
<211> 897
<212> DNA
<213> *Homo sapiens*

<400> 31	ccacgcgtcc gccggccggg ctgtctcgagg gtcttgagccc cggacagggt gtgggtggtag	60
ctccccacgg	gtccccactgg gccccctacc tgcttccttc tccccccage ggatcttt	120
cgggtccccca	ggacacttccgg tgccgaaagggt ccggccgggg agatctgttc acggatttca	180
ggagctgtgt	aaaaaggggccg ccggccggcc gtttccttgggg ctgtttggacc cgctgtggcc	240
ccaggggggcc	ctgggtccggc ttgggtttttcc gcatctttcc tcggccgtgc aggtttcccg	300
ccgggttgtac	aaggccggacgc tggtttggact gcattttttcc caggctcttc ctggccaaagg	360
tgcttcctcg	cgaggcttcgg tgcttgagctt ggcttcgggt cggtttcacgg cccctgtgtc	420
cggacttttc	cagttttcctcg ccaggatccgg ctgtttttcc cttttttttttt atggatccgg	480
cggctgtggc	ccccggggggcc ttgggtgtgt ttatccatgtt attgatgtcc ttgttccggcg	540
ccacaacccgt	ctggggggccct ttccggggggcc cggggggggcc acggggggcc taatccatgt	600
ggtgccgggg	ctgggtccggc tgccgggtgg acatgtttcc ttgtttttttt tgccatgttt	660
ccggggggcc	gtcttcctacc caatccggggg ctccggggggcc ttccggggggcc ttccggggcc	720
gtgaggggcgc	ccaggggggcc tgccggggggcc ttccggggggcc atccggggggcc cccctttact	780
gatggccctgt	gtcacccaaaaaa taatggggcc ttccggggggcc aaaaaaaaaaaa aaaaaaaaaaaa	840
aaaaaaaaaaa	aaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa aaaaaaaaaaaa	900

<210> 32
<211> 990
<212> DNA
<213> Homo sapiens

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (879)..(879)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (888)..(888)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (897)..(897)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (899)..(899)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (901)..(901)

<223> n equals a,t,g, or c

<400> 32

ggggaaatgc	agtgcacgca	ggagtaaagg	tggggaggcag	gacagagctg	ggacacagg	60
atggagagg	ggttcagcg	gccttagag	ggcagacta	cagggtgcgg	gcgttgagaa	120
tccaggaga	ggagcgaaa	cagaagagg	gcagaagacc	ggggcaactt	tgggttgacg	180
acggccctcg	ccatgtgg	agccaaggca	cactggctac	cagggtcccc	acacagtccc	240
gggttgtcc	tggttctgtt	ggttcgttgc	ctggggggcc	gggtggccca	ggaggggtca	300
gagccggctt	tgcgtgggg	ggatgtggctt	gtgtgtctgt	agccctggccg	agctgtgc	360
ggggggcccg	ggggggcccg	ggatgtgggg	gtgtgtctgt	ggatgtgggg	attgtgtcg	420
gtcccaaccc	accacccatgc	gcacggacgg	atggcaccagg	tggggccatc	ttggggccatc	480
tacttcgac	agggttcgtt	gaacgggg	gtgtgtttt	acggggctt	tgggtcttcc	540
gtatggccct	tccgggggtt	ctatcagttt	ccgttccatc	ttgtgtgggt	gtacaaccgc	600
caaaatgttc	agggtggatc	gtatgttcac	acgtggctt	tcatcttcagc	ctttggccaa	660
gatcttgcac	tgaccggga	ggcagccacc	agctctgtc	tactgtccctt	ggacccctgg	720
gaccggatgt	cttcggccct	gggttgggg	naatctactg	gtgtgttgaa	aatactcaag	780
ttttcttcgc	tttcctcatc	ttccatcttc	aaggacccaa	gtttttcaag	cacaagaatc	840
cagccccctg	tccggcccttc	ttggcccttc	ttggccccana	aacagcanaa	gcaggganana	900
nactccctt	ggctccatc	ccacctttt	gcatggaaac	cttgccaaa	cacccaagg	960
taaaaaaaaa	ataaaaaatgc	ggcatctcca				990

<210> 33

<211> 1384

<212> DNA

<213> Homo sapiens

<400> 33

tcggatgtttt	tttttttttt	tttgaccacc	attttctagt	tgtttttattt	atagattcat	60
ccaggctgg	ccaaatggac	ggccggatata	ggaaaggaga	gggggggttt	agcatactgg	120
caggaggg	tctgaaggaa	atccatcg	atcccaagg	atataggaa	ctaaggagg	180
gaataaagaca	gcacagatca	ggagaaagg	agatagtgg	gatatgtctgg	aacaggataca	240
gtgaat	ctcaatgttca	ggatgtgggg	ggaggaggca	gcgttcagag	tktgggg	300
ctaaagg	aacttcaaa	gtggacagg	tcaggagg	gcacaa	argatgtca	360
gtttatccat	ttttccatgtt	tcacacttcc	gtctgtata	cttcgcwag	ytytrytyt	420
ytctttaact	tgggtgtttt	gcacagg	tcatgc	argtggtat	ggarccagag	480
ggatgttcct	tccgttccct	gtgtgttctt	ggggcaagaga	ggggcaagaga	aagtgtcg	540
gggtgtggat	cttgcgttgc	aaaracttgg	gttcctcagag	aggggaaat	aggaaaggcc	600
agaaatcttg	gttttccat	ccacccatgtt	gatcccccgc	acgcaggcc	agagcacact	660
gttcccccagg	gtccaaaggcc	agttccatgtt	gtcccccgc	acgcaggcc	gttcacgtcg	720
gtatcttgc	aaaggcttgc	atgcacggcc	acgtgttgc	catcagg	acctggacac	780
tttggccgtt	gtacaccc	accacatgg	acccggaa	gttagacaccc	cgccacgggg	840
ctacgaagga	ggcaggaggcc	cggtcaaa	caccgccttc	gttccacagg	acctgggtcg	900

```

aggatagatggc cccamtggg ccattggccgg tttccccctgc tggtctatgg tgktggcttc 960
ggccgcgcage aaatggccact ggcccgggg gtgccttcc cagggtcgct ccccccggcc 1020
ccctcgacgc agctcgggca ggcttcacaga ccacccaggca ctcccccttc acgaggacgc 1080
gtcttcgaccc ctccctggggc cactccggccc ccaggggccag aaggaccaga accaaaggca 1140
ggccggggact gttagggga cctggtagcc agtgtgtgtt ggctcccaad atgtcggtgg 1200
tggtctcgcaaa cccacaatgg cccgggttctt ctggcccttct tcgtttccg ctctctcc 1260
tggatcttc ccccgccgac cctgtatgtc tgcccccttctt aggtctcggtt aaccctcttc 1320
ccataacctgt gtcccgatctc tgccctgttccc cccactctta ctctctgtt cactgcagg 1380
ccccccccc

<210> 34
<211> 809
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (307)..(307)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (751)..(751)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (756)..(756)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (804)..(804)
<223> n equals a,t,g, or c

<400> 34
ccgtctgtcc cccgtcgccgg cgccagaacga caccggagcc atccgtgtgg agggcaagtg 60
cctgggtgggt tgccgactcca gcccgtcgcc ggacccggcc gcacccctctt cccttagggcat 120
ctccgtcgcc tccggcggccg ccaagggtggc ctccatcccgcc acggggagca ccaaccacga 180
ggccgtccggat atggcaaccg gcaaccatggc catcttatcc gaccaggatgat tagaaatataat 240
ttggcaaacccat ttggatcttc cttccatgttcc atttgttagca ccggagaaaaag ggatttatataat 300
cttcgtatcc cttccatgttca aagtgttatata cagacaaaaacc atccggatggc gttaatatgc 360
gaatggcttcc ccaggatgtcc cccggccatggc aggagacccatg gatgtccacca gagaaagctgc 420
tagcaatggc tgccgtcgcc tcatggaaaag ggaaagacaaa gtccatctca aacttggagat 480
aggcaaccctc atggggggctt ggaaatactc cacattttcg ggcttcttgg ttgtttcttctt 540
ataaaacacag agccggccatgg atgggggggg atggccaaac tgacccggagg atttccgcctt 600
ttaaaacacc cttccatgttca cttccatgttcc acatccgttg tcccaaccttcc gtccgactgt 660
tttgcgtatgg gaaggaaatgg ttccatgttgg acacatccgtt tcccaaccttcc gtccgactgt 720
ggatgttgc cttccatgttcc ggaaacccggg ntttantttatgg ttttttatgg gacaaagggtt 780
ttaaagggaga attgaatttt ttcgttttga

<210> 35
<211> 1215
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1212)..(1212)
<223> n equals a,t,g, or c

<400> 35
ggccggccggat ctcccgatctcc cgggtgtccgg gactcggttc tcccgccagg gggcgccact 60
ccccggccgtt tgccggccatgg acggccggatgg gggccggccgg gggccggccactt cccttggccca 120
ggccggccatgg ttcggccatgg ggaaaggggggatgg gggaggatgtt ccggccgggggggggggggtt 180
ggccggccatgg cttccatgttcc acatccgttcc acccccccttcc accccccgggggggggggggggtt 240
ggccggccatgg cttccatgttcc acatccgttcc acccccccttcc accccccgggggggggggggtt 300

```

cctcgagggg	accccgggg	gcgaggagag	gggggacccg	gggggcccac	cgggcctgcc	360
ggggagtgtc	cggtggcttc	gogatccgc	ttaeggccca	agcgttccga	gagccggglg	420
cetcggct	ctgacgcacc	ttccgccttc	gaccgggtgc	tggtgaaacca	gcagggacat	480
taacgacccg	tcacccggca	gttccacccgc	cggtgcctgc	gggtactacta	cttcgcgtc	540
catgcaccgc	tcataccgggc	cagccgtcag	ttatgtatcg	tgaaagaatgg	caaatccatt	600
gctcttcttc	tccaggtttt	cggggggtgg	cacaaggccg	cctcgcttc	ggkgggggcc	660
atggtgaggcc	tggaggctga	gaccaagggt	ttgggtcagg	ttggtgttggg	tgactacatt	720
ggcacatctat	ccacatcaa	gacagacagc	accccttcgg	gatttctgt	gtactccgc	780
tggcacagct	ccccccatctt	ttgtttagtc	ccactgcaaa	gtggactcat	gtcttcact	840
cttggaaaggag	gttgtgaggcc	tgacaaacccag	gtcatccagg	aggggctggcc	ccccctggaaat	900
atttgtaaatg	atctagggggg	ttgggttagag	cattccctcg	ctctgtgtgc	gcaaggaaatg	960
ggaacagtgg	ctgtctcgca	tcaggcttgg	cagcatgggg	caglggttgg	atttctgccc	1020
aagccacaggag	gatgtgtgtc	tgctgtggca	tttgtaatccc	caagtgtgtc	tggccaggaa	1080
gccccacgttgc	gggtgttcttc	tttcgttcc	ttgtgttcc	tggtatccctc	ccaccccttc	1140
ctgtctcggttgc	ggccggccct	tttctcagag	atcaactaat	aaacctaaga	acccctaaaaa	1200
aaaaaaaaaaaa	anggg					1215

<210> 36

<211> 1311

<212> DNA

<213> Homo sapiens

<400> 36

ggtcgaccctt	cgcgtccgc	ctcagacacc	gtgttcttcc	gcttgggaga	ggggaaaggcag	60
atctcgaggac	atctctgtgc	caggccagaa	accgcacc	tgcatgttcc	tccctgggat	120
ggacgtgggg	ccccagtc	ttggccaccc	ttggctgaag	ctgtctgtgc	tcctgtgtgt	180
gtgtcccttc	aggggccaa	ccaaacccagg	ttgtctacggg	atcccaaggga	tgcccccgcct	240
gccccggggca	ccaggaaagg	atgggtacga	ccggactgc	ggggcccaagg	gggagccagg	300
aatccccaggcc	atccccgggg	tcggagacc	caaaaggccg	aaaggagaaat	ccggcttacc	360
ccggccatct	ggggaaaaatg	ggcccatggg	accccttggg	atggcagggg	tgcccgcccc	420
catggccatc	cttggagagac	cagggtgggg	ggggcagatcc	aaaggaaaaat	tcacgtca	480
gttacacgttc	actccggcaga	ccccccgc	ccctgcaccc	aacaggctga	tcacattca	540
cgccgttcc	accaacccgc	aggggagatta	tgacacgac	actggcaat	tcacactgtca	600
atgtccccggc	cttctactact	ttgttccatcc	ccggctgc	acagccaaacc	ttgcgtgtc	660
gtgttacccgc	aggccgtca	aaagtgttac	cttctgttgg	cacacgttcc	aaaccaatca	720
ggtcacgttc	gggggggtgc	ttgtttaggtt	tgccgtggcc	ttgggggtgt	ttgttggctgt	780
caatgtactac	tacacatgtt	ttggccatcca	ggggctgtgc	ttggccatccc	ttggccatccc	840
gttcttcgttcc	gactgtgggg	ggccatgtcc	ctggagcccc	acggggcccttc	cacccctcc	900
agcttcttcgttcc	atgtggccac	cttactggcc	agttgttccatc	tttgttccatc	ccatccatccc	960
caccatgttcc	atctttcttc	caggggggcc	acccgttccatcc	accccccactg	ccccccctcc	1020
ccatgggttcc	tcttccttc	ttggccatcc	tttaggtatcc	ttgttgggtt	ttgttgggtt	1080
acacttaacc	aatgttccat	ttgtactgtcc	tttttttttt	tttttttttc	aagtatttgg	1140
aaaaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1200
aaaaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1260
aaaaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	a

1311

<210> 37

<211> 350

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<222> (4)..(4)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (7)..(7)

<223> n equals a,t,g, or c

<220>

<221> misc_feature

<222> (9)..(9)

<223> n equals a,t,g, or c

<400> 37

gggnatnang	cttcctgctc	ttccccgact	agggcgccga	gatgcgtcg	agacccacgg	60
gccttccacc	tccctcaga	tccctgcatgg	accggaccta	ctggcccgatc	tgatctcttg	120
ccttagaccat	tctcccccttc	agggagccca	cctgaccca	cccccaactgc	accccttccc	180
catgggttct	tctcccttc	tgaacctt	taggagtca	tgccttgtgt	gttctggga	240
cacttaacca	atgccttcgt	gtactggccat	tctttttttt	tttttttcaa	gtattggaa	300
gggtggggag	ataataaaa	aatatcatgaa	atcaaaaaaa	aaaaaaaaaa	aaaaaaaaag	350
<210> 38						
<211> 622						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						
<222> (316)..(316)						
<223> n equals a,t,g, or c						
<220>						
<221> misc_feature						
<222> (511)..(511)						
<223> n equals a,t,g, or c						
<220>						
<221> misc_feature						
<222> (525)..(525)						
<223> n equals a,t,g, or c						
<220>						
<221> misc_feature						
<222> (578)..(578)						
<223> n equals a,t,g, or c						
<220>						
<221> misc_feature						
<222> (582)..(582)						
<223> n equals a,t,g, or c						
<220>						
<221> misc_feature						
<222> (599)..(599)						
<223> n equals a,t,g, or c						
<220>						
<221> misc_feature						
<222> (614)..(614)						
<223> n equals a,t,g, or c						
<400> 38						
ggggagcaga	tctgaggaca	tctctgtgcc	aggcccgaaaa	ccggccacct	gcagttccct	60
ctccggatg	gacgtggggc	ccagtcctc	gccccacctt	gggtgtaa	tgcgtgtgt	120
cttgcgtgc	ctgccccctca	ggggccaa	caacacaggc	tgtacgggg	tcccaaggat	180
ggccggccct	ccyggggccac	cagggaaggg	tgggtacgac	ggactgcggg	ggcccaagggg	240
ggagccaga	atccaggccat	tcggggatcc	gaggacccaa	arrggcaga	ggagaacccg	300
gtttacccgg	ccatctctgg	aaaawtggyc	catggkaccc	cctggatgtc	cagggtgtcc	360
ggcccatgg	cattcttgg	gaggcaggta	graggcaga	tacaacgaga	aattcccgatc	420
aktgtcacgg	cactccggaga	ccacagcccc	tgacccaaca	gtgtatagat	caacgcgtc	480
taacaacccg	aggagatata	cacgcacactg	naagtactg	aaagnccggc	ttacacttgc	540
tacacgcgtg	ataaacaact	ggctgtgtga	caacgcgnta	angggactt	tggcaacnc	600
aaacataggc	aatngcgggg	ct				622
<210> 39						
<211> 1333						
<212> DNA						
<213> Homo sapiens						
<220>						
<221> misc_feature						

<222> (485)..(486)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (493)..(493)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (496)..(496)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (587)..(587)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (633)..(633)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (1330)..(1330)
<223> n equals a,t,g, or c

<400> 39

agctgttacc	aaagaaggatt	tttcaacttag	ctctcatgaa	agatccttag	tcttgg	60 .
atttagaatc	ctgcagcagc	ccacccatcta	agagcaagar	ccaaagatgt	ttgtcttgct	120
ctatgttaca	agttttgc	tttgtgc	ttgacaacaa	ccccgtatac	agttgaaagg	180
agagaactac	ttccccaggat	atatctcgac	catttcggc	ttgcctggac	ctccaggccc	240
ccttggagac	aatgttcc	ctggggccca	ttgtcgatc	ggcccttccag	gaagagatgg	300
tagagccgc	aaaaaggagg	tttttttttt	aaaggaaact	cgaggtttg	gaggtaaagac	360
ttggcccgat	ggtttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	420
catatggccca	gggggggggg	aaaaaaaagg	tttttttttt	tttttttttt	tttttttttt	480
agacmtnatg	taatgttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	540
gtctttaatcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	600
tatatttaac	aaatgttcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	660
ttcatctgtt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	720
gtatccatgtt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	780
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	840
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	900
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	960
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1020
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1080
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1140
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1200
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1260
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1320
tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1333

<210> 40
<211> 1211
<212> DNA
<213> Homo sapiens

<400> 40

tcggattttt	tttttttttt	tttggatgtat	aaaaagggtt	ggatttaatg	aaggggaaaa	60
aaaaggccgc	ggggggccgc	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	120
tttgcaccc	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	180
ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	240
ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	300
ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	360
ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	420
ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	ttttggatgtat	480

cctgcaggcc	accgacaaga	actcaact	gggcatggag	ggtgccaaca	gcattttcc	900
cgggttcctg	ctctttcccg	atatggggc	ctgcaccttg	ggctgcttca	cattcacccc	960
gctccccct	gcgcacaa	ctcaact	ccccaacacc	acccttgc	cagcacaatgc	1020
acacagtgg	gttgggttga	tgcgtctgag	tgaatgatgt	aataaaactt	tcaaggccaa	1080
aaaaaaaaaa	aaaagact	taatgttca	tcaacaatc	accaggatgc	ggtgtatccag	1140
actgaaaaaa	tgcgagacgc	c				1161

<210> 43
<211> 687
<212> DNA
<213> Homo sapiens

<400> 43						
ccccggcccc	cccccgagtt	tttttttttt	tttttgccct	tgaaragttt	atttactcat	60
tcacccatca	gcattcacca	agccctactg	kgtgcattgg	ctgggcaagg	ggkggkttt	120
ggggtagatgg	gaggcgttgt	ggcagggggg	gggggggttg	atgtgaagca	gcccacagg	180
caggcctca	tatctggaaa	gaggcaggaa	ccggaaaaaa	tgcgttgg	accctccatg	240
cccgatgtg	atgtttgtc	ggttggccgt	aggaaagacgt	tctccccctg	ctccagcttg	300
aggacatgc	cacccgtgtt	gacccggatg	gttggtagg	catagtcac	gaaggatggcc	360
acccatgtgt	cacccgtccg	gcccacgtat	aggttcacgc	acaggttcc	tcagagactg	420
gggtgttagg	tggatgtakta	ragacccggc	accttcacgg	tgaacttgc	actgcgggc	480
tcataatgtt	tgatgtatgtt	ggkgatccag	ttgtcsaagg	ggatgttctg	gtcccsoggc	540
aggggggacgt	tgatggkttt	tgatggcarar	aaaggcattt	tctggkkggc	ctqagtctcc	600
cgattcacct	ttgggtctgg	ggcttggccg	cccttggcaa	ccttaggccc	atggggccct	660
ttggggccgc	ttttctgtat	tccagga				687

<210> 44
<211> 1194
<212> DNA
<213> Homo sapiens

<400> 44						
ttggtccatg	gggggggacc	gtcaggggaa	agcccttccc	gcctctgggg	aaggraactt	60
ccgccttcga	ccgcggccgg	taggtctcg	gtctctgtc	ccactgtgc	tcagccccgt	120
ggccctcacag	gacaccaggt	tccaggagg	cgtctgacac	agtatgtatg	tgaagatccc	180
atggggccatg	atcccgatgt	tgtatgttgc	ctctgtctgc	ggccctaattgc	atatctccca	240
ggcccgatcc	atgcgtccac	ggccccccage	atcccttgc	atcccggttg	tccctggac	300
acctgtggcc	gtatggccaa	ctggggacccc	agggtataaa	ggagagaaaa	ggcttccagg	360
gctggctgta	gaccatggtg	atgtcgagaa	gaaggagggac	ccaggatgtt	ctggaaatcc	420
aggaaaaatgc	ggcccccgggg	gtcccatgtt	cccttaaaatgt	ggcccccggg	ccccctggagc	480
cccaggcccc	aaagggtaat	cgggagacta	caaggccacc	cagaaaaatcg	cettctctgc	540
caacaagaacc	taacaaatcc	ccctcgccg	ggaccagacc	atccgcttc	accacgtat	600
cacaacaaatgc	aaacaacaaat	atggcccccg	caatggccatg	ttcacctgc	agggtggcccg	660
tcttactact	ttcacccatcc	accggccatc	tcggggaaat	cttgcgtgt	acccatcg	720
tgccgggggg	ctgtgcacaga	agggtgttac	cttctgtgt	catgtcttac	acaccttcca	780
ggtcacccac	gggtgcattgg	tccctcaactg	ggagcagggg	gagaacgtt	tccctggagg	840
caccgacaaac	aacttcatgg	ttggccatgg	gggtggccaa	acatctttt	ccgggttccct	900
gctctttcca	gatatgtgggg	cttgcattgt	gggtgttcc	acatccaccc	cggtcccccc	960
tgcccgacaa	gctcaacttca	cccccaacat	ccccccttgc	ccagccaaatg	cacacagatg	1020
ggcttgggtt	atgtcgatgt	tgtatgtat	aaataaaatc	tccaaaggcca	aggacatgt	1080
gtctaaatca	acttcgttgc	ccagcacctg	gcacaccaga	atgtccatgc	tcaaaaatgt	1140
ttgttacatg	aatgtatgaa	ccatgtatg	atgaaaaaaaaa	aaaaaaaaaa	aaaa	1194

<210> 45
<211> 1792
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (19)..(19)
<223> n equals a,t,g, or c

<220>
<221> misc_feature
<222> (132)..(132)
<223> n equals a,t,g, or c

```

<220>
<221> misc_feature
<222> (185)..(185)
<223> n equals a,t,g, or c

<400> 45
tccggcccat tgccgaant ggccggtags cgtgtacgg ggaaggctta tataascaga 60
gttcgtttta gttaacgcgtca gatcgtcgaa agccggccatcc acgtcggtttt gaccctccata 120
ggaaaggccg gnccgatcca gcytccccggc ttagcttag cccggccggac gataccawtt 180
tcacncaggaa accaggatcg accactaggg ttttggaaaaa agctatttag gtgacacat 240
agaaggatcg cctgcaggta cgggtccggaa attccgggtt cgacccacgg gtccgggtcc 300
gccccaggccgccccccgggg agggccggcc caagccggccaa gactccacccgg gggtcatacg 360
ggagacggccg cggccggcccccgggg cggcgggtt ctccggccgg gtctggccgg 420
ggcggtggac ggccagacccg ggagccggcac cgtccccggc gacaaaggct tcggggccgc 480
accaggatcac ccgaatcgatcc ctccgttgc tttccccggag gtcgggtgc ctctctcggt 540
gtctttttctc gccccgggtca cccaaagccggtt tttcccccaatg gtatggggcg ttgtcccttt 600
taacaaatgg tctgttgaaacg acggggatgtt tacaacccccc agccacggggg ttttccacgg 660
tcctttatgtt gggccatcc tgcatacgcc cccctcaacc cccggagagac acgctacgt 720
ggaaaggatcg ctgtcggtt cccaaacggcc cgtggggccatg cttcataccg ctgggtacag 780
gagagatgtt ctggatattcc accggccctcc accggatgtt catacctcgcc gggggccggg 840
ggcattttccat ctcatcgtc acctgttgcggc gggagatgtca gtcacacgtcg tggigactgg 900
ggcaagctg ctgcataccacg atctgttgcg atgtacttcc accatgttgcg ggtttttttt 960
atatcccttc ttttttccacc tctaagggtt ctggggatgtt gtcaggggaa agayagatag 1020
ttgttaaaaatc tctaaatggctt taatataatcc gtttttttttgcg taatggaaacg acggggctag 1080
atgtttccaca tggcccccacca ctaaaaggcc tttccctgtt gtttggggccca ccatgtttttt 1140
ctgcatacccg ccaggctgtca grrgagtgggg caccagggtt acatggccac tgatctttttt 1200
ggccactttccat ctggacaaatcggaaatggcc accggccctcc accgttgcatttgcg tacatcttgc 1260
ggggcccttgc ctggggcttgc gtttggccacc gggggccatcc gtttttttttgcg gctgggggggg 1320
ggggaggccgg ggagggccggg tcaagggtttt gtttttttttgcg cactgttttttgc 1380
agctgttctgtt cttttttttttgcg catggccggaa tttaaaactactt gaaatggccca agtggcccg 1440
gccccggccacccg agacccggccggcc accatgttgcg gggctgttgc accgttgcgtt caccattttttt 1500
ggctggggact taatctgttc accggggggccctt ttttttttttgcg gtttttttttgcg atgcgtttaga 1560
gactgttccca aaatggatgtt gggcccttgcg atgttgcgtt accattttttttgcg ttcaaaagaca 1620
ggggaggatgtca taatagatgg aaacggccatcc ctagtttttttgcg aaaaaaaaaaaaaaaa 1680
aaaaaaaaaaaaaaa aaaaaaaaaaaaaaaaaggcc gggccgttca gaggatccctt cggggggccca aagcttacgc 1740
gtgtcatcgca cgtcatatgtt ctctccctat agtagtgcgtt ttataatgttgc 1792

```

```

<210> 46
<211> 1412
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<222> (1363)..(1363)
<223> n equals a,t,g, or c

<400> 46
ccacggcgttc ggctctgttttcc cagggggccccc ccggaggagag gggcccccgg ccggccaggct 60
ccacccgggtt catcgccggag acggggccagg ccggggccccc cccggccggca ggggtgtcttgc 120
ggccgggggtt gccccggggcc gttggacggccg acggccggggcc gggccacccgttcc cccggccggcc 180
aaaggcttcggc gggccggccacca gatccatccca agtttttttttgcg ttttttttttgcg ccaggacttcc 240
cggtgtccctt tctgtgttttttgcg ttttttttttgcg gtttttttttgcg gtttttttttgcg ccaggacttcc 300
gggggggtttt ctcttttttttgcg aaaaatggccg ttttttttttgcg gtttttttttgcg gtttttttttgcg aacccccggca 360
ccgggggttttccat cccggccatcc ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg cttaccccccgg 420
agagagacccg ctatcggttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 480
ataccgttttttgcg gtacaggaga gtttttttttgcg aatccacccgg cccctccaggaa gtttttttttgcg gtttttttttgcg 540
cttgcggggggcc cccggggggca ttccatccatca ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 600
acgtcggttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 660
ttatgggggttttttttttgcg ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 720
ggggggaaatggccg atatggatgtt ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 780
ggaaaggccggcc gtttttttttgcg ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 840
ggccacttccat cccggccatcc ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 900
ggccactgtac ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 960
ttgtatcttaca ctctggggcc cccggccatcc ttttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 1020
ctgtgggggttttttttttgcg gggggggggcc gtttttttttgcg gtttttttttgcg gtttttttttgcg gtttttttttgcg 1080

```

ggccgacact	gtggccagct	gtctgtcttt	acactgcatg	cagaagttta	aacactgaag	1140
tgcgcgaaatg	gccccgtccg	ccgcacagag	acccccactt	tagtttgccc	ttgttccacgc	1200
tttgcctacc	ataggccct	gggacttaaac	ctgctcaggc	gggccccccg	ccatgtcaaa	1260
ataggatgc	gttagagact	gttccaaag	tcctgtggcc	tcctttaaatg	gcatgtacaa	1320
tttaagtgc	aagacaggga	gttcaataaa	agatggaaag	ccnnttccag	ttaaaaaaaaaa	1380
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaa	aaaaaaa	aaaaaaa	1412
<210> 47						
<211> 646						
<212> DNA						
<213> Homo sapiens						
<400> 47						
cgatcttc	cgtgggagcc	agcgagcctc	tccctgtat	cttacgtct	caaggatcca	60
gttccacca	tggaaatgaga	aaatggggaa	agaagtcatc	tagcgtctt	ctactcaaag	120
tgttgtccat	ggaccacagc	catcgatc	acctggggatc	ttcttggaaag	aatgttagaa	180
actcaggcct	ccccccaaag	tcgtcccttt	tataagacc	ccagaagctt	ttgttggggc	240
agagcagcat	ctgttcgaaga	gacacaaact	agccccagag	gtgtcacagg	aagtccacag	300
caaggacatt	ggttttgtat	ttgtttccat	agtcctgtca	agatataatg	tgatggctgt	360
gtctccgtcc	ccttcgtcagc	gtctggggatg	gtctgtttacc	attttcccttg	gttccatcatcg	420
gttccatcatcg	gttgggtccct	actatggat	caagccgtcg	ccacctcaaa	ttccctccat	480
gatgccacca	caaattccac	aataccagcc	cctgggttag	caagtacatc	acatgccttt	540
ggcccaatag	ggcccttgc	ttggcaagga	gatgccccac	tttgcatgtat	gcaaagagta	600
tccacaccta	cccccaata	tgaaggaaat	tcaacccggc	gtcgac		646
<210> 48						
<211> 2536						
<212> DNA						
<213> Homo sapiens						
<220>						
<221>	misc_feature					
<222>	(2)..(3)					
<223>	n equals a,t,g, or c					
<400> 48						
gnntgacac	cagcgccctc	gagcgatgga	aaagctgtct	gcctcggtgg	aggagcggtt	60
cgccacactc	cgaggcggtc	gttgcggccgc	aggccccctc	agaatgtctg	ctctccacag	120
ctggggccgc	gatggccaga	gttgcggccgc	aggctgttgc	tcgttgcggg	ctcagtgcaca	180
gtgctgatgt	ggcggcggagg	cacagacgtg	ggaggccgcg	ggggccgggg	aggccaccccc	240
ccaggatcaca	ccatgttgc	ctcccccgtt	tcgcgttgc	aggaccgttt	caactccacc	300
ctggggccctt	cgaggaggca	ggaggagagc	ttggcttgggg	ttctctggggg	gtctgagccac	360
tgctgtccgt	ctggggccggg	cgatcttagag	caatgttgc	gggtgtctgg	caatgttgagc	420
ggggkacgtgg	ggggggcggtt	ggatcttgc	ggggaggcagg	ttggcagggg	catggcaggca	480
tgccggccagg	tctgttcgtt	ggcccccggg	ggcggaggatc	tcgttgcgtgt	cgagatccctc	540
atgtccgttt	aggccggatgt	ttgttgcggat	ggcggaggatc	tcgttgcgtgt	gggtctccgg	600
ctgcacacccg	tttgggggggg	gggggggggg	gggggggggg	gggggggggg	atttttttttt	660
gttgcggcc	ggccggccgg	tttttttttt	tttttttttt	tttttttttt	tttttttttt	720
ctacggctga	atcttacttc	ggccggccgtt	ggcccaatgg	gggggggttt	ggggggccat	780
ggggatgtagg	gttgcggccg	tttttttttt	tttttttttt	tttttttttt	tttttttttt	840
gttgcggccg	gttgcgttcc	ccccctgttt	tttttttttt	tttttttttt	tttttttttt	900
gttgcggccg	caaggccgttg	ggcccttggat	ggcttcacgg	tttttttttt	tttttttttt	960
tcagccctgc	aggccctgtc	aggaggatcc	tttttttttt	tttttttttt	tttttttttt	1020
aatgactcac	tgtatgtact	ccagacatgt	gttggggggcc	aggggcgctgt	tctgtgtgtc	1080
ctggggccaa	ccaaaggcc	tatcttttcc	gatgtttttt	ggcttgcacca	ggggccacca	1140
gagcatgtca	caagatgtat	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1200
ggccatgtcc	ccatgttgc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1260
gacactgtgg	ctggggact	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1320
ctctgggtct	ggctccggga	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1380
aaatgtggcc	ggggacggcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1440
caatgtggcc	gggggggggg	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1500
ggatgtggcc	ccccccggcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1560
ggatgtggcc	ggccggccat	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1620
ggatgtggcc	ggggggggcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1680
ggatgtggcc	ggggggggcc	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1740
ggcttattatg	atccagagac	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1800
agcgcgggtc	tgacttggca	tttttttttt	tttttttttt	tttttttttt	tttttttttt	1860

caggggcgtgg	ccgcgtaga	ctccgggtgg	tacgaccctg	agggccttgg	gaataaagccg	1920
gtggccgaga	ggccggccag	ccccggcace	ctggggctct	tcacgcctcat	ctcgccgtcg	1980
caggccggg	aaacgcgttg	ctgcgaccct	gtcatggggc	actgtggccca	ctcgaggagg	2040
ccgtcaccc	tcttcaggg	ggccctgtctc	atggggacc	cagaaccttgc	acacgcgttg	2100
actgggttcc	cggccacgt	gtctacgtcg	gtcgaaaggaa	cagcgggggc	ggccggctcc	2160
tggggtctcg	cctgagacgg	ggcaccttgc	ctctggcggag	cggccacccc	gggccccggag	2220
cgccaccccg	ccccggcg	cctctecca	ccccggggc	ggccgggtcc	aggagggttc	2280
ggggccccc	atgcagact	ttggctgtgc	gcgatcccc	aagaacccct	ccaggggccgg	2340
cctggggagg	agccgactct	ccgacccttc	gtcccttcca	ctggcccttc	aggtcgattc	2400
cctgggttcc	aggctcccc	ggccggggc	cgccaccccg	catactaaac	gatcgaggaa	2460
taaagacact	tggttttttt	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	2520
aaaaaaaaaa	ggccgc					2536

<210> 49
<211> 1530
<212> DNA
<213> Homo sapiens

<400> 49						
tccatgtata	ggagacagt	aaagagatgg	gggtggcatt	ttcttccagg	agagttgtgg	60
ggagatgacc	gttagtgtat	aagcgcgcc	ctactctgc	ctggcgagac	caccaaagct	120
ggatgtgaaacc	cagctgaaacc	ttggccgcag	cagcccccgg	ggcttggggc	gtctcgactcg	180
ggaaacacaca	ggaggatgg	ggcccttcc	ctgtaaagcg	ggggccagg	tccgtattcc	240
tgaggccgt	tccacccgg	ccccggccc	ggcagggttgc	ttgggggggg	aagaacccac	300
ggatccatcg	tctgtcatct	gaacccatgg	gtatctgtgg	cttctgttgc	ccattgtaaaat	360
ctgcacagg	caactaaat	caacaggac	ctgcaggcca	gggcacccctg	aatccccgg	420
gaaaccccggt	caataatgtc	ttcccttgc	atggatggcga	gacggggcgg	agggttgcacaa	480
aggcgatgca	ggagaaccac	gacgtctgg	caggccgggg	aaggatggga	cgatgtggaga	540
gaaggggagaa	cgaggagcc	atggaaaatgt	ttaaagaaaaaa	ggcatcaaaag	gtgtatcaagg	600
ctcaagagaga	tcccgatggaa	aaatggccc	caaggggctt	gcaggggccc	ttggagagaa	660
aggccctccga	ggagagactg	ggcccttgcgg	gcagaagggg	aataaagggtg	actgtgggtcc	720
cactgtgtcc	gaggggccaa	ggggcaacat	tggccctttg	ggcccaactg	gtttaccggg	780
ccccatggcc	cctatggaa	agctctgtcc	caaggggggaa	gtgggaccc	cgggggccca	840
gggtgagcc	ggatccgggg	gaataaagg	ctggaaaagg	gttggaggag	agaaaaggaa	900
aatctgtgt	actctgttgc	ttccaaaaat	ttcttctact	gtggggctcc	cgggtgtcg	960
caatggatgt	tctccatgt	tgccaaaaat	atttgtaaaat	atctgttata	acgaaatttca	1020
ccattatgt	acacgacgg	ggaaaatcc	gttgcacat	gtctgggtct	attacttcc	1080
cttacacatc	actgtgttcc	ccaggatgt	tcagggtct	ttttgtcaaaa	atggagataaa	1140
aatactgcac	ccaaaatgt	cttacatgc	ctctgaggac	caggcccttc	ggccgtttgt	1200
cctgcagctg	aagctcgccc	atgggtgt	gtgcagggt	acaggaggag	agaggttcaa	1260
tggctgtt	gtctgttgc	acatgtacaa	actttccaca	gggtttcttc	ttttcagcag	1320
ccctgcac	aggagatgtt	aaaaatccgc	cacccatcc	atccaaatcc	gtttgggtat	1380
aacttattca	gtatgttttta	tttttattaaat	ttcttccaaatt	attacaataa	tctaaaaaaag	1440
gttggaaatgg	aaaaatgtt	ccaaaaactt	atctctgtta	acttacttatt	ttttccaggag	1500
taataatatta	aaataaaaaaa	aaaaaaaaaa				1530

<210> 50
<211> 229
<212> PRT
<213> Homo sapiens

<400> 50															
Met	Asp	Leu	Leu	Gln	Phe	Leu	Ala	Phe	Leu	Phe	Val	Leu	Leu	Ser	
1				5				10				15			
Gly	Met	Gly	Ala	Thr	Gly	Thr	Leu	Arg	Thr	Ser	Leu	Asp	Pro	Ser	Leu
20				25					30						
Glu	Ile	Tyr	Lys	Lys	Met	Phe	Glu	Val	Lys	Arg	Arg	Glu	Gln	Leu	Leu
35				40					45						
Ala	Leu	Lys	Asn	Leu	Ala	Gln	Leu	Asn	Asp	Ile	His	Gln	Gln	Tyr	Lys
50				55				60							
Ile	Leu	Asp	Val	Met	Leu	Lys	Gly	Leu	Phe	Lys	Val	Leu	Glu	Asp	Ser
65				70					75				80		

<210> 51
<211> 421
<212> PRT
<213> *Homo sapiens*

```

<400> 51
Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu
      5           10          15

Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly
      20          25          30

Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His
      35          40          45

Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp
      50          55          60

Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr
      65          70          75          80

Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys
      85          90          95

Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala
      100         105         110

Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu
      115         120         125

Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu
      130         135         140

Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr
      145         150         155         160

```

Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro
 165 170 175
 Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190
 Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205
 Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220
 Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240
 Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
 245 250 255
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met
 290 295 300
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
 305 310 315 320
 His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335
 Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln
 340 345 350
 Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly
 355 360 365
 Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Arg Ala Leu Pro
 370 375 380
 Ala Gln Ala Pro Pro Ala Ser Phe Gly Ala Arg Gly Ala Asp Met Gln
 385 390 395 400
 Pro Thr Thr Gly Ser Trp Pro Pro Gly Ala Gly Thr Arg Glu Ala Glu
 405 410 415
 Gly Gly Gly Gly Pro
 420

<210> 52
 <211> 240
 <212> PRT
 <213> Homo sapiens

<400> 52
 His Ala Ser Ala Ala Arg Ala Ala Ala Gly Ser Glu Pro Arg Thr Gly
 1 5 10 15
 Cys Gly Gly Ser Ser His Arg Val Pro Leu Gly Pro Ser Pro Ala Ser
 20 25 30

Leu Ser Pro Gln Arg Asp Leu Phe Gly Pro Pro Gly Pro Pro Gly Ala
 35 40 45
 Glu Val Thr Ala Glu Thr Leu Leu His Glu Phe Gln Glu Leu Leu Lys
 50 55 60
 Glu Ala Thr Glu Arg Arg Phe Ser Gly Leu Leu Asp Pro Leu Leu Pro
 65 70 75 80
 Gln Gly Ala Gly Leu Arg Leu Val Gly Glu Ala Phe His Cys Arg Leu
 85 90 95
 Gln Gly Pro Arg Arg Val Asp Lys Arg Thr Leu Val Glu Leu His Gly
 100 105 110
 Phe Gln Ala Pro Ala Ala Gln Gly Ala Phe Leu Arg Gly Ser Gly Leu
 115 120 125
 Ser Leu Ala Ser Gly Arg Phe Thr Ala Pro Val Ser Gly Ile Phe Gln
 130 135 140
 Phe Ser Ala Ser Leu His Val Asp His Ser Glu Leu Gln Gly Lys Ala
 145 150 155 160
 Arg Leu Arg Ala Arg Asp Val Val Cys Val Leu Ile Cys Ile Glu Ser
 165 170 175
 Leu Cys Gln Arg His Thr Cys Leu Glu Ala Val Ser Gly Leu Glu Ser
 180 185 190
 Asn Ser Arg Val Phe Thr Leu Gln Val Gln Gly Leu Leu Gln Leu Gln
 195 200 205
 Ala Gly Gln Tyr Ala Ser Val Phe Val Asp Asn Gly Ser Gly Ala Val
 210 215 220
 Leu Thr Ile Gln Ala Gly Ser Ser Phe Ser Gly Leu Leu Leu Gly Thr
 225 230 235 240

<210> 53
 <211> 281
 <212> PRT
 <213> Homo sapiens

<400> 53
 Met Gly Ser Arg Gly Gln Gly Leu Leu Leu Ala Tyr Cys Leu Leu Leu
 1 5 10 15
 Ala Phe Ala Ser Gly Leu Val Leu Ser Arg Val Pro His Val Gln Gly
 20 25 30
 Glu Gln Gln Glu Trp Glu Gly Thr Glu Glu Leu Pro Ser Pro Pro Asp
 35 40 45
 His Ala Glu Arg Ala Glu Glu Gln His Glu Lys Tyr Arg Pro Ser Gln
 50 55 60
 Asp Gln Gly Leu Pro Ala Ser Arg Cys Leu Arg Cys Cys Asp Pro Gly
 65 70 75 80
 Thr Ser Met Tyr Pro Ala Thr Ala Val Pro Gln Ile Asn Ile Thr Ile
 85 90 95
 Leu Lys Gly Glu Lys Gly Asp Arg Gly Asp Arg Gly Leu Gln Gly Lys
 100 105 110

Tyr Gly Lys Thr Gly Ser Ala Gly Ala Arg Gly His Thr Gly Pro Lys
 115 120 125

Gly Gln Lys Gly Ser Met Gly Ala Pro Gly Glu Arg Cys Lys Ser His
 130 135 140

Tyr Ala Ala Phe Ser Val Gly Arg Lys Lys Pro Met His Ser Asn His
 145 150 155 160

Tyr Tyr Gln Thr Val Ile Phe Asp Thr Glu Phe Val Asn Leu Tyr Asp
 165 170 175

His Phe Asn Met Phe Thr Gly Lys Phe Tyr Cys Tyr Val Pro Gly Leu
 180 185 190

Tyr Phe Phe Ser Leu Asn Val His Thr Trp Asn Gln Lys Glu Thr Tyr
 195 200 205

Leu His Ile Met Lys Asn Glu Glu Glu Val Ala Ile Leu Phe Ala Gln
 210 215 220

Val Gly Asp Arg Ser Ile Met Gln Ser Gln Ser Leu Met Leu Glu Leu
 225 230 235 240

Arg Glu Gln Asp Gln Val Trp Val Arg Leu Tyr Lys Gly Glu Arg Glu
 245 250 255

Asn Ala Ile Phe Ser Glu Glu Leu Asp Thr Tyr Ile Thr Phe Ser Gly
 260 265 270

Tyr Leu Val Lys His Ala Thr Glu Pro
 275 280

<210> 54
 <211> 205
 <212> PRT
 <213> Homo sapiens

<400> 54
 Met Leu Gly Ala Lys Pro His Trp Leu Pro Gly Pro Leu His Ser Pro
 1 5 10 15

Gly Leu Pro Leu Val Leu Val Leu Ala Leu Gly Ala Gly Trp Ala
 20 25 30

Gln Glu Gly Ser Glu Pro Val Leu Leu Glu Gly Glu Cys Leu Val Val
 35 40 45

Cys Glu Pro Gly Arg Ala Ala Ala Gly Gly Pro Gly Gly Ala Ala Leu
 50 55 60

Gly Glu Ala Pro Pro Gly Arg Val Ala Phe Ala Ala Val Arg Ser His
 65 70 75 80

His His Glu Pro Ala Gly Glu Thr Gly Asn Gly Thr Ser Gly Ala Ile
 85 90 95

Tyr Phe Asp Gln Val Leu Val Asn Glu Gly Gly Gly Phe Asp Arg Ala
 100 105 110

Ser Gly Ser Phe Val Ala Pro Val Arg Gly Val Tyr Ser Phe Arg Phe
 115 120 125

His Val Val Lys Val Tyr Asn Arg Gln Thr Val Gln Val Ser Leu Met
 130 135 140

Leu	Asn	Thr	Trp	Pro	Val	Ile	Ser	Ala	Phe	Ala	Asn	Asp	Pro	Asp	Val
145					150					155					160
Thr	Arg	Glu	Ala	Ala	Thr	Ser	Ser	Val	Leu	Leu	Pro	Leu	Asp	Pro	Gly
					165				170				175		
Asp	Arg	Val	Ser	Leu	Arg	Leu	Arg	Arg	Gly	Asn	Leu	Leu	Gly	Gly	Trp
					180				185				190		
Lys	Tyr	Ser	Ser	Phe	Ser	Gly	Phe	Leu	Ile	Phe	Pro	Leu			
					195			200		205					

<210> 55
<211> 189
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (9)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 55																
Leu	Ala	Leu	Leu	Leu	Leu	Xaa	Ala	Cys	Cys	Pro	Val	Arg	Ala			
1					5			10		.		15				
Gln	Asn	Asp	Thr	Glu	Pro	Ile	Val	Leu	Glu	Gly	Lys	Cys	Leu	Val	Val	
					20			25				30				
Cys	Asp	Ser	Ser	Pro	Ser	Ala	Asp	Gly	Ala	Val	Thr	Ser	Ser	Leu	Gly	
					35			40				45				
Ile	Ser	Val	Arg	Ser	Gly	Ser	Ala	Lys	Val	Ala	Phe	Ser	Ala	Thr	Arg	
					50			55				60				
Ser	Thr	Asn	His	Glu	Pro	Ser	Glu	Met	Ser	Asn	Arg	Thr	Met	Thr	Ile	
					65			70			75			80		
Tyr	Phe	Asp	Gln	Val	Leu	Val	Asn	Ile	Gly	Asn	His	Phe	Asp	Leu	Ala	
					85				90				95			
Ser	Ser	Ile	Phe	Val	Ala	Pro	Arg	Lys	Gly	Ile	Tyr	Ser	Phe	Ser	Phe	
					100			105				110				
His	Val	Val	Lys	Val	Tyr	Asn	Arg	Gln	Thr	Ile	Gln	Val	Ser	Leu	Met	
					115			120			125					
Gln	Asn	Gly	Tyr	Pro	Val	Ile	Ser	Ala	Phe	Ala	Gly	Asp	Gln	Asp	Val	
					130			135			140					
Thr	Arg	Glu	Ala	Ala	Ser	Asn	Gly	Val	Leu	Leu	Met	Glu	Arg	Glu		
					145			150			155			160		
Asp	Lys	Val	His	Leu	Lys	Leu	Glu	Arg	Gly	Asn	Leu	Met	Gly	Gly	Trp	
					165				170			175				
Lys	Tyr	Ser	Thr	Phe	Ser	Gly	Phe	Leu	Val	Phe	Pro	Leu				
					180			185								

<210> 56
<211> 201
<212> PRT

<213> Homo sapiens

<400> 56
 Ser Gln Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg Asp Gly Ala
 1 5 10 15

Pro Gly Ala Pro Gly Glu Lys Gly Glu Gly Gly Arg Pro Gly Leu Pro
 20 25 30

Gly Pro Arg Gly Asp Pro Gly Pro Arg Gly Glu Ala Gly Pro Ala Gly
 35 40 45

Pro Thr Gly Pro Ala Gly Glu Cys Ser Val Pro Pro Arg Ser Ala Phe
 50 55 60

Ser Ala Lys Arg Ser Glu Ser Arg Val Pro Pro Pro Ser Asp Ala Pro
 65 70 75 80

Leu Pro Phe Asp Arg Val Leu Val Asn Glu Gln Gly His Tyr Asp Ala
 85 90 95

Val Thr Gly Lys Phe Thr Cys Gln Val Pro Gly Val Tyr Tyr Phe Ala
 100 105 110

Val His Ala Thr Val Tyr Arg Ala Ser Leu Gln Phe Asp Leu Val Lys
 115 120 125

Asn Gly Glu Ser Ile Ala Ser Phe Phe Gln Phe Phe Gly Gly Trp Pro
 130 135 140

Lys Pro Ala Ser Leu Ser Gly Gly Ala Met Val Arg Leu Glu Pro Glu
 145 150 155 160

Asp Gln Val Trp Val Gln Val Gly Val Gly Asp Tyr Ile Gly Ile Tyr
 165 170 175

Ala Ser Ile Lys Thr Asp Ser Thr Phe Ser Gly Phe Leu Val Tyr Ser
 180 185 190

Asp Trp His Ser Ser Pro Val Phe Ala
 195 200

<210> 57

<211> 245

<212> PRT

<213> Homo sapiens

<400> 57
 Met Asp Val Gly Pro Ser Ser Leu Pro His Leu Gly Leu Lys Leu Leu
 1 5 10 15

Leu Leu Leu Leu Leu Pro Leu Arg Gly Gln Ala Asn Thr Gly Cys
 20 25 30

Tyr Gly Ile Pro Gly Met Pro Gly Leu Pro Gly Ala Pro Gly Lys Asp
 35 40 45

Gly Tyr Asp Gly Leu Pro Gly Pro Lys Gly Glu Pro Gly Ile Pro Ala
 50 55 60

Ile Pro Gly Ile Arg Gly Pro Lys Gly Gln Lys Gly Glu Pro Gly Leu
 65 70 75 80

Pro Gly His Pro Gly Lys Asn Gly Pro Met Gly Pro Pro Gly Met Pro
 85 90 95

Gly Val Pro Gly Pro Met Gly Ile Pro Gly Glu Pro Gly Glu Glu Gly
 100 105 110

Arg Tyr Lys Gln Lys Phe Gln Ser Val Phe Thr Val Thr Arg Gln Thr
 115 120 125

His Gln Pro Pro Ala Pro Asn Ser Leu Ile Arg Phe Asn Ala Val Leu
 130 135 140

Thr Asn Pro Gln Gly Asp Tyr Asp Thr Ser Thr Gly Lys Phe Thr Cys
 145 150 155 160

Lys Val Pro Gly Leu Tyr Tyr Phe Val Tyr His Ala Ser His Thr Ala
 165 170 175

Asn Leu Cys Val Leu Leu Tyr Arg Ser Gly Val Lys Val Val Thr Phe
 180 185 190

Cys Gly His Thr Ser Lys Thr Asn Gln Val Asn Ser Gly Gly Val Leu
 195 200 205

Leu Arg Leu Gln Val Gly Glu Glu Val Trp Leu Ala Val Asn Asp Tyr
 210 215 220

Tyr Asp Met Val Gly Ile Gln Gly Ser Asp Ser Val Phe Ser Gly Phe
 225 230 235 240

Leu Leu Phe Pro Asp
 245

<210> 58
 <211> 278
 <212> PRT
 <213> Homo sapiens

<400> 58
 Met Gln Trp Leu Arg Val Arg Glu Ser Pro Gly Glu Ala Thr Gly His
 1 5 10 15

Arg Val Thr Met Gly Thr Ala Ala Leu Gly Pro Val Trp Ala Ala Leu
 20 25 30

Leu Leu Phe Leu Leu Met Cys Glu Ile Pro Met Val Glu Leu Thr Phe
 35 40 45

Asp Arg Ala Val Ala Ser Asp Cys Gln Arg Cys Cys Asp Ser Glu Asp
 50 55 60

Pro Leu Asp Pro Ala His Val Ser Ser Ala Ser Ser Ser Gly Arg Pro
 65 70 75 80

His Ala Leu Pro Glu Ile Arg Pro Tyr Ile Asn Ile Thr Ile Leu Lys
 85 90 95

Gly Asp Lys Gly Asp Pro Gly Pro Met Gly Leu Pro Gly Tyr Met Gly
 100 105 110

Arg Glu Gly Pro Gln Gly Glu Pro Gln Gly Ser Lys Gly Asp
 115 120 125

Lys Gly Glu Met Gly Ser Pro Gly Ala Pro Cys Gln Lys Arg Phe Phe
 130 135 140

Ala Phe Ser Val Gly Arg Lys Thr Ala Leu His Ser Gly Glu Asp Phe

145	150	155	160												
Gln	Thr	Leu	Leu	Phe	Glu	Arg	Val	Phe	Val	Asn	Leu	Asp	Gly	Cys	Phe
				165					170					175	
Asp	Met	Ala	Thr	Gly	Gln	Phe	Ala	Ala	Pro	Leu	Arg	Gly	Ile	Tyr	Phe
				180					185				190		
Phe	Ser	Leu	Asn	Val	His	Ser	Trp	Asn	Tyr	Lys	Glu	Thr	Tyr	Val	His
				195			200		205						
Ile	Met	His	Asn	Gln	Lys	Glu	Ala	Val	Ile	Leu	Tyr	Ala	Gln	Pro	Ser
				210			215		220						
Glu	Arg	Ser	Ile	Met	Gln	Ser	Gln	Ser	Val	Met	Leu	Asp	Leu	Ala	Tyr
				225			230		235					240	
Gly	Asp	Arg	Val	Trp	Val	Arg	Leu	Phe	Lys	Arg	Gln	Arg	Glu	Asn	Ala
				245			250		255						
Ile	Tyr	Ser	Asn	Asp	Phe	Asp	Thr	Tyr	Ile	Thr	Phe	Ser	Gly	His	Leu
				260			265		270						
Ile	Lys	Ala	Glu	Asp	Asp										
				275											

<210> 59
<211> 289
<212> PRT
<213> Homo sapiens

<400> 59															
Met	Phe	Val	Leu	Leu	Tyr	Val	Thr	Ser	Phe	Ala	Ile	Cys	Ala	Ser	Gly
1								10						15	
Gln	Pro	Arg	Gly	Asn	Gln	Leu	Lys	Gly	Glu	Asn	Tyr	Ser	Pro	Arg	Tyr
							20		25				30		
Ile	Cys	Ser	Ile	Pro	Gly	Leu	Pro	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Ala
							35		40			45			
Asn	Gly	Ser	Pro	Gly	Pro	His	Gly	Arg	Ile	Gly	Leu	Pro	Gly	Arg	Asp
						50		55			60				
Gly	Arg	Asp	Gly	Arg	Lys	Gly	Glu	Lys	Gly	Glu	Lys	Gly	Thr	Ala	Gly
						65		70			75			80	
Leu	Arg	Gly	Lys	Thr	Gly	Pro	Leu	Gly	Leu	Ala	Gly	Glu	Lys	Gly	Asp
						85		90			95				
Gln	Gly	Glu	Thr	Gly	Lys	Gly	Pro	Ile	Gly	Pro	Glu	Gly	Glu	Lys	
						100		105			110				
Gly	Glu	Val	Gly	Pro	Ile	Gly	Pro	Pro	Gly	Pro	Lys	Gly	Asp	Arg	Gly
						115		120			125				
Glu	Gln	Gly	Asp	Pro	Gly	Leu	Pro	Gly	Val	Cys	Arg	Cys	Gly	Ser	Ile
						130		135			140				
Val	Leu	Lys	Ser	Ala	Phe	Ser	Val	Gly	Ile	Thr	Thr	Ser	Tyr	Pro	Glu
						145		150			155			160	
Glu	Arg	Leu	Pro	Ile	Ile	Phe	Asn	Lys	Val	Leu	Phe	Asn	Glu	Gly	Glu
						165		170					175		

His Tyr Asn Pro Ala Thr Gly Lys Phe Ile Cys Ala Phe Pro Gly Ile
 180 185 190
 Tyr Tyr Ser Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala Ile
 195 200 205
 Gly Leu Val His Asn Gly Gln Tyr Arg Ile Lys Thr Phe Asp Ala Asn
 210 215 220
 Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Val Ile Tyr Leu Gln
 225 230 235 240
 Pro Glu Asp Glu Val Trp Leu Glu Ile Phe Phe Thr Asp Gln Asn Gly
 245 250 255
 Leu Phe Ser Asp Pro Gly Trp Ala Asp Ser Leu Phe Ser Gly Phe Leu
 260 265 270
 Leu Tyr Val Asp Thr Asp Tyr Leu Asp Ser Ile Ser Glu Asp Asp Glu
 275 280 285
 Leu

<210> 60
 <211> 285
 <212> PRT
 <213> Homo sapiens
 <400> 60
 Met Ile Pro Trp Val Leu Leu Ala Cys Ala Leu Pro Cys Ala Ala Asp
 1 5 10 15
 Pro Leu Leu Gly Ala Phe Ala Arg Arg Asp Phe Arg Lys Gly Ser Pro
 20 25 30
 Gln Leu Val Cys Ser Leu Pro Gly Pro Gln Gly Pro Pro Gly Pro Pro
 35 40 45
 Gly Ala Pro Gly Pro Ser Gly Met Met Gly Arg Met Gly Phe Pro Gly
 50 55 60
 Lys Asp Gly Gln Asp Gly His Asp Gly Asp Arg Gly Asp Ser Gly Glu
 65 70 75 80
 Glu Gly Pro Pro Gly Arg Thr Gly Asn Arg Gly Lys Pro Gly Pro Lys
 85 90 95
 Gly Lys Ala Gly Ala Ile Gly Arg Ala Gly Pro Arg Gly Pro Lys Gly
 100 105 110
 Val Asn Gly Thr Pro Gly Lys His Gly Thr Pro Gly Lys Lys Gly Pro
 115 120 125
 Lys Gly Lys Gly Glu Pro Gly Leu Pro Gly Pro Cys Ser Cys Gly
 130 135 140
 Ser Gly His Thr Lys Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr
 145 150 155 160
 Pro Arg Glu Arg Leu Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu
 165 170 175
 Gly Gly His Tyr Asn Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro
 180 185 190

Gly Ile Tyr Tyr Phe Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu
 195 200 205

Ala Ile Gly Leu Val His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp
 210 215 220

Ala Asn Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Ile Leu Ala
 225 230 235 240

Leu Lys Gln Gly Asp Glu Val Trp Leu Gln Ile Phe Tyr Ser Glu Gln
 245 250 255

Asn Gly Leu Phe Tyr Asp Pro Tyr Trp Thr Asp Ser Leu Phe Thr Gly
 260 265 270

Phe Leu Ile Tyr Ala Asp Gln Asp Asp Pro Asn Glu Val
 275 280 285

<210> 61
<211> 146
<212> PRT
<213> Homo sapiens

<400> 61
Thr Arg Ser Leu Val Gly Ser Asp Ala Gly Pro Gly Pro Arg His Gln
 1 5 10 15

Pro Leu Ala Phe Asp Thr Glu Phe Val Asn Ile Gly Gly Asp Phe Asp
 20 25 30

Ala Ala Ala Gly Val Phe Arg Cys Arg Leu Pro Gly Ala Tyr Phe Phe
 35 40 45

Ser Phe Thr Leu Gly Lys Leu Pro Arg Lys Thr Leu Ser Val Lys Leu
 50 55 60

Met Lys Asn Arg Asp Glu Val Gln Ala Met Ile Tyr Asp Asp Gly Ala
 65 70 75 80

Ser Arg Arg Arg Glu Met Gln Ser Gln Ser Val Met Leu Ala Leu Arg
 85 90 95

Arg Gly Asp Ala Val Trp Leu Leu Ser His Asp His Asp Gly Tyr Gly
 100 105 110

Ala Tyr Ser Asn His Gly Lys Tyr Ile Thr Phe Ser Gly Phe Leu Val
 115 120 125

Tyr Pro Asp Leu Ala Pro Ala Ala Pro Pro Gly Leu Gly Ala Ser Glu
 130 135 140

Leu Leu
 145

<210> 62
<211> 251
<212> PRT
<213> Homo sapiens

<400> 62
Met Lys Ile Pro Trp Gly Ser Ile Pro Val Leu Met Leu Leu Leu
 1 5 10 15

Leu Gly Leu Ile Asp Ile Ser Gln Ala Gln Leu Ser Cys Thr Gly Pro
 20 25 30
 Pro Ala Ile Pro Gly Ile Pro Gly Ile Pro Gly Thr Pro Gly Pro Asp
 35 40 45
 Gly Gln Pro Gly Thr Pro Gly Ile Lys Gly Glu Lys Gly Leu Pro Gly
 50 55 60
 Leu Ala Gly Asp His Gly Glu Phe Gly Glu Lys Gly Asp Pro Gly Ile
 65 70 75 80
 Pro Gly Asn Pro Gly Lys Val Gly Pro Lys Gly Pro Met Gly Pro Lys
 85 90 95
 Gly Gly Pro Gly Ala Pro Gly Ala Pro Gly Pro Lys Gly Glu Ser Gly
 100 105 110
 Asp Tyr Lys Ala Thr Gln Lys Ile Ala Phe Ser Ala Thr Arg Thr Ile
 115 120 125
 Asn Val Pro Leu Arg Arg Asp Gln Thr Ile Arg Phe Asp His Val Ile
 130 135 140
 Thr Asn Met Asn Asn Asn Tyr Glu Pro Arg Ser Gly Lys Phe Thr Cys
 145 150 155 160
 Lys Val Pro Gly Leu Tyr Tyr Phe Thr Tyr His Ala Ser Ser Arg Gly
 165 170 175
 Asn Leu Cys Val Asn Leu Met Arg Gly Arg Glu Arg Ala Gln Lys Val
 180 185 190
 Val Thr Phe Cys Asp Tyr Ala Tyr Asn Thr Phe Gln Val Thr Thr Gly
 195 200 205
 Gly Met Val Leu Lys Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala
 210 215 220
 Thr Asp Lys Asn Ser Leu Leu Gly Met Glu Gly Ala Asn Ser Ile Phe
 225 230 235 240
 Ser Gly Phe Leu Leu Phe Pro Asp Met Glu Ala
 245 250

<210> 63
 <211> 975
 <212> PRT
 <213> Homo sapiens

<400> 63
 Met Pro Cys Pro Ser Ala Leu Val Tyr Arg Val Asn Phe Arg Pro Arg
 1 5 10 15
 Tyr Val Thr Arg Tyr Lys Thr Val Thr Gln Leu Glu Trp Arg Cys Cys
 20 25 30
 Pro Gly Phe Arg Gly Gly Asp Cys Gln Glu Gly Pro Lys Asp Pro Val
 35 40 45
 Lys Thr Leu Arg Pro Thr Pro Ala Arg Pro Arg Asn Ser Leu Lys Lys
 50 55 60
 Ala Thr Asp Asn Glu Pro Ser Gln Phe Ser Glu Pro Arg Lys Thr Leu

65	70	75	80
Ser Pro Thr Gly Thr Ala Gln Pro Ser Trp		Gly Val Asp Pro Lys Glu	
85		90	95
Gly Pro Gln Glu Leu Gln Glu Lys	Lys Ile Gln Val Leu Glu Glu Lys		
100	105		110
Val Leu Arg Leu Thr Arg Thr Val	Leu Asp Leu Gln Ser Ser Leu Ala		
115	120	125	
Gly Val Ser Glu Asn Leu Lys His Ala Thr Gln Asp Asp Ala Ser Arg			
130	135	140	
Thr Arg Ala Pro Gly Leu Ser Ser Gln His Pro Lys Pro Asp Thr Thr			
145	150	155	160
Val Ser Gly Asp Thr Glu Thr Gly Gln Ser Pro Gly Val Phe Asn Thr			
165	170	175	
Lys Glu Ser Gly Met Lys Asp Ile Lys Ser Glu Leu Ala Glu Val Lys			
180	185	190	
Asp Thr Leu Lys Asn Lys Ser Asp Lys Leu Glu Glu Leu Asp Gly Lys			
195	200	205	
Val Lys Gly Tyr Glu Gly Gln Leu Arg Gln Leu Gln Glu Ala Ala Gln			
210	215	220	
Gly Pro Thr Val Thr Met Thr Thr Asn Glu Leu Tyr Gln Ala Tyr Val			
225	230	235	240
Asp Ser Lys Ile Asp Ala Leu Arg Glu Glu Leu Met Glu Gly Met Asp			
245	250	255	
Arg Lys Leu Ala Asp Leu Lys Asn Ser Cys Glu Tyr Lys Leu Thr Gly			
260	265	270	
Leu Gln Gln Cys Asp Asp Tyr Gly Ser Ser Tyr Leu Gly Val Ile			
275	280	285	
Glu Leu Ile Gly Glu Lys Glu Thr Ser Leu Arg Lys Glu Ile Asn Asn			
290	295	300	
Leu Arg Ala Arg Leu Gln Glu Pro Ser Ala Gln Ala Asn Cys Cys Asp			
305	310	315	320
Ser Glu Lys Asn Gly Asp Ile Gly Gln Gln Ile Lys Thr Leu Asp Gln			
325	330	335	
Lys Ile Glu Arg Val Ala Glu Ala Thr Arg Met Leu Asn Gly Arg Leu			
340	345	350	
Asp Asn Glu Phe Asp Arg Leu Ile Val Pro Glu Pro Asp Val Asp Phe			
355	360	365	
Asp Ala Lys Trp Asn Glu Leu Asp Ala Arg Ile Asn Val Thr Glu Lys			
370	375	380	
Asn Ala Glu Glu His Cys Phe Tyr Ile Glu Glu Thr Leu Arg Gly Ala			
385	390	395	400
Ile Asn Gly Glu Val Gly Asp Leu Lys Gln Leu Val Asp Gln Lys Ile			
405	410	415	
Gln Ser Leu Glu Asp Arg Leu Gly Ser Val Leu Leu Gln Met Thr Asn			
420	425	430	

Asn Thr Gly Ala Glu Leu Ser Pro Pro Gly Ala Ala Ala Leu Pro Gly
 435 440 445
 Val Ser Gly Ser Gly Asp Glu Arg Val Met Met Glu Leu Asn His Leu
 450 455 460
 Lys Asp Lys Val Gln Val Glu Asp Ile Cys Leu Leu Asn Ile Gln
 465 470 475 480
 Gly Lys Pro His Gly Met Glu Gly Ala Leu Pro Asn Arg Glu Asp Arg
 485 490 495
 Ala Val Arg Asp Ser Leu His Leu Leu Lys Ser Leu Asn Asp Thr Met
 500 505 510
 His Arg Lys Phe Gln Glu Thr Glu Gln Thr Ile Gln Lys Leu Gln Gln
 515 520 525
 Asp Phe Ser Phe Leu Tyr Ser Gln Leu Asn His Thr Glu Asn Asp Val
 530 535 540
 Thr His Leu Gln Lys Glu Met Ser Asn Cys Arg Ala Gly Glu Asn Ala
 545 550 555 560
 Gly Met Gly Arg Phe Thr Lys Val Gly Glu Gln Glu Arg Thr Val Asp
 565 570 575
 Thr Leu Pro Ser Pro Gln His Pro Val Ala His Cys Cys Ser Gln Leu
 580 585 590
 Glu Glu Arg Trp Gln Arg Leu Gln Ser Gln Val Ile Ser Glu Leu Asp
 595 600 605
 Ala Cys Lys Glu Cys Thr Gln Gly Val Gln Arg Glu Val Ser Met Val
 610 615 620
 Glu Gly Arg Val Ser His Met Glu Lys Thr Cys Ser Lys Leu Asp Ser
 625 630 635 640
 Ile Ser Gly Asn Leu Gln Arg Ile Lys Glu Gly Leu Asn Lys His Val
 645 650 655
 Ser Ser Leu Trp Asn Cys Val Arg Gln Met Asn Gly Thr Leu Arg Ser
 660 665 670
 His Ser Arg Asp Ile Ser Gly Leu Lys Asn Ser Val Gln Gln Phe Tyr
 675 680 685
 Ser His Val Phe Gln Ile Ser Thr Asp Leu Gln Asp Leu Val Lys Phe
 690 695 700
 Gln Pro Ser Ala Lys Ala Pro Ser Pro Pro Pro Ala Glu Ala Pro
 705 710 715 720
 Lys Glu Pro Leu Gln Pro Glu Pro Ala Pro Pro Arg Pro Ser Gly Pro
 725 730 735
 Ala Thr Ala Glu Asp Pro Gly Arg Arg Pro Val Leu Pro Gln Arg Pro
 740 745 750
 Pro Glu Glu Arg Pro Pro Gln Pro Pro Gly Ser Thr Gly Val Ile Ala
 755 760 765
 Glu Thr Gly Gln Ala Gly Pro Pro Ala Gly Ala Gly Val Ser Gly Arg
 770 775 780

Gly Leu Pro Arg Gly Val Asp Gly Gln Thr Gly Ser Gly Thr Val Pro
785 790 795 800

Gly Ala Glu Gly Phe Ala Gly Ala Pro Gly Tyr Pro Lys Ser Pro Pro
805 810 815

Val Ala Ser Pro Gly Ala Pro Val Pro Ser Leu Val Ser Phe Ser Ala
820 825 830

Gly Leu Thr Gln Lys Pro Phe Pro Ser Asp Gly Gly Val Val Leu Phe
835 840 845

Asn Lys Val Leu Val Asn Asp Gly Asp Val Tyr Asn Pro Ser Thr Gly
850 855 860

Val Phe Thr Ala Pro Tyr Asp Gly Arg Tyr Leu Ile Thr Ala Thr Leu
865 870 875 880

Thr Pro Glu Arg Asp Ala Tyr Val Glu Ala Val Leu Ser Val Ser Asn
885 890 895

Ala Ser Val Ala Gln Leu His Thr Ala Gly Tyr Arg Arg Glu Phe Leu
900 905 910

Glu Tyr His Arg Pro Pro Gly Ala Leu His Thr Cys Gly Gly Pro Gly
915 920 925

Ala Phe His Leu Ile Val His Leu Lys Ala Gly Asp Ala Val Asn Val
930 935 940

Val Val Thr Gly Gly Lys Leu Ala His Thr Asp Phe Asp Glu Met Tyr
945 950 955 960

Ser Thr Phe Ser Gly Val Phe Leu Tyr Pro Phe Leu Ser His Leu
965 970 975

<210> 64
<211> 158
<212> PRT
<213> Homo sapiens

<400> 64
Met Thr Pro Val Asp Val Pro Val Thr Asn Pro Ala Ala Thr Ile Leu
1 5 10 15

Pro Val His Val Tyr Pro Leu Pro Gln Gln Met Arg Val Ala Phe Ser
20 25 30

Ala Ala Arg Thr Ser Asn Leu Ala Pro Gly Thr Leu Asp Gln Pro Ile
35 40 45

Val Phe Asp Leu Leu Leu Asn Asn Leu Gly Glu Thr Phe Asp Leu Gln
50 55 60

Leu Gly Arg Phe Asn Cys Pro Val Asn Gly Thr Tyr Val Phe Ile Phe
65 70 75 80

His Met Leu Lys Leu Ala Val Asn Val Pro Leu Tyr Val Asn Leu Met
85 90 95

Lys Asn Glu Glu Val Leu Val Ser Ala Tyr Ala Asn Asp Gly Ala Pro
100 105 110

Asp His Glu Thr Ala Ser Asn His Ala Ile Leu Gln Leu Phe Gln Gly
115 120 125

Asp Gln Ile Trp Leu Arg Leu His Arg Gly Ala Ile Tyr Gly Ser Ser
 130 135 140

Trp Lys Tyr Ser Thr Phe Ser Gly Tyr Leu Leu Tyr Gln Asp
 145 150 155

<210> 65
 <211> 605
 <212> PRT
 <213> Homo sapiens

<400> 65
 Met Gly Tyr Leu Glu Leu Lys Glu Asn Gln Gly His Arg Asp Ile Gln
 1 5 10 15

Glu Leu Glu Ser Gln Val Cys Leu Glu Cys Gln Gly Lys Pro Gly Ala
 20 25 30

Met Gly Met Pro Gly Ala Lys Gly Glu Ile Gly Gln Lys Gly Glu Ile
 35 40 45

Gly Pro Met Gly Ile Pro Gly Pro Gln Gly Pro Pro Gly Pro His Gly
 50 55 60

Leu Pro Gly Ile Gly Lys Pro Gly Gly Pro Gly Leu Pro Gly Gln Pro
 65 70 75 80

Gly Pro Lys Gly Asp Arg Gly Pro Lys Gly Leu Pro Gly Pro Gln Gly
 85 90 95

Leu Arg Gly Pro Lys Gly Asp Lys Gly Phe Gly Met Pro Gly Ala Pro
 100 105 110

Gly Val Lys Gly Pro Pro Gly Met His Gly Pro Pro Gly Pro Val Gly
 115 120 125

Leu Pro Gly Val Gly Lys Pro Gly Val Thr Gly Phe Pro Gly Pro Gln
 130 135 140

Gly Pro Leu Gly Lys Pro Gly Ala Pro Gly Glu Pro Gly Pro Gln Gly
 145 150 155 160

Pro Ile Gly Val Pro Gly Val Gln Gly Pro Pro Gly Ile Pro Gly Ile
 165 170 175

Gly Lys Pro Gly Gln Asp Gly Ile Pro Gly Gln Pro Gly Phe Pro Gly
 180 185 190

Gly Lys Gly Glu Gln Gly Leu Pro Gly Leu Pro Gly Pro Pro Gly Leu
 195 200 205

Pro Gly Ile Gly Lys Pro Gly Phe Pro Gly Pro Lys Gly Asp Arg Gly
 210 215 220

Met Gly Gly Val Pro Gly Ala Leu Gly Pro Arg Gly Glu Lys Gly Pro
 225 230 235 240

Ile Gly Ala Pro Gly Ile Gly Pro Pro Gly Glu Pro Gly Leu Pro
 245 250 255

Gly Ile Pro Gly Pro Met Gly Pro Pro Gly Ala Ile Gly Phe Pro Gly
 260 265 270

Pro Lys Gly Glu Gly Ile Val Gly Pro Gln Gly Pro Pro Gly Pro

275	280	285
Lys Gly Glu Pro Gly Leu Gln Gly Phe Pro Gly Lys Pro Gly Phe Leu		
290	295	300
Gly Glu Val Gly Pro Pro Gly Met Arg Gly Leu Pro Gly Pro Ile Gly		
305	310	315
320		
Pro Lys Gly Glu Ala Gly Gln Lys Gly Val Pro Gly Leu Pro Gly Val		
325	330	335
Pro Gly Leu Leu Gly Pro Lys Gly Glu Pro Gly Ile Pro Gly Asp Gln		
340	345	350
Gly Leu Gln Gly Pro Pro Gly Ile Pro Gly Ile Gly Gly Pro Ser Gly		
355	360	365
Pro Ile Gly Pro Pro Gly Ile Pro Gly Pro Lys Gly Glu Pro Gly Leu		
370	375	380
Pro Gly Pro Pro Gly Phe Pro Gly Ile Gly Lys Pro Gly Val Ala Gly		
385	390	395
400		
Leu His Gly Pro Pro Gly Lys Pro Gly Ala Leu Gly Pro Gln Gly Gln		
405	410	415
Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro		
420	425	430
Ala Val Met Pro Pro Thr Pro Pro Pro Gln Gly Glu Tyr Leu Pro Asp		
435	440	445
Met Gly Leu Gly Ile Asp Gly Val Lys Pro Pro His Ala Tyr Gly Ala		
450	455	460
460		
Lys Lys Gly Lys Asn Gly Glu Pro Ala Tyr Glu Met Pro Ala Phe Thr		
465	470	475
480		
Ala Glu Leu Thr Ala Pro Phe Pro Pro Val Gly Ala Pro Val Lys Phe		
485	490	495
Asn Lys Leu Leu Tyr Asn Gly Arg Gln Asn Tyr Asn Pro Gln Thr Gly		
500	505	510
510		
Ile Phe Thr Cys Glu Val Pro Gly Val Tyr Tyr Phe Ala Tyr His Val		
515	520	525
525		
His Cys Lys Gly Gly Asn Val Trp Val Ala Leu Phe Lys Asn Asn Glu		
530	535	540
540		
Pro Val Met Tyr Thr Tyr Asp Glu Tyr Lys Lys Gly Phe Leu Asp Gln		
545	550	555
560		
Ala Ser Gly Ser Ala Val Leu Leu Leu Arg Pro Gly Asp Arg Val Phe		
565	570	575
575		
Leu Gln Met Pro Ser Glu Gln Ala Ala Gly Leu Tyr Ala Gly Gln Tyr		
580	585	590
590		
Val His Ser Ser Phe Ser Gly Tyr Leu Leu Tyr Pro Met		
595	600	605

<210> 66
<211> 194
<212> PRT

<213> Homo sapiens

<400> 66
 Arg Gly Pro Trp Leu Pro Trp Asn Thr Gly Pro Pro Gly Pro Pro Gly
 1 5 10 15

Pro Pro Gly Pro Pro Gly Ala Pro Gly Ala Phe Asp Glu Thr Gly Ile
 20 25 30

Ala Gly Leu His Leu Pro Asn Gly Gly Val Glu Gly Ala Val Leu Gly
 35 40 45

Lys Gly Gly Lys Pro Gln Phe Gly Leu Gly Glu Leu Ser Ala His Ala
 50 55 60

Thr Pro Ala Phe Thr Ala Val Leu Thr Ser Pro Phe Pro Ala Ser Gly
 65 70 75 80

Met Pro Val Lys Phe Asp Arg Thr Leu Tyr Asn Gly His Ser Gly Tyr
 85 90 95

Asn Pro Ala Thr Gly Ile Phe Thr Cys Pro Val Gly Gly Val Tyr Tyr
 100 105 110

Phe Ala Tyr His Val His Val Lys Gly Thr Asn Val Trp Val Ala Leu
 115 120 125

Tyr Lys Asn Asn Val Pro Ala Thr Tyr Thr Tyr Asp Glu Tyr Lys Lys
 130 135 140

Gly Tyr Leu Asp Gln Ala Ser Gly Gly Ala Val Leu Gln Leu Arg Pro
 145 150 155 160

Asn Asp Gln Val Trp Val Gln Met Pro Ser Asp Gln Ala Asn Gly Leu
 165 170 175

Tyr Ser Thr Glu Tyr Ile His Ser Ser Phe Ser Gly Phe Leu Leu Cys
 180 185 190

Pro Thr

<210> 67
 <211> 244
 <212> PRT
 <213> Homo sapiens

<400> 67
 Met Leu Leu Leu Gly Ala Val Leu Leu Leu Ala Leu Pro Gly His
 1 5 10 15

Asp Gln Glu Thr Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu Pro
 20 25 30

Lys Gly Ala Cys Thr Gly Trp Met Ala Gly Ile Pro Gly His Pro Gly
 35 40 45

His Asn Gly Ala Pro Gly Arg Asp Gly Arg Asp Gly Thr Pro Gly Glu
 50 55 60

Lys Gly Glu Lys Gly Asp Pro Gly Leu Ile Gly Pro Lys Gly Asp Ile
 65 70 75 80

Gly Glu Thr Gly Val Pro Gly Ala Glu Gly Pro Arg Gly Phe Pro Gly
 85 90 95

Ile Gln Gly Arg Lys Gly Glu Pro Gly Glu Gly Ala Tyr Val Tyr Arg
 100 105 110

Ser Ala Phe Ser Val Gly Leu Glu Thr Tyr Val Thr Ile Pro Asn Met
 115 120 125

Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Asn His Tyr Asp
 130 135 140

Gly Ser Thr Gly Lys Phe His Cys Asn Ile Pro Gly Leu Tyr Tyr Phe
 145 150 155 160

Ala Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe
 165 170 175

Lys Lys Asp Lys Ala Met Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Asn
 180 185 190

Asn Val Asp Gln Ala Ser Gly Ser Val Leu Leu His Leu Glu Val Gly
 195 200 205

Asp Gln Val Trp Leu Gln Val Tyr Gly Glu Gly Glu Arg Asn Gly Leu
 210 215 220

Tyr Ala Asp Asn Asp Asn Asp Ser Thr Phe Thr Gly Phe Leu Leu Tyr
 225 230 235 240

His Asp Thr Asn

<210> 68
 <211> 361
 <212> PRT
 <213> Homo sapiens

<400> 68
 Thr Arg Pro Asp Ser Leu Asn Glu Leu Gln Thr Thr Val Glu Gly Gln
 1 5 10 15

Gly Ala Asp Leu Ala Asp Leu Gly Ala Thr Lys Asp Arg Ile Ile Ser
 20 25 30

Glu Ile Asn Arg Leu Gln Gln Glu Ala Thr Glu His Ala Thr Glu Ser
 35 40 45

Glu Glu Arg Phe Arg Gly Leu Glu Glu Gly Gln Ala Gln Ala Gly Gln
 50 55 60

Cys Pro Ser Leu Glu Gly Arg Leu Gly Arg Leu Glu Gly Val Cys Glu
 65 70 75 80

Arg Leu Asp Thr Val Ala Gly Gly Leu Gln Gly Leu Arg Glu Gly Leu
 85 90 95

Ser Arg His Val Ala Gly Leu Trp Ala Gly Leu Arg Glu Thr Asn Thr
 100 105 110

Thr Ser Gln Met Gln Ala Ala Leu Leu Glu Lys Leu Val Gly Gly Gln
 115 120 125

Ala Gly Leu Gly Arg Arg Leu Gly Ala Leu Asn Ser Ser Leu Gln Leu
 130 135 140

Leu Glu Asp Arg Leu His Gln Leu Ser Leu Lys Asp Leu Thr Gly Pro

145	150	155	160												
Ala	Gly	Glu	Ala	Gly	Pro	Pro	Gly	Pro	Pro	Gly	Leu	Gln	Gly	Pro	Pro
165				170							175				
Gly	Pro	Ala	Gly	Pro	Pro	Gly	Ser	Pro	Gly	Lys	Asp	Gly	Gln	Glu	Gly
180				185						190					
Pro	Ile	Gly	Pro	Pro	Gly	Pro	Gln	Gly	Glu	Gly	Val	Glu	Gly	Ala	
195				200							205				
Pro	Ala	Ala	Pro	Val	Pro	Gln	Val	Ala	Phe	Ser	Ala	Ala	Leu	Ser	Leu
210				215						220					
Pro	Arg	Ser	Glu	Pro	Gly	Thr	Val	Pro	Phe	Asp	Arg	Val	Leu	Leu	Asn
225				230						235			240		
Asp	Gly	Gly	Tyr	Tyr	Asp	Pro	Glu	Thr	Gly	Val	Phe	Thr	Ala	Pro	Leu
245				250						255					
Ala	Gly	Arg	Tyr	Leu	Leu	Ser	Ala	Val	Leu	Thr	Gly	His	Arg	His	Glu
260										265			270		
Lys	Val	Glu	Ala	Val	Leu	Ser	Arg	Ser	Asn	Gln	Gly	Val	Ala	Arg	Val
275										280			285		
Asp	Ser	Gly	Gly	Tyr	Glu	Pro	Glu	Gly	Leu	Glu	Asn	Lys	Pro	Val	Ala
290						295				300					
Glu	Ser	Gln	Pro	Ser	Pro	Gly	Thr	Leu	Gly	Val	Phe	Ser	Leu	Ile	Leu
305						310					315			320	
Pro	Leu	Gln	Ala	Gly	Asp	Thr	Val	Cys	Val	Asp	Leu	Val	Met	Gly	Gln
325						330							335		
Leu	Ala	His	Ser	Glu	Glu	Pro	Leu	Thr	Ile	Phe	Ser	Gly	Ala	Leu	Leu
340						345						350			
Tyr	Gly	Asp	Pro	Glu	Leu	Glu	His	Ala							
355						360									

<210> 69
<211> 333
<212> PRT
<213> Homo sapiens

400> 69															
Met	Arg	Ile	Trp	Trp	Leu	Leu	Leu	Ala	Ile	Glu	Ile	Cys	Thr	Gly	Asn
1					5				10				15		
Ile	Asn	Ser	Gln	Asp	Thr	Cys	Arg	Gln	Gly	His	Pro	Gly	Ile	Pro	Gly
20					25							30			
Asn	Pro	Gly	His	Asn	Gly	Leu	Pro	Gly	Arg	Asp	Gly	Arg	Asp	Gly	Ala
35					40						45				
Lys	Gly	Asp	Lys	Gly	Asp	Ala	Gly	Glu	Pro	Gly	Arg	Pro	Gly	Ser	Pro
50					55						60				
Gly	Lys	Asp	Gly	Thr	Ser	Gly	Glu	Lys	Gly	Glu	Arg	Gly	Ala	Asp	Gly
65					70						75			80	
Lys	Val	Glu	Ala	Lys	Gly	Ile	Lys	Gly	Asp	Gln	Gly	Ser	Arg	Gly	Ser
85					90							95			

Pro Gly Lys His Gly Pro Lys Gly Leu Ala Gly Pro Met Gly Glu Lys
 100 105 110
 Gly Leu Arg Gly Glu Thr Gly Pro Gln Gly Gln Lys Gly Asn Lys Gly
 115 120 125
 Asp Val Gly Pro Thr Gly Pro Glu Gly Pro Arg Gly Asn Ile Gly Pro
 130 135 140
 Leu Gly Pro Thr Gly Leu Pro Gly Pro Met Gly Pro Ile Gly Lys Pro
 145 150 155 160
 Gly Pro Lys Gly Glu Ala Gly Pro Thr Gly Pro Gln Gly Glu Pro Gly
 165 170 175
 Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly Glu Lys Gly Lys
 180 185 190
 Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe Thr Val Gly Leu
 195 200 205
 Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Val Pro Ile Lys Phe Asp
 210 215 220
 Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr Ala Ala Gly Lys
 225 230 235 240
 Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr Tyr His Ile Thr
 245 250 255
 Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys Asn Gly Val Lys
 260 265 270
 Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu Asp Gln Ala Ser
 275 280 285
 Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu Val Trp Leu Gln
 290 295 300
 Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala Asp Glu Asp Asp
 305 310 315 320
 Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser Pro
 325 330

<210> 70
 <211> 229
 <212> PRT
 <213> Homo sapiens

<400> 70
 Met Asp Leu Leu Gln Phe Leu Ala Phe Leu Phe Val Leu Leu Leu Ser
 1 5 10 15
 Gly Met Gly Ala Thr Gly Thr Leu Arg Thr Ser Leu Asp Pro Ser Leu
 20 25 30
 Glu Ile Tyr Lys Lys Met Phe Glu Val Lys Arg Arg Glu Gln Leu Leu
 35 40 45
 Ala Leu Lys Asn Leu Ala Gln Leu Asn Asp Ile His Gln Gln Tyr Lys
 50 55 60
 Ile Leu Asp Val Met Leu Lys Gly Leu Phe Lys Val Leu Glu Asp Ser
 65 70 75 80

Arg Thr Val Leu Thr Ala Ala Asp Val Leu Pro Asp Gly Pro Phe Pro
 85 90 95
 Gln Asp Glu Lys Leu Lys Asp Ala Phe Ser His Val Val Glu Asn Thr
 100 105 110
 Ala Phe Phe Gly Asp Val Val Leu Arg Phe Pro Arg Ile Val His Tyr
 115 120 125
 Tyr Phe Asp His Asn Ser Asn Trp Asn Leu Leu Ile Arg Trp Gly Ile
 130 135 140
 Ser Phe Cys Asn Gln Thr Gly Val Phe Asn Gln Gly Pro His Ser Pro
 145 150 155 160
 Ile Leu Ser Leu Met Ala Gln Glu Leu Gly Ile Ser Glu Lys Asp Ser
 165 170 175
 Asn Phe Gln Asn Pro Phe Lys Ile Asp Arg Thr Glu Phe Ile Pro Ser
 180 185 190
 Thr Asp Pro Phe Gln Lys Ala Leu Arg Glu Glu Glu Lys Arg Arg Lys
 195 200 205
 Lys Glu Glu Lys Arg Lys Glu Ile Arg Lys Gly Pro Arg Ile Ser Arg
 210 215 220
 Ser Gln Ser Glu Leu
 225

<210> 71
 <211> 229
 <212> PRT
 <213> Homo sapiens

<400> 71
 Met Asp Leu Leu Gln Phe Leu Ala Phe Leu Phe Val Leu Leu Ser
 1 5 10 15
 Gly Met Gly Ala Thr Gly Thr Leu Arg Thr Ser Leu Asp Pro Ser Leu
 20 25 30
 Glu Ile Tyr Lys Lys Met Phe Glu Val Lys Arg Arg Glu Gln Leu Leu
 35 40 45
 Ala Leu Lys Asn Leu Ala Gln Leu Asn Asp Ile His Gln Gln Tyr Lys
 50 55 60
 Ile Leu Asp Val Met Leu Lys Gly Leu Phe Lys Val Leu Glu Asp Ser
 65 70 75 80
 Arg Thr Val Leu Thr Ala Ala Asp Val Leu Pro Asp Gly Pro Cys Pro
 85 90 95
 Gln Asp Glu Lys Leu Lys Asp Ala Phe Ser His Val Val Glu Asn Thr
 100 105 110
 Ala Phe Phe Gly Asp Val Val Leu Arg Phe Pro Arg Ile Val His Tyr
 115 120 125
 Tyr Phe Asp His Asn Ser Asn Trp Asn Leu Leu Ile Arg Trp Gly Ile
 130 135 140
 Ser Phe Cys Asn Gln Thr Gly Val Phe Asn Gln Gly Pro His Ser Pro

145	150	155	160
Ile Leu Ser Leu Met Ala Gln Glu Leu Gly Ile Ser Glu Lys Asp Ser			
165	170	175	
Asn Phe Gln Asn Pro Phe Lys Ile Asp Arg Thr Glu Phe Ile Pro Ser			
180	185	190	
Thr Asp Pro Phe Gln Lys Ala Leu Arg Glu Glu Lys Arg Arg Lys			
195	200	205	
Lys Glu Glu Lys Arg Lys Glu Ile Arg Lys Gly Pro Arg Ile Ser Arg			
210	215	220	
Ser Gln Ser Glu Leu			
225			

<210> 72
<211> 459
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (321)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (345)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 72			
Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu			
1	5	10	15
Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly			
20	25	30	

Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His			
35	40	45	

Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp			
50	55	60	

Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr			
65	70	75	80

Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys			
85	90	95	

Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala			
100	105	110	

Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu			
115	120	125	

Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu			
130	135	140	

Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr			
145	150	155	160

Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro			
165	170	175	

Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190
 Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205
 Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220
 Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240
 Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
 245 250 255
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met
 290 295 300
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
 305 310 315 320
 Xaa Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335
 Pro Gly Glu Lys Gly Glu Lys Lys Xaa Leu Arg Gly Glu Pro Gly Pro
 340 345 350
 Gln Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro
 355 360 365
 Gly Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Gly Pro Cys
 370 375 380
 Arg His Arg His Pro Gln Pro Pro Ser Gly Gln Glu Gly Gly His Ala
 385 390 395 400
 Thr Asn Tyr Arg Asp Arg Gly Pro Gln Glu Pro Gly Arg Glu Arg Leu
 405 410 415
 Arg Val Val Ala Ala Pro Glu Ala Asp Gln Ala Arg Leu Pro Leu Leu
 420 425 430
 Pro Gly Leu Gly Gln Leu Pro Pro Gly Thr Ala Arg Pro Tyr Leu Leu
 435 440 445
 Met Ser Ser Gly Ser Leu Leu Pro Ser Arg Pro
 450 455

<210> 73
 <211> 443
 <212> PRT
 <213> Homo sapiens

<400> 73
 Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu
 1 5 10 15

Pro Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly

20	25	30
Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His		
35	40	45
Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp		
50	55	60
Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr		
65	70	75
Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys		
85	90	95
Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala		
100	105	110
Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu		
115	120	125
Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu		
130	135	140
Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr		
145	150	155
160		
Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro		
165	170	175
Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly		
180	185	190
Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly		
195	200	205
Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro		
210	215	220
Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val		
225	230	235
240		
Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Gly		
245	250	255
Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser		
260	265	270
Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn		
275	280	285
His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met		
290	295	300
Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly		
305	310	315
320		
His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His		
325	330	335
Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln		
340	345	350
Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly		
355	360	365
Glu Lys Ser His Trp Gly Glu Gly Leu His Gln Leu Arg Glu Ala Leu		
370	375	380

Lys Ile Leu Ala Glu Arg Val Leu Ile Leu Glu Thr Met Ile Gly Leu
 385 390 395 400

Tyr Glu Pro Glu Leu Gly Ser Gly Ala Gly Pro Ala Gly Thr Gly Thr
 405 410 415

Pro Ser Leu Leu Arg Gly Lys Arg Gly Gly His Ala Thr Asn Tyr Arg
 420 425 430

Ile Val Ala Pro Arg Ser Arg Asp Glu Arg Gly
 435 440

<210> 74
 <211> 12
 <212> PRT
 <213> Homo sapiens

<400> 74
 Gly Arg Pro Arg Pro Pro Ala Leu Val Leu Ala Arg
 1 5 10

<210> 75
 <211> 19
 <212> PRT
 <213> Homo sapiens

<400> 75
 Gly Thr Ala Arg Pro Tyr Leu Leu Met Ser Ser Gly Ser Leu Leu Pro
 1 5 10 15

Ser Arg Pro

<210> 76
 <211> 421
 <212> PRT
 <213> Homo sapiens

<400> 76
 Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu
 1 5 10 15

Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly
 20 25 30

Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His
 35 40 45

Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp
 50 55 60

Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr
 65 70 75 80

Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys
 85 90 95

Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala
 100 105 110

Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu
 115 120 125
 Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu
 130 135 140
 Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr
 145 150 155 160
 Val Ile Glu Gln Pro Val Pro Ser Thr Pro Ala Thr Pro Glu Asp Pro
 165 170 175
 Ala Pro Leu Trp Gly Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190
 Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205
 Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220
 Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240
 Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
 245 250 255
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met
 290 295 300
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
 305 310 315 320
 His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335
 Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln
 340 345 350
 Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly
 355 360 365
 Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Arg Ala Leu Pro
 370 375 380
 Ala Gln Ala Pro Pro Ala Ser Phe Gly Ala Arg Gly Ala Asp Met Gln
 385 390 395 400
 Pro Thr Thr Gly Ser Trp Pro Pro Gly Ala Gly Thr Arg Glu Ala Glu
 405 410 415
 Gly Gly Gly Gly Pro
 420

<210> 77
 <211> 421
 <212> PRT
 <213> Homo sapiens

<400> 77
Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu
1 5 10 15
Pro Gly Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly
20 25 30
Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His
35 40 45
Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp
50 55 60
Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr
65 70 75 80
Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys
85 90 95
Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala
100 105 110
Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu
115 120 125
Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu
130 135 140
Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr
145 150 155 160
Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro
165 170 175
Ala Pro Leu Trp Gly Pro Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
180 185 190
Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
195 200 205
Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
210 215 220
Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
225 230 235 240
Gly Thr Pro Gly Val Arg Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
245 250 255
Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
260 265 270
Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
275 280 285
His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met
290 295 300
Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
305 310 315 320
His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
325 330 335
Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln
340 345 350

Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly
 355 360 365

Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Arg Ala Leu Pro
 370 375 380

Ala Gln Ala Pro Pro Ala Ser Phe Gly Ala Arg Gly Ala Asp Met Gln
 385 390 395 400

Pro Thr Thr Gly Ser Trp Pro Pro Gly Ala Gly Thr Arg Glu Ala Glu
 405 410 415

Gly Gly Gly Pro
 420

<210> 78

<211> 458

<212> PRT

<213> Homo sapiens

<400> 78

Met Gly Gly Pro Arg Ala Trp Ala Leu Leu Cys Leu Gly Leu Leu Leu
 1 5 10 15

Pro Gly Gly Ala Ala Trp Ser Ile Gly Ala Ala Pro Phe Ser Gly
 20 25 30

Arg Arg Asn Trp Cys Ser Tyr Val Val Thr Arg Thr Ile Ser Cys His
 35 40 45

Val Gln Asn Gly Thr Tyr Leu Gln Arg Val Leu Gln Asn Cys Pro Trp
 50 55 60

Pro Met Ser Cys Pro Gly Ser Ser Tyr Arg Thr Val Val Arg Pro Thr
 65 70 75 80

Tyr Lys Val Met Tyr Lys Ile Val Thr Ala Arg Glu Trp Arg Cys Cys
 85 90 95

Pro Gly His Ser Gly Val Ser Cys Glu Glu Val Ala Ala Ser Ser Ala
 100 105 110

Ser Leu Glu Pro Met Trp Ser Gly Ser Thr Met Arg Arg Met Ala Leu
 115 120 125

Arg Pro Thr Ala Phe Ser Gly Cys Leu Asn Cys Ser Lys Val Ser Glu
 130 135 140

Leu Thr Glu Arg Leu Lys Val Leu Glu Ala Lys Met Thr Met Leu Thr
 145 150 155 160

Val Ile Glu Gln Pro Val Pro Pro Thr Pro Ala Thr Pro Glu Asp Pro
 165 170 175

Ala Pro Leu Trp Gly Pro Pro Ala Gln Gly Ser Pro Gly Asp Gly
 180 185 190

Gly Leu Gln Asp Gln Val Gly Ala Trp Gly Leu Pro Gly Pro Thr Gly
 195 200 205

Pro Lys Gly Asp Ala Gly Ser Arg Gly Pro Met Gly Met Arg Gly Pro
 210 215 220

Pro Gly Pro Gln Gly Pro Pro Gly Ser Pro Gly Arg Ala Gly Ala Val
 225 230 235 240

Gly Thr Pro Gly Glu Arg Gly Pro Pro Gly Pro Pro Gly
 245 250 255
 Pro Pro Gly Pro Pro Ala Pro Val Gly Pro Pro His Ala Arg Ile Ser
 260 265 270
 Gln His Gly Asp Pro Leu Leu Ser Asn Thr Phe Thr Glu Thr Asn Asn
 275 280 285
 His Trp Pro Gln Gly Pro Thr Gly Pro Pro Gly Pro Pro Gly Pro Met
 290 295 300
 Gly Pro Pro Gly Pro Pro Gly Pro Thr Gly Val Pro Gly Ser Pro Gly
 305 310 315 320
 His Ile Gly Pro Pro Gly Pro Thr Gly Pro Lys Gly Ile Ser Gly His
 325 330 335
 Pro Gly Glu Lys Gly Glu Arg Gly Leu Arg Gly Glu Pro Gly Pro Gln
 340 345 350
 Gly Ser Ala Gly Gln Arg Gly Glu Pro Gly Pro Lys Gly Asp Pro Gly
 355 360 365
 Glu Lys Ser His Trp Asn Gln Ser Trp Gly Leu Gly Gly Pro Cys Arg
 370 375 380
 His Arg His Pro Gln Pro Pro Ser Gly Gln Glu Gly Gly His Ala Thr
 385 390 395 400
 Asn Tyr Arg Asp Arg Gly Pro Gln Glu Pro Gly Arg Glu Arg Leu Arg
 405 410 415
 Val Val Ala Ala Pro Glu Ala Asp Gln Ala Arg Leu Pro Leu Leu Pro
 420 425 430
 Gly Leu Gly Gln Leu Pro Pro Gly Thr Ala Arg Pro Tyr Leu Leu Met
 435 440 445
 Ser Ser Gly Ser Leu Leu Pro Ser Arg Pro
 450 455

<210> 79
 <211> 240
 <212> PRT
 <213> Homo sapiens

<400> 79
 His Ala Ser Ala Ala Arg Ala Ala Ala Gly Ser Glu Pro Arg Thr Gly
 1 5 10 15
 Cys Gly Gly Ser Ser His Arg Val Pro Leu Gly Pro Ser Pro Ala Ser
 20 25 30
 Leu Ser Pro Gln Arg Asp Leu Phe Gly Pro Pro Gly Pro Pro Gly Ala
 35 40 45
 Glu Val Thr Ala Glu Thr Leu Leu His Glu Phe Gln Glu Leu Leu Lys
 50 55 60
 Glu Ala Thr Glu Arg Arg Phe Ser Gly Leu Leu Asp Pro Leu Leu Pro
 65 70 75 80
 Gln Gly Ala Gly Leu Arg Leu Val Gly Glu Ala Phe His Cys Arg Leu

85	90	95
Gln Gly Pro Arg Arg Val Asp Lys Arg Thr Leu Val Glu		Leu His Gly
100 105		110
Phe Gln Ala Pro Ala Ala Gln Gly Ala Phe Leu Arg Gly Ser Gly Leu		
115 120		125
Ser Leu Ala Ser Gly Arg Phe Thr Ala Pro Val Ser Gly Ile Phe Gln		
130 135		140
Phe Ser Ala Ser Leu His Val Asp His Ser Glu Leu Gln Gly Lys Ala		
145 150		155 160
Arg Leu Arg Ala Arg Asp Val Val Cys Val Leu Ile Cys Ile Glu Ser		
165 170		175
Leu Cys Gln Arg His Thr Cys Leu Glu Ala Val Ser Gly Leu Glu Ser		
180 185		190
Asn Ser Arg Val Phe Thr Leu Gln Val Gln Gly Leu Leu Gln Leu Gln		
195 200		205
Ala Gly Gln Tyr Ala Ser Val Phe Val Asp Asn Gly Ser Gly Ala Val		
210 215		220
Leu Thr Ile Gln Ala Gly Ser Ser Phe Ser Gly Leu Leu Leu Gly Thr		
225 230		235 240

<210> 80
<211> 256
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (75)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (187)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (229)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (232)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (235)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (236)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (237)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 80

Met	Leu	Gly	Ala	Lys	Pro	His	Trp	Leu	Pro	Gly	Pro	Leu	His	Ser	Pro
1				5				10					15		

Gly	Leu	Pro	Leu	Val	Leu	Val	Leu	Leu	Ala	Gly	Ala	Gly	Trp	Ala
					20			25				30		

Gln	Glu	Gly	Ser	Glu	Pro	Val	Leu	Leu	Glu	Gly	Glu	Cys	Leu	Val	Val
						35		40			45				

Cys	Glu	Pro	Gly	Arg	Ala	Ala	Ala	Gly	Gly	Pro	Gly	Gly	Ala	Ala	Leu
					50		55			60					

Gly	Glu	Ala	Pro	Pro	Gly	Arg	Val	Ala	Phe	Xaa	Ala	Val	Arg	Ser	His
					65		70			75			80		

His	His	Glu	Pro	Ala	Gly	Glu	Thr	Gly	Asn	Gly	Thr	Ser	Gly	Ala	Ile
					85			90			95				

Tyr	Phe	Asp	Gln	Val	Leu	Val	Asn	Glu	Gly	Gly	Phe	Asp	Arg	Ala	
					100			105			110				

Ser	Gly	Ser	Phe	Val	Ala	Pro	Val	Arg	Gly	Val	Tyr	Ser	Phe	Arg	Phe
					115			120			125				

His	Val	Val	Lys	Val	Tyr	Asn	Arg	Gln	Thr	Val	Gln	Val	Ser	Leu	Met
					130			135			140				

Leu	Asn	Thr	Trp	Pro	Val	Ile	Ser	Ala	Phe	Ala	Asn	Asp	Pro	Asp	Val
					145			150			155			160	

Thr	Arg	Glu	Ala	Ala	Thr	Ser	Ser	Val	Leu	Leu	Pro	Leu	Asp	Pro	Gly
					165			170			175				

Asp	Arg	Val	Ser	Leu	Arg	Leu	Arg	Arg	Gly	Xaa	Ser	Thr	Gly	Trp	Leu
					180			185			190				

Glu	Ile	Leu	Lys	Phe	Leu	Trp	Leu	Pro	His	Leu	Pro	Ser	Leu	Lys	Asp
					195			200			205				

Pro	Ser	Leu	Ser	Ser	Thr	Arg	Ile	Gln	Pro	Leu	Thr	Thr	Phe	Phe	Cys
					210			215			220				

Pro	Leu	Leu	Pro	Xaa	Lys	Gln	Xaa	Lys	Gln	Xaa	Xaa	Ser	Leu	Trp
					225			230			235			240

Leu	Leu	Ser	His	Leu	Phe	Ala	Trp	Glu	Pro	Val	Pro	Asn	Thr	Gln	Val
					245			250			250			255	

<210> 81

<211> 205

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (80)

<223> Xaa equals any of the naturally occurring L-amino acids

<220>

<221> SITE

<222> (93)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 81

Met	Leu	Gly	Ala	Lys	Pro	His	Trp	Leu	Pro	Gly	Pro	Leu	His	Ser	Pro
1				5				10					15		

Gly	Leu	Pro	Leu	Val	Leu	Val	Leu	Leu	Ala	Leu	Gly	Ala	Gly	Trp	Ala
				20				25				30			

Gln	Glu	Gly	Ser	Glu	Pro	Val	Leu	Leu	Glu	Gly	Glu	Cys	Leu	Val	Val
						35		40			45				

Cys	Glu	Pro	Gly	Arg	Ala	Ala	Ala	Gly	Gly	Pro	Gly	Gly	Ala	Ala	Leu
	50				55					60					

Gly	Glu	Ala	Pro	Pro	Gly	Arg	Val	Ala	Phe	Ala	Ala	Val	Arg	Ser	Xaa
	65				70				75			80			

His	His	Glu	Pro	Ala	Gly	Glu	Thr	Gly	Asn	Gly	Thr	Xaa	Gly	Ala	Ile
		85					90				95				

Tyr	Phe	Asp	Gln	Val	Leu	Val	Asn	Glu	Gly	Gly	Phe	Asp	Arg	Ala
		100					105				110			

Ser	Gly	Ser	Phe	Val	Ala	Pro	Val	Arg	Gly	Val	Tyr	Ser	Phe	Arg	Phe
	115					120					125				

His	Val	Val	Lys	Val	Tyr	Asn	Arg	Gln	Thr	Val	Gln	Val	Ser	Leu	Met
	130					135					140				

Leu	Asn	Thr	Trp	Pro	Val	Ile	Ser	Ala	Phe	Ala	Asn	Asp	Pro	Asp	Val
	145				150				155			160			

Thr	Arg	Glu	Ala	Ala	Thr	Ser	Ser	Val	Leu	Leu	Pro	Leu	Asp	Pro	Gly
	165					170					175				

Asp	Arg	Val	Ser	Leu	Arg	Leu	Arg	Gly	Asn	Leu	Leu	Gly	Gly	Trp	
	180					185					190				

Lys	Tyr	Ser	Ser	Phe	Ser	Gly	Phe	Leu	Ile	Phe	Pro	Leu		
	195				200				205					

<210> 82

<211> 180

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (102)

<223> Xaa equals any of the naturally occurring L-amino acids

<400> 82

Ala	Cys	Cys	Pro	Val	Arg	Ala	Gln	Asn	Asp	Thr	Glu	Pro	Ile	Val	Leu
1					5			10		15					

Glu	Gly	Lys	Cys	Leu	Val	Val	Cys	Asp	Ser	Ser	Pro	Ser	Ala	Asp	Gly
	20						25					30			

Ala	Val	Thr	Ser	Ser	Leu	Gly	Ile	Ser	Val	Arg	Ser	Gly	Ser	Ala	Lys
	35						40				45				

Val	Ala	Phe	Ser	Ala	Thr	Arg	Ser	Thr	Asn	His	Glu	Pro	Ser	Glu	Met
	50					55				60					

Ser Asn Arg Thr Met Thr Ile Tyr Phe Asp Gln Val Leu Val Asn Ile
 65 70 75 80
 Gly Asn His Phe Asp Leu Ala Ser Ser Ile Phe Val Ala Pro Arg Lys
 85 90 95
 Gly Ile Tyr Ser Phe Xaa Phe His Val Val Lys Val Tyr Asn Arg Gln
 100 105 110
 Thr Ile Gln Val Ser Leu Met Gln Asn Gly Tyr Pro Val Ile Ser Ala
 115 120 125
 Phe Ala Gly Asp Gln Asp Val Thr Arg Glu Ala Ala Ser Asn Gly Val
 130 135 140
 Leu Leu Leu Met Glu Arg Glu Asp Lys Val His Leu Lys Leu Glu Arg
 145 150 155 160
 Gly Asn Leu Met Gly Gly Trp Lys Tyr Ser Thr Phe Ser Gly Phe Leu
 165 170 175
 Val Phe Pro Leu
 180

<210> 83
 <211> 241
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (62)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (191)
 <223> Xaa equals any of the naturally occurring L-amino acids

<400> 83
 Ala Gly Glu Gly Pro Arg Arg Glu Pro Pro Trp Pro Ala Pro Gln
 1 5 10 15

Ile Cys Pro Ala Gly Arg Gly Gly Gly Thr Arg Ala Gly Gly Gly
 20 25 30
 Ala Gly Arg Ser Ser Gly Arg Gly Glu Gly Tyr Gly Asp Leu Arg
 35 40 45

Val Ala Ala Pro Leu Arg Ala Glu Pro Pro Leu Leu Ser Xaa Cys Arg
 50 55 60

Pro Ala Tyr Pro Ala Gly Leu Pro Gly Pro Arg Gly Asp Pro Gly Pro
 65 70 75 80

Arg Gly Glu Ala Gly Pro Ala Gly Pro Thr Gly Pro Ala Gly Glu Cys
 85 90 95

Ser Val Pro Pro Arg Ser Ala Phe Ser Ala Lys Arg Ser Glu Ser Arg
 100 105 110

Val Pro Pro Pro Ser Asp Ala Pro Leu Pro Phe Asp Arg Val Leu Val
 115 120 125

Asn Glu Gln Gly His Tyr Asp Ala Val Thr Gly Lys Phe Thr Cys Gln

130	135	140
Val Pro Gly Val Tyr Tyr Phe Ala Val His Ala Thr Val Tyr Arg Ala		
145 150 155 160		
Ser Leu Gln Phe Asp Leu Val Lys Asn Gly Glu Ser Ile Ala Ser Phe		
165 170 175		
Phe Gln Phe Phe Gly Gly Trp Pro Lys Pro Ala Ser Leu Ser Xaa Gly		
180 185 190		
Ala Met Val Arg Leu Glu Pro Glu Asp Gln Val Trp Val Gln Val Gly		
195 200 205		
Val Gly Asp Tyr Ile Gly Ile Tyr Ala Ser Ile Lys Thr Asp Ser Thr		
210 215 220		
Phe Ser Gly Phe Leu Val Tyr Ser Asp Trp His Ser Ser Pro Val Phe		
225 230 235 240		
Ala		

<210> 84
<211> 245
<212> PRT
<213> Homo sapiens

<400> 84		
Met Asp Val Gly Pro Ser Ser Leu Pro His Leu Gly Leu Lys Leu Leu		
1 5 10 15		
Leu Leu Leu Leu Leu Pro Leu Arg Gly Gln Ala Asn Thr Gly Cys		
20 25 30		
Tyr Gly Ile Pro Gly Met Pro Gly Leu Pro Gly Ala Pro Gly Lys Asp		
35 40 45		
Gly Tyr Asp Gly Leu Pro Gly Pro Lys Gly Glu Pro Gly Ile Pro Ala		
50 55 60		
Ile Pro Gly Ile Arg Gly Pro Lys Gly Gln Lys Gly Glu Pro Gly Leu		
65 70 75 80		
Pro Gly His Pro Gly Lys Asn Gly Pro Met Gly Pro Pro Gly Met Pro		
85 90 95		
Gly Val Pro Gly Pro Met Gly Ile Pro Gly Glu Pro Gly Glu Gly		
100 105 110		
Arg Tyr Lys Gln Lys Phe Gln Ser Val Phe Thr Val Thr Arg Gln Thr		
115 120 125		
His Gln Pro Pro Ala Pro Asn Ser Leu Ile Arg Phe Asn Ala Val Leu		
130 135 140		
Thr Asn Pro Gln Gly Asp Tyr Asp Thr Ser Thr Gly Lys Phe Thr Cys		
145 150 155 160		
Lys Val Pro Gly Leu Tyr Tyr Phe Val Tyr His Ala Ser His Thr Ala		
165 170 175		
Asn Leu Cys Val Leu Leu Tyr Arg Ser Gly Val Lys Val Val Thr Phe		
180 185 190		
Cys Gly His Thr Ser Lys Thr Asn Gln Val Asn Ser Gly Gly Val Leu		

195	200	205
Leu Arg Leu Gln Val Gly Glu	Glu Val Trp Leu Ala Val Asn Asp Tyr	
210	215	220
Tyr Asp Met Val Gly Ile Gln Gly Ser Asp	Ser Val Phe Ser Gly Phe	
225	230	235
Leu Leu Phe Pro Asp		
245		

<210> 85
<211> 76
<212> PRT
<213> *Homo sapiens*

```

<400> 85
Ala Leu Pro Arg Leu Gly Arg Ala Asp Ala Leu Glu Thr His Gly Pro
      1           5           10          15

Ser Thr Ser Leu Ser Phe Leu His Gly Pro Thr Leu Leu Ala Ser Leu
      20          25          30

His Pro Cys Leu Asp His Ser Pro Leu Gln Gly Ala His Pro Asp Pro
      35          40          45

Pro Pro Leu His Pro Leu Pro Met Gly Ser Leu Leu Pro Leu Asn Phe
      50          55          60

Phe Arg Ser His Cys Leu Cys Gly Ser Trp Asp Thr
      65          70          75

```

<210> 86
<211> 185
<212> PRT
<213> *Homo sapiens*

```
<220>
<221> SITE
<222> (72)
<223> Xaa equals any of the naturally occurring L-amino acids
```

```
<220>
<221> SITE
<222> (86)
<223> Xaa equals any of the naturally occurring L-amino acids
```

<220>
<221> SITE
<222> (88)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (90)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (109)
<223> Xaa equals any of the naturally occurring L-amino acids

52202

<221> SITE
<222> (119)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (148)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (153)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (171)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (172)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (178)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (183)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 86
Met Asp Val Gly Pro Ser Ser Leu Pro His Leu Gly Leu Lys Leu Leu
1 5 10 15

Leu Leu Leu Leu Leu Pro Leu Arg Gly Gln Ala Asn Thr Gly Cys
20 25 30

Tyr Gly Ile Pro Gly Met Pro Gly Leu Pro Gly Ala Pro Gly Lys Asp
35 40 45

Gly Tyr Asp Gly Leu Pro Gly Pro Lys Gly Glu Pro Gly Ile Gln Pro
50 55 60

Phe Arg Asp Pro Arg Thr Gln Xaa Ala Glu Gly Arg Thr Arg Leu Thr
65 70 75 80

Arg Pro Ser Trp Glu Xaa Trp Xaa Met Xaa Pro Pro Gly Met Pro Gly
85 90 95

Val Pro Ala His Gly His Pro Trp Arg Ala Gly Glu Xaa Gly Arg Tyr
100 105 110

Lys Gln Lys Phe Gln Ser Xaa Ser Arg His Ser Glu Thr Thr Ala Pro
115 120 125

Asp Pro Thr Ala Asp Arg Ser Thr Arg Ser Asn Asn Arg Arg Arg Tyr
130 135 140

Thr Arg His Xaa Lys Ser Leu Lys Xaa Arg Leu Thr Leu Ala Thr Arg
145 150 155 160

Val Ile Ser Asn Trp Leu Cys Asp Glu Arg Xaa Xaa Gly Thr Leu Gly
165 170 175

Asn Xaa Asn Ile Gly Asn Xaa Gly Ala
180 185

<210> 87
<211> 127
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (127)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 87
Met Phe Val Leu Leu Tyr Val Thr Ser Phe Ala Ile Cys Ala Ser Gly
1 5 10 15

Gln Pro Arg Gly Asn Gln Leu Lys Gly Glu Asn Tyr Ser Pro Arg Tyr
20 25 30

Ile Cys Ser Ile Pro Gly Leu Pro Gly Pro Pro Gly Pro Pro Gly Ala
35 40 45

Asn Gly Ser Pro Gly Pro His Gly Arg Ile Gly Leu Pro Gly Arg Asp
50 55 60

Gly Arg Asp Gly Arg Lys Gly Glu Lys Gly Glu Lys Gly Thr Ala Gly
65 70 75 80

Leu Arg Gly Lys Thr Gly Pro Leu Gly Leu Ala Gly Glu Lys Gly Asp
85 90 95

Gln Gly Glu Thr Gly Lys Gly Pro Ile Gly Pro Glu Gly Glu Lys
100 105 110

Gly Glu Val Gly Pro Ile Gly Pro Pro Gly Pro Lys Gly Asp Xaa
115 120 125

<210> 88
<211> 285
<212> PRT
<213> Homo sapiens

<400> 88
Met Ile Pro Trp Val Leu Leu Ala Cys Ala Leu Pro Cys Ala Ala Asp
1 5 10 15

Pro Leu Leu Gly Ala Phe Ala Arg Arg Asp Phe Arg Lys Gly Ser Pro
20 25 30

Gln Leu Val Cys Ser Leu Pro Gly Pro Gln Gly Pro Pro Gly Pro Pro
35 40 45

Gly Ala Pro Gly Pro Ser Gly Met Met Gly Arg Met Gly Phe Pro Gly
50 55 60

Lys Asp Gly Gln Asp Gly His Asp Gly Asp Arg Gly Asp Ser Gly Glu
65 70 75 80

Glu Gly Pro Pro Gly Arg Thr Gly Asn Arg Gly Lys Pro Gly Pro Lys
85 90 95

Gly Lys Ala Gly Ala Ile Gly Arg Ala Gly Pro Arg Gly Pro Lys Gly
 100 105 110

Val Asn Gly Thr Pro Gly Lys His Gly Thr Pro Gly Lys Lys Gly Pro
 115 120 125

Lys Gly Lys Lys Gly Glu Pro Gly Leu Pro Gly Pro Cys Ser Cys Gly
 130 135 140

Ser Gly His Thr Lys Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr
 145 150 155 160

Pro Arg Glu Arg Leu Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu
 165 170 175

Gly Gly His Tyr Asn Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro
 180 185 190

Gly Ile Tyr Tyr Phe Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu
 195 200 205

Ala Ile Gly Leu Val His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp
 210 215 220

Ala Asn Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Ile Leu Ala
 225 230 235 240

Leu Lys Gln Gly Asp Glu Val Trp Leu Gln Ile Phe Tyr Ser Glu Gln
 245 250 255

Asn Gly Leu Phe Tyr Asp Pro Tyr Trp Thr Asp Ser Leu Phe Thr Gly
 260 265 270

Phe Leu Ile Tyr Ala Asp Gln Asp Asp Pro Asn Glu Val
 275 280 285

<210> 89
<211> 205
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (5)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (27)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (104)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (119)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 89
Phe Phe Phe Xaa Pro Gly Leu Pro Gly Leu Pro Cys Pro Leu Ser
 1 5 10 15

Ala Leu Leu Ala Glu Ser Arg Arg Ala Arg Xaa Pro Trp Arg Ser Arg
 20 25 30

Gly Thr Phe Glu Pro Arg Ala Arg Pro Gly Met His Ala Pro Gly Pro
 35 40 45

Pro Gly Leu Phe Ser Gly Pro Gly Leu Thr Val Ala Pro Arg Pro Arg
 50 55 60

Gly Pro Ala Gly Gly Gly Glu Val Gly Val His Gln Glu Ala Gly
 65 70 75 80

Glu Gly Asp Val Leu Ala Val Val Ala Val Gly Ala Val Ala Val Val
 85 90 95

Val Val Ala Glu Gln Pro Glu Xaa Ser Pro Arg Arg Arg Ala Ser Ile
 100 105 110

Thr Leu Trp Leu Cys Ile Xaa Ala Ala Pro Arg Arg Ala Val Val Val
 115 120 125

Asn His Gly Leu His Leu Val Ala Val Leu His Gln Leu Asn Arg Gln
 130 135 140

Arg Leu Thr Arg Gln Leu Ala Gln Arg Glu Gly Glu Val Gly Ala
 145 150 155 160

Gly Glu Thr Ala Ala Glu His Ala Gly Arg Arg Val Glu Val Ala Ala
 165 170 175

Asn Val Asp Glu Leu Gly Val Glu Gly Glu Trp Leu Val Pro Arg Pro
 180 185 190

Gly Pro Ala Ser Glu Pro Thr Lys Leu Arg Ala Leu Cys
 195 200 205

<210> 90

<211> 251

<212> PRT

<213> Homo sapiens

<400> 90

Met Lys Ile Pro Trp Gly Ser Ile Pro Val Leu Met Leu Leu Leu
 1 5 10 15

Leu Gly Leu Ile Asp Ile Ser Gln Ala Gln Leu Ser Cys Thr Gly Pro
 20 25 30

Pro Ala Ile Pro Gly Ile Pro Gly Ile Pro Gly Thr Pro Gly Pro Asp
 35 40 45

Gly Gln Pro Gly Thr Pro Gly Ile Lys Gly Glu Lys Gly Leu Pro Gly
 50 55 60

Leu Ala Gly Asp His Gly Glu Phe Gly Glu Lys Gly Asp Pro Gly Ile
 65 70 75 80

Pro Gly Asn Pro Gly Lys Val Gly Pro Lys Gly Pro Met Gly Pro Lys
 85 90 95

Gly Gly Pro Gly Ala Pro Gly Ala Pro Gly Pro Lys Gly Glu Ser Gly
 100 105 110

Asp Tyr Lys Ala Thr Gln Lys Ile Ala Phe Ser Ala Thr Arg Thr Ile
 115 120 125

Asn Val Pro Leu Arg Arg Asp Gln Thr Ile Arg Phe Asp His Val Ile
 130 135 140
 Thr Asn Met Asn Asn Asn Tyr Glu Pro Arg Ser Gly Lys Phe Thr Cys
 145 150 155 160
 Lys Val Pro Gly Leu Tyr Tyr Phe Thr Tyr His Ala Ser Ser Arg Gly
 165 170 175
 Asn Leu Cys Val Asn Leu Met Arg Gly Arg Glu Arg Ala Gln Lys Val
 180 185 190
 Val Thr Phe Cys Asp Tyr Ala Tyr Asn Thr Phe Gln Val Thr Thr Gly
 195 200 205
 Gly Met Val Leu Lys Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala
 210 215 220
 Thr Asp Lys Asn Ser Leu Leu Gly Met Glu Gly Ala Asn Ser Ile Phe
 225 230 235 240
 Ser Gly Phe Leu Leu Phe Pro Asp Met Glu Ala
 245 250

<210> 91
 <211> 168
 <212> PRT
 <213> Homo sapiens

<220>
 <221> SITE
 <222> (34)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (40)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (44)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (51)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (57)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (62)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
 <221> SITE
 <222> (65)
 <223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (83)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 91
Pro Gly Ile Arg Lys Arg Arg Pro Gln Gly Pro His Gly Pro Lys Val
1 5 10 15
Ala Gln Gly Pro Glu Ala Pro Ser Pro Lys Val Asn Arg Glu Thr Gln
20 25 30
Ala Xaa Gln Lys Met Pro Phe Xaa Ala Thr Arg Xaa Ile Asn Val Pro
35 40 45
Leu Arg Xaa Asp Gln Thr Ile Arg Xaa Asp His Val Ile Xaa Asn Met
50 55 60
Xaa Asn Asn Tyr Glu Pro Arg Ser Gly Lys Phe Thr Cys Lys Val Pro
65 70 75 80
Gly Leu Xaa Tyr Phe Thr Tyr His Ala Ser Ser Arg Gly Asn Leu Cys
85 90 95
Val Asn Leu Met Arg Gly Arg Ala Gln Lys Val Val Thr Phe
100 105 110
Cys Asp Tyr Ala Tyr Asn Thr Phe Gln Val Thr Thr Gly Gly Met Val
115 120 125
Leu Lys Leu Glu Gln Gly Glu Asn Val Phe Leu Gln Ala Thr Asp Lys
130 135 140
Asn Ser Leu Leu Gly Met Glu Gly Ala Asn Ser Ile Phe Ser Gly Phe
145 150 155 160
Leu Leu Phe Pro Asp Met Glu Ala
165

<210> 92
<211> 255
<212> PRT
<213> Homo sapiens

<400> 92
His Ser Met Met Met Lys Ile Pro Trp Gly Ser Ile Pro Val Leu Met
1 5 10 15
Leu Leu Leu Leu Leu Gly Leu Ile Asp Ile Ser Gln Ala Gln Leu Ser
20 25 30
Cys Thr Gly Pro Pro Ala Ile Pro Gly Ile Pro Gly Ile Pro Gly Thr
35 40 45
Pro Gly Pro Asp Gly Gln Pro Gly Thr Pro Gly Ile Lys Gly Glu Lys
50 55 60
Gly Leu Pro Gly Leu Ala Gly Asp His Gly Glu Phe Gly Glu Lys Gly
65 70 75 80
Asp Pro Gly Ile Pro Gly Asn Pro Gly Lys Val Gly Pro Lys Gly Pro
85 90 95
Met Gly Pro Lys Gly Gly Pro Gly Ala Pro Gly Ala Pro Gly Pro Lys
100 105 110

Gly Glu Ser Gly Asp Tyr Lys Ala Thr Gln Lys Ile Ala Phe Ser Ala
 115 120 125

Thr Arg Thr Ile Asn Val Pro Leu Arg Arg Asp Gln Thr Ile Arg Phe
 130 135 140

Asp His Val Ile Thr Asn Met Asn Asn Asn Tyr Glu Pro Arg Ser Gly
 145 150 155 160

Lys Phe Thr Cys Lys Val Pro Gly Leu Tyr Tyr Phe Thr Tyr His Ala
 165 170 175

Ser Ser Arg Gly Asn Leu Cys Val Asn Leu Met Arg Gly Arg Glu Arg
 180 185 190

Ala Gln Lys Val Val Thr Phe Cys Asp Tyr Ala Tyr Asn Thr Phe Gln
 195 200 205

Val Thr Thr Gly Gly Met Val Leu Lys Leu Glu Gln Gly Glu Asn Val
 210 215 220

Phe Leu Gln Ala Thr Asp Lys Asn Ser Leu Leu Gly Met Glu Gly Ala
 225 230 235 240

Asn Ser Ile Phe Ser Gly Phe Leu Leu Phe Pro Asp Met Glu Ala
 245 250 255

<210> 93
<211> 258
<212> PRT
<213> Homo sapiens

<400> 93
 Ala Phe Ala Lys Ser Tyr Leu Gly Asp Thr Ile Glu Gly Thr Pro Ala
 1 5 10 15

Gly Thr Gly Pro Glu Phe Pro Gly Arg Pro Thr Arg Pro Val Leu Pro
 20 25 30

Gln Arg Pro Pro Glu Glu Arg Pro Pro Gln Pro Pro Gly Ser Thr Gly
 35 40 45

Val Ile Ala Glu Thr Gly Gln Ala Gly Pro Pro Ala Gly Ala Gly Val
 50 55 60

Ser Gly Arg Gly Leu Pro Arg Gly Val Asp Gly Gln Thr Gly Ser Gly
 65 70 75 80

Thr Val Pro Gly Ala Glu Gly Phe Ala Gly Ala Pro Gly Tyr Pro Lys
 85 90 95

Ser Pro Pro Val Ala Ser Pro Gly Ala Pro Val Pro Ser Leu Val Ser
 100 105 110

Phe Ser Ala Gly Leu Thr Gln Lys Pro Phe Pro Ser Asp Gly Gly Val
 115 120 125

Val Leu Phe Asn Lys Val Leu Val Asn Asp Gly Asp Val Tyr Asn Pro
 130 135 140

Ser Thr Gly Val Phe Thr Ala Pro Tyr Asp Gly Arg Tyr Leu Ile Thr
 145 150 155 160

Ala Thr Leu Thr Pro Glu Arg Asp Ala Tyr Val Glu Ala Val Leu Ser
 165 170 175

Val Ser Asn Ala Ser Val Ala Gln Leu His Thr Ala Gly Tyr Arg Arg
 180 185 190
 Glu Phe Leu Glu Tyr His Arg Pro Pro Gly Ala Leu His Thr Cys Gly
 195 200 205
 Gly Pro Gly Ala Phe His Leu Ile Val His Leu Lys Ala Gly Asp Ala
 210 215 220
 Val Asn Val Val Val Thr Gly Gly Lys Leu Ala His Thr Asp Phe Asp
 225 230 235 240
 Glu Met Tyr Ser Thr Phe Ser Gly Val Phe Leu Tyr Pro Phe Leu Ser
 245 250 255
 His Leu

<210> 94
<211> 232
<212> PRT
<213> Homo sapiens

<400> 94
 Thr Arg Pro Val Leu Pro Gln Arg Pro Pro Glu Glu Arg Pro Pro Gln
 1 5 10 15
 Pro Pro Gly Ser Thr Gly Val Ile Ala Glu Thr Gly Gln Ala Gly Pro
 20 25 30
 Pro Ala Gly Ala Gly Val Ser Gly Arg Gly Leu Pro Arg Gly Val Asp
 35 40 45
 Gly Gln Thr Gly Ser Gly Thr Val Pro Gly Ala Glu Gly Phe Ala Gly
 50 55 60
 Ala Pro Gly Tyr Pro Lys Ser Pro Pro Val Ala Ser Pro Gly Ala Pro
 65 70 75 80
 Val Pro Ser Leu Val Ser Phe Ser Ala Gly Leu Thr Gln Lys Pro Phe
 85 90 95
 Pro Ser Asp Gly Gly Val Val Leu Phe Asn Lys Val Leu Val Asn Asp
 100 105 110
 Gly Asp Val Tyr Asn Pro Ser Thr Gly Val Phe Thr Ala Pro Tyr Asp
 115 120 125
 Gly Arg Tyr Leu Ile Thr Ala Thr Leu Thr Pro Glu Arg Asp Ala Tyr
 130 135 140
 Val Glu Ala Val Leu Ser Val Ser Asn Ala Ser Val Ala Gln Leu His
 145 150 155 160
 Thr Ala Gly Tyr Arg Arg Glu Phe Leu Glu Tyr His Arg Pro Pro Gly
 165 170 175
 Ala Leu His Thr Cys Gly Gly Pro Gly Ala Phe His Leu Ile Val His
 180 185 190
 Leu Lys Ala Gly Asp Ala Val Asn Val Val Thr Gly Gly Lys Leu
 195 200 205
 Ala His Thr Asp Phe Asp Glu Met Tyr Ser Thr Phe Ser Gly Val Phe

210

215

220

Leu Tyr Pro Phe Leu Ser His Leu
 225 230

<210> 95
 <211> 98
 <212> PRT
 <213> Homo sapiens

<400> 95
 Met Ala Val Leu Pro Gly Pro Leu Gln Leu Leu Gly Val Leu Leu Thr
 1 5 10 15
 Ile Ser Leu Ser Ser Ile Arg Leu Ile Gln Ala Gly Ala Tyr Tyr Gly
 20 25 30
 Ile Lys Pro Leu Pro Pro Gln Ile Pro Pro Gln Met Pro Pro Gln Ile
 35 40 45
 Pro Gln Tyr Gln Pro Leu Gly Gln Gln Val Pro His Met Pro Leu Ala
 50 55 60
 Lys Asp Gly Leu Ala Met Gly Lys Glu Met Pro His Leu Gln Tyr Gly
 65 70 75 80
 Lys Glu Tyr Pro His Leu Pro Gln Tyr Met Lys Glu Ile Gln Pro Ala
 85 90 95
 Val Asp

<210> 96
 <211> 542
 <212> PRT
 <213> Homo sapiens

<400> 96
 Met Gln Ala Cys Gly Gln Leu Cys Ser Gly Ala Pro Gly Glu Gln Asp
 1 5 10 15
 Ser Gln Val Ser Glu Ile Leu Ser Ala Leu Glu Arg Arg Val Leu Asp
 20 25 30
 Ser Glu Gly Gln Leu Arg Leu Val Gly Ser Gly Leu His Thr Val Glu
 35 40 45
 Ala Ala Gly Glu Ala Arg Gln Ala Thr Leu Glu Gly Leu Gln Glu Val
 50 55 60
 Val Gly Arg Leu Gln Asp Arg Val Asp Ala Gln Asp Glu Thr Ala Ala
 65 70 75 80
 Glu Phe Thr Leu Arg Leu Asn Leu Thr Ala Ala Arg Leu Gly Gln Leu
 85 90 95
 Glu Gly Leu Leu Gln Ala His Gly Asp Glu Gly Cys Gly Ala Cys Gly
 100 105 110
 Gly Val Gln Glu Glu Leu Gly Arg Leu Arg Asp Gly Val Glu Arg Cys
 115 120 125
 Ser Cys Pro Leu Leu Pro Pro Arg Gly Pro Gly Ala Gly Pro Gly Val

130	135	140			
Gly	Gly	Pro Ser Arg Gly	Pro Leu Asp Gly	Phe Ser Val Phe Gly	Gly
145		150		155	160
Ser	Ser	Gly Ser Ala Leu Gln	Ala Leu Gln	Gly Glu Leu Ser	Glu Val
		165		170	175
Ile	Leu	Ser Phe Ser Ser Leu Asn	Asp Ser Leu Asn	Glu Leu Gln	Thr
		180	185		190
Thr	Val	Glu Gly Gln Gly Ala Asp	Leu Ala Asp Leu	Gly Ala Thr	Lys
		195	200		205
Asp	Arg	Ile Ile Ser Glu Ile Asn	Arg Leu Gln	Gln Glu Ala	Thr Glu
		210	215		220
His	Ala	Thr Glu Ser Glu Glu Arg	Phe Arg Gly	Leu Glu Gly	Gln
		225	230	235	240
Ala	Gln	Ala Gly Gln Cys Pro Ser	Leu Glu Gly Arg	Leu Gly Arg	Leu
		245	250		255
Glu	Gly	Val Cys Glu Arg Leu Asp	Thr Val Ala Gly	Gly Leu Gln	Gly
		260	265		270
Leu	Arg	Glu Leu Ser Arg His Val	Ala Gly Leu Trp	Ala Gly Leu	
		275	280	285	
Arg	Glu	Thr Asn Thr Thr Ser Gln	Met Gln Ala Ala	Leu Leu Glu	Lys
		290	295		300
Leu	Val	Gly Gly Gln Ala Gly	Leu Gly Arg Arg	Leu Gly Ala	Leu Asn
		305	310	315	320
Ser	Ser	Leu Gln Leu Leu Glu Asp	Arg Leu His Gln	Leu Ser	Leu Lys
		325	330		335
Asp	Leu	Thr Gly Pro Ala Gly Glu	Ala Gly Pro Pro	Gly Pro Pro	Gly
		340	345		350
Leu	Gln	Gly Pro Pro Gly Pro Ala	Gly Pro Pro	Gly Ser Pro	Gly Lys
		355	360		365
Asp	Gly	Gln Glu Gly Pro Ile	Gly Pro Pro Gly	Pro Gln Gly Glu	Gln
		370	375	380	
Gly	Val	Glu Gly Ala Pro Ala Ala	Pro Val Pro Gln	Val Ala Phe	Ser
		385	390	395	400
Ala	Ala	Leu Ser Leu Pro Arg Ser	Glu Pro Gly	Thr Val Pro	Phe Asp
		405	410		415
Arg	Val	Leu Leu Asn Asp Gly	Gly Tyr Tyr Asp	Pro Glu Thr	Gly Val
		420	425		430
Phe	Thr	Ala Pro Leu Ala Gly	Arg Tyr Leu	Leu Ser Ala	Val Leu Thr
		435	440		445
Gly	His	Arg His Glu Lys Val	Glu Ala Val	Leu Ser Arg	Ser Asn Gln
		450	455		460
Gly	Val	Ala Arg Val Asp Ser	Gly Gly Tyr	Glu Pro Glu	Gly Leu
		465	470	475	480
Asn	Lys	Pro Val Ala Glu Ser	Gln Pro Ser	Pro Gly	Thr Leu Gly Val
		485	490		495

Phe Ser Leu Ile Leu Pro Leu Gln Ala Gly Asp Thr Val Cys Val Asp		
500	505	510
Leu Val Met Gly Gln Leu Ala His Ser Glu Glu Pro Leu Thr Ile Phe		
515	520	525
Ser Gly Ala Leu Leu Tyr Gly Asp Pro Glu Leu Glu His Ala		
530	535	540

<210> 97
<211> 333
<212> PRT
<213> Homo sapiens

<400> 97			
Met Arg Ile Trp Trp Leu Leu Leu Ala Ile Glu Ile Cys Thr Gly Asn			
1	5	10	15
Ile Asn Ser Gln Asp Thr Cys Arg Gln Gly His Pro Gly Ile Pro Gly			
20	.	25	30
Asn Pro Gly His Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Ala			
35	40	45	
Lys Gly Asp Lys Gly Asp Ala Gly Glu Pro Gly Arg Pro Gly Ser Pro			
50	55	60	
Gly Lys Asp Gly Thr Ser Gly Glu Lys Gly Glu Arg Gly Ala Asp Gly			
65	70	75	80
Lys Val Glu Ala Lys Gly Ile Lys Gly Asp Gln Gly Ser Arg Gly Ser			
85	90	95	
Pro Gly Lys His Gly Pro Lys Gly Leu Ala Gly Pro Met Gly Glu Lys			
100	105	110	
Gly Leu Arg Gly Glu Thr Gly Pro Gln Gly Gln Lys Gly Asn Lys Gly			
115	120	125	
Asp Val Gly Pro Thr Gly Pro Glu Gly Pro Arg Gly Asn Ile Gly Pro			
130	135	140	
Leu Gly Pro Thr Gly Leu Pro Gly Pro Met Gly Pro Ile Gly Lys Pro			
145	150	155	160
Gly Pro Lys Gly Glu Ala Gly Pro Thr Gly Pro Gln Gly Glu Pro Gly			
165	170	175	
Val Arg Gly Ile Arg Gly Trp Lys Gly Asp Arg Gly Glu Lys Gly Lys			
180	185	190	
Ile Gly Glu Thr Leu Val Leu Pro Lys Ser Ala Phe Thr Val Gly Leu			
195	200	205	
Thr Val Leu Ser Lys Phe Pro Ser Ser Asp Val Pro Ile Lys Phe Asp			
210	215	220	
Lys Ile Leu Tyr Asn Glu Phe Asn His Tyr Asp Thr Ala Ala Gly Lys			
225	230	235	240
Phe Thr Cys His Ile Ala Gly Val Tyr Tyr Phe Thr Tyr His Ile Thr			
245	250	255	
Val Phe Ser Arg Asn Val Gln Val Ser Leu Val Lys Asn Gly Val Lys			

260	265	270	
Ile Leu His Thr Lys Asp Ala Tyr Met Ser Ser Glu Asp Gln Ala Ser			
275	280	285	
Gly Gly Ile Val Leu Gln Leu Lys Leu Gly Asp Glu Val Trp Leu Gln			
290	295	300	
Val Thr Gly Gly Glu Arg Phe Asn Gly Leu Phe Ala Asp Glu Asp Asp			
305	310	315	320
Asp Thr Thr Phe Thr Gly Phe Leu Leu Phe Ser Ser Pro			
325	330		

<210> 98
<211> 159
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (43)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (155)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 98
Gln Glu Gly Ser Glu Pro Val Leu Leu Glu Gly Glu Cys Leu Val Val
1 5 10 15

Cys Glu Pro Gly Arg Ala Ala Ala Gly Gly Pro Gly Gly Ala Ala Leu
20 25 30

Gly Glu Ala Pro Pro Gly Arg Val Ala Phe Xaa Ala Val Arg Ser His
35 40 45

His His Glu Pro Ala Gly Glu Thr Gly Asn Gly Thr Ser Gly Ala Ile
50 55 60

Tyr Phe Asp Gln Val Leu Val Asn Glu Gly Gly Phe Asp Arg Ala
65 70 75 80

Ser Gly Ser Phe Val Ala Pro Val Arg Gly Val Tyr Ser Phe Arg Phe
85 90 95

His Val Val Lys Val Tyr Asn Arg Gln Thr Val Gln Val Ser Leu Met
100 105 110

Leu Asn Thr Trp Pro Val Ile Ser Ala Phe Ala Asn Asp Pro Asp Val
115 120 125

Thr Arg Glu Ala Ala Thr Ser Ser Val Leu Leu Pro Leu Asp Pro Gly
130 135 140

Asp Arg Val Ser Leu Arg Leu Arg Arg Gly Xaa Ser Thr Gly Trp
145 150 155

<210> 99
<211> 27
<212> DNA

<213> Homo sapiens

<400> 99
gcggcaagct ttttgcaaag ccttagc

27

<210> 100

<211> 287

<212> PRT

<213> Homo sapiens

<400> 100

Pro Arg Val Arg Lys Glu Pro Glu Ala Met Gln Trp Leu Arg Val Arg
1 5 10 15Glu Ser Pro Gly Glu Ala Thr Gly His Arg Val Thr Met Gly Thr Ala
20 25 30Ala Leu Gly Pro Val Trp Ala Ala Leu Leu Phe Leu Leu Met Cys
35 40 45Glu Ile Pro Met Val Glu Leu Thr Phe Asp Arg Ala Val Ala Ser Asp
50 55 60Cys Gln Arg Cys Cys Asp Ser Glu Asp Pro Leu Asp Pro Ala His Val
65 70 75 80Ser Ser Ala Ser Ser Ser Gly Arg Pro His Ala Leu Pro Glu Ile Arg
85 90 95Pro Tyr Ile Asn Ile Thr Ile Leu Lys Gly Asp Lys Gly Asp Pro Gly
100 105 110Pro Met Gly Leu Pro Gly Tyr Met Gly Arg Glu Gly Pro Gln Gly Glu
115 120 125Pro Gly Pro Gln Gly Ser Lys Gly Asp Lys Gly Glu Met Gly Ser Pro
130 135 140Gly Ala Pro Cys Gln Lys Arg Phe Phe Ala Phe Ser Val Gly Arg Lys
145 150 155 160Thr Ala Leu His Ser Gly Glu Asp Phe Gln Thr Leu Leu Phe Glu Arg
165 170 175Val Phe Val Asn Leu Asp Gly Cys Phe Asp Met Ala Thr Gly Gln Phe
180 185 190Ala Ala Pro Leu Arg Gly Ile Tyr Phe Phe Ser Leu Asn Val His Ser
195 200 205Trp Asn Tyr Lys Glu Thr Tyr Val His Ile Met His Asn Gln Lys Glu
210 215 220Ala Val Ile Leu Tyr Ala Gln Pro Ser Glu Arg Ser Ile Met Gln Ser
225 230 235 240Gln Ser Val Met Leu Asp Leu Ala Tyr Gly Asp Arg Val Trp Val Arg
245 250 255Leu Phe Lys Arg Gln Arg Glu Asn Ala Ile Tyr Ser Asn Asp Phe Asp
260 265 270Thr Tyr Ile Thr Phe Ser Gly His Leu Ile Lys Ala Glu Asp Asp
275 280 285

<210> 101
<211> 162
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (1)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the naturally occurring L-amino acids

<220>
<221> SITE
<222> (48)
<223> Xaa equals any of the naturally occurring L-amino acids

<400> 101
Xaa Leu Trp Asp Pro Gly Leu Pro Gly Val Cys Arg Cys Gly Ser Ile
1 5 10 15

Val Leu Lys Ser Ala Phe Ser Val Gly Ile Thr Thr Ser Tyr Pro Glu
20 25 30

Xaa Arg Leu Pro Ile Ile Phe Asn Lys Val Leu Leu Pro Arg Gly Xaa
35 40 45

Ala Leu Gln Pro Cys His Arg Gly Ser Ser Ser Val Leu Ser Gln Gly
50 55 60

Ile Tyr Tyr Phe Ser Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala
65 70 75 80

Ile Gly Leu Val His Asn Gly Gln Tyr Arg Ile Lys Thr Phe Asp Ala
85 90 95

Asn Thr Gly Asn His Asp Val Ala Ser Gly Ser Thr Val Ile Tyr Leu
100 105 110

Gln Pro Glu Asp Glu Val Trp Leu Glu Ile Phe Phe Thr Asp Gln Asn
115 120 125

Gly Leu Phe Ser Asp Pro Gly Trp Ala Asp Ser Leu Phe Ser Gly Phe
130 135 140

Leu Leu Tyr Val Asp Thr Asp Tyr Leu Asp Ser Ile Ser Glu Asp Asp
145 150 155 160

Glu Leu

<210> 102
<211> 15
<212> PRT
<213> Homo sapiens

<400> 102
Gly Ser Ile Val Leu Lys Ser Ala Phe Ser Val Gly Ile Thr Thr
1 5 10 15

<210> 103
<211> 14
<212> PRT
<213> Homo sapiens

<400> 103
Gly Ile Tyr Tyr Phe Ser Tyr Asp Ile Thr Leu Ala Asn Lys
1 5 10

<210> 104
<211> 13
<212> PRT
<213> Homo sapiens

<400> 104
Asp Ser Leu Phe Ser Gly Phe Leu Leu Tyr Val Asp Thr
1 5 10

<210> 105
<211> 13
<212> PRT
<213> Homo sapiens

<400> 105
Asn His Asp Val Ala Ser Gly Ser Thr Val Ile Tyr Leu
1 5 10

<210> 106
<211> 126
<212> PRT
<213> Homo sapiens

<400> 106
Ser Ala Phe Thr Val Ile Leu Ser Lys Ala Tyr Pro Ala Val Gly Ala
1 5 10 15

Pro Ile Pro Phe Asp Glu Ile Leu Tyr Asn Arg Gln Gln His Tyr Asp
20 25 30

Pro Arg Ser Gly Ile Phe Thr Cys Lys Ile Pro Gly Ile Tyr Tyr Phe
35 40 45

Ser Tyr His Ile His Val Lys Gly Thr His Val Trp Val Gly Leu Tyr
50 55 60

Lys Asn Gly Thr Pro Thr Met Tyr Thr Tyr Asp Glu Tyr Ser Lys Gly
65 70 75 80

Tyr Leu Asp Gln Ala Ser Gly Ser Ala Ile Met Glu Leu Thr Glu Asn
85 90 95

Asp Gln Val Trp Leu Gln Leu Pro Asn Ala Glu Ser Asn Gly Leu Tyr
100 105 110

Ser Ser Glu Tyr Val His Ser Ser Phe Ser Gly Phe Leu Val
115 120 125

<210> 107
<211> 126

<212> PRT
<213> Homo sapiens

<400> 107
Ser Ala Phe Ser Val Ala Val Thr Lys Ser Tyr Pro Arg Glu Arg Leu
1 5 10 15
Pro Ile Lys Phe Asp Lys Ile Leu Met Asn Glu Gly Gly His Tyr Asn
20 25 30
Ala Ser Ser Gly Lys Phe Val Cys Gly Val Pro Gly Ile Tyr Tyr Phe
35 40 45
Thr Tyr Asp Ile Thr Leu Ala Asn Lys His Leu Ala Ile Gly Leu Val
50 55 60
His Asn Gly Gln Tyr Arg Ile Arg Thr Phe Asp Ala Asn Thr Gly Asn
65 70 75 80
His Asp Val Ala Ser Gly Ser Thr Ile Leu Ala Leu Lys Gln Gly Asp
85 90 95
Glu Val Trp Leu Gln Ile Phe Tyr Ser Glu Gln Asn Gly Leu Phe Tyr
100 105 110
Asp Pro Tyr Trp Thr Asp Ser Leu Phe Thr Gly Phe Leu Ile
115 120 125